



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification:

C12N 1/21, A61K 38/16,
A61K 38/17, C07K 14/00,
C07K 14/435, C07K 16/00,
C12N 5/10, C12N 15/11,
C12N 15/12, C12N 15/63,
G01N 33/50

A1

(11) International Publication Number:

WO 00/06698

(43) International Publication Date:

10 February 2000 (10.02.2000)

(21) International Application Number:

PCT/US99/17130

(22) International Filing Date:

29 July 1999 (29.07.1999)

Published

(30) Priority Data:

60/094,657	30 July 1998 (30.07.1998)	US
60/095,454	06 August 1998 (06.08.1998)	US
60/095,455	06 August 1998 (06.08.1998)	US
60/095,486	05 August 1998 (05.08.1998)	US
60/096,319	12 August 1998 (12.08.1998)	US

(60) Parent Application or Grant

HUMAN GENOME SCIENCES, INC. [/];
 (). KOMATSOU, George, A. [/]; (). ROSEN, Craig, A. [/];
 (). RUBEN, Steven, M. [/]; (). DUAN, Roxanne [/];
 (). MOORE, Paul, A. [/]; (). SHI, Yanggu [/]; (). LAFLEUR,
 David [/]; (). WEI, Ying-Fei [/]; (). NI, Jian [/];
 (). FLORENCE, Kimberly, A. [/]; (). YOUNG, Paul, F. [/];
 (). BREWER, Laurie, A. [/]; (). SOPPET, Daniel, R. [/];
 (). ENDRESS, Gregory, A. [/]; (). EBNER, Reinhard [/];
 (). OLSEN, Henrik, S. [/]; (). MUCENSKI, Michael [/];
 (). KOMATSOU, George, A. [/]; (). ROSEN, Craig, A. [/];
 (). RUBEN, Steven, M. [/]; (). DUAN, Roxanne [/];
 (). MOORE, Paul, A. [/]; (). SHI, Yanggu [/]; (). LAFLEUR,
 David [/]; (). WEI, Ying-Fei [/]; (). NI, Jian [/];
 (). FLORENCE, Kimberly, A. [/]; (). YOUNG, Paul, F. [/];
 (). BREWER, Laurie, A. [/]; (). SOPPET, Daniel, R. [/];
 (). ENDRESS, Gregory, A. [/]; (). EBNER, Reinhard [/];
 (). OLSEN, Henrik, S. [/]; (). MUCENSKI, Michael [/];
 (). HOOVER, Kenley, K. : ().

(54) Title: 98 HUMAN SECRETED PROTEINS

(54) Titre: 98 PROTEINES HUMAINES SECRÉTES

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

(57) Abrégé

La présente invention concerne de nouvelles protéines humaines sécrétées, ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des méthodes de recombinaison permettant de produire les protéines humaines sécrétées. L'invention concerne enfin des méthodes diagnostiques et thérapeutiques utilisées dans le traitement de troubles associés à ces nouvelles protéines humaines sécrétées.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 1/21, 5/10, 15/11, 15/12, 15/63, A61K 38/16, 38/17, C07K 14/00, 14/435, 16/00, G01N 33/50		A1	(11) International Publication Number: WO 00/06698 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17130 (22) International Filing Date: 29 July 1999 (29.07.99) (30) Priority Data: 60/094,557 30 July 1998 (30.07.98) US 60/095,486 5 August 1998 (05.08.98) US 60/095,455 6 August 1998 (06.08.98) US 60/095,454 6 August 1998 (06.08.98) US 60/096,319 12 August 1998 (12.08.98) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KOMATSOUKIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Ol- ney, MD 20832 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; Apartment 102, 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFI, EUR, David [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). WEI, Ying-Fei [CN/US]; 242 Gravatt Drive, Berkeley, CA 94705 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; Apartment 115, 410 Van Dyke Street, St. Paul, MN 55119-4321 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). MUCENSKI, Michael [US/US]; 3265 Mandale Drive, Cincinnati, OH 45239 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW; ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.			
(54) Title: 98 HUMAN SECRETED PROTEINS			
(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to those novel human secreted proteins.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	RS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5

98 Human Secreted Proteins

Field of the Invention

10

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

5

15

Background of the Invention

20

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

10

25

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

15

30

35

20

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

40

25

45

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

30

50

55

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

5 In specific embodiments, the polynucleotides of the invention are less than
300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further
10 embodiment, polynucleotides of the invention comprise at least 15 contiguous
nucleotides of the coding sequence, but do not comprise all or a portion of any intron.
15 In another embodiment, the nucleic acid comprising the coding sequence does not
contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the
genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid
sequence contained in SEQ ID NO:X or the cDNA contained within the clone
20 deposited with the ATCC. For example, the polynucleotide can contain the
nucleotide sequence of the full length cDNA sequence, including the 5' and 3'
untranslated sequences, the coding region, with or without the signal sequence, the
secreted protein coding region, as well as fragments, epitopes, domains, and variants
25 of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a
molecule having the translated amino acid sequence generated from the
15 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X
was often generated by overlapping sequences contained in multiple clones (contig
analysis). A representative clone containing all or most of the sequence for SEQ ID
20 NO:X was deposited with the American Type Culture Collection ("ATCC"). As
shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the
ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,
Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the
35 terms of the Budapest Treaty on the international recognition of the deposit of
microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those
polynucleotides capable of hybridizing, under stringent hybridization conditions, to
45 sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within
the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an
overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750
30 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's
50 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's

5 solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

10 Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.

5 Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

25 Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available, proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

35 Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

40 25 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxiribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA

5

10

15

20

25

30

35

40

45

50

55

that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

(See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The translation product of this gene is a human glycoprotein-associated amino acid transporter (See, e.g., Genbank Accession No. emb1CAA10198.11 (AJ130718); all references available through this accession are hereby incorporated by reference herein). Amino acid transport across cellular membranes is mediated by multiple transporters with overlapping specificities. The transport system L, which mediates Na⁺-independent exchange of large neutral amino acids, consists of a novel amino acid permease-related protein (LAT1 or AmAT-L-1c) which for surface expression and function requires formation of disulfide-linked heterodimers with the glycosylated heavy chain of the h4F2/CD98 surface antigen. h4F2hc also associates with other mammalian light chains, e.g. γ -LAT1 from mouse and human which are

approximately 48% identical with LAT1 and thus belong to the same family of glycoprotein-associated amino acid transporters.

The novel heterodimers form exchangers which mediate the cellular efflux of cationic amino acids and the Na⁺-dependent uptake of large neutral amino acids.

These transport characteristics and kinetic and pharmacological fingerprints identify them as y⁺L-type transport systems. mRNA encoding y⁺LAT1 is detectable in most adult tissues and expressed at high levels in kidney cortex and intestine. This indicates that the y⁺LAT1-4F2hc heterodimer, besides participating in amino acid uptake/secretion in many cell types, is the basolateral amino acid exchanger involved in transepithelial reabsorption of cationic amino acids; hence, its defect might be the cause of the human genetic disease lysinuric protein intolerance.

The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

Preferred polypeptides comprise the following amino acid sequence:

LALYSALFSYSGWDTLN (SEQ ID NO: 237), VTEEIKNPERNLPL (SEQ ID NO: 238), IGISMPIVT (SEQ ID NO: 239), IYILTNVAYYTVL (SEQ ID NO: 240), SDAVAVTFADQ (SEQ ID NO: 241), VALSCFGGLNASI (SEQ ID NO: 242), SRLFFVGSREGHLPD (SEQ ID NO: 243), SFSYWFFVGLS (SEQ ID NO: 244), VGQLYLRWKEP (SEQ ID NO: 245), RPRPLKLSVFFPIVFC (SEQ ID NO: 246), DTINSLIGI (SEQ ID NO: 247), LLAAACICLLTFINCA YVKWGT LVQDIFTYAKVLALIAVI VAGIVRLCQGASTHFENSFEGSSFAVGDIALALYSALFSYSGWDTLNYVTEEIKNPERNLPLSIGISMPIVTIYILTNVAYYTVLDMRDILASDAVAVTFADQIFGIFNWIPLSVALSFCGGLNASIVAASRLFFVGSREGHLPDAICMIHVERFTPVPSSLFNGIMALIYLCVEDIFQLNYYSFYSYWFVGLSIVGQLYLRWKEPDRPRPLKLSVFFPIVFCCTIFLVA VPLYSDTINSLIGIAIALSGLPFYFLIRVPEHKRPLYLRRI VGSATRYLQVLCMSVAAEMDLEDGGEMPKQRDPKSN (SEQ ID NO: 249) and/or ATALPPKIVGSATRYLQVLCMSVAAEMDLEDGGEMPKQRDPKSN (SEQ ID NO: 248). Polynucleotides encoding these polypeptides are also provided.

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 monocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal

transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both THP-1 monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes.

This gene is expressed primarily in endothelial cells and brain, and, to a lesser extent, in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the neural or gastrointestinal systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulation system or central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 124 as residues: Glu-102 to Asn-110, Arg-256 to Leu-266, Pro-316 to Trp-328, Pro-331 to Arg-336, Met-350 to Gly-358. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain combined with its homology to a amino acid transporter and biological activity of increasing ion flux in monocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,

Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1550 of SEQ ID NO: 11, b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

Preferred polypeptides of the invention comprise the following amino acid sequence:

5 AARGSGVRDPLEEAVCPFSDLQLHAGRTTALFKAVRQGHLSLQRLLLSFVCL
CPAPRGGAYRGRQASLSCGGLHPVRASRLCLPKQAWAMAGAPPVSLPPCS
10 LISDCCASNQRDSVG (SEQ ID NO: 250). Polynucleotides encoding these
polypeptides are also provided.

5 This gene is expressed primarily in cord blood cells, and, to a lesser extent, in
frontal lobe of the brain.

15 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
20 10 not limited to, developmental, reproductive, hematopoietic or neural disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
25 15 immune and central nervous systems, expression of this gene at significantly higher or
lower levels is routinely detected in certain tissues or cell types (e.g., immune,
developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue
30 or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
20 fluid from an individual not having the disorder.

35 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 125 as residues: His-56 to Gln-65, Leu-80 to Ile-85.
Polynucleotides encoding said polypeptides are also provided.

40 25 The tissue distribution in cord blood cells indicates polynucleotides and
polypeptides corresponding to this gene are useful for the treatment and diagnosis of
hematopoietic related disorders such as anemia, pancytopenia, leukopenia,
thrombocytopenia or leukemia since stromal cells are important in the production of
45 cells of hematopoietic lineages. Representative uses are described in the "Immune
Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,
30 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo
culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or
50 chemotherapy of neoplasia.

5 The gene product may also be involved in lymphopoiesis, therefore, it can be
used in immune disorders such as infection, inflammation, allergy, immunodeficiency
10 etc. In addition, this gene product may have commercial utility in the expansion of
stem cells and committed progenitors of various blood lineages, and in the
5 differentiation and/or proliferation of various cell types. Alternatively,
polynucleotides and polypeptides corresponding to this gene are useful for the
15 diagnosis and treatment of cancer and other proliferative disorders. Expression within
embryonic tissue and other cellular sources marked by proliferating cells indicates
that this protein may play a role in the regulation of cellular division. Similarly,
20 embryonic development also involves decisions involving cell differentiation and/or
apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or
tissue differentiation and could again be useful in cancer therapy. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as
15 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO:12 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
35 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
40 25 formula of a-b, where a is any integer between 1 to 1743 of SEQ ID NO:12, b is an
integer of 15 to 1757, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 3

30 This gene is expressed primarily in human T cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as
50 reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T cell lymphoma, immunodeficiencies, in addition to other immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 126 as residues: Met-1 to Phe-10. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human T cell lymphomas indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:13, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The protein product of this clone shares sequence homology with the C-terminus of a human N-acetylglucosamine-phosphate mutase (See, e.g., Genbank Accession No. gb|AAC72409.11 (AF102265); all references available through this accession are hereby incorporated by reference herein.) Hofmann, et al. (Eur. J. Biochem. 221:741-747 (1994)) studied the N-acetylglucosamine-phosphate mutase of *Saccharomyces cerevisiae* and showed it to be essential for viability. A *S. cerevisiae* *agm1* deletion mutant progressed through only approximately five cell cycles to form a 'string' of undivided cells with an abnormal cell morphology resembling

glucosamine auxotrophic mutants. Expression of the AGM1 gene on a multi-copy plasmid led to a significantly increased N-acetylglucosamine-phosphate mutase activity. Unlike over-expression of the *S. cerevisiae* AGM1 gene in a phosphoglucomutase (pgm1 delta/pgm2 delta) double deletion mutant which could restore phosphoglucomutase activity, over-expression of the PGM2 gene encoding the major isoenzyme of phosphoglucomutase did not increase N-acetylglucosamine-phosphate mutase activity and did not restore growth of agm1 deletion mutant cells. These observations indicate that the different hexosephosphate mutases of *S. cerevisiae* have partially overlapping substrate specificities but, nevertheless, distinct physiological functions. The human N-acetylglucosamine-phosphate mutase is expected to share at least some biological activities with the Agm1 protein.

Preferred polypeptide fragments of the invention comprise the following amino acid sequences: LSKAFLDSPNRL LAVEMNTDHLRLTVPNGIGALKLRXM EHYFSQGLSVQLFNDGSKGLNHL CGAD FVKSHQKPPQGMEIKSN ERCCSFD GDADRIVYYYHDADGHFHLIDGDKIATLISSFLKELLVEIGESLNIGVVQTAYANGSSTRYLEEVMKVPVYCTKTGVKHLHHKAQEFDIGVYFEANGHTALFST AVEMKIKQSAEQLEDKKRKA AKMLENIIDLFNQAAGDAISDMLVIEAILALK GLTVQQWDALYTDLPNRQLKVQVADRRVISTTXAERQAVTPPGLQEAINDL VKKYKLSRA FVRPSGTEDVVRVYAEADSQESADHLAHEVSLAVFQLAGGIGERPQPGF (SEQ ID NO: 251), LSKAFLDSPNRL LAVEMNTDHLRLTV (SEQ ID NO: 252), PNGIGALKLRXMEHYFSQGLSVQLFNDG (SEQ ID NO: 253), SKGKL NHL CGAD FVKSHQKPPQGMEIKS (SEQ ID NO: 254), NERCCSFDGDADRIV YYYHDADGHFHLI (SEQ ID NO: 255), DGDKIATLISSFLKELLVEIGESLNIGV (SEQ ID NO: 256), VQTAYANGSSTRYLEEVMKVPVYCTKTG (SEQ ID NO: 257), VKHLHHKAQEFDIGVYFEANGHTALFS (SEQ ID NO: 258), TAVEMK IKQSAEQLEDKKRKA AKMLENI (SEQ ID NO: 259), IDLFNQAAGDAISDMLVIEAILALKGLT (SEQ ID NO: 260), VQQWDALYTDLPNRQLKVQVADRR VIST (SEQ ID NO: 261), TXAERQAVTPPGLQEAINDLVKKYKLSR (SEQ ID NO: 262), AFVRPSGTEDVVRVYAEADSQESA (SEQ ID NO: 263), and/or DH LAHEVSLAVFQLAGGIGERPQPGF (SEQ ID NO: 264). Polynucleotides encoding these polypeptides are also provided.

5 The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

10 This gene is expressed primarily in fetal brain, and, to a lesser extent, in a wide variety of human tissues.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders, particularly of the central nervous system. 20 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central and peripheral nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or 25 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 127 as residues: Asn-36 to Lys-42, Lys-53 to Gln-60, Ile-64 to Ala-77, Ala-128 to Tyr-135, Lys-184 to Ala-199, Leu-245 to Leu-250. Polynucleotides encoding said polypeptides are also provided.

35 The tissue distribution of N-acetylglucosamine-phosphate mutase in fetal 40 brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 45 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to 30 the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, 50 demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital

malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3726 of SEQ ID NO:14, b is an integer of 15 to 3740, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in human stomach and stomach tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the gastrointestinal system, particularly cancer or ulcers of stomach tissue. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the

5 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
particularly of the digestive system, expression of this gene at significantly higher or
10 lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal,
or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma,
5 urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
15 the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

The tissue distribution in tumors of the stomach indicates that polynucleotides
20 and polypeptides corresponding to this gene are useful for diagnosis, treatment and
intervention of these tumors. In addition to other tumors where expression has been
indicated. Additionally, the protein product of this gene may play a role in the normal
function of the stomach and/or digestive system. Furthermore, the protein may also be
25 used to determine biological activity, to raise antibodies, as tissue markers, to isolate
cognate ligands or receptors, to identify agents that modulate their interactions, in
15 addition to its use as a nutritional supplement. Protein, as well as, antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy targets
30 for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
20 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO: 15 and may have been publicly available prior to conception of
35 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
40 25 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1182 of SEQ ID NO: 15, b is an
integer of 15 to 1196, where both a and b correspond to the positions of nucleotide
45 residues shown in SEQ ID NO: 15, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 6

Preferred polypeptides of the invention comprise the following amino acid
50 sequences:

FEIALPRESNITVLIKLGTPDLLAKPCYIVISKRHITMLSIKSGERIVFTFSCQSPENH
FVIEIQKNIDCMSPGCPFGEVQLQPSTSLPTLNRTFIWDVKAHKSIGLELQ
FSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKM (SEQ ID
NO: 266), and/or GTRAAPGLGAWGRRSPSPSPRRPGVMAGLNCGVSIALL
LGVLLGAARLPRGAFAFEIALPRESNITVLIKLGTPDLLAKPCYIVISKRHITM
LSIKSGERIVFTFSCQSPENH FVIEIQKNIDCMSPGCPFGEVQLQPSTSLPTLNRT
FTIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCS
NGTVSRIKMQFGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGS
ATLMSANYPEGFPDELMTWQFVVPAPHLRASVSFLNFNLSNCERKEERVEYY
IPGSTTNPEVFKLEDKQPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQH
PQNESNKIYVVDLSNERAMSLTIEPRPVKQSRKFVPGCFVCLESRTCSSNLTLS
SGSKHKISFLCDDLTRLWMNVEKP (SEQ ID NO: 265). Polynucleotides encoding
these polypeptides are also provided.

This gene is expressed primarily in placenta, and to a lesser extent in, prostate
and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, male and female infertility, and associated disorders of the
reproductive system. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the reproductive system, expression of this gene at
significantly higher or lower levels is routinely detected in certain tissues or cell types
(e.g., reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
amniotic fluid, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder, relative
to the standard gene expression level, i.e., the expression level in healthy tissue or
bodily fluid from an individual not having the disorder.

The tissue distribution of this gene in the prostate, placenta and ovary
indicates that polynucleotides and polypeptides corresponding to this gene are useful
for treatment, prevention, and/or diagnosis of male or female infertility, endocrine

disorders, fetal deficiencies, ovarian failure, amenorrhea, ovarian cancer, benign prostate hyperplasia and prostate cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within placental tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2195 of SEQ ID NO:16, b is an integer of 15 to 2209, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The translation product of this gene shares homology with the human and rat HNK-1 sulfotransferase protein (See, e.g., Genbank Accession Nos. gblAAB88123.11 (AF022729) and gil29213061gblAAC04707.11 (AF033827); all references available through these accessions are hereby incorporated herein by reference.) Ong E, et al. (J Biol Chem. 273(9):5190-5 (1998)) have characterized the human HNK-1 sulfotransferase, and show that it is involved in the synthesis of the HNK-1

carbohydrate epitope which is expressed on various adhesion molecules in the nervous system and on immune cells (e.g., natural killer cells) and is suggested to play a role in cell-cell and cell-substratum interactions. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with HNK-1 sulfotransferase proteins. Such activities are known in the art, some of which are described elsewhere herein, or in, for example, Bakker, et al., J Biol Chem. 272:29942-6 (1997), incorporated herein by reference. Based on sequence similarity between sulfotransferases, a consensus sequence for the active site was developed (Ong, et al., supra). The consensus pattern is as follows: xxRPDzzzz, where x represents hydrophobic amino acid residues and z represents any amino acid residue. Therefore,

Preferred polypeptides of the invention comprise the following amino acid sequences: FVRDPFVRL (SEQ ID NO: 267), FLFVRDPFVRLIS (SEQ ID NO: 268), FLFVRDPFVRLISAF (SEQ ID NO: 269), and/or YLHTSFSPHTGPPLPTPG PDRDRELTADSDVDEFLDKFLSAGVKQSDLPRKETEQQPAPGSMEENVRGY DWSPRDARRSPDQGRQQAERRSVLRGFCANSSLAFTKERAFDDIPNSELSHL IVDDRHGAICYVPKVACTNWKRVMIVLSGSLLHRGAPYRDPLRIPREHVH NASAHLTFNKFWRRYGLSRHLMKVKLKKYTKFLFVRDPFVRLISAFRSK FELENEEFYRKFAVPMRLRYANHTSI.PASAREAFRAGLKVSFANFIQYLLDPH TEKLAPFNEHWRQVYRLCHPCQIDYDFVGKLETLDAAQLLQLLQVDRQ LRFPPSYRNRTASSWEEDWFAKIPLAWRQQLYKLYEADFLFGYPKPENLL RD (SEQ ID NO: 270). Polynucleotides encoding these polypeptides are also provided.

Further preferred are the sulfotransferase active site polypeptides listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C-terminal to the sulfotransferase active site polypeptides. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the sulfotransferase active site polypeptides, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domains are characteristic of a signature specific to sulfotransferase proteins. The nucleotides sequence of this gene was found to be

homologous to the human hypoxanthine guanine phosphoribosyl transferase 2 cDNA which is known to be involved in the purine salvage pathway resulting in the maintenance of homeostatic levels of uric acid (See Genbank Accession No. T30127).

The gene encoding the disclosed cDNA is believed to reside on chromosome

7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed to a very high level in HL-60 myelogenous leukemia cell lines, and to a lesser extent, in most cell types of the immune system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, myelopoiesis, and metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, metabolic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 130 as residues: Ser-39 to Gly-46, Leu-49 to Ala-62, Lys-79 to Ala-93, Gly-95 to Asp-105, Ser-107 to Val-127, Gly-193 to Leu-200, Lys-218 to Ser-227, Lys-234 to Thr-239, Pro-366 to Asp-379; Pro-406 to Asp-414. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in HL-60 myelogenous leukemia cell lines and homology to HNK-1 sulfotransferase proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention and/or treatment of a variety of immune system disorders, including but not limited to, those involving the HNK-1 carbohydrate epitope. (e.g. HNK-1 as an auto-antigen

5 in peripheral demyelinating neuropathy). Representative uses are described in the
"Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14,
10 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, expression of this gene product
in tonsils indicates a role in regulating the proliferation, survival, differentiation,
5 and/or activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
15 other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting
immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
10 product is involved in immune functions. Therefore it is also used as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
20 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
25 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
30 Disease, scleroderma and tissues. Moreover, the protein may represent a secreted
factor that influences the differentiation or behavior of other blood cells, or that
20 recruits hematopoietic cells to sites of injury. In addition, this gene product may have
commercial utility in the expansion of stem cells and committed progenitors of
35 various blood lineages, and in the differentiation and/or proliferation of various cell
types. Alternatively, the homology to a conserved purine metabolism protein may
suggest that polynucleotides and polypeptides corresponding to this gene are useful
40 25 for the diagnosis, prevention, and/or treatment of various metabolic disorders such as
Tay-Sach's Disease, phenylketonuria, galactosemia, porphyrias, Hurler's syndrome,
and various urogenital disorders related to metabolic conditions, particularly Lesch-
45 Nyhan syndrome. Furthermore, the protein may also be used to determine biological
activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors,
30 to identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
50 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

10

15

20

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1760 of SEQ ID NO:17, b is an integer of 15 to 1774, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

25

30

35

40

45

50

55

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS) promoter element. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway, a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: KLVRLQVPVRNSRVDPVRVRSKIGSRRWMLQLI MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVPYLYFDMGAAVLCA SFMSFGVKRRWFALGAALQLAISTYAA YIGGYVHYGDWLKVRMYSRTVAII GGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLCVAYSLQHSKEDRLA YLNHLPGGELMIQLFFVLYGILALAFLSGYYVTLAAQLAVLLPPVMLLIDG NVAYWHNTRRVEFWNQMKLLGESVGIFGTAVILATDG (SEQ ID NO: 271).

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVP YLYFDMGAAVLCASFMSFGVKRRWFALGAALQLAISTYAA YIGGYVHYGD

5
10
15
20
25
30
35
40
45
50
55

WLKVRMYSRTVAIGGFLVLASGAGELYRRKPRSRSLQSTGGVFLGIYLCVA
YSLQHSKEDRLAYLNHLPGGELMIQLFFVLYGILAPGLSVRLLRDPRCPDPGC
TAAPCHAAH (SEQ ID NO: 272). Polynucleotides encoding these polypeptides are also provided.

5
10
15
20
25
30
35
40
45
50
55

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in endometrial tumors, and to a lesser extent, in T-cells, pituitary and to a certain extent in most cell types.

5
10
15
20
25
30
35
40
45
50
55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, female reproductive, immune, or endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and/or immune systems expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5
10
15
20
25
30
35
40
45
50
55

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 131 as residues: Ala-27 to Asp-34, Tyr-116 to Leu-125. Polynucleotides encoding said polypeptides are also provided.

5
10
15
20
25
30
35
40
45
50
55

The tissue distribution predominantly in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of a range of immune and/or reproductive disorders including endometriosis, endometritis, and endometrioma. Similarly, the tissue distribution in T-cells and the ability of supernatants expressing this gene to stimulate the GAS promoter element in T-cells indicates polynucleotides and

polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells; or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in pituitary indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of the Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-

hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO: 18, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of the myeloid leukemia cell line AML-193 to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating myeloid leukemia cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: SNEILLSFPQNYIQLNGSLIHGLWNLASLFS NLCLFVLMPEAFFFESEGFAGLKKGIRARILETLVMLLLALLILGIVWVAS ALIDNDAASMESLYDLWEFYLPYLYSCISLMGCLLLLCTPVGLSRMFTVMG HLLVKPTILEDLDEQIYIITLEEEALQRRNLGLSSSVEYNIMELEQELENVKTL KTKLERRKKASAWERNLVPAVMVLLLIETISIVLLVACNILCLLVDETAM PKGTRGPGIGNASLSTFGFVGAALIEIILIFYIMVSSVVGFYSLRFFGNFTPKKD DTTMTKIIGNCVSILVLSSALPVMSTRITGTRFDLLGDFGRFNWLGNFYIVLS YNLLFAIVTTCLVRKFTSAVREELFKALGLHKLHLPNTSRDSETAKPSVNGH

5 QKAL (SEQ ID NO: 273). Polynucleotides encoding these polypeptides are also provided.

10 This gene is expressed primarily in fetal heart, and to a lesser extent, in colon and the adult pulmonary system.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, heart, lung and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, pulmonary and digestive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 132 as residues: Glu-67 to Asn-74, Glu-88 to Asn-93, Lys-95 to Ala-107, Ala-147 to Arg-153, Phe-197 to Thr-205, Pro-292 to His-308. Polynucleotides encoding said polypeptides are also provided.

40 The tissue distribution in fetal heart, colon and pulmonary tissues and the biological activity in increasing the permeability of the plasma membrane of the myeloid leukemia cell line AML-193 to calcium, likely indicating that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention, and/or detection of a range of disorders including a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, myocardial infarction, myocarditis, ischemia, thrombosis, coronary artery disease,

arteriosclerosis, and/or atherosclerosis; pulmonary edema and embolism, bronchitis and/or cystic fibrosis; Crohn's Disease and/or colon cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2004 of SEQ ID NO:19, b is an integer of 15 to 2018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The protein product of this clone shares sequence homology with the human MaxiK channel beta 2 subunit (See, Genbank Accession No. gblAAD23380.1|AF099137_1 (AF099137); all references available through this accession are hereby incorporated herein by reference), which is believed to be a modulatory subunit of the voltage and Ca^{2+} activated K^{+} (MaxiK) channel. Additionally, this protein shares homology to the human calcium-activated potassium

channel beta subunit, which, when combined with its corresponding alpha subunit and modulating peptide, are believed to be useful in treating asthma, angina, hypertension, incontinence, migraine, irritable bowel syndrome (IBS). The subsequent heteromultimer that forms upon combining the alpha, beta, and modulator subunits are also thought to be useful in preventing premature labour, preventing and treating cerebral ischemia, inducing pain modulation and decreasing neurogenic inflammation in a patient (See GeneSeq Accession No. R85306).

Preferred polypeptides comprise the soluble domain, which consists of the following amino acid sequence: RSYMQSVWTEESQCTLLNASITETFNCFSFCGP DCWKLSQYPCLQVYVNLTSSEKLLLYHTEETIKINQKCSYIPKCGKNFEESM SLVNVVMENFRKYQHFCYS DPEGNQKSVILTKLYSSNVI.FHSLFWPTCMMMA GGVAIVAMVKL TQYLSLLCERIQRINR (SEQ ID NO: 274). Polynucleotides encoding these polypeptides are also provided. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with modulatory subunits of voltage and Ca²⁺ activated K⁺ channel proteins. Such activities are known in the art, some of which are described in Wallner, et al., PNAS 96:4137-4142 (1999), incorporated herein by reference.

This gene is expressed primarily in adrenal gland tumor, and to a lesser extent, in Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and immune disorders, particularly Hodgkin's Lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 133 as residues: Trp-25 to Gln-30, Pro-50 to Gln-57, Pro-93 to Glu-101, Arg-114 to Cys-121, Ser-123 to Gln-129, Ile-177 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adrenal gland tumor and its identification as the modulatory subunit of the voltage and Ca^{2+} activated K^{+} (MaxiK) channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, expression in proliferative immune tissues combined with its homology to a novel human K channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in Hodgkin's lymphoma indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2084 of SEQ ID NO:20, b is an integer of 15 to 2098, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The translation product of this gene shares homology with collagen and collagen like proteins (See, e.g., Genbank Accession Nos. gi12920535|gb|AAC39658.11 (AF018081) and gi12384942|gb|AAB69961.11 (AF022985); all references available through these accession numbers are hereby incorporated by reference herein). Additionally, it has been determined that this gene has homology to the human Kruppel related zinc finger protein (HTF10) which is known to be important as a transcription factor, particularly in development (See Genebank Accession No.L11672).

5 In a specific embodiment, polypeptides comprising the amino acid sequence
of the open reading frame upstream of the predicted signal peptide are contemplated
10 by the present invention. Specifically, polypeptides of the invention comprise the
following amino acid sequence: AFAHLQLGPMWKLWRAEEGAAALGGALFLL
5 FALGVRQLLKQRRPMGFPPGPPGLPFIGNIYSLAASSELPHVYMRKQSQVYG
EVQPRRAPGREGRQAGPGWPGPSWLDLWPPLGRLVGTSPCAGCPLRDTRFPG
15 LEGRS PRRRAPLQGEPRPCR (SEQ ID NO: 275). Polynucleotides encoding these
polypeptides are also provided.

This gene is expressed primarily in human erythroleukemia cell line (HEL),
20 serum induced smooth muscle, and to a lesser extent in human 8 week whole embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
25 not limited to, leukemia, musculoskeletal, or developmental disorders. Similarly,
15 polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the hematopoietic
system and muscular system, expression of this gene at significantly higher or lower
30 levels is routinely detected in certain tissues or cell types (e.g., immune,
20 musculoskeletal, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
35 amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue
or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

40 Preferred polypeptides of the present invention comprise immunogenic
25 epitopes shown in SEQ ID NO: 134 as residues: Leu-30 to Gly-38, Arg-67 to Val-72,
Val-76 to Ala-89, Pro-118 to Arg-123, Gly-129 to Ala-136, Leu-138 to Arg-146.
Polynucleotides encoding said polypeptides are also provided.

45 The tissue distribution in human erythroleukemia cell line (HEL), and serum
30 induced smooth muscle, and the shared homology with collagen and collagen like
proteins indicates that polynucleotides and polypeptides corresponding to this gene
50 are useful for disorders of hematopoietic or muscular systems, such as leukemia and

muscular dystrophy. Additionally, the shared homology with collagen proteins would suggest that this protein may also be important in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.).

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1732 of SEQ ID NO:21, b is an integer of 15 to 1746, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRVRIGLTLLLCVLLSLASASSDEEGSQD
ESLGFQDYFDIR (SEQ ID NO: 276). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 135 as residues: Ser-22 to Ser-41, Glu-43 to Thr-50,

Ser-63 to Leu-68, Ser-71 to Gly-84, Ser-96 to Gly-114. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation

modulating activity or induction of other cytokines;
immunostimulating/immunosuppressant activities (e.g., for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to
chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or
nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for
control of fertility); chemotactic and chemokinetic activities (e.g., for treating
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating
haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating
septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other
hyperproliferative disease; for regulation of metabolism, behaviour, and many others.
Also contemplated is the use of the corresponding nucleic acid in gene therapy
procedures. Furthermore, the protein may also be used to determine biological
activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:22 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 2862 of SEQ ID NO:22, b is an
integer of 15 to 2876, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

A preferred polypeptide variant of the invention comprises the following
amino acid sequence: MARGSLRRLRLRLVLGLWLALLRSVAGEQAPGTAPC
SRGSSWSADLDKCMDCSTSCPLPA ALAHPWGRSEPDLRAGAAFWLFGLE

5

10

15

20

25

30

35

40

45

50

55

TMPQE REVHHPHRGDRRRGLPSCGADPVTMCPLPAGARPLIIHSSILEPVSAS
QTRREPSSSNHK GGGGR (SEQ ID NO: 277). Polynucleotides encoding these
polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome
16. Accordingly, polynucleotides related to this invention are useful as a marker in
linkage analysis for chromosome 16.

This gene is expressed primarily in tumor growth factor or lipopolysaccharide
treated bone marrow stroma, epithelioid sarcoma, umbilical vein endothelial cells, and
to a lesser extent, in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, hematopoiesis or immune disorders. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the hematopoietic,
integumentary, or immune systems expression of this gene at significantly higher or
lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic,
immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 136 as residues: Pro-35 to Trp-42, Pro-65 to Asp-72,
Thr-86 to Phe-93, Ile-97 to Glu-103. Polynucleotides encoding said polypeptides are
also provided.

The tissue distribution in tumor growth factor or lipopolysaccharide treated
bone marrow stroma, epithelioid sarcoma, and umbilical vein endothelial cells
indicates that polynucleotides and polypeptides corresponding to this gene are useful
for the diagnosis, prevention, and/or treatment of a variety of immune system
disorders. Representative uses are described in the "Immune Activity" and "infectious

5 disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere
herein. Briefly, the expression of this gene product indicates a role in regulating the
10 proliferation; survival; differentiation; and/or activation of hematopoietic cell
lineages, including blood stem cells. This gene product is involved in the regulation of
15 cytokine production, antigen presentation, or other processes suggesting a usefulness
in the treatment of cancer (e.g., by boosting immune responses).

15 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also used as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
20 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
25 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, scleroderma and tissues. Moreover, the protein may represent a secreted
factor that influences the differentiation or behavior of other blood cells, or that
30 recruits hematopoietic cells to sites of injury. In addition, this gene product may have
commercial utility in the expansion of stem cells and committed progenitors of
20 various blood lineages, and in the differentiation and/or proliferation of various cell
types.

35 The secreted protein can be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
that modulate their interactions and as nutritional supplements. It may also have a
40 25 very wide range of biological activities although no evidence for any is provided in
the specification. Typical of these are cytokine, cell proliferation/differentiation
modulating activity or induction of other cytokines;
45 immunostimulating/immunosuppressant activities (e.g., for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
30 regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to
chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or
50 nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for
55

control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:23, b is an integer of 15 to 1052, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

20' FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The translation product of this gene shares sequence homology with chromaffin granule amine transporter protein which is thought to be important in vesicle membrane amine transport, particularly in the neural and endocrine tissue, and the human vesicular monoamine transporter hVMAT1 which is involved in the regulation of amine storage in cardiovascular, endocrine, and central nervous system function (See, Genbank Accession Nos. gi1314290 and gb1AAC50472.11; all references available through these accession numbers are hereby incorporated by reference herein). Based on these sequence similarities, The translation product of this gene is expected to share at least some biological activities with amine transporter proteins. Such activities are known in the art, some of which are described in Erickson, et al., PNAS 93:5166-5171 (1996), and/or Liu, et al., Cell 70:539-551 (1992), which are both incorporated herein by reference.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSFLDPTLSLFLVLEKFNL PAGYVGLVFLGMAL SYAISSPLFGLLSDKRPPLRKWLLVFGNLITAGCYMLLGPVPILHIKSQLWLL VLILVVSGLSAGMSIIPTFEILSCAHENGFEGLSTLGLVSGLFSAMWSIGAF MGPTLGGFLYEKIGFEWAAAIQGLWALISGLAMGLFYLLEYSRRKRKSKSQNIL STEEFERTLLPNET (SEQ ID NO: 278). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in colon cancer, osteoclastoma, and T-cell lymphoma, and to a lesser extent in many tumor or proliferative tissues such as endometrial tumor, chondrosarcoma, induced umbilical vein endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases resulting from disorders in small molecule transport (i.e., signalling molecules) in afflicted tissues and organs, particularly of the endocrine and central nervous systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal, immune, and/or digestive systems and cancer expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 137 as residues: Ser-114 to Asn-123, Thr-127 to Thr-132. Polynucleotides encoding said polypeptides are also provided.

10

15

20

25

30

35

40

45

50

55

The tissue distribution in colon cancer, osteoclastoma, and T-cell lymphoma and homology to amine transporter family members indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders or diseases resulted from small molecule transport in afflicted tissues and organs, particularly that of colon, osteoclast or T-cells. The expression in cancer tissues, and shared homology with transporter proteins may also indicate its role in anti-cancer drug resistance. Additionally, the protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; or for identifying inhibitors or promoters of the transport of toxic molecules to vesicles, for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1527 of SEQ ID NO:24, b is an integer of 15 to 1541, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene shares sequence homology with the human prolyl 4-hydroxylase alpha (II) subunit which is important in catalyzing the formation of 4-hydroxyproline in collagens which is essential for the folding of newly synthesised collagen polypeptide chains into triple-helical molecules (See Genbank Accession No. g01AAB71339.11; all references available through this accession are hereby incorporated herein by reference). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Prolyl 4-hydroxylase proteins. Such activities are known in the art, some of which are described in Annunen, et al., J. Biol. Chem. 272:17342-17348 (1997) which is incorporated herein by reference.

When tested against U937 myeloid and Jurkat T-cell cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates myeloid cells and T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

5 GTREARLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSL
EASENIRALKDGYEKVEQDLPAFEDLEGAARALMRLQDVYMLNVKGLAR
10 GVLFQRTGSAITDLYSPKRLFSLTGDDCFQVGKVAYDMGDY YHAIPWLEEA
VSLFRGSYGEWKTEDEASLEDALDHLAFAYFRAGNVSCALSLSREFLLYSPD
5 NKRMAARNVLKYERLLAESPNHVVAEAVIQRPNIHLQTRDTYEGLCQTL
GSQPTLYQIPSLYCSYETNSNAYLLLQPIRKEVIHLEPYIALYHDFVSDSEAQ
15 KIRELAEPWLQRSVVASGEKQLQVEYRISKSAWLKDTVDLKLVTLNHRIAA
LTGLDVRPPYAEYLQVVNYGIGGHYEPHFDHATSPSSPLYRMKSGNRVATFM
IYLSSVEAGGATAFIYANLSVPVVRNAALFWWNLHRSGEGSDTLHAGCP
10 VLVGDKWVANKWIHEYGQEFRRPCSSSPED (SEQ ID NO: 282). Additional,

20 Preferred polypeptides comprise the following amino acid sequence: GTREA
RLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSL
EASENIRALKDGYEKVEQDLPAFEDLEGAARAL (SEQ ID NO: 279), ALMRLQD (SEQ
25 ID NO: 280), and/or VEAGGAT (SEQ ID NO: 281). Polynucleotides
15 encoding these polypeptides are also provided.

This gene is expressed primarily in lymph node breast cancer, colon
carcinoma, and to a lesser extent in osteoblasts and adipocytes.

30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are
35 not limited to, disorders of connective and immune tissues, particularly autoimmune
disorders. Similarly, polypeptides and antibodies directed to these polypeptides are
useful in providing immunological probes for differential identification of the
tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
40 25 particularly of the connective tissues in breast, colon, bone, and fat, expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., immune, connective, or cancerous and wounded tissues) or bodily
fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another
45 tissue or cell sample taken from an individual having such a disorder, relative to the
30 standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

50

55

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 138 as residues: Ser-74 to Ala-84, Gln-156 to Tyr-
10 161, Tyr-184 to Asn-189, Ser-218 to Ile-223, Pro-299 to Ser-308, His-359 to Thr-368,
Tyr-390 to Asp-404. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in lymph node breast cancer and colon carcinoma and
homology to prolyl 4-hydroxylase alpha (II) subunit indicates that polynucleotides
15 and polypeptides corresponding to this gene are useful for intervention of connective
tissue disorders and diseases (e.g. arthritis, trauma, tendonitis, chondromalacia and
inflammation), as well as, in the diagnosis or treatment of various autoimmune
20 disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as
well as dwarfism, spinal deformation, and specific joint abnormalities as well as
chondrodysplasias ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis,
25 Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Alternatively,
the tissue distribution within various tissue carcinomas and tumor tissues, and
15 biological activity reflected by the binding and activation of the GAS promoter
element indicates that polynucleotides and polypeptides corresponding to this gene
are useful for the diagnosis and treatment of cancer and other proliferative disorders.

30 Expression in cellular sources marked by proliferating cells indicates that this
protein may play a role in the regulation of cellular division. Similarly, embryonic
20 development also involves decisions involving cell differentiation and/or apoptosis in
pattern formation. Thus this protein may also be involved in apoptosis or tissue
35 differentiation and could again be useful in cancer therapy. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

40 25 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:25 and may have been publicly available prior to conception of
45 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
30 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
50 formula of a-b, where a is any integer between 1 to 2065 of SEQ ID NO:25. b is an

integer of 15 to 2079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

In an additional embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: IQPSHAALLHCRSTFRKTECLDPW WVRRQLLGMA GIGGLQKMKAPHTGVLHLGSVWVFLGPFLG VGYTLTFNPL SGCMSTVRWLN SNITANRTLRSVCHVTPLHRSLS PHDGEYLRQMLLNSSSR AGEAGSWG Y (SEQ ID NO: 283). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 20. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 20.

This gene is expressed primarily in fetal liver, and, to a lesser extent, in a variety of fetal and other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, liver disorders and cancers (e.g., hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 139 as residues: Ser-67 to Tyr-75. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention: To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO:26, b is an integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The translation product of this gene shares sequence homology with human laminin B1 which is thought to be an important structural extracellular matrix component involved in cell migration and signalling, particularly in stimulating epithelial cell growth and differentiation (See, Genbank Accession No gill186837).

5

47

10

15

20

25

30

35

40

45

50

55

Preferred polypeptides of the invention comprise the following amino acid sequences: CSSPPGRLPWCWTAPRTLKGHGLISTLRLTAPLHLAWKMMLS RKALFVLLNTPVLFHALEGRFLFSKLCHHHTIQRTLTVPKFRSS (SEQ ID NO: 284), RSPTS RVQLLKRQSCPCQRNDLNEEPQHFTHYAIYDFIVKGSCFCNG HADQCIPVHGFRPVKAPGTFHMHVHGKCM (SEQ ID NO: 285), and/or HNTAG SHCQHCAPLYNDRPWEAADGKTGAPNECRTCKCNHADTCHFDVNVWEAS GNRSGGVCDDCQHNTGQYQRCCKPGFYRDLRRPFSAPDACKPCSCHPV GSAVLPANSVTFCDPNSNGDCPKPGVAGRRCDRCMVGYWGFGDYGCRP CDCAGSCDPITGDCISSHTDIDWYHEVPDFRPVHNKSEPAWEWEDAQGFSA L HSGKCECKEQT LGNAKAFCGMKYSYVLKIKILSAHDKGTHVEVNVKIK KVLKSTKLKIFRGKANIISRIMDGQ RMHLSNPQSWFGIPCSRT (SEQ ID NO: 286). Polynucleotides encoding these polypeptides are also provided.

Included in this invention as preferred domains are Laminin-type EGF-like (LE) domain signatures, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Laminins are the major noncollagenous components of basement membranes that mediate cell adhesion, growth migration, and differentiation. They are composed of distinct but related alpha, beta and gamma chains. The three chains form a cross-shaped molecule that consist of a long arm and three short globular arms. The long arm consists of a coiled coil structure contributed by all three chains and cross-linked by interchain disulfide bonds. Beside different types of globular domains each subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminal to that of the EGF-like module. It is known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the LE domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. A schematic representation of the topology of the four disulfide bonds in the LE domain is shown below.

30

5

84

10

5

[illegible]

15

10

20

'a': conserved aromatic residue

'G': conserved glycine (lower case = less conserved)

15 's': region similar to the EGF-like domain

25

'*': position of the pattern

30

20

In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of LE domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes. We derived a signature pattern for the LE domain which covers the C-terminal half of the repeat starting with the fourth conserved cysteine. The consensus pattern is as follows: C-x(1,2)-C-x(5)-G-x(2)-C-x(2)-C-x(3,4)-[FYW]-x(3,15)-C [All C's are involved in disulfide bonds]

40.

Preferred polypeptides of the invention comprise the following amino acid sequence: CDDCQIINTEGQYQCRCKPGFYRDLRRPFSAPDACKPC (SEQ ID NO: 287) and/or CPCKPGVAGRRCDRCMVGYWGFGDYGCRPCDCAGSC (SEQ ID NO: 288). Polynucleotides encoding these polypeptides are also provided.

45

Further preferred are polypeptides comprising the laminin-type EGF-like domains listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence encoded by this gene. The additional contiguous amino acid residues is N-terminal or C-terminal to the laminin-type EGF-

50

55

5 like domain. Alternatively, the additional contiguous amino acid residues is both N-
terminal and C-terminal to the laminin-type EGF-like domain, wherein the total N-
10 and C-terminal contiguous amino acid residues equal the specified number. The
above preferred polypeptide domain is characteristic of a signature specific to
5 Laminin proteins. Based on the sequence similarity, the translation product of this
gene is expected to share at least some biological activities with Laminin proteins.
15 Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in osteoblastic tissues and cell types,
including osteoblasts, osteoblastomas and osteoclastomas. Expression is also
20 abundant in vascular-pulmonary tissues such as lung, micro-vasculature, pulmonary,
endothelial and smooth muscle cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
25 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, cancer and malignancies (particularly of osteoblastic tissues and
15 rhabdomyosarcoma), as well as cardiovascular and respiratory or pulmonary disorders
such as athsma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stoke,
30 thrombosis hypertension, inflammation and wound healing. Similarly, polypeptides
and antibodies directed to these polypeptides are useful in providing immunological
20 probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the cardio-respiratory system,
35 and skeletal system expression of this gene at significantly higher or lower levels is
routinely detected in certain tissues or cell types (e.g., skeletal, osteoblast, cardio-
respiratory, vascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
40 25 pulmonary surfactant, serum, plasma, urine, synovial fluid and spinal fluid) or another
tissue or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
45 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
30 epitopes shown in SEQ ID NO: 140 as residues: Ser-28 to Cys-34, Thr-51 to Thr-58,
Tyr-64 to Asn-81, Asp-111 to Lys-116, Asp-145 to Phe-160, Pro-203 to Glu-217.

50 Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in osteoblastic tissues and cell types and homology to
laminin indicates that polynucleotides and polypeptides corresponding to this gene are
10 useful for the treatment, prevention and diagnosis of cardiovascular and respiratory or
pulmonary disorders such as asthma, pulmonary edema, pneumonia, atherosclerosis,
5 restenosis, stroke, angina, thrombosis hypertension, inflammation and wound healing.
As a homolog of laminin, this gene product quite possibly has a role in cell adhesion,
15 migration, proliferation, angiogenesis, chondrogenesis, wound healing and
oncogenesis. An EST (Int J Cancer 1996 May 16;66(4):571-577) with an identical
sequence to part of this contig was shown to be differentially expressed in human
20 primary myoblasts and embryonal rhabdomyosarcoma and therefore might have an
important role in the determination or maintenance of the normal phenotype, and thus
its loss is possibly involved in the progression of malignancies, particularly of skeletal
muscle. Similarly, the homology to a laminin would suggest a role in the detection
25 and treatment of disorders and conditions afflicting connective tissues (e.g. arthritis,
trauma, tendonitis, chondromalacia and inflammation) in the diagnosis or treatment of
various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and
dermatomyositis as well as dwarfism, spinal deformation, and specific joint
30 abnormalities as well as chondrodysplasias i.e. spondyloepiphyseal dysplasia
congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal
chondrodysplasia type Schmid. Furthermore, the protein may also be used to
determine biological activity, to raise antibodies, as tissue markers, to isolate cognate
35 ligands or receptors, to identify agents that modulate their interactions, in addition to
its use as a nutritional supplement. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the
40 above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:27 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 3365 of SEQ ID NO:27, b is an integer of 15 to 3379, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: NISSQYCILKSLEMMISGLKLLVFLKFPENY CLSTETLQMPNRHLRLSKATCYLMKCLLPYFE (SEQ ID NO: 289).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta, brain, and to a lesser extent, in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, behavioral, or nervous system disorders, such as: depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, dementia, paranoia, addictive behavior, epilepsy, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD). Other diseases and conditions related to expression in the placenta might include developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 141 as residues: Ala-16 to Leu-22. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions.

Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, expression in placenta would suggest a possible role in the treatment and diagnosis of developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders.

Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1992 of SEQ ID NO:28, b is an integer of 15 to 2006, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The translation product of this gene shares sequence homology with the murine transforming protein (See, e.g., Genbank Accession No. gi53529|emb|CAA36859.1); all references available through this accession are hereby incorporated by reference herein).

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PIEGTPAGTGPEFPGRPTRPQRMRSLSISHPQC HLLLLLLLLFLILAILVDVKWYLVLFICISLMTSDVEHLFMCLLAIRISSWR NVY (SEQ ID NO: 290). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in activated and basal T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in activated T-cells and the homology to a murine transforming protein indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3056 of SEQ ID NO:29, b is an

integer of 15 to 3070, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene was shown to have homology to the Mus musculus ALG-2 protein, which is known to code for a Ca(2+)-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-2 mediate Ca(2+)-regulated signals along the death pathway and may play a role in the onset of Alzheimer's Disease (See e.g., Genbank Accession No. gil1213520; all references available through this accession are hereby incorporated by reference herein).

Preferred polypeptides comprise the following amino acid sequence: NWVPTCLCPSAPCSFHLLSRFKCLFSPQRLTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV (SEQ ID NO: 291), and/or QRLTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV (SEQ ID NO: 292). Polynucleotides encoding these polypeptides are also provided.

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element). Thus, it is likely that this gene activates immune or leukemia cells through the Jaks-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MFYKLTLLCELSVAGVTQAASQRPLQRLPRHICSQRXPPGRCLLKAXLQTTWXXPKPI PRLSPPLXSDPKR (SEQ ID NO: 293). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

5 This gene is expressed primarily in placenta, and to a lesser extent, in a variety of other tissues and cell types.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 143 as residues: Arg-24 to Arg-31, Ile-33 to Gly-41. Polynucleotides encoding said polypeptides are also provided.

35 The tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention and/or diagnosis of developmental anomalies, fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells combined with the observed ISRE activity, and homology to the apoptosis linked, ALG-2 indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2213 of SEQ ID NO:30, b is an integer of 15 to 2227, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

5

59

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

10

15

20

25

30

35

40

45

50

55

The translation product of this gene was shown to have homology to the human histo-blood group A transferase (See, e.g., Genbank Accession No. gblAAD26573.1/AF134413_1 (AF134413); all references available through this accession are hereby incorporated by reference herein) which is known to represent one of the major allogeneic antigens in both erythrocytes and tissues of humans. It has been proposed that the A phenotype is associated with the glycosyltransferase that converts the H substance associated with the O phenotype to A through the addition of alpha1-3-N-acetylgalactosamine or alpha1-3-galactosyl residues to the H antigen Fuc-alpha1-2Gal- beta1-R. Therefore, the primary product of the histo-blood group A is its respective glycosyltransferase. Preferred polypeptides of the invention comprise the following amino acid sequence: TSSPVFSFCMAVREPDHLQ RVSLPRYNVSASLQWLPCHRIVLQPWHMCAMWELGQVLFHPVAPREGAAPS PVSTLTWPSSCSHSESTMELELQF (SEQ ID NO: 294), LPCHRIV (SEQ ID NO: 296), SLQWLPCHRIVLQPW (SEQ ID NO: 297), and/or MAVREPDHLQRVSLPR (SEQ ID NO: 295). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in 12-week-old human embryo. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, pre-natal disorders, hematopoietic disorders, or cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, lymph, developing, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in 12 week old embryo indicates that polynucleotides
and polypeptides corresponding to this gene are useful for the treatment and diagnosis
10 of developmental anomalies, fetal deficiencies, pre-natal disorders and cancer.
Similarly, expression within embryonic tissue and other cellular sources marked by
5 proliferating cells indicates that this protein may play a role in the regulation of
cellular division. Similarly, embryonic development also involves decisions involving
15 cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also
be involved in apoptosis or tissue differentiation and could again be useful in cancer
therapy. Alternatively, the tissue distribution and homology to human blood group A
20 and B glycosyltransferase enzymes indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and diagnosis of hematopoietic
related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or
leukemia since stromal cells are important in the production of cells of hematopoietic
25 lineages. Representative uses are described in the "Immune Activity" and "infectious
disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere
15 herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow
transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of
neoplasia.
30

The gene product may also be involved in lymphopoiesis, therefore, it can be
20 used in immune disorders such as infection, inflammation, allergy, immunodeficiency
etc. In addition, this gene product may have commercial utility in the expansion of
35 stem cells and committed progenitors of various blood lineages, and in the
differentiation and/or proliferation of various cell types. Furthermore, the protein may
also be used to determine biological activity, to raise antibodies, as tissue markers, to
40 isolate cognate ligands or receptors, to identify agents that modulate their interactions,
25 in addition to its use as a nutritional supplement. Protein, as well as, antibodies
directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.
45

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:31 and may have been publicly available prior to conception of
50 the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1274 of SEQ ID NO:31, b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The translation product of this gene shares sequence homology with CD97 (EMRI), which is thought to be important in both adhesion and signaling processes early after leukocyte activation (See, e.g., Genbank Accession No. gil784994; all references available through this accession are hereby incorporated by reference herein). EMRI belongs to a novel family of G-protein receptors that has recently been recognized on the basis of homologous primary amino acid sequences, comprises receptors to hormones of the secretin/vasoactive intestinal peptide/glucagon family, parathyroid hormone and parathyroid hormone-related peptides, growth hormone-releasing factor, corticotropin-releasing factor, and calcitonin. Proteins with seven transmembrane segments (7TM) define a superfamily of receptors (7TMreceptors) sharing the same topology: an extracellular N-terminus, three extramembranous loops on either side of the plasma membrane, and a cytoplasmic C-terminal tail. Upon ligand binding, cytoplasmic portions of the activated receptor interact with heterotrimeric G-coupled proteins to induce various second messengers, which subsequently activate various signal transduction pathways depending upon the specific G-coupled protein associated with the receptor. Preferred polypeptides of the invention comprise the following amino acid sequence: CFKRKPKREHCSCP
ITYQSLGDILNASFFSKRKGMEVKLNYSYVVS GTIGLKEKISLSEPVFLTRHN
QPGDKRTKHICVY WEGSEGGRWSTEGCSHVHNSGYTKCKCFHLSSFAVLV
ALAPKEDPVLTVITQVGLTISLLCLFLAILTFLLCRPIQNTSTSLHLELSLCLFLA
HLLFLTGINRTEPEVLCSSIIAGLLHFLYLACFTWMLLEGLHLFTVRNLKVAN
YTSTGRFKKRFMYPVGYGIPAVIIAVSAIVGPQNYGTFTHCWLKLDKGFIWSF
MGPVAVIILINLVFYFQVI.WILRSKLSSLNKEVSTIQDTRVMTFKAISQLFILGC
SWGLGFFMVEEVGKTIGSIIAYSFTIINTLQGVLLFVVHCLLNROVRMEYKKW

FSGMRKGVETESTEMSRSTTQTKTEEVGKSSEIFIKGGTASSSAESTKQPQPQ
 VHLVSAAWLKMN (SEQ ID NO: 298), and/or FFWKENLRRNGSREDFARRATQ
 LIQSVELSIWNASFASPGKGQISEFDIVYETKRCNETRENAFLEAGNNTMDINC
 ADALKGNLRESTAV ALSLINLLGIF SEQ ID NO: 299. Polynucleotides

encoding these polypeptides are also provided.

Included in this invention as preferred domains are two EGF-like protein domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). First, a sequence of about forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present in a large number of membrane-bound and extracellular, mostly animal proteins. Many of these proteins require calcium for their biological function and a calcium-binding site has been found to be located at the N-terminus of some EGF-like domains. Calcium-binding is crucial for numerous protein-protein interactions. We have used the N-terminal part of the EGF domain as a consensus pattern. It includes the negative N-terminus and the possible hydroxylation site. The consensus pattern is as follows: [DEQN].[DEQN]{2}.C.{3,14}.C.{3,7}.C.[DN].{4}[FY].C [The four C's are involved in disulfide bonds].

Preferred polypeptides of the invention comprise the following amino acid sequence: DINECETGLAKCKYKAYCRNKVGGYIC (SEQ ID NO: 300).

Polynucleotides encoding these polypeptides are also provided. Secondly, post-translational hydroxylation of aspartic acid or asparagine to form erythro-beta-hydroxyaspartic acid or erythro-beta-hydroxyasparagine has been identified in a number of proteins with domains homologous to (EGF). Based on sequence comparisons of the EGF-homology region that contains hydroxylated Asp or Asn, a consensus sequence located in the N-terminal of EGF-like domains has been identified that seems to be required by the hydroxylase(s). The consensus sequence is as follows: C.[DN].{4}[FY].C.C.

Preferred polypeptides of the invention comprise the following amino acid sequence: CRNKVGGYICSC (SEQ ID NO: 301). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the calcium-binding EGF-like domain and aspartic acid and asparagine hydroxylation site listed above, and at least

5 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the
sequence referenced in Table I for this gene and the embodiments listed herein. The
10 additional contiguous amino acid residues is N-terminal or C-terminal to one or both
of the listed domains. Alternatively, the additional contiguous amino acid residues is
5 both N-terminal and C-terminal to one or both of the listed domains, wherein the total
N- and C-terminal contiguous amino acid residues equal the specified number. The
15 above preferred polypeptide domains are characteristic of a signature specific to EGF-
like proteins. Based on the sequence similarity and conserved domains, The
translation product of this gene is expected to share at least some biological activities
10 with EGF-like proteins. Such activities are known in the art, some of which are
described elsewhere herein.

This gene is expressed primarily in eosinophils.

25 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, hematopoietic disorders or anemias and leukemias,
30 immunodeficiencies; infection, lymphomas, auto-immunities and cancer. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
20 a number of disorders of the above tissues or cells, particularly of the immune and
hematopoietic systems, expression of this gene at significantly higher or lower levels
35 is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, or
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,
synovial fluid and spinal fluid) or another tissue or cell sample taken from an
40 25 individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

45 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 145 as residues: Ser-22 to Ser-30, Pro-33 to Cys-48,
30 Asp-50 to Lys-67, Pro-117 to Ser-130. Polynucleotides encoding said polypeptides
are also provided.

5 The tissue distribution in eosinophils combined with its homology to a known
human seven transmembrane domain protein indicates that polynucleotides and
10 polypeptides corresponding to this gene are useful for the diagnosis and treatment of
cancer and other proliferative disorders, particularly considering the fact that the
5 majority of 7 transmembrane receptors are tightly associated with signal transduction
pathways which are integral to the modulation of the cell cycle. As such, the protein
15 product of this gene may play a role in the regulation of cellular division, where loss
of regulation may result in proliferating cells and the onset of tumors or cancer.
Additionally, the expression in hematopoietic cells and tissues indicates that this
20 protein may play a role in the proliferation, differentiation, and/or survival of
hematopoietic cell lineages. In such an event, this gene is useful in the treatment of
lymphoproliferative disorders, and in the maintenance and differentiation of various
hematopoietic lineages from early hematopoietic stem and committed progenitor
25 cells. Similarly, embryonic development also involves decisions involving cell
differentiation and/or apoptosis in pattern formation. Thus this protein may also be
15 involved in apoptosis or tissue differentiation and could again be useful in cancer
therapy. Similarly, the tissue distribution and homology to CD97 indicates that the
30 protein product of this gene might be a marker for differentiation and activation of
eosinophils, and therefore is useful for the diagnosis and treatment of immune
20 disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies
(e.g., AIDS), immuno-suppressive conditions (transplantation) and hematopoietic
35 disorders. Representative uses are described in the "Immune Activity" and "infectious
disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere
herein. In addition this gene product is applicable in conditions of general microbial
40 25 infection, inflammation or cancer. Furthermore, the protein may also be used to
determine biological activity, to raise antibodies, as tissue markers, to isolate cognate
ligands or receptors, to identify agents that modulate their interactions, in addition to
45 its use as a nutritional supplement. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the
30 above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3266 of SEQ ID NO:32, b is an integer of 15 to 3280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene has been found to have homology to the rat neural F box protein NFB42, in addition to a conserved *Caenorhabditis elegans* C14B1.3 protein (See, e.g., Genbank Accession Nos. gi13851648|gb|AAC97505.11 (AF098301) and gi1558270; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: ALCPPHLLNVTVPAPSCRHVK KVVASPPSTMIAMDAPHSKAALDSINELPENILLELFTHVPARQLLLNCRL VCSLWRDLIDMTLWKRKCLREGFITKDWDPVADWKIFYFLRSLHRNLLR NPCAEEDMFAWQIDFNGGDRWKVESLPGAHTDFDPKVKKYFVTSYEMCL KSQLVDLVAEGYWEELDTFRPDIVVKDWFAARADCGCTYQLKVQLASA DYFVLASFEPPTVTIQWNNATWTEVSYTFSDYPRGVRYILFQHGGRTQY WAGWYGPRVTNSSIVSPKMTRNQASSEAQPGQKHGQEEAAQSPYRAVV QIF (SEQ ID NO: 302). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune cells, especially primary dendritic cells, and T cells, and to a lesser extent in a variety of other tissues including breast, keratinocytes, epididymus (cauda), lung, multiple sclerosis, endometrial stromal cells, IL4 induced umbilical vein endothelial cells, fetal kidney, fetal dura mater, rejected kidney, and osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders, particularly of the immune system or endothelial cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 146 as residues: Pro-41 to Cys-47, Phe-52 to Gly-59, Pro-62 to His-70. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in T-cells indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

5 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
10 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
5 Disease, scleroderma and tissues. Moreover, the protein may represent a secreted
factor that influences the differentiation or behavior of other blood cells, or that
15 recruits hematopoietic cells to sites of injury. In addition, this gene product may have
commercial utility in the expansion of stem cells and committed progenitors of
various blood lineages, and in the differentiation and/or proliferation of various cell
20 types.

The secreted protein can also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
that modulate their interactions and as nutritional supplements. It may also have a
25 very wide range of biological activities although no evidence for any is provided in
the specification. Typical of these are cytokine, cell proliferation/differentiation
15 modulating activity or induction of other cytokines:
immunostimulating/immunosuppressant activities (e.g., for treating human
30 immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to
20 chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or
nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for
35 control of fertility); chemotactic and chemokinetic activities (e.g. for treating
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating
haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating
40 septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other
hyperproliferative disease; for regulation of metabolism, behaviour, and many others.
Also contemplated is the use of the corresponding nucleic acid in gene therapy
45 procedures. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
50 related to SEQ ID NO:33 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1283 of SEQ ID NO:33, b is an integer of 15 to 1297, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The translation product of this gene shares sequence homology with the human, mouse, and bovine dopamine hydroxylase which is thought to be important in the modification of dopamine, a neurotransmitter (See Genbank Accession Nos. gi130474, gi162965, and/or gi2358082; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: RQRSWNPGT
NCYHPNMPDAFLTCETVIFAWAIGGEGFSYPPHVGLSLGTPLDPHYVLEEVH
YDNPTYEEGLIDNSGLRLFYTM DIRKYDAGVIEAGLWVSLFHTIPPGMPEF
QSEGHCTLECLEEALEAEKPSGIHVFAVLLHAHLA GRGIRLRHFRKGKEMKL
LAYDDDFDNFQEFQYLKEEQTILPGDNLITECRYNTKDRAEMTWGGLSTR
SEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEIYRPVTTWPFIIKSPKQYK
NLSFMDAMNKF KWT KKEGLSFNKLVLSPVNVRC SKTDNAEWSIPRNSIT
SRYRKTL (SEQ ID NO: 303). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MCCWPLLLWGLLPGTAAGGSGRTYPHRTLLDSEK
YWLGSQRGSQIAFRLQV RTAGYVGFGFSPTGAMASADIVVGGVAHGR
PYLQDYFTNANRELKKDAQDYHLEYAMENSTHTIIEFTRELHTCDINDKS
ITDSTVRVIWAYHIE DAGEAGPKYHDSNRGTSRLRLNPEKTSVLSTALPYF
DLVNQDVPIPNKDTTYWCQMFKIPVFQEKHHVIKVEPVIQRGHESLVHHILL
YQCSNNFNDSPGIRARIAITPTCPMHSSPV KL (SEQ ID NO: 304).
Polynucleotides encoding these polypeptides are also provided.

5 This gene is expressed primarily in brain, the pulmonary system, and to a lesser extent in kidney.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological
20 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain
25 tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., sputum, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy
30 tissue or bodily fluid from an individual not having the disorder.

35 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 147 as residues: Ser-33 to Trp-38, Gly-40 to Gly-45, Asn-93 to Asp-105, Thr-128 to Thr-137, Glu-150 to Lys-167, Pro-197 to Tyr-203, Cys-242 to Asn-247, Ser-253 to Tyr-258, His-307 to Glu-314, Glu-357 to Gly-362,
40 Trp-373 to Gln-378, Ser-402 to Glu-408. Polynucleotides encoding said polypeptides are also provided.

45 The tissue distribution in brain and homology to a protein involved in the modification of dopamine indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of
50 neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of
55 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive

compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the homology to dopamine hydroxylase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2170 of SEQ ID NO:34, b is an integer of 15 to 2184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.

5 The Jak-STAT pathway is a large, signal transduction pathway involved in the
differentiation and proliferation of cells. Therefore, activation of the Jak-STAT
10 pathway, reflected by the binding of the GAS element, can be used to indicate
proteins involved in the proliferation and differentiation of cells. Thus, it is likely that
5 this gene activates T-cells through the JakStat signal transduction pathway.

15 This gene is expressed in a variety of human normal and diseased tissues
including breast, infant adrenal gland, skin tumor, colon, pituitary, Wilm's tumor, and
to a lesser extent in other tissues.

20 Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, breast cancer and other proliferative disorders, afflicting endocrine or
endothelial tissues. Similarly, polypeptides and antibodies directed to these
25 polypeptides are useful in providing immunological probes for differential
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the endocrine system or of breast and/or breast lymph
nodes, expression of this gene at significantly higher or lower levels is routinely
30 detected in certain tissues or cell types (e.g., reproductive, endocrine, or cancerous
and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial
20 fluid and spinal fluid) or another tissue or cell sample taken from an individual having
such a disorder, relative to the standard gene expression level, i.e., the expression
35 level in healthy tissue or bodily fluid from an individual not having the disorder.

40 The tissue distribution in breast, infant adrenal gland, skin tumor, colon,
pituitary, and Wilm's tumor, and biological activity in activating the GAS promoter
25 element indicates that polynucleotides and polypeptides corresponding to this gene
are useful for the detection, treatment, and/or prevention of various endocrine
disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and
disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex,
45 ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-,
30 hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and
testes. Alternatively, the tissue distribution and biological activity indicates that
50 polynucleotides and polypeptides corresponding to this gene are useful for the

diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells. (i.e., breast, skin and Wilin's tumors) indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antihodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 935 of SEQ ID NO:35, b is an integer of 15 to 949, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: TGTFWSPRSQRRGCCGRRAPRPEAMENGA-VYS PTTEEDPGPARGPSGLAAYFFMGRPLLLRRVLKGLQLLLSLLAFICEEVVSQ CTLCGGLYFFEFVSCSAFLLSLLILIVYCTPFYERVDTTKVKSDFYITLTGTCV FLLASIHVSTIIDRTSAEIAAIVFGFIASFMFLDFFITMLYEKRQESQLRKPENTT RAEALTEPLNA (SEQ ID NO: 305). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in dendritic cells, and to a lesser extent in melanocytes, fetal liver and spleen and several other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, and disorders of the hepatic and immune systems.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, hepatic, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 149 as residues: Phe-63 to Ser-75, Thr-97 to Ser-102, Glu-128 to Arg-143. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the diagnosis and treatment of a variety of
10 immune system disorders. Representative uses are described in the "Immune
Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,
5 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in
dendritic cells indicates a role in the regulation of the proliferation; survival;
15 differentiation; and/or activation of potentially all hematopoietic cell lineages,
including blood stem cells. This gene product is involved in the regulation of cytokine
production, antigen presentation, or other processes that may also suggest a usefulness
20 in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also used as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
25 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
15 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
30 lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, scleroderma and tissues. Moreover, the protein may represent a secreted
35 factor that influences the differentiation or behavior of other blood cells, or that
recruits hematopoietic cells to sites of injury. In addition, this gene product may have
commercial utility in the expansion of stem cells and committed progenitors of
various blood lineages, and in the differentiation and/or proliferation of various cell
40 25 types. Alternatively, the tissue distribution in fetal liver indicates that polynucleotides
and polypeptides corresponding to this gene are useful for the detection and treatment
of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver
45 metabolic diseases and conditions that are attributable to the differentiation of
hepatocyte progenitor cells). In addition the expression in fetus would suggest a
30 useful role for the protein product in developmental abnormalities, fetal deficiencies,
pre-natal disorders and various wound-healing models and/or tissue trauma.
50 Furthermore, the protein may also be used to determine biological activity, raise

antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3324 of SEQ ID NO:36, b is an integer of 15 to 3338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ASAPRVMRGLAGFPALSGLASVCLWATFSAQLPGPVAATSWTPAPLGC SAARS GPEKRLGTAAPGSAASLAQAGPGAPCRVLPVDPAPAALNVREPGWLGGFLFDGALLQVLLNFLRKSTDVLMDTREAESLEV E (SEQ ID NO: 306).

In another embodiment polypeptides of the invention comprise the following amino acid sequence: NKLHSFPVFLS QLLDRQLLHAPQTLTPHCGGSSRPGP SHPPWLLIQLPCVHVALWQMLRDFSDSRITPSTLTTQAAQTAAPAKDQESDIVGGEGILCDIAFLQEDHPLGVGGASAPSSRRELSRRGVHTQTLPEDGTLHGTPSSSFDCGIKYIISWPLAPGCDLPSLELSLVCKGVSSCMGFAAG (SEQ ID NO: 307). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in endothelial cells, lung, and fetal kidney, and to a lesser extent in epididymis, keratinocytes and cerebellum.

5 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
10 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, cardiovascular diseases involving endothelial cell disturbances such as
5 atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides
are useful in providing immunological probes for differential identification of the
15 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
particularly of the cardiovascular system, expression of this gene at significantly
higher or lower levels is routinely detected in certain tissues or cell types (e.g.,
20 cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
25 individual not having the disorder.

15 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 150 as residues: Arg-47 to Leu-54. Polynucleotides
encoding said polypeptides are also provided.

30 The tissue distribution in endothelial cells indicates that polynucleotides and
polypeptides corresponding to this gene are useful for diagnosing and treating
20 disorders of endothelial cells such as atherosclerosis, vasculitis, cardiovascular
disease, and emphysema. The secreted protein can also be used to determine
35 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify agents that modulate their interactions and as nutritional
supplements. The polypeptide may possess a wide range of undetected biological
40 25 activities. Typical of these are cytokine, cell proliferation/differentiation modulating
activity or induction of other cytokines; immunostimulating/immunosuppressant
activities (e.g., for treating human immunodeficiency virus infection, cancer,
45 autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for
treating anaemia or as adjunct to chemotherapy); stimulation of growth of
30 bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation
of follicle stimulating hormone (for control of fertility); chemotactic and
50 chemokinetic activities (e.g., for treating infections, tumours); haemostatic or

5 thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as
10 antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the
5 corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or
15 immunotherapy targets for the above listed tissues

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
10 related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
20 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 1549 of SEQ ID NO:37, b is an integer of 15 to 1563, where both a and b correspond to the positions of nucleotide
30 residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

20 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by
35 the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PGRPTRPTKNKVCVCLGMLFWAYPICVFIDSL
SCQPCLWSTGATSHFNSPTTSPLFTLFMPICALAPNPFT QLGKLLDDR (SEQ ID
40 NO: 308). Polynucleotides encoding these polypeptides are also provided.
25

This gene is expressed primarily in meningioma.

Therefore, polynucleotides and polypeptides of the invention are useful as
45 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, tumors or disorders of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
50 immunological probes for differential identification of the tissue(s) or cell type(s). For

5 a number of disorders of the above tissues or cells, particularly of the central nervous
system, expression of this gene at significantly higher or lower levels is routinely
10 detected in certain tissues or cell types (e.g., neural, or cancerous and wounded
tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal
5 fluid) or another tissue or cell sample taken from an individual having such a disorder,
relative to the standard gene expression level, i.e., the expression level in healthy
15 tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 151 as residues: His-29 to Thr-34. Polynucleotides
20 encoding said polypeptides are also provided.

The tissue distribution in meningioma indicates polynucleotides and
polypeptides corresponding to this gene are useful for the detection, treatment, and/or
prevention of neurodegenerative disease states, behavioral disorders, or inflammatory
25 conditions. Representative uses are described in the "Regeneration" and
15 "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and
elsewhere herein. Briefly, the uses include, but are not limited to the detection,
treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
30 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
20 cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
35 learning disabilities, ALS, psychoses, autism, and altered behaviors, including
disorders in feeding, sleep patterns, balance, and perception, as well as disorders of
the meninges such as meningioma and meningitis. In addition, the gene or gene
40 25 product may also play a role in the treatment and/or detection of developmental
disorders associated with the developing embryo, sexually-linked disorders, or
disorders of the cardiovascular system. Furthermore, the protein may also be used to
45 determine biological activity, to raise antibodies, as tissue markers, to isolate cognate
ligands or receptors, to identify agents that modulate their interactions, in addition to
30 its use as a nutritional supplement. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the
50 above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:38, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene has been shown to encode a human brain specific mitochondrial carrier (Genbank Accession No. gi13851540|gb|AAD04346.1| (AF078544); all references available through this accession are hereby incorporated herein by reference) which shares sequence homology with the human body weight disorder associated gene C5 product which is known to be differentially expressed in obese compared to lean mice (See GeneSeq Accession No. R91281). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with mitochondrial carriers proteins. Such activities are known in the art, some of which are described in Sanchis et al, J. Biol. Chem. 273:34611-34615 (1998), incorporated herein by reference.

Included in this invention as preferred domains are mitochondrial energy transfer protein (METP) domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Structurally, members of the family of mitochondrial energy transfer proteins consist of three tandem repeats of a domain of approximately one hundred residues. Each of these domains contains two transmembrane regions. As a signature pattern, we selected one of the most conserved regions in the repeated domain, located just after the first transmembrane region. To detect this widespread family of proteins, a consensus sequence was developed that contains the most conserved regions in the repeated domain. The consensus pattern is as follows: P.[DE].[LIVAT].[RK].[LRH].[LIVMFY].[QMAIGV].

Preferred polypeptides of the invention comprise the following amino acid sequences: PVDLTCTRLQ (SEQ ID NO: 309) and PTDVLKIRMQ (SEQ ID NO: 310). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the METP domains of the sequence listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C-terminal to the METP domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the METP domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to mitochondrial energy transfer proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome X. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome X.

This gene is expressed primarily in brain, and to a lesser extent, in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders and immune disorders and/or obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive, immune, and nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 152 as residues: Gln-189 to Gly-195. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain and homology to mitochondrial carrier proteins indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1416 of SEQ ID NO:39, b is an integer of 15 to 1430, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

Preferred polypeptides of the invention comprise the following amino acid sequence: MTFGSTISPTSTHASPGLGCCSWLLEDLEEQLYCSAFEEAALTR
RICNPTSCWLPDMEELLHRQVLALQTRVLLGMWLRRAWDTWVSPRRVAP
GSRCLLTASHPCTEKRRKASAXQRNLGYPLAMLCLLVLTGLSVLIVAIHILEL
10 LIDEAAMPGRMQGTSLGQVSFSLGSGFAGVIQVVLIFYLMVSSVVGFFYSPLF
RSLRPRWHDAMTQIIGNCVCLLVSSALPVFSKTLGLTRFDLLGDFGRFNWL
GNFYIVFLYNAAFAGLTTLCLVKTFATAAVRAELIRAFGLDRLPLPVSGFPQAS
RKTQHQ (SEQ ID NO: 311). Polynucleotides encoding such polypeptides are also provided.

15 This gene is expressed primarily in immune system tissues (e.g. resting T-cells, primary dendritic cells, and neutrophils, apoptotic T-cells) and umbilical vein. This gene is expressed to a lesser extent in the gastrointestinal tissue (e.g. small intestine, colon), brain (e.g. cerebellum, frontal cortex), aorta endothelial cells, skin tumor, embryonic tissue, thymus, and cancers (e.g. cheek, breast, synovial).

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for
40 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and gastrointestinal tract expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and
45 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
50
55

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 153 as residues: Asp-21 to Ser-29. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells (e.g. T-cells, dendritic cells, neutrophils) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in skin tumors and cancerous tissue (e.g. cheek, breast, synovial sarcoma) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression in cellular sources such as embryonic tissue marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the

expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution in cerebellum and frontal cortex indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.


Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2089 of SEQ ID NO:40, b is an integer of 15 to 2103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The polypeptide of this gene has been determined to have a zinc finger (Zinc finger, C2H2 type) domain at about amino acid position 16-50 of the amino acid sequence referenced in Table 1 for this gene. Therefore,

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: LCVCLVYLCMYGVCLCVIVCVSGVSLCLYVWGVSVCDVCVSVFMCVCLCVIFCVYGVKPRTEHYHSPHLAKQKAFREMCGRHDVSAAGIFQSYV (SEQ ID NO: 312). Polynucleotides encoding these polypeptides are also provided. 'Zinc finger' domains are nucleic acid-binding protein structures first identified in the *Xenopus* transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides. A schematic representation of a zinc finger domain is shown below:



Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc-dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains is present.

This gene is expressed primarily in salivary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, salivary gland related diseases, diseases of the mouth, and other digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., saliva, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 154 as residues: Gly-46 to His-54. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of salivary gland related diseases (mumps, calculi formation in ducts, sarcoidosis, facial palsy, tumors, Sjogrens Syndrome) and other digestive system disorders. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2335 of SEQ ID NO:41, b is an integer of 15 to 2349, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

This gene is expressed primarily in fetal tissue (e.g. spleen, liver, brain), cancerous tissues (e.g. ovarian, colon, stomach, parathyroid) and to a lesser extent in immune cells and tissue (e.g. B-cells, T-cells, bone marrow), and reproductive organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, particularly of the colon and ovaries, disorders of the developing fetus, neurodegenerative conditions, and immune system disorders.

5
10
15
20
25
30
35
40
45
50
55

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 155 as residues: Lys-35 to Lys-47. Polynucleotides encoding said polypeptides are also provided.

15 The expression of this gene within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

20
25
30
35
40
45
50
55

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in

modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (such as T-cells and B-cells) and immune tissues (bone marrow) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in parathyroid indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for

the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Additionally, the tissue distribution in brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1545 of SEQ ID NO:42, b is an integer of 15 to 1559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in skin tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders, particularly skin cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 156 as residues: Pro-38 to Gly-44, Phe-56 to Thr-64. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in skin indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment, diagnosis, and/or prevention
10 of various skin disorders including congenital disorders (i.e. nevi, moles, freckles,
Mongolian spots, hemangiomas, port-wine syndrome); integumentary tumors (i.e.
5 keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma,
malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma),
injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder,
15 psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune
disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma,
20 pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and
xanthelasma. Moreover, such disorders may predispose increased susceptibility to
viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox,
25 molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea,
athletes foot, and ringworm). Protein, as well as, antibodies directed against the
15 protein may show utility as a tumor marker and immunotherapy targets for the above
listed tumors and tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:43 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
35 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1752 of SEQ ID NO:43, b is an
40 25 integer of 15 to 1766, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 34

30 The translation product of this gene shares sequence homology with mitogen-
induced prostate carcinoma (mouse) which is thought to be important in the etiology
of cancer. In this respect, this gene is mitogen-induced and/or involved in cell
50 proliferation.

Preferred polypeptides of the invention comprise the following amino acid sequence: GHMPYGWLTEIRAVYPAFDKNNPSNKLVSTNTVTAAHIKKF
TFVCMALSLTLCFVMFWTPNVSEKILIDIGVDFAEALCVVPLRIFSFFPVPVT
VRAHLTGWMLTLKKTFFVLAPSSVLRIVLIASLVVLPYLGVHGATLGVGSLLA
GFVGESTMVAIAACYVYRKQKKKMENESATEGEDSAMTDMPPTEEVTDIVE
MREENE (SEQ ID NO: 313) and/or QVVFVAILLHSHLECREPLLIPILSLYMGALVRCCTLCLGYYKNIHDIIPDRSGPELGGDATIRKMLSFWWPLALILATQRISR
PIVNLFVSRDLGGSSAATEAVAILTATYPV (SEQ ID NO: 314). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in early infant and adult brain, retina, fetal tissue (e.g., liver, spleen, whole embryo) and to a lesser extent in immune cells (e.g., monocytes and T-cells), colon, and parathyroid tumor tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, disorders of the immune system and nervous system.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system (cancers), expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 157 as residues: Arg-122 to Ser-139, Met-144 to Glu-149. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution and homology to mitogen induced prostate carcinoma
(mouse) indicates that polynucleotides and polypeptides corresponding to this gene
10 are useful for the study and treatment of cancers, including but not limited to the
colon, parathyroid, and adrenal glands. Moreover, the expression within fetal tissue,
5 and other cellular sources marked by proliferating cells indicates this protein may
play a role in the regulation of cellular division, and may show utility in the diagnosis,
15 treatment, and/or prevention of developmental diseases and disorders, including
cancer, and other proliferative conditions. Representative uses are described in the
"Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere
20 herein. Briefly, developmental tissues rely on decisions involving cell differentiation
and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
25 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
15 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
30 polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
35 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
40 modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
25 insight into the regulation of cellular growth and proliferation. The tissue distribution
in immune cells (T-cells, monocytes) indicates polynucleotides and polypeptides
45 corresponding to this gene are useful for the diagnosis and treatment of a variety of
immune system disorders. Representative uses are described in the "Immune
30 Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,
20, and 27, and elsewhere herein. Briefly, the expression of this gene product
50 indicates a role in regulating the proliferation; survival; differentiation; and/or

5 activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
10 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

5 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
15 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
20 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
25 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
30 in the differentiation and/or proliferation of various cell types. The tissue distribution
in brain indicates polynucleotides and polypeptides corresponding to this gene are
useful for the detection, treatment, and/or prevention of neurodegenerative disease
35 states, behavioral disorders, or inflammatory conditions. Representative uses are
described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in
Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not
limited to the detection, treatment, and/or prevention of Alzheimer's Disease,
40 Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,
encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,
congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms,
hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
45 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,
and altered behaviors, including disorders in feeding, sleep patterns, balance, and
30 perception. In addition, elevated expression of this gene product in regions of the
50 brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2558 of SEQ ID NO:44, b is an integer of 15 to 2572, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

This gene is expressed primarily in adult pulmonary tissue, umbilical vein, prostate, and fetal tissue (e.g., heart).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the pulmonary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 158 as residues: Arg-45 to Gly-51, Glu-75 to Asn-81.

Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pulmonary tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. Additionally, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene is involved in the regulation of cell division, particularly since it is expressed in fetal tissue. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in

proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 512 of SEQ ID NO:45, b is an integer of 15 to 526, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene is expressed primarily in adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fat metabolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 159 as residues: Pro-96 to Ser-106. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Furthermore, the protein product of this gene may show utility in ameliorating conditions which occur secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1018 of SEQ ID NO:46, b is an integer of 15 to 1032, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 37

This gene is expressed primarily in adult brain tissue, testes, placenta, kidney, infant and fetal tissue (e.g., liver, spleen, lung) and to a lesser extent in immune cells (e.g., T-cells and neutrophils) and in cancerous tissues (e.g., ovarian tumor, Hodgkins lymphoma, pancreas, T-cell).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, CNS disorders, disorders of the testicles, cancer, particularly ovarian, pancreatic, T-cell, and Hodgekin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, CNS, and testes expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, urogenital, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"

5 and "Regeneration" sections below and elsewhere herein. Briefly, developmental
tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
10 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
5 death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
15 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
20 also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
25 differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
15 modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. The tissue distribution
30 indicates polynucleotides and polypeptides corresponding to this gene are useful for
the diagnosis and treatment of a variety of immune system disorders. Representative
20 uses are described in the "Immune Activity" and "infectious disease" sections below,
in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the
expression of this gene product indicates a role in regulating the proliferation;
35 survival; differentiation; and/or activation of hematopoietic cell lineages, including
blood stem cells. This gene product is involved in the regulation of cytokine
40 production, antigen presentation, or other processes suggesting a usefulness in the
treatment of cancer (e.g. by boosting immune responses).

45 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
30 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
50 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

5 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
10 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
5 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
15 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
in the differentiation and/or proliferation of various cell types. Additionally, the
20 tissue distribution in testes indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and diagnosis of conditions
concerning proper testicular function (e.g. endocrine function, sperm maturation), as
well as cancer. Therefore, this gene product is useful in the treatment of male
25 infertility and/or impotence. This gene product is also useful in assays designed to
15 identify binding agents, as such agents (antagonists) are useful as male contraceptive
agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis
of testicular cancer. The testes are also a site of active gene expression of transcripts
30 that is expressed, particularly at low levels, in other tissues of the body. Therefore,
this gene product is expressed in other specific tissues or organs where it may play
20 related functional roles in other processes, such as hematopoiesis, inflammation, bone
formation, and kidney function, to name a few possible target indications.
35 Furthermore, the protein may also be used to determine biological activity, raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
that modulate their interactions, in addition to its use as a nutritional supplement.
40 25 Protein, as well as, antibodies directed against the protein may show utility as a tumor
marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
45 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:47 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
50 cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2666 of SEQ ID NO:47, b is an integer of 15 to 2680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in endometrial stromal cells; endometrial tumors, keratinocytes, fetal tissue (e.g. liver, spleen) and to a lesser extent in endothelial cells and immune cells (e.g., T-cells).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometrial carcinoma and immune cells disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be

transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium. Additionally, polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of endometrial carcinoma. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. The tissue distribution in immune cells such as helper T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
in the differentiation and/or proliferation of various cell types. The tissue distribution
in keratinocytes indicates polynucleotides and polypeptides corresponding to this
gene are useful for the treatment, diagnosis, and/or prevention of various skin
disorders. Representative uses are described in the "Biological Activity",
"Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections
below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful
in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles,
freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary
tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell
carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's
sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat
disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity,
autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea,
scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae,
purpura, and xanthelasma. In addition, such disorders may predispose increased
susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts,
chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas,
impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this
gene may also be useful for the treatment or diagnosis of various connective tissue
disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.),
autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma,
dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and

5 chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial
osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).
10 Furthermore, the protein may also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
5 that modulate their interactions, in addition to its use as a nutritional supplement.
Protein, as well as, antibodies directed against the protein may show utility as a tumor
15 marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 10 related to SEQ ID NO:48 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 1716 of SEQ ID NO:48, b is an
integer of 15 to 1730, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.
30

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

20 This gene is expressed primarily in LNCAP cells (prostate cell line) and retina
35 derived N2b5HR cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
40 25 not limited to, prostate cancer and eye disorders. Similarly, polypeptides and,
antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the male urogenital and
45 reproductive system expression of this gene at significantly higher or lower levels is
30 routinely detected in certain tissues or cell types (e.g., cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or
50 another tissue or cell sample taken from an individual having such a disorder, relative

5 to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 162 as residues: Asn-50 to Ser-57. Polynucleotides encoding said polypeptides are also provided.

15 The expression in prostate may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas,
20 ductal carcinomas, squamous cell carcinomas; or as hormones or factors with systemic or reproductive functions. The tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness,
25 impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma, retinchoroiditis, retinopathy and retinoschisis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,
30 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
40 25 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1261 of SEQ ID NO:49, b is an
45 integer of 15 to 1275, where both a and b correspond to the positions of nucleotide
30 residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: RCCCRGCSRARLCPPARSTAVAPECRGAHPSR
AMRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRRGTQRPCYKVIYFHD
TSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 315).

Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRRGG
TQRPCYKVIYFHDTSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 316). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and human thyroid and to a lesser extent in amniotic cells and human endometrial stromal cells-treated with progesterone.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, thyroid disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 163 as residues: Ser-75 to Leu-81. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of endocrine
10 disorders of the thyroid.

Many polynucleotide sequences, such as EST sequences, are publicly
5 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:50 and may have been publicly available prior to conception of
15 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 10 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1748 of SEQ ID NO:50, b is an
integer of 15 to 1762, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

This gene is expressed primarily in human testes tumor and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as
30 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, disorders of the testicles including but not limited to testicular
35 cancer and immune system disorders. Similarly, polypeptides and antibodies directed
to these polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the male reproductive system and immune system
40 25 expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, immune, cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or
45 another tissue or cell sample taken from an individual having such a disorder, relative
to the standard gene expression level, i.e., the expression level in healthy tissue or
30 bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 164 as residues: His-31 to Gly-41. Polynucleotides
10 encoding said polypeptides are also provided.

15 The tissue distribution in testes, particularly testicular tumors, indicates that
5 polynucleotides and polypeptides corresponding to this gene are useful for the
treatment and diagnosis of conditions concerning proper testicular function (e.g.
endocrine function, sperm maturation), as well as cancer. Therefore, this gene product
is useful in the treatment of male infertility and/or impotence. This gene product is
also useful in assays designed to identify binding agents, as such agents (antagonists)
20 are useful as male contraceptive agents. Similarly, the protein is believed to be useful
in the treatment and/or diagnosis of testicular cancer. The testes are also a site of
active gene expression of transcripts that is expressed, particularly at low levels, in
other tissues of the body. Therefore, this gene product is expressed in other specific
25 tissues or organs where it may play related functional roles in other processes, such as
hematopoiesis, inflammation, bone formation, and kidney function, to name a few
possible target indications. The tissue distribution in bone marrow indicates
30 polynucleotides and polypeptides corresponding to this gene are useful for the
diagnosis and treatment of a variety of immune system disorders. Representative uses
are described in the "Immune Activity" and "infectious disease" sections below, in
25 Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the
expression of this gene product indicates a role in regulating the proliferation;
35 survival; differentiation; and/or activation of hematopoietic cell lineages, including
blood stem cells. This gene product is involved in the regulation of cytokine
production, antigen presentation, or other processes suggesting a usefulness in the
40 treatment of cancer (e.g. by boosting immune responses).

45 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
30 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
50 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2045 of SEQ ID NO:51, b is an integer of 15 to 2059, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

The translation product of this gene shares sequence homology with protocadherins, which are related to cadherin, and possess cell adhesive ability. Cadherins are glycosylated integral membrane proteins that are involved in cell-cell adhesion.

This gene is expressed primarily in brain (infant, adult frontal lobe, manic depression tissue) and to a lesser extent in epididymus, healing groin wounds, ovary, adipocytes, and fetal tissue (e.g., kidney and retina).

5 Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
15 not limited to, neurodegenerative disorders, impaired male and female fertility,
developmental disorders, fibrosis, and manic depression. Similarly, polypeptides and
20 antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the nervous system and
25 reproductive system expression of this gene at significantly higher or lower levels is
routinely detected in certain tissues or cell types (e.g., neural, reproductive, cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and
spinal fluid) or another tissue or cell sample taken from an individual having such a
disorder, relative to the standard gene expression level, i.e., the expression level in
30 healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 165 as residues: Val-35 to Lys-41, Ser-68 to Gln-73,
Glu-88 to Glu-93, Arg-156 to Gly-163, Ala-199 to Gly-206, Asp-216 to Ser-226, Thr-
30 249 to Asn-254, Asp-339 to Pro-345, Ile-370 to Gly-379, Pro-429 to Glu-434, Arg-
461 to Pro-466, Ala-475 to Thr-482, Pro-585 to Gly-593, Glu-631 to Gln-639, Pro-
20 674 to Pro-682, Gln-715 to Gly-720, Ser-736 to Arg-742. Polynucleotides encoding
said polypeptides are also provided.

35 BLAST analysis reveals high homology to protocadherin sequences. These
sequences are related to cadherin, and possess cell adhesive ability. Such proteins
may have regulatory functions in the cell, as well as the cell-cell adhesive properties.
40 Antibodies produced against these sequences are useful for modulating the binding
activity of these protocadherins, and can be used therapeutically. The tissue
25 distribution in brain indicates polynucleotides and polypeptides corresponding to this
gene are useful for the detection, treatment, and/or prevention of neurodegenerative
45 disease states, behavioral disorders, or inflammatory conditions. Representative uses
are described in the "Regeneration" and "Hyperproliferative Disorders" sections
30 below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but
are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease,
50
55

5 Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,
encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,
10 congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms,
hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
5 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,
and altered behaviors, including disorders in feeding, sleep patterns, balance, and
15 perception. In addition, elevated expression of this gene product in regions of the
brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,
10 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. The tissue distribution in epididymus indicates that polynucleotides and
polypeptides corresponding to this gene are useful for the treatment and diagnosis of
20 conditions concerning proper testicular function (e.g. endocrine function, sperm
maturation), as well as cancer. Therefore, this gene product is useful in the treatment
25 of male infertility and/or impotence. This gene product is also useful in assays
designed to identify binding agents, as such agents (antagonists) are useful as male
contraceptive agents. Similarly, the protein is believed to be useful in the treatment
30 and/or diagnosis of testicular cancer. The testes are also a site of active gene
expression of transcripts that is expressed, particularly at low levels, in other tissues
20 of the body. Therefore, this gene product is expressed in other specific tissues or
organs where it may play related functional roles in other processes, such as
35 hematopoiesis, inflammation, bone formation, and kidney function, to name a few
possible target indications. Moreover, the expression within fetal tissue (e.g., kidney
and retina) and other cellular sources marked by proliferating cells indicates this
40 protein may play a role in the regulation of cellular division, and may show utility in
the diagnosis, treatment, and/or prevention of developmental diseases and disorders,
45 including blindness, cancer, and other proliferative conditions. Representative uses
are described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and elsewhere herein. Briefly, developmental tissues rely on decisions
30 involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
50 death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions; in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3268 of SEQ ID NO:52, b is an integer of 15 to 3282, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 43

Preferred polypeptides of the invention comprise the following amino acid sequence:

IRHEQQGEEDDEHARPLAESLLLAIDLLFCPDFTVQSHRRSTVDSAEDVHSL
DSCEYIWEAGVGFAHSPQPNYIHDMMRMELLKLLTCFSEAMYLPPAPESGS
TNPWVQFFCSTENRHALLFTSLLNTVCAYPDVGYGIPYNHLLFSDYREPLVE
EAAQVLIVTLDHDSASSASPTVDGTTTGTAMDDADPPGPENLFVNYLSRIHRE
EDFQFILKGIARLLSNPLLQTYLPNSTKKDPVPPGAASSLLEALRLQEIPLLRA
EEQRRPRIIPCPHLLPQRCPPGRSV (SEQ ID NO: 317). Polynucleotides encoding
such polypeptides are also provided.

This gene is expressed primarily in brain, breast, breast cancer tissue and to a lesser extent in epididymus, amniotic cells, and embryo tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, impaired CNS function, male sterility, and breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, male reproductive, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 166 as residues: Pro-22 to Pro-31, Ser-38 to His-43, Asp-74 to Leu-79, Asp-113 to Glu-121, Leu-157 to Val-166, Ala-189 to Arg-196, Gin-206 to Arg-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the cerebellum, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11.

5 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the
detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
10 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
5 cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
15 learning disabilities, ALS, psychoses, autism, and altered behaviors, including
disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
expression of this gene product in regions of the brain indicates it plays a role in
20 normal neural function.

Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. The tissue distribution in epididymus indicates that polynucleotides and
25 polypeptides corresponding to this gene are useful for the treatment and diagnosis of
15 conditions concerning proper testicular function (e.g. endocrine function, sperm
maturation), as well as cancer. Therefore, this gene product is useful in the treatment
of male infertility and/or impotence. This gene product is also useful in assays
30 designed to identify binding agents, as such agents (antagonists) are useful as male
contraceptive agents. Similarly, the protein is believed to be useful in the treatment
20 and/or diagnosis of testicular cancer. The testes are also a site of active gene
expression of transcripts that is expressed, particularly at low levels, in other tissues
35 of the body. Therefore, this gene product is expressed in other specific tissues or
organs where it may play related functional roles in other processes, such as
hematopoiesis, inflammation, bone formation, and kidney function, to name a few
40 25 possible target indications. The expression in the breast tissue may indicate its uses in
the diagnosis and/or treatment of breast neoplasia and breast cancers, such as
fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's Disease, medullary
45 carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and
apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and
30 abscess, duct ectasia, fat necrosis and fibrocystic diseases. Moreover, the expression
within embryonic tissue and other cellular sources marked by proliferating cells
50 indicates this protein may play a role in the regulation of cellular division, and may

show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:53, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

Contact of cells with supernatant expressing the product of this gene increases the permeability of monocytes to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells.

This gene is expressed primarily in CD34 positive cells derived from human cord blood.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; defects in hematopoietic stem and progenitor cells; susceptibility to chemotherapy and irradiation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 167 as residues: Ala-38 to Leu-59, Ala-63 to Thr-71, Lys-82 to Leu-91, Glu-97 to Ser-107, Gln-143 to Ala-149, Ile-153 to Leu-158, Ser-169 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

5
10
15
20
25
30
35
40
45
50
55

Elevated expression of this gene product in CD34 positive hematopoietic cells indicates that it is expressed by early stem and progenitor cells of the hematopoietic lineages. Therefore, this may represent a soluble factor that is able to control the survival, proliferation, differentiation, or activation of all hematopoietic lineages, including stem and progenitor cells. Thus, it could be quite useful, for example, in ex vivo expansion of stem cell numbers for hematopoietic disorders or for cancer patients. Alternately, it may represent a factor that influences the hematopoietic microenvironment by affecting stromal cells that release other factors required for hematopoietic development. Additionally, the tissue distribution in CD34 positive cells also indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis; therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:54, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

This gene is expressed primarily in breast and 12-week old human embryos and to a lesser extent in stomach cancer and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer; stomach cancer; embryonic defects; hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene product in stomach cancer indicates it is useful as a marker or therapeutic target for stomach cancer. Alternately, expression in breast tissue is influenced by the presence or absence of breast cancer tissue, and may thus also serve as a diagnostic marker for this cancer as well. Expression in the developing embryo may correlate with the normal development of human embryos, and expression in the liver is involved in the regulation of normal liver function and/or liver regeneration.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1079 of SEQ ID NO:55, b is an integer of 15 to 1093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in human hypothalamus derived from a patient with schizophrenia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, schizophrenia; neurological disorders; impaired nervous system function. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 169 as residues: Glu-34 to Trp-39. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the hypothalamus, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal

cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 618 of SEQ ID NO:56, b is an integer of 15 to 632, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The translation product of this gene shares sequence homology with human lecithin-cholesterol acyltransferase (LCAT), which catalyses the transfer of fatty acid from the sn-2 position of lecithin to the free hydroxyl group of cholesterol. Preferred polypeptides of the invention comprise the following amino acid sequence: RLVYN
KTSRATQFPDGVDRVPFGKTFSLFLDPSKSSVGSYFHTMVESLVGWGYT
RGEDVRGAPYDWRRAPNENGPYFLALREMIEMYQLYGGPVVLVAHSMGN
MYTLYFLQRQPQAWKDKYIRAFVSLGAPWGGVAKTLRLVLSGDNNRIPVIG

5 PLKIREQQRS AVSTSWLLPYN YTWSP EKVFVQTPTIN YTLRDYRKFFQDIGFE
10 DGWLMRQDTEGLVEATMPPGVQLHCLYGTGVPTPDSFYYESFPDRDPKICFG
DGDGT VNLKSALQCQAWQSRQEHQVLLQELPGSEHIEMLANATTLAYLKRV
LLGP (SEQ ID NO: 318). Polynucleotides encoding such polypeptides are also
5 provided.

15 This gene is expressed primarily in osteoblasts & dendritic cells and to a lesser extent in muscle and other hematopoietic cell lineages.

Therefore, polynucleotides and polypeptides of the invention are useful as
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; osteoporosis;
osteopetrosis; muscle degeneration. Similarly, polypeptides and antibodies directed to
25 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
15 tissues or cells, particularly of the skeletal and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
30 urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,
20 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 170 as residues: Cys-65 to Ser-71. Polynucleotides encoding said polypeptides are also provided.

40 25 The tissue distribution and homology to lecithin-cholesterol acyltransferase (LCAT) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. For example,
45 atherosclerosis is a pathological condition of mammals characterised by the accumulation of cholesterol in the arteries, which leads to heart disease, strokes, heart
30 attacks and peripheral vascular disease. The enzyme could be used in a novel method of treating atherosclerosis, which involves increasing the level of LCAT activity,
50 which then causes a decrease in the accumulation of cholesterol. The method and the

5 products can be used for the prophylaxis and treatment of atherosclerosis, and
associated heart disease, myocardial infarction, stroke and peripheral vascular disease,
10 as well as individuals suffering from Fish Eye Syndrome (caused by LCAT
deficiency) or Classic LCAT Deficiency Syndrome. Alternately, elevated expression
5 of this gene product in osteoblasts and hematopoietic cell lineages indicates that it
may play additional roles in bone turnover, regulation of immune system function,
15 and muscular function.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO:57 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 2673 of SEQ ID NO:57, b is an
integer of 15 to 2687, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 48

20 When tested against HELA epithelial cell lines, supernatants removed from
cells containing this gene activated the GAS assay. Thus, it is likely that this gene
35 activates epithelial cells through the Jak-STAT signal transduction pathway. The
gamma activating sequence (GAS) is a promoter element found upstream of many
genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a
40 large, signal transduction pathway involved in the differentiation and proliferation of
25 cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the
GAS element, can be used to indicate proteins involved in the proliferation and
45 differentiation of cells.

This gene is expressed primarily in adult brain, infant brain, fibroblasts,
30 embryonic and fetal tissue (e.g., spleen, liver), placenta and to a lesser extent in
endocrine organs, cancerous colon and breast.

5 Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
15 not limited to, dementia, epilepsy, schizophrenia, and developmental abnormalities.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
20 providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
neural system, endocrine system, and during development, expression of this gene at
25 significantly higher or lower levels is routinely detected in certain tissues or cell types
(e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

15 The tissue distribution in brain indicates polynucleotides and polypeptides
corresponding to this gene are useful for the detection, treatment, and/or prevention of
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.
30 Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
the uses include, but are not limited to the detection, treatment, and/or prevention of
35 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
40 compulsive disorder, depression, panic disorder, learning disabilities, ALS,
25 psychoses, autism, and altered behaviors, including disorders in feeding, sleep
patterns, balance, and perception. In addition, elevated expression of this gene product
in regions of the brain indicates it plays a role in normal neural function.

45 Potentially, this gene product is involved in synapse formation,
30 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. In addition, the expression of this gene product in synovium (synovial
50 sarcoma) would suggest a role in the detection and treatment of disorders and

5 conditions afflicting the skeletal system, in particular osteoporosis, bone cancer,
connective tissue disorders (e.g. arthritis, trauma, tendonitis, chondromalacia and
10 inflammation). The protein is also useful in the diagnosis or treatment of various
autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and
5 dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and
chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial
15 osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid,
etc.). The tissue distribution in endocrine tissues indicates polynucleotides and
polypeptides corresponding to this gene are useful for the detection, treatment, and/or
20 prevention of various endocrine disorders and cancers. Representative uses are
described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding
Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein.
Briefly, the protein can be used for the detection, treatment, and/or prevention of
25 Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the
pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-,
15 hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,
hypoparathyroidism), hypothalamus, and testes. Additionally, the expression within
30 fetal tissue, cancerous colon and breast, and other cellular sources marked by
proliferating cells indicates this protein may play a role in the regulation of cellular
20 division, and may show utility in the diagnosis, treatment, and/or prevention of
developmental diseases and disorders, including cancer, and other proliferative
35 conditions. Representative uses are described in the "Hyperproliferative Disorders"
and "Regeneration" sections below and elsewhere herein. Briefly, developmental
tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
40 formation.

25 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
45 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
30 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
50 also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 605 of SEQ ID NO:58, b is an integer of 15 to 619, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 49

Preferred polypeptides of the invention comprise the following amino acid sequence or a subfragment thereof: MNKEDKVWNDCKGVNKLTLNLEEQYIILIFQ
NGLDPPANMVFESIINEIGIKNNISNFFAKIPFEEANGRLVACTRITYEESIKGSC
GQKENKIKTVSFESKIQLRSKQEFQFFDEEETGENHTIFIGPVEKLIVYPPPPA
KGGISVTNEDLHCLNEGEFLNDVIIDFYLYLVLEKLKEDADRIHIFSSFFYK
RLNQRERRNHETTNSIQQKRHGRVKTWTRHVDIFEKDFIFVPLNEAAHWFL
AVVCFPGLEKPKYEPNPHYHENAVIQKCSTVEDSCISSASEMESCSQNSSAK

PVIKKMLNKKHCIAVIDSNPGQEESDPYKRNICSVKYSVKKINHTASENEEF
NKGESTSQKS' (SEQ ID NO: 319). Polynucleotides encoding such polypeptides are
also provided.

This gene is expressed primarily in fetal tissue, stomach, brain, endometrial
cells, and bone and to a lesser extent in prostate, retina, adipocytes, smooth muscle,
and tumors of the endometrium, ovaries, and parathyroid.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, disorders of the endocrine system, ulcers, stomach cancer, epilepsy,
schizophrenia, dementia, bone growth, developmental disorders and resorption.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
digestive system and neural systems expression of this gene at significantly higher or
lower levels is routinely detected in certain tissues or cell types (e.g., neural,
endocrine system, cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides
corresponding to this gene are useful for the detection, treatment, and/or prevention of
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.
Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
the uses include, but are not limited to the detection, treatment, and/or prevention of
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
compulsive disorder, depression, panic disorder, learning disabilities, ALS.

psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,

neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Expression of this gene product in stomach tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of stomach cancer, and cancer in general. The expression within embryonic, fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers; or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in parathyroid tumor indicates polynucleotides and polypeptides corresponding to this

gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. The tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1364 of SEQ ID NO:59, b is an integer of 15 to 1378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

5

10

15

20

25

30

35

40

45

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

The translation product of this gene shares good protein homology with Xenopus NaDC-2 gene and a rabbit renal sodium/dicarboxylate cotransporter. The translation product of this gene also shares good homology with a rat placental protein which is a sodium-coupled high affinity dicarboxylate transporter. Therefore, it is likely that the translated product encoded by this gene shares similar biological activity.

This gene is expressed primarily in the placenta and colon adenocarcinoma. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental abnormalities as well as failure to thrive anomalies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system and colon, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 173 as residues: Lys-166 to Gly-181. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human placenta and the shared homology of this translation product to a rat placental protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product is produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or

5 survival of the developing embryo or fetus. Expression of this gene product in a
vascular-rich tissue such as the placenta also indicates that this gene product is
10 produced more generally in endothelial cells or within the circulation. In such
instances, it may play more generalized roles in vascular function, such as in
5 angiogenesis. It may also be produced in the vasculature and have effects on other
cells within the circulation, such as hematopoietic cells. It may serve to promote the
15 proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well
as other cells throughout the body. The tissue distribution in colon tissue indicates
that polynucleotides and polypeptides corresponding to this gene are useful for the
20 diagnosis and/or treatment of disorders involving the colon. Expression of this gene
product in colon tissue indicates involvement in digestion, processing, and
elimination of food, as well as a potential role for this gene as a diagnostic marker or
causative agent in the development of colon cancer, and cancer in general.

25 Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:60 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1112 of SEQ ID NO:60, b is an
35 integer of 15 to 1126, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

40 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 51

This gene is expressed primarily in the spinal cord.

45 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, paralysis, neurologic disorders. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes for
50 differential identification of the tissue(s) or cell type(s). For a number of disorders of

5 the above tissues or cells, particularly of the nervous system, expression of this gene
at significantly higher or lower levels is routinely detected in certain tissues or cell
10 types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
5 from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
15 having the disorder.

The tissue distribution in spinal cord indicates polynucleotides and
polypeptides corresponding to this gene are useful for the detection, treatment, and/or
20 prevention of neurodegenerative disease states, behavioral disorders, or inflammatory
conditions. Representative uses are described in the "Regeneration" and
"Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and
elsewhere herein. Briefly, the uses include, but are not limited to the detection,
25 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
15 diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
30 mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
learning disabilities, ALS, psychoses, autism, and altered behaviors, including
20 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
expression of this gene product in regions of the brain indicates it plays a role in
35 normal neural function.

Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
40 survival. Furthermore, the protein may also be used to determine biological activity,
25 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
45 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
50 related to SEQ ID NO:61 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2064 of SEQ ID NO:61, b is an integer of 15 to 2078, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene is expressed primarily in keratinocytes, brain, fetal tissues, pericardium, stomach, and cancerous tissues (e.g., stomach, adrenals, parathyroid, germ cell, colon, breast):

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders, neurodegenerative and developmental disorders, heart disease, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular and gastrointestinal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of

Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in keratinocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita,

5
10
15
20
25
30
35
40
45
50
55

familial osteoarthritis, Ateleosteogenesis type II, metaphyscal chondrodysplasia type Schmid). The expression within fetal tissue (e.g., spleen and liver) and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

10
15
20
25
30
35
40
45
50
55

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Additionally, the tissue distribution in the pericardium of the heart indicates that the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b; where a is any integer between 1 to 748 of SEQ ID NO:62, b is an integer of 15 to 762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

This gene is expressed primarily in the brain and in cartilage and to a lesser extent in the retina, activated T-cells, pineal gland, the lungs, and in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases, such as epilepsy and dementia, osteoarthritis, retinopathies, hematopoietic diseases, emphysema, and lung cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurologic system, cartilage and musculature, vision, the hematopoietic system, and the pulmonary system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 176 as residues: Arg-34 to Cys-44. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, connective tissue disorders (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation). The protein is also useful in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.). Additionally, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have

5 applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
10 polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
5 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
15 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
20 insight into the regulation of cellular growth and proliferation. Furthermore, the
protein may also be used to determine biological activity; to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
25 antibodies directed against the protein may show utility as a tumor marker and/or
15 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:63 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
20 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
35 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-h, where a is any integer between 1 to 1080 of SEQ ID NO:63, b is an
integer of 15 to 1094, where both a and b correspond to the positions of nucleotide
40 residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

45 This gene is expressed primarily in umbilical vein endothelial cells induced by
IL-4.

30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
50 biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, angiogenesis, inflammatory disorders, hematopoietic disease.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the angiogenic and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in endothelial cells indicates polynucleotides and polypeptides corresponding to this gene are useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines, immunostimulating/immunosuppressant activities (e.g. for treating human

immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1347 of SEQ ID NO:64, b is an integer of 15 to 1361, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 55

This gene is expressed primarily in both normal and cancerous pancreas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diabetes, gastrointestinal disorders, and pancreatic cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and blood systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded

tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pancreas indicates that the protein products of this gene are useful as a therapeutic and/or diagnostic agent for pancreatic disorders and disorders of the endocrine and exocrine system, including but not limited to diabetes, blood disorders, pancreatic cancer, gastrointestinal diseases, hormonal imbalance, autoimmune disorders, cystic fibrosis, pancreatitis, and gallstones. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 933 of SEQ ID NO:65, b is an integer of 15 to 947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene shares sequence homology with oxidoreductase. Preferred polypeptides of the invention comprise the following amino acid sequence: MSPLSAARAALRVYAVGA AVILAQLLRRCRGGFLEPVXPPRP
DRVAIVTGGTDGIGYSTANIWRD LGMHVIIAGNND SKAKQVVSKIKEETLND
KVEFLYCDLASMTSIRQFVQKFKMKKIPLHVLINNAGVMMVPQRKTRDGFE
HFGLNYLGHIFLLTNLLD TLKESGSPGHSARVVTVSSATHYVAELNMDDLQS

SACYSPHAA YAQSKLALVLFYHLQRLAAEGSHVTANVVDPGVVNTDXYK
HVFWATRLAKKLLGWLLFKTPDEGAWTSIYAAVTPELEGVGGRYLYNEKET
KSLHVTYNQKLQQQLWSKSCMTGVLDVTL (SEQ ID NO: 320). The mature
form of this protein begins at residue 32. Thus, polypeptides comprising residues 2-
330 and 32-330 of the sequence shown above are also provided. Polynucleotides
encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following
amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEP
VXPPRPDRVAIVTGGTDGIG YSTANIWRDLACMLS (SEQ ID NO: 321).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in breast cancer cells, osteoclastoma, wilm's
tumor, thymus stromal cells, and T cell helper I.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, cancer, e.g., breast cancer, osteoclastoma, and wilm's tumor. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the immune system,
expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, kidney, immune, hematopoietic, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, breast milk,
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

The tissue distribution in breast cancer tissue, combined with the homology to
oxidoreductase indicates that polynucleotides and polypeptides corresponding to this
gene are useful for diagnosis and treatment of cancer, particularly, breast cancer,
osteoclastoma, and wilm's tumor. This protein may play a role in the regulation of
cellular division, and may show utility in the diagnosis, treatment, and/or prevention
of developmental diseases and disorders, including cancer, and other proliferative

5 conditions. Representative uses are described in the "Hyperproliferative Disorders"
and "Regeneration" sections below and elsewhere herein. Briefly, developmental
10 tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
formation.

5 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
15 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
potential roles in proliferation and differentiation, this gene product may have
20 applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
25 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
15 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
30 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
20 protein may also be used to determine biological activity, to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
35 interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

40 25 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:66 and may have been publicly available prior to conception of
45 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
30 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
50 formula of a-b, where a is any integer between 1 to 1362 of SEQ ID NO:66; b is an

integer of 15 to 1376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

This gene is expressed primarily in monocytes, T cell helper II and B cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly B-cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 180 as residues: Asp-30 to Val-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in monocytes, T cell helper, and B cell lymphoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of B cell lymphoma. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

5 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

10 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
5 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
15 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
20 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
25 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
15 in the differentiation and/or proliferation of various cell types. Furthermore, the
protein may also be used to determine biological activity, raise antibodies, as tissue
30 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
20 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:67 and may have been publicly available prior to conception of
40 the present invention. Preferably, such related polynucleotides are specifically
25 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
45 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 2420 of SEQ ID NO:67; b is an
30 integer of 15 to 2434, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

This gene is expressed primarily in human lung cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary diseases and/or disorders, particularly cancers of the lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary lavage, pulmonary surfactant, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 181 as residues: Phe-39 to Asp-45. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lung cancer tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as ARDS, cystic fibrosis, and cancer, particularly lung cancer. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1072 of SEQ ID NO:68, b is an integer of 15 to 1086, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

This gene is expressed primarily in larynx carcinoma and early stage human lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

5 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental, gastrointestinal, and pulmonary diseases and/or
10 disorders, particularly larynx carcinoma. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes for
5 differential identification of the tissue(s) or cell type(s). For a number of disorders of
the above tissues or cells, particularly of the immune system, expression of this gene
15 at significantly higher or lower levels is routinely detected in certain tissues or cell
types (e.g., developmental, gastrointestinal, pulmonary, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, pulmonary lavage,
20 sputum, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

25 Preferred polypeptides of the present invention comprise immunogenic
15 epitopes shown in SEQ ID NO: 182 as residues: His-42 to Lys-49. Polynucleotides
encoding said polypeptides are also provided.

30 The tissue distribution in larynx carcinoma and early stage human lung
indicates that polynucleotides and polypeptides corresponding to this gene are useful
for treating immune system disorders such as cancer, particularly larynx carcinoma.
20 This protein may play a role in the regulation of cellular division, and may show
utility in the diagnosis, treatment, and/or prevention of developmental diseases and
35 disorders, including cancer, and other proliferative conditions. Representative uses are
described in the "Hyperproliferative Disorders" and "Regeneration" sections below
and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell
40 25 differentiation and/or apoptosis in pattern formation.

45 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
30 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
50 also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:69, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 60

Preferred polypeptides of the invention comprise the following amino acid sequence: MEVTTEDTSRTDVSEPATSGGAADGVTSIAPTAVASSTTAASITTA
ASSMTVASSAPTTAASSTTVASIAPTTTASSMTAASSTPMTLALPAPTSTXTGR
TPSTTATGHPSLTALAQVPKSSALPRTATLATLATRAQTVATTANTSSPMST
RPSPSKHMPSDTAASPVPMPXPQAQGPISQVSVDQPVVNTTXKSTXMPSNTT
XEPLTQAVVDKTLVVLLLVLTFTVLVLFALQAYESYKKKDYTVQVDYLI

NGMYADSEM (SEQ ID NO: 322). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARCELPGLRCRPRPRAGPQAPSYCPATRPPG ACCARMRLLEWRVYLRLTCATKDGMARECPITWLSPPAKPDFAQRH SVK PTALQGGRWSRLGASP (SEQ ID NO: 323). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in adipocytes, osteoblasts, cerebellum, hypothalamus and Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, skeletal, neural, and immune diseases and/or disorders, particularly Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, skeletal, neural, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 183 as residues: Pro-33 to Gln-40, Gly-51 to Arg-56. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in Hodgkin's lymphoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as cancer, particularly Hodgkin's lymphoma. The secreted protein can also be used to determine biological activity, to

5
10
15
20
25
30
35
40
45
50
55

raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20
25
30
35
40
45
50
55

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1628 of SEQ ID NO:70, b is an integer of 15 to 1642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

The translation product of this gene shares sequence homology with polypeptide in the cystatin family. Cystatin polypeptides are cysteine protease inhibitors. For an analysis of the composition of several members of the cystatin family, see Gene (1987) 61(3):329-338, incorporated herein by reference. The cystatin activity of polypeptides encoded by this gene is measured by several assays known in the art including assays described in coowned, copending US Patent Application, Serial No. 08/744,138, incorporated herein by reference. Preferred polypeptides of the invention comprise the following amino acid sequence: LPATVEFAVHTFNQQSKD YYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQESTEL NNTFTCFFTISTRPWMTQFSLNKC (SEQ ID NO: 324). Fragments of such polypeptides having cystatin activity (cysteine protease inhibitory activity are particularly preferred). Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LLWARGLGRAKSAVPTVST MLGLPWKGGLS WALLLLLGSQILLIYAWHFHEQRDCDEHNVMARYLPATVEFAVHTFNQQS KDYYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQE STELNNTFTCFFTISTRPWMTQFSLNK TCLEGFH (SEQ ID NO: 325).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in testes and epididymus. For a review of a cystatin showing testes-specific expression see Mol. Endocrinol. (1992 Oct.) 6(10):1653-1664, incorporated herein by reference.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, They should therefore serve a protective function to regulate the activities of such endogenous proteinases, which otherwise may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity can normally not be measured in body fluids, but can be detected extracellularly in conditions like endotoxin-induced sepsis, metastasizing cancer, and at local inflammatory processes

5 in rheumatoid arthritis, purulent bronchiectasis and periodontitis. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
10 immunological probes for differential identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the immune,
15 expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and
spinal fluid) or another tissue or cell sample taken from an individual having such a
disorder, relative to the standard gene expression level, i.e., the expression level in
20 healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 184 as residues: Phe-31 to Asp-38, Asn-59 to Tyr-65,
Ser-76 to Glu-82, Thr-96 to Cys-108, Gln-111 to Asn-118. Polynucleotides encoding
25 said polypeptides are also provided.

15 The tissue distribution in testes and epididymus, combined with the
homology to cystatins indicates that polynucleotides and polypeptides corresponding
to this gene are useful for the treatment and diagnosis of conditions concerning proper
testicular function (e.g. endocrine function, sperm maturation), as well as cancer.
30 Therefore, this gene product is useful in the treatment of male infertility and/or
impotence. This gene product is also useful in assays designed to identify binding
agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly,
the protein is believed to be useful in the treatment and/or diagnosis of testicular
cancer. The testes are also a site of active gene expression of transcripts that is
expressed, particularly at low levels, in other tissues of the body. Therefore, this gene
40 product is expressed in other specific tissues or organs where it may play related
functional roles in other processes, such as hematopoiesis, inflammation, bone
formation, and kidney function, to name a few possible target indications.
Representative uses are described in the "Hyperproliferative Disorders" and
45 "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues
30 rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
50 death, as occurs in the development of some cancers, or in failure to control the extent

5 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
10 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
5 also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
15 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
20 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
25 protein may also be used to determine biological activity, to raise antibodies, as tissue
15 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
30 immunotherapy targets for the above listed tissues.

Cysteine proteinase inhibitors of the cystatin superfamily are ubiquitous in the
20 body and are generally tight-binding inhibitors of papain-like cysteine proteinases,
35 such as cathepsins B, H, L, S, and K. They should therefore serve a protective
function to regulate the activities of such endogenous proteinases, which otherwise
may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity
can normally not be measured in body fluids, but can be detected extracellularly in
40 25 conditions like endotoxin-induced sepsis, metastasizing cancer, and at local
inflammatory processes in rheumatoid arthritis, purulent bronchiectasis and
periodontitis, which indicates that a tight cystatin regulation is a necessity in the
normal state. A deficiency state in which the levels of the intracellular cystatin,
45 cystatin B, are lowered due to mutations has recently been shown to segregate with a
30 form of progressive myoclonus epilepsy, which points to additional specialized
functions of cystatins. Moreover, results showing that chicken cystatin inhibits polio
virus replication, human cystatin C inhibits corona- and herpes simplex virus
50

5 replication, and human cystatin A inhibits rhabdovirus-induced apoptosis in cell
cultures indicates that cystatins play additional roles in the human defense system.
10 The cystatins constitute a superfamily of evolutionarily related proteins, all composed
of at least one 100-120 residue domain with conserved sequence motifs.

5 The previously well characterized single-domain human members of this
superfamily could be grouped in two protein families. The Family 1 members,
15 cystatins (or stefins) A and B, contain approximately 100 amino acid residues, lack
disulfide bridges, and are not synthesized as preproteins with signal peptides. The
Family 2 cystatins (cystatins C, D, S, SN, and SA) are secreted proteins of approx.
20 120 amino acid residues (Mr 13,000-14,000) and have two characteristic intrachain
disulfide bonds. Recently, we identified an additional human cystatin superfamily
member by EST1-sequencing in epithelial cell derived cDNA libraries which we
named cystatin E. The same cystatin was independently discovered by differential
25 display experiments as a mRNA species down-regulated in breast tumor tissue, but
present in the surrounding epithelium and reported under the name cystatin M.
Cystatin E/M is an atypical, secreted low-Mr cystatin in that it is a glycoprotein and
just shows 30-35% sequence identity in alignments with the human Family 2
30 cystatins, which shows that additional cystatin families are yet to be identified. The
cystatin E/M gene has been localized to chromosome 2, whereas all human Family 2
cystatin genes are clustered on the short arm of chromosome 20, which further
35 stresses that cystatin E/M is just distantly related to the other secreted human low-Mr
cystatins. It is believed therefore, that polypeptides encoded by this gene are useful in
diagnosing and treating disease consistent with the aforementioned conditions in
which cystatins are implicated.

40 25 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:71 and may have been publicly available prior to conception of
45 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
30 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
50 formula of a-b, where a is any integer between 1 to 907 of SEQ ID NO:71, b is an

integer of 15 to 921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

The translation product of this gene shares sequence homology with Neutrophil Gelatinase-Associated Lipocalin which is thought to be important in immune regulation (See Genbank and Geneseq Accession Nos. embiCAA58127.1, and U55627034, respectively; all references and information available through these accessions are hereby incorporated herein by reference; for example, Biochem. Biophys. Res. Commun. 202 (3), 1468-1475 (1994), and FEBS Lett. 314 (3), 386-388 (1992)).

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide, are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LEQKLELHRGGGRSRTSGSPGLQEFGTREERGE GEQRTGREFSGNGGRAVEAARMRLLCGLWLWLSLLKVLQAQTPTPLPLPP PMQSFQGNQFQGEWFVLGLAGNSFRPEHRALLNAFTATFELSDDGRFEVWN AMTRGQHCDTWSYVLIPAAQPGQFTVDHGVGRSWLLPPGTLDQFICLGRAQ GLSDDNIVFPDVTGXALDL XSLPWVAAPA (SEQ ID NO: 326). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in epididymus and osteoclastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and skeletal diseases and/or disorders, particularly cancers such as osteoclastoma testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid).

5 or another tissue or cell sample taken from an individual having such a disorder,
relative to the standard gene expression level, i.e., the expression level in healthy
10 tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
5 epitopes shown in SEQ ID NO: 185 as residues: Met-82 to Thr-90. Polynucleotides
encoding said polypeptides are also provided.

15 The tissue distribution in epididymus and homology to neutrophil gelatinase-
associated lipocalin indicates that polynucleotides and polypeptides corresponding to
this gene are useful for diagnosis and treatment of skin diseases and immune system
20 disorders such as cancer, particularly osteoclastoma. The secreted protein can also be
used to determine biological activity, to raise antibodies, as tissue markers, to isolate
cognate ligands or receptors, to identify agents that modulate their interactions, and as
nutritional supplements. It may also have a very wide range of biological activities.
25 Representative uses are described in the "Chemotaxis" and "Binding Activity"
sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere
herein. Briefly, the protein may possess the following activities: cytokine, cell
proliferation/differentiation modulating activity or induction of other cytokines;
30 immunostimulating/immunosuppressant activities (e.g. for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy);
35 stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for
treating wounds, stimulation of follicle stimulating hormone (for control of fertility);
chemotactic and chemokinetic activities (e.g. for treating infections, tumors);
hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction
40 etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as
antimicrobials; for treating psoriasis or other hyperproliferative diseases; for
regulation of metabolism, and behavior. Also contemplated is the use of the
corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies
45 directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.
30

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID NO:72, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 63

The translation product of this gene was shown to have homology to colipase which plays an essential role in the intestinal fat digestion by anchoring lipase on lipid/water interfaces in the presence of bile salts (See Genbank Accession No. gb|AAA03513.1; all references and information available through this accession are hereby incorporated by reference herein).

This gene is expressed primarily in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive diseases and/or disorders, particularly epididymus-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, bile, chyme, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 186 as residues: Ile-40 to Cys-49, Arg-52 to Cys-57,

Ser-94 to Trp-99, Gly-105 to Gly-111. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases and disorders of the epididymus. Polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 666 of SEQ ID NO:73, b is an integer of 15 to 680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: MCVCKERKRGREKEGGVTPTMTSNFPFCTLILGI
AQAQACPGCPGDWPGLGSGVGEGLHHIRTCRTPIPCSPAPAAACLGS
GHLARLPCVLRLLWPVPANLSSPFRLEALHCSFWSSPLLPAIILAFFGFRDLLTDFL
LAACLLTFQKTPLELPMVHLLVATPCYQMLDNPLPSAAAN WC (SEQ ID
NO: 327). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in melanocytes and placenta and to a lesser extent in bone marrow and many cells of the immune system, including B-cells, dendritic cells, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin cancer and disorders of the reproductive and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., reproductive tissue, hematopoietic tissue, melanocytes and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the skin, the reproductive system, and the immune system, particularly cancers. Representative uses are described in the "Biological Activity".

"Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions; in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1619 of SEQ ID NO:74, b is an integer of 15 to 1633, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 65

Preferred polypeptides of the invention comprise the following amino acid sequence: YLWGRPRLRMAGTSPSAPWGKREKLGHKLPVALQGYHPWIL
LECTVFWARVVLACFSLYLIRGPNICINRQPEPTYQKACNLDCSSDFGQER
APAWELLGPESEQRRLREYTAQGLQSLASSHRWRQFKTEGKMRGGASPLPWL
10 CFW LCSYKGS DNSLKP VVPGPTLCPQSLVSPSVHPSTRSASLGRHRAEAA
(SEQ ID NO: 328). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the
25 following amino acid sequence: MPGILAGIPVKDLCLSLQGFRLLLCVCPGWL
SGWMGGQKGSPRIVDIG (SEQ ID NO: 329). Polynucleotides encoding these polypeptides are also provided. This gene maps to chromosome 15, accordingly, polynucleotides of the invention is used in linkage analysis as a marker for chromosome 15.

20 This gene is expressed primarily in brain and breast and to a lesser extent in the liver, pancreas, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
40 25 not limited to, disorders affecting the brain and CNS, the reproductive system, or the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, the reproductive system, and the immune
45 30 system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., brain and other tissue of the nervous system, mammary tissue, endocrine tissue, hepatic tissue, reproductive tissue, cells
50

5 and tissue of the immune system, cancerous and wounded (tissues) or bodily fluids
(e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell.
10 sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
5 individual not having the disorder.

15 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 188 as residues: Met-37 to Ser-43. Polynucleotides
encoding said polypeptides are also provided.

20 The tissue distribution in brain cells indicates that polynucleotides and
10 polypeptides corresponding to this gene are useful for the diagnosis and treatment of
disorders affecting the central nervous system, the reproductive system, and the
immune system, including cancers. Representative uses are described in the
"Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,
25 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the
15 detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
30 cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
20 learning disabilities, ALS, psychoses, autism, and altered behaviors, including
disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
35 expression of this gene product in regions of the brain indicates it plays a role in
normal neural function.

40 Potentially, this gene product is involved in synapse formation,
25 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
45 identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
30 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

50 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b: where a is any integer between 1 to 1008 of SEQ ID NO:75, b is an integer of 15 to 1022, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 66

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AKGEERKEAFSLKMOVLSSEPISFGLMYLYLGV
FFHLIYPGALSITTLGKHSHPFFTAEQNSTVWMEHTLFHQSPVASHLVCFQSF
AFSE (SEQ ID NO: 330). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the brain and the immune system, in particular T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain, such as Alzheimer's or disorders affecting the immune system, such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and CNS and the immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the brain and CNS or disorders affecting the immune system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1170 of SEQ ID NO:76, b is an

integer of 15 to 1184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

The translation product of this gene shares sequence homology with penacidin-2 which is thought to be a members of a new family of antimicrobial peptides from the hemolymph of shrimps *Penaeus vannamei*. The molecules display antimicrobial activity against fungi and bacteria with a predominant activity against Gram-positive bacteria.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPAHPASPPLMTLSLQLAELVHFVCAFAQSQWTGVYPMMPPLKPTPLCFA CVPCR (SEQ ID NO: 331). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly disorders affecting the spleen, including bacterial and fungal infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, and cells and tissue of the immune system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in spleen and homology to the penaeidin family of
antibiotics indicates that polynucleotides and polypeptides corresponding to this gene
10 are useful for the diagnosis and treatment of disorders affecting the spleen, especially
fungal and bacterial infections. Representative uses are described in the "Immune
5 Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,
20, and 27, and elsewhere herein. Briefly, the expression of this gene product
15 indicates a role in regulating the proliferation, survival, differentiation, and/or
activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
10 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
25 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
15 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
30 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
20 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
40 25 in the differentiation and/or proliferation of various cell types. Furthermore, the
protein may also be used to determine biological activity, raise antibodies, as tissue
markers, to isolate cognate ligands or receptors; to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
45 antibodies directed against the protein may show utility as a tumor marker and/or
30 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 298 of SEQ ID NO:77, b is an integer of 15 to 312, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 68**

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating immune and hematopoietic cells and tissue cell types. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

Moreover, when tested in TF-1 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: c-fos, c-jun, egr-1, b561, bcl-2, CD40, cyclin D2, GADPH, ICER, MAD3, p21, STAT3, ID3, and STAT-1. When tested in U937 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: egr2, MKP1, ATF3, B562, cyclin D, cyclin D2, GATA3, MAD3, p21, TGF, DHFR, and JAK3. Based upon these results, it is anticipated that polynucleotides and polypeptides corresponding to this gene are useful as agonists or antagonists of the above referenced genes. Such activity is useful in therapeutic and/or diagnostic applications as referenced and more specifically discussed elsewhere herein.

In specific embodiments, polypeptides of the invention comprise the sequence: MLLEVYGDISISVTVAIPL (SEQ ID NO: 332), MHSPCQSKAADGLGKSETE (SEQ ID NO: 333), and/or MLKSLGLSTN (SEQ ID NO: 334). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AQLAEECFYMLLEVYGDISISVTVAIPLMHSPCQSKAADGLGKSETEMLKSLGLSTNMSPFHLLGLKVFLTWALTQAICLY FFEVQPLGLLALNFFCTATAGLKELCMHPPSLAFTPEFHTLSPLAIPSFSGTS VLSNSHTIPLSLYLPFPKSRMPDTLHLLVHSLPLVHSQVLPVKDVTIEWPLC QRCLGSTCH Q (SEQ ID NO: 335). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 11 - 27 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 28 to 143 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in neutrophils and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and/or diseases affecting the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune; hematopoietic, cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

5

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 191 as residues: Pro-97 to Asp-104. Polynucleotides encoding said polypeptides are also provided.

15

The tissue distribution in neutrophils and T-cells, combined with the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

20

25

30

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

40

45

50

55

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1356 of SEQ ID NO:78, b is an integer of 15 to 1370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 69

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEVQVSLFQMFCSSIFCSH
EHTHLPGTFWLFLFLFLPSPCFLPFLALETVRWPCWHHPTSFELCY
PGTSIYYASRGGXPNSSEX (SEQ ID NO: 336). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the immune system, and neutrophils in particular. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., blood cells,

5 and cells and tissue of the immune system, and cancerous and wounded tissues) or
10 bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another
tissue or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
5 fluid from an individual not having the disorder.

15 The tissue distribution in neutrophils indicates that polynucleotides and
polypeptides corresponding to this gene are useful for the diagnosis and treatment of
disorders affecting the immune system and neutrophils in particular. Representative
uses are described in the "Immune Activity" and "infectious disease" sections below,
20 in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the
expression of this gene product indicates a role in regulating the proliferation;
survival; differentiation; and/or activation of hematopoietic cell lineages, including
blood stem cells. This gene product is involved in the regulation of cytokine
25 production, antigen presentation, or other processes suggesting a usefulness in the
15 treatment of cancer (e.g. by boosting immune responses).

30 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
20 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
35 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
40 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
25 influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
45 in the differentiation and/or proliferation of various cell types. Furthermore, the
30 protein may also be used to determine biological activity, raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
50 interactions, in addition to its use as a nutritional supplement. Protein, as well as,

55

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 354 of SEQ ID NO:79, b is an integer of 15 to 368, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: XNXKSPLTIGNKSWSTAVAAALELVDPPGCRNSARDSPELVHLGKGRPRKLMTYLFCSSISLLLLKVHSSGHQDIRKAKSKVPRLLIQCPQORE (SEQ ID NO: 337). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting smooth muscle tissue, particularly vascular conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of smooth muscle tissue expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 193 as residues: Ser-18 to Val-31. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution primarily in smooth muscle indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting smooth muscle tissue. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1074 of SEQ ID NO:80, b is an integer of 15 to 1088, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 71

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by

the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPEENLSPSTPSQMPTIWVKLCLLQVCHGLFP LLKHWSQPMPLCVTLAPVSYWL (SEQ ID NO: 338). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in fetal heart, smooth muscle, and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular, vascular, or neural diseases and/or disorders, particularly defects or injury to cardiac muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscular, vascular, neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating defects to the heart either due to injury or congenital defects. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,

5 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
10 diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
5 mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
learning disabilities, ALS, psychoses, autism, and altered behaviors, including
15 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
expression of this gene product in regions of the brain indicates it plays a role in
normal neural function. Furthermore, the protein may also be used to determine
20 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify agents that modulate their interactions, in addition to its use as a
nutritional supplement. Protein, as well as, antibodies directed against the protein may
show utility as a tumor marker and/or immunotherapy targets for the above listed
25 tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:81 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
20 cumbersome. Accordingly, preferably excluded from the present invention are one or
35 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1848 of SEQ ID NO:81, b is an
integer of 15 to 1862, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.
40

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 72

45 The translation product of this gene shares sequence homology with adipose
complement related protein which is thought to be important in regulating energy
metabolism, insulin levels and fat stores. Moreover, the protein product of this gene
30 has also been shown to have homology to the complement subcomponent C1q A-
chain precursor and HP-25 protein (See Genbank and Geneseq Accession Nos.
50 emb|CAA41664.1, dbj|BAA02352.1, and W98013; all references and information

5 available through this accession are hereby incorporated by reference herein). Based
on the sequence similarity, the translation product of this gene is expected to share at
10 least some biological activities with complement proteins.

15 In another embodiment, polypeptides comprising the amino acid sequence of
the open reading frame upstream of the predicted signal peptide are contemplated by
the present invention. Specifically, polypeptides of the invention comprise the
following amino acid sequence: PRVRKEPEAMQWLRVRESPGEATGHRVTMG
20 TAALGPVWAALLLFLLMCEIPMVELTFDRAVASDCQRCCDSEDPLDPAHVSS
ASSSGRPHALPEIRPYINITLKGDKGDPGPMGLPGYMGREGPQGEPPQGSK
GDKGEMGSPGAPCQKRFFAFSVGRKTALHSGEDFQTLLEFVVFVNLDCG
25 FDMATGQFAAPLRGHIYFFSLNVHSWNYKETYVHIMHNQKEAVILYAQPS
ERSIMQSQSVMLDLAYGDRVWVRLFKRQRENAIYSNDFDTYITFSGHLIKA
EDD (SEQ ID NO: 339). Polynucleotides encoding these polypeptides are also
provided.

30 This gene is expressed primarily in placenta and, fetal kidney, and umbilical
vein and to a lesser extent in fetal heart, fetal liver/spleen, microvascular endothelial
cells and cancers of the lung and pharynx.

35 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, vascular, renal, and reproductive diseases and/or disorders, particularly
40 cancers of the lung and pharynx. Similarly, polypeptides and antibodies directed to
these polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the pulmonary and immune systems, expression of this
45 gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., vascular, renal, reproductive, immune, hematopoietic, pulmonary, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid and spinal fluid) or another tissue or cell sample taken from an individual having
50 such a disorder, relative to the standard gene expression level, i.e., the expression
level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 195 as residues: Asp-36 to Asp-48, Ser-57 to His-62, Lys-77 to Gly-84, Met-92 to Gly-114, Gln-203 to Ile-209, Lys-231 to Tyr-239. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pharynx or lung, combined with the homology to adipose complement related proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancers of the pharynx or lung by modifying the metabolic balance in such tissues. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1604 of SEQ ID NO:82, b is an integer of 15 to 1618, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 73

The translation product of this gene shares sequence homology with a hypothetical 54.7 kD protein (F37A4.1) from *Caenorhabditis elegans* (SwissProt locus YPT1_CAEEL, accession P41879). The protein product of this gene also has homology to the human NG26 which is thought to contain a human major histocompatibility complex class III and is involved in T-cell maturation (See Genbank Accession No. gblAAD18079.11 (AF129756); all references and information available through this accession are hereby incorporated by reference herein; for example, J. Neurochem. 69 (6), 2516-2528 (1997)). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with nitric oxide synthase proteins.

Preferred polypeptides of the invention comprise the following amino acid sequence: MLYPGSVYLLQKALMPVLLQGQARLVEECNGRRAKLLACDGNE
IDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYSVLGWNHP
GFAGSTGVFPQNEANAMDVVVQFAIHLRGFQPQDIIYAWSIGGFTATWAA
MSYPDVSAMILDASFDDLVLPLALKVMPDSWRGLVTRTVRQHLNLNNAEQLC
RYQGPVLLIRRTKDEIITTTVPEDIMSNRGNLLLLKLLQHRYPVMAEEGLRV
VRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGPDFPWSVGEDMS
ADGRRQLAI FLARKHLHNFEATHCTPLPAQNFQMPWHL (SEQ ID NO: 340).

Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VCPKWCRFLTMLGHCCYFWQVWPASEALAA
GPTPSTGSSSPSWKQHIGTSLQKTRGSLPTTTLTSGAGQSTSTGKNPAAGR
SLEGALPAGVWPCEAQPCTGGQQTPT SSTGLRSLVRSPATWWRTPT (SEQ ID NO: 341). Polynucleotides encoding these polypeptides are also provided.

Preferred polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEIYREXDSERAPASVPETPTAVTAPHSSSWDTYYQ
PRALEKHADSILALASVFWSISYYSSPFAFFYL YRKGYSLSKVVPFSHYAG
TLLLLLAGVACXRGIGRWTPNPQYRQFITILEATHRNQSSSENKRQLANYNFD
FRSWPVDFHWEPPSSRKESRGGPSRRGVALLRPEPLHRGTADTLNVRVKKL

5 PCQITSYLVAHTLGRRLYPGSVYLLQKALMPVLLQGQARLVEECNGRRAK
LLACDGNEIDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYS
10 VLGWNHPGFAGSTGVFPQNEANAMDVVVQFAIHR LGFQPQDIITYAWSI
GGFTATWAAMSYPDV SAMILDASFDDL VPLALKVMPDSWRGLVTRTVRQ
5 HLNLNNAEQLCRYQGPVLLIRRTKDEIITTTVPEDIMSNRGNDLLLKLLQHRY
PRVMAEEGLRVVRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGP
15 DFPWSVGEDMSADGRRQLALFLARKHLHNFEATHCT PLPAQNFQMPWHL

(SEQ ID NO: 342). Polynucleotides encoding these polypeptides are also provided. A preferred polypeptide variant of the invention comprises the following amino acid
20 sequence: HERAXGPSRGHGELLSCVLGPRLYKIYRERDSERAPASVPETPTA
VTAPHSSSWDTYYQP RALEKHADSILALASVFWSISYSSPFAFFLYRKG Y
LSLSKVVPFSHYAGTLLLLLAGV ACSEALAAGPTPSTGSSSPSWKQHIGTSLQ
KTRGSLPTTTLTSGAGQSTSTGKNPAAGRSLEGALPAGVWPCFAQSPCTGG
25 QQTPSSTGL RSCLVRSPATWW RTP (SEQ ID NO: 343). Polynucleotides
15 encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome
30 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in cerebellum, pituitary, fetal liver, and
20 primary dendritic cells and to a lesser extent in a wide range of tissues and developmental stages (i.e. fetal and adult tissue, etc.).

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
40 25 not limited to, neural, developmental, and immune diseases and/or disorders, particularly those involving self recognition and T- and B-cell maturation, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
45 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the
30 neural or hormonal system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental,
50 immune, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., serum,

5 plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell
sample taken from an individual having such a disorder, relative to the standard gene
10 expression level, i.e., the expression level in healthy tissue or bodily fluid from an
individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 196 as residues: Thr-23 to Lys-34, Leu-41 to Ser-47,
15 Ala-57 to Ala-68, Pro-89 to Gly-101, Pro-110 to Pro-117. Polynucleotides encoding
said polypeptides are also provided.

10 The tissue distribution in developmental and immune cells, combined with the
homology to the human major histocompatibility complex class III region, indicates
that polynucleotides and polypeptides corresponding to this gene are useful for
treatment and diagnosis of cancer and other proliferative disorders. Representative
25 uses are described in the "Immune Activity" and "infectious disease" sections below,
in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the
expression of this gene product indicates a role in regulating the proliferation;
15 survival; differentiation; and/or activation of hematopoietic cell lineages, including
blood stem cells. This gene product is involved in the regulation of cytokine
production, antigen presentation, or other processes suggesting a usefulness in the
treatment of cancer (e.g. by boosting immune responses).

20 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
35 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
40 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
45 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
50 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and

in the differentiation and/or proliferation of various cell types. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2020 of SEQ ID NO:83; b is an integer of 15 to 2034, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 74

The translation product of this gene shares sequence homology with the hr-1 protein from the snail nervous system (EMBL HPBRIGENE) which codes for nitric oxide synthetase and which is thought to be important in mediating a variety of cellular responses, including vasodilation. Preferred polypeptides of the invention comprise the following amino acid sequence: MFKRHQRLKKDSTQAEEDLSEQ EQNQLNVLKKHGYVVGRVGRFLYSEEQKDNIPFEFDADSLAFDMENDPVM GTHKSTKQVELTAQDVKDAHWFYDTPGITKENCILNLLTEKEVNIVLPTQSIV PRTFVLKPGMVLFLGAIGRIDFLQGNQSAWFTVVASNILPVHITSLDRADALY QKHAGHTLLQIPMGGKERMAGFPPLVAEDIMLKEGLGASEAVADIKFSSAG WVSVTPNFKDRLHLRGYTPEGTVLTVRPPLLPYIVNIKGQRIKKSVA YKTKKP PSLMYNVRKKKGKINV. (SEQ ID NO: 344). Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MLPARLPFRLLSLFLRGSAPTAARHGLREPLLERCAA
ASSFQHSSSLGREL PYDPVDTEGFGEGGDMQERFLFPEYILDPEPQPTREKQL
QELQQQQEEEEERQRQQRREERRQQLRARSREHPVVGHDPALPPSGVNCS
GCGAXLHCQDAGVPGYLPREKFLRTAEADGGLARTVCQRCWLLSHHRRALR
LQVSREQYLELVSAALRXPGPSLVLYMVDLLDLPDALLPDLPALVGPKQLIV
LGNKVDLLPQDAPGYRQLRERLWEDCARAGLLAPGTKGHSAPSRTSHR
TGRIRIRTGPAQWSCGTCG (SEQ ID NO: 345). Polynucleotides encoding these polypeptides are also provided.

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in early stage human brain, smooth muscle, and endometrial tumor and to a lesser extent in a variety of tissues representing many organs and developmental states.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular, vascular, and neural diseases and/or disorders, particularly congestive heart disease and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and neural systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, vascular, neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,

urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 197 as residues: Phe-42 to Leu-48, Pro-53 to Asp-58, Pro-81 to Glu-123, Asp-256 to Trp-269, Gly-282 to Ser-306, Arg-333 to Gly-339, Arg-403 to Gln-425, Ser-446 to Asn-452, His-475 to Gln-480, Gly-592 to Met-597, Pro-635 to His-642, Lys-667 to Lys-672, Lys-678 to Ser-684. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and vascular tissues, combined with the homology to nitric oxide synthetase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of congestive heart failure and neurological degenerative disorders. polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to

microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2226 of SEQ ID NO:84, b is an integer of 15 to 2240, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

The translation product of this gene shares sequence homology with the human KE04p, in addition to an unidentified C.elegans gene.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 9 - 25 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 to 8 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PSFRERVETGGGGPVTIIGTEGPFLPLPGGTRM NMTQARVLVAADVGLVAVLLYASIHKJEEGHLAVYYRGGALLTSPSGPGYH

IMLPFITFRSVQTTLQTDEVKNVPCGTSGGVMIYIDRIEVVNMLAPYAVFDIV
RNYTADYDKTLIFNKHHELNQFCSAHTLQEVYIELFDQIDENLKQALQKDL
NLMAPGLTIQAVRVTKPKIPEAIRNFELMEAEKTKLLIAAQKQKVVEKEA
ETERKKAVIEAEKIAQVAKIRFQQKVMKEKETEKRISEIEDAAFLAREKAKA
DAEYYAAHKYATSNKHKLTPYELKKYQAIASNSKIYFGSNIPNMFVDSSC
ALKYSD IRTGRESSLPSKEALEPSGENVIQNKESTG (SEQ ID NO: 346).

Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

This gene is expressed primarily in fetal tissue, including 8 week whole embryo, fetal liver spleen, nine week old early stage human, fetal heart, fetal liver, fetal lung, and placenta and to a lesser extent in a variety of cancers, and other normal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and diseases of fetal development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal tissues, especially the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, hepatic, immune, hematopoietic, pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 198 as residues: Leu-68 to Lys-74, Tyr-109 to Lys-115, Gln-200 to Val-205, Lys-207 to Lys-214, Glu-237 to Ile-244, Ala-271 to Thr-

279, Ser-317 to Ser-329, Gln-342 to Gly-348. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution of this gene (primarily fetal tissue and cancerous tissue, both of which are undergoing rapid growth) indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and disorders of fetal development. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1474 of SEQ ID NO:85, b is an integer of 15 to 1488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid and T-cells, and to a lesser extent in other immune cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WSTGNASWEKKDNFILSADFEMMGLGNRR
SMKSPPLVLAALVACIIVLGFNYWASSRSVDLQTRIMELEGRVRRRAAERG
AVELKKNEFQGELEKQRFQLDKIQSSHNFQLESVNKLYQDEKAVLVNNTTGT
ERLIRVLQDQLKTLQRNYGRLQQDVLQFQKNQTNLERKFSYDLSQCINQMKE
VKEQCEERIEEVTKKGNEAVASRDLSNNNDQRQQQLALSEPQPRQLQAAGL

5
10
15
20
25
30
35
40
45
50
55

PHTEVPQKGKGNVLGN SKSQTPAPSSEVVLDSKRQVEKEETNEIQV VNEE
PQRDRLPQEPGREQVVEDRPVGGRGFGGAGELGQTPQVQAALXVSQENPE
MEGPERDQLVIPDGQEEEQEAAGEGRNQKLRGEDDYNMDENEAESETDKQ
AALAGNDRNIDVFNVE DQKRDTINLLDQREKRNHTL (SEQ ID NO: 347).

5 Polynucleotides encoding these polypeptides are also provided.

15 The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

20 This gene is expressed primarily in human endometrial tumor and other tumors and to a lesser extent in a variety of other healthy adult and fetal tissues

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental diseases and/or disorders, particularly cancer and other
15 proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
20 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endometrial tissue, cervix and uterus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues
25 or cell types (e.g., developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 199 as residues: Asn-6 to Lys-12, Leu-65 to Phe-70, Glu-73 to His-88, Gln-123 to Gln-135, Gln-142 to Leu-156, Arg-173 to Gly-181, Asp-189 to Gln-199, Ser-204 to Arg-209, Glu-219 to Gly-225, Gly-229 to Pro-238, Ser-246 to Asn-256, Glu-263 to Arg-276. Polynucleotides encoding said polypeptides
35 are also provided.

40 The tissue distribution in endometrial tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

5 endometrial, cervical and uterine cancer. Because of potential roles in proliferation
and differentiation, this gene product may have applications in the adult for tissue
10 regeneration and the treatment of cancers. It may also act as a morphogen to control
cell and tissue type specification. Therefore, the polynucleotides and polypeptides of
5 the present invention are useful in treating, detecting, and/or preventing said disorders
and conditions, in addition to other types of degenerative conditions. Thus this protein
15 may modulate apoptosis or tissue differentiation and is useful in the detection,
treatment, and/or prevention of degenerative or proliferative conditions and diseases.
The protein is useful in modulating the immune response to aberrant polypeptides, as
20 may exist in proliferating and cancerous cells and tissues. The protein can also be
used to gain new insight into the regulation of cellular growth and proliferation.
Furthermore, the protein may also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
25 that modulate their interactions, in addition to its use as a nutritional supplement.

15 Protein, as well as, antibodies directed against the protein may show

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
30 related to SEQ ID NO:86 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
20 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
35 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 3160 of SEQ ID NO:86, b is an
integer of 15 to 3174, where both a and b correspond to the positions of nucleotide
40 25 residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

45 The translation product of this gene shares sequence homology with protein
disulfide isomerase from *Acanthamoeba castellanii* (See Genbank Locus
30 ACADISPROA accession L28174, genpep locus 456013) which is thought to be
important in converting proteins into their native conformations. The protein product
50 of this gene was also shown to have homology to a phospholipase C homologue

derived from a mast cell cDNA library (See Geneseq Accession No. R99411). All references and information available through these accessions are hereby incorporated by reference herein - for example, Gene 150 (1), 175-179 (1994).

Included in this invention as preferred domains are endoplasmic reticulum targeting sequence domain and the thioredoxin family active site domain, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Proteins that permanently reside in the lumen of the endoplasmic reticulum (ER) seem to be distinguished from newly synthesized secretory proteins by the presence of the C-terminal sequence Lys-Asp-Glu-Leu (KDEL) [1,2]. While KDEL is the preferred signal in many species, variants of that signal are used by different species. This situation is described in the following table.

Signal	Species-----
KDEL	Vertebrates, Drosophila, Caenorhabditis elegans, plants
HDEL	Saccharomyces cerevisiae, Kluyveromyces lactis, plants
DDEL	Kluyveromyces lactis
ADEL	Schizosaccharomyces pombe (fission yeast)
SDEL	Plasmodium falciparum

The signal is usually very strictly conserved in major ER proteins but some minor ER proteins have divergent sequences (probably because efficient retention of these proteins is not crucial to the cell). Proteins bearing the KDEL-type signal are not simply held in the ER, but are selectively retrieved from a post-ER compartment by a receptor and returned to their normal location. The consensus pattern is as follows: [KRHQA]-[DENQ]-E-L>. Thioredoxins are small proteins of approximately one hundred amino- acid residues which participate in various redox reactions via the reversible oxidation of an active center disulfide bond. They exist in either a reduced form or an oxidized form where the two cysteine residues are linked in an intramolecular disulfide bond. Thioredoxin is present in prokaryotes and eukaryotes and the sequence around the redox-active disulfide bond is well conserved. Bacteriophage T4 also encodes for a thioredoxin but its primary structure is not homologous to bacterial, plant and vertebrate thioredoxins. A number of eukaryotic

5 proteins contain domains evolutionary related to thioredoxin, all of them seem to be
protein disulphide isomerases (PDI). PDI (EC 5.3.4.1) is an endoplasmic reticulum
10 enzyme that catalyzes the rearrangement of disulfide bonds in various proteins. The
various forms of PDI which are currently known are: - PDI major isozyme: a
5 multifunctional protein that also function as the beta subunit of prolyl 4-hydroxylase
(EC 1.14.11.2), as a component of oligosaccharyl transferase (EC 2.4.1.119), as
15 thyroxine deiodinase (EC 3.8.1.4), as glutathione-insulin transhydrogenase (EC
1.8.4.2) and as a thyroid hormone-binding protein - ERp60 (ER-60; 58 Kd
microsomal protein). ERp60 was originally thought to be a phosphoinositide-specific
20 phospholipase C isozyme and later to be a protease. - ERp72. - P5. All PDI contains
two or three (ERp72) copies of the thioredoxin domain. The consensus pattern is as
follows: [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWTSE]-x(2)-[FYWGTV]-C-
[GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT]. The two C's form the redox-
25 active bond.

15 Preferred polypeptides of the invention comprise the following amino acid
sequence: SLHRFVLSQAKDEL (SEQ ID NO: 348), FIKFFAPWCGHCKALPTW
(SEQ ID NO: 349), and/or FIKFYAPWCGHCKTLPTW (SEQ ID NO: 350).
30 Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the endoplasmic reticulum
20 targeting sequence domain and thioredoxin family active site domain of the sequence
referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75
35 additional contiguous amino acid residues of this referenced sequence. The additional
contiguous amino acid residues is N-terminal or C-terminal to the endoplasmic
reticulum targeting sequence domain and thioredoxin family active site domain.
40 25 Alternatively, the additional contiguous amino acid residues is both N-terminal and
C-terminal to the endoplasmic reticulum targeting sequence domain and thioredoxin
family active site domain, wherein the total N- and C-terminal contiguous amino acid
45 residues equal the specified number. Based on the sequence similarity, the translation
product of this gene is expected to share at least some biological activities with
30 thioredoxin proteins. Such activities are known in the art, some of which are
described elsewhere herein.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: RRGRGVPGPRGRRLWSAACGHCQRLQPTWN
DLGDKYNSMEXAKVYVAKVDCTAHS DVC SAQGV RGYPTLKLFPQGEAV
KYQGPRDFQTLNWM LQTLNEEPVTPEPEVEPPSAPELKQGLYEL SASNFELH
VAQGDHFIKFFAPWCGHCKALAPTWEQLALGLEHSETVKIGKVDCTQHY
FLCSGNQVRGYPTLLWFRDGKKVDQYKGKRDLESLREYVESQLQRTETGA
TETVTPSEAPVLA AEPEADKGTVLALTENNFD DTTAEGITFIKFYAPWCGHC
KTLAPTWEELSKKEFPGLAGVKIAEVDCTAERNICKYSVRGYPTLLLFRRGGK
KVSEHSGGRDLDS LHRFVLSQAKDEL (SEQ ID NO: 351). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in human chondrosarcoma and endothelial cells and to a lesser extent in a wide range of normal and diseased adult and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chondrosarcoma and other cancers and proliferative disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, skeletal, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in chondrosarcoma, combined with the homology to protein disulfide isomerase and phospholipase C indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

5 chondrosarcoma and other cancers and proliferative disorders, and possibly as a
reagent for in vitro production of proteins. Representative uses are described in the
10 "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere
herein. Briefly, developmental tissues rely on decisions involving cell differentiation
5 and/or apoptosis in pattern formation.

15 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
20 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
25 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
30 modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
20 insight into the regulation of cellular growth and proliferation. Moreover, the
expression in endothelial cells indicates the protein is useful in the detection,
35 treatment, and/or prevention of a variety of vascular disorders and conditions, which
include, but are not limited to microvascular disease, vascular leak syndrome,
aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis,
40 and/or atherosclerosis. Furthermore, the protein may also be used to determine
biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify agents that modulate their interactions, in addition to its use as a
45 nutritional supplement. Protein, as well as, antibodies directed against the protein may
show utility as a tumor marker and/or immunotherapy targets for the above listed
30 tissues.

50 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are

5 related to SEQ ID NO:87 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
10 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
5 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 2766 of SEQ ID NO:87, b is an
15 integer of 15 to 2780, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 78**

This gene is expressed primarily in thyroid and thymus

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
25 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, thyroid diseases including thyroid cancer and diseases of function
15 including Grave's Disease, hyper- and hypo- thyroidism as well as Diseases of the
thymus. Similarly, polypeptides and antibodies directed to these polypeptides are
30 useful in providing immunological probes for differential identification of the
tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
20 particularly of the endocrine and immune systems, expression of this gene at
significantly higher or lower levels is routinely detected in certain tissues or cell types
35 (e.g., endocrine, immune, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
taken from an individual having such a disorder, relative to the standard gene
40 25 expression level, i.e., the expression level in healthy tissue or bodily fluid from an
individual not having the disorder.

The tissue distribution in thyroid cells and tissues indicates that
45 polynucleotides and polypeptides corresponding to this gene are useful for diagnosis
and treatment of diseases of the thyroid and thymus. Representative uses are
30 described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding
Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein.
50 Briefly, the protein can be used for the detection, treatment, and/or prevention of

Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1047 of SEQ ID NO:88, b is an integer of 15 to 1061, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 79

The translation product of this gene shares sequence homology with collagen which is thought to be important as a structural material in a variety of human tissues and products including hair, nails, muscle and bone.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPQGPAASPQRLRGLLLLLLQLPAPSSASEIPKGKQK AHSGRGRWWTCIMECA YKGQQECLVETGALGPMAFRVHLGSQVGMDSKEK RGNV (SEQ ID NO: 352). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and to a lesser extent in 12 week old early stage human, cpdidymus, healing groin wound, synovial hypoxia,

stromal cells, ulcerative colitis, breast and 8 week old embryo, as well as a variety of other normal and diseased cell types from adult and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders as well as Diseases of smooth muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 202 as residues: Glu-32 to Glu-46, Pro-63 to Ala-71, Pro-81 to Lys-90, Ser-97 to Trp-111, Lys-130 to Ser-135, Leu-147 to Cys-154, Asp-179 to Asn-186, Ser-219 to Gly-229. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and homology to collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of vascular diseases and/or disorders.

Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis),

5 atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus
erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and
10 pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In
addition, such disorders may predispose increased susceptibility to viral and bacterial
5 infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum,
herpes zoster, boils, cellulitis, crysipelas, impetigo, tinea, athletes foot, and
15 ringworm).

Moreover, the protein product of this gene may also be useful for the
treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma,
20 tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e.,
rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal
deformation, joint abnormalities, and chondrodysplasias (i.e. spondylocpiphysal
dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal
25 chondrodysplasia type Schmid). Moreover, the protein is useful in the detection,
treatment, and/or prevention of a variety of vascular disorders and conditions, which
include, but are not limited to microvascular disease, vascular leak syndrome,
aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis,
30 and/or atherosclerosis. Furthermore, the protein may also be used to determine
biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
20 receptors, to identify agents that modulate their interactions, in addition to its use as a
nutritional supplement. Protein, as well as, antibodies directed against the protein may
35 show utility as a tumor marker and/or immunotherapy targets for the above listed
tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
40 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:89 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
45 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
30 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1328 of SEQ ID NO:89, b is an
50

integer of 15 to 1342, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

This gene is expressed primarily in immune cells and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T cell or B cell leukemia and various immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 203 as residues: Gly-3 to Gln-9. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases such as immunodeficiencies and T cell and/or B cell leukemia. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

5

10

15

20

25

30

35

40

45

50

55

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:90, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.

30

5

10

15

20

25

30

35

40

45

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

The translation product of this gene shares sequence homology with IgE receptor. See for example, Isolation and Characterization of cDNAs coding for the Beta Subunit of the High-affinity Receptor for Immunoglobulin E, Proc. Natl. Acad. Sci. U S A. (1988 Sep.) 85(17): 6483-6487. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with IgE receptor proteins. Such activities are known in the art, some of which are described elsewhere herein. IgE and its receptors are believed to have evolved as a mechanism to protect mammals against parasites. But other and intrinsically innocuous antigens can subvert this system to provoke an allergic response. For human populations in industrialized countries, allergy and asthma now represent a far greater threat than parasitic infection, and the main impetus for current studies of the IgE system is the hope of understanding and intervening in the aetiology of allergic diseases. The high-affinity receptor for immunoglobulin (Ig) E (Fc epsilon RI) on mast cells and basophils plays a key role in IgE-mediated allergies. Fc epsilon RI is composed of one alpha, one beta, and two gamma chains, which are all required for cell surface expression of Fc epsilon RI, but only the alpha chain is involved in the binding to IgE. Fc epsilon RI-IgE interaction is highly species specific, and rodent Fc epsilon RI does not bind human IgE. New homolog can be used to develop anti-allergic agents. FcR deliver signals when they are aggregated at the cell surface. The aggregation of FcR having immunoreceptor tyrosine-based activation motifs (ITAMs) activates sequentially src family tyrosine kinases and syk family tyrosine kinases that connect transduced signals to common activation pathways shared with other receptors. FcR with ITAMs elicit cell activation, endocytosis, and phagocytosis. The nature of responses depends primarily on the cell type. The aggregation of FcR without ITAM does not trigger cell activation. Most of these FcR internalize their ligands, which can be endocytosed, phagocytosed, or transcytosed. The fate of internalized receptor-ligand complexes depends on defined sequences in the intracytoplasmic domain of the receptors. The coaggregation of different FcR results in positive or negative cooperation. Some FcR without ITAM use FcR with ITAM as signal transduction subunits. The coaggregation of antigen receptors or of FcR having ITAMs with FcR having immunoreceptor tyrosine-based inhibition motifs (ITIMs)

negatively regulates cell activation. FcR therefore appear as the subunits of multichain receptors whose constitution is not predetermined and which deliver adaptative messages as a function of the environment.

The polypeptide of this gene has been determined to have four transmembrane domains at about amino acid position 51 - 67, 89 - 105, 119 - 135, and 190 - 206 of the amino acid sequence referenced in Table I for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ETRVKTSLELLRTQLEPTGTVGNTIMTSQPVPN ETIIVLPSNVINFSQAEKPEPTNQGD~~SLKKHLHAEIKVIGTIQILCGMMVLSL~~ GILASASFSPNFTQVTSTLLNSAYPFIGPFFFIISGSLSIATEKRLTKLLVHSSLV GSILSALSALVGFIILSVKQATLNPASLQCELDKNNIPTRSYVSYFYHDSLYTT DCYTAKASLAGXLSLMLICTLLEFCLAVLTAVLRWKQAYSDFPGSVLFLPH SYIGNSGMSSKMTIHDCGYEELLTS (SEQ ID NO: 353). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MMVLSLGIILASASFSPNFTQVTSTLLNSAYPFIGPFFFI ISGSLSIATEKRLTKLLVHSSLVGSILSALSALVGFIILSVKQATLNPASLQCELDKNNIPTRSYVSYFYHDSLYTTDCYTAKASLAGXLSLMLICTLLEFCL AVLTAVLRWKQAYSDFPGSVLFLPHSYIGNSGMSSKMTIHDCGYEELLTS (SEQ ID NO: 354). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune system tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system diseases and/or disorders such as cancer. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 204 as residues: Gln-23 to Lys-39, Glu-150 to Thr-158. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells and tissues combined with the homology to IgE receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that

influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1556 of SEQ ID NO:91, b is an integer of 15 to 1570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 82

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GASCEGGGAAARAALGVHRSQKALLVFRRTL
SNLLYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLRLSRLLHPEAH
VPPAADRGASLQCVLHQAAPKSRPRSPAAGAALLHXPRTGDEPCREFHGN
GFPGPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSL

5 AFLSSLMFTSRNGLVGC GASCEGGGAAARAALGVHRSQKALLVFRRTLSNL
LYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLRSRLHPEAHVPP
10 AAD RGASLQCVLHQAAPKSRPRSPAAGAALLHXPRRTGDEPCREFHNGNFP
GPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSLA

5 FLSSLMFTSRNGLVGC (SEQ ID NO: 355). Polynucleotides encoding these
polypeptides are also provided.

15 The gene encoding the disclosed cDNA is believed to reside on chromosome
7. Accordingly, polynucleotides related to this invention are useful as a marker in
linkage analysis for chromosome 7.

20 10 This gene is expressed primarily in activated T cells, and to a lesser extent in a
wide variety of human tissues.

25 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
15 not limited to, immune and hematopoietic diseases and/or disorders, particularly
immunodeficiencies. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
30 identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the immune system, expression of this gene at
20 significantly higher or lower levels is routinely detected in certain tissues or cell types
(e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids
(e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
35 sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
40 25 individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 205 as residues Pro-67 to Ser-73. Polynucleotides
45 encoding said polypeptides are also provided.

50 The tissue distribution in activated T cells indicates that polynucleotides and
30 polypeptides corresponding to this gene are useful for diagnosis and treatment of
immunodeficiencies. Representative uses are described in the "Immune Activity" and
"infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and

elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 2936 of SEQ ID NO:92, b is an integer of 15 to 2950, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 83

The translation product of this gene was shown to have homology to the human transmembrane protein (See Genbank Accession No. gblAAC51364.11 (AF000959); all references and information available through this accession are hereby incorporated by reference herein; for example; Genomics 42 (2), 245-251 (1997)) which is thought to be implicated in velo-cardio-facial syndrome.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MGSAALEILGLVLCLVGWGGILACGLPMWQVTAFLD HNIVTAQTTWKGLWMSCVVQSTGTCSAKCTTRCWL (SEQ ID NO: 356). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 22. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 22.

This gene is expressed primarily in dementia brain tissue, and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly dementia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 206 as residues: Ser-201 to Tyr-217. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dementia brain tissue, combined with the homology to the transmembrane protein, indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of dementia, and potentially for velo-cardio-facial syndrome. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:93 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1708 of SEQ ID NO:93, b is an integer of 15 to 1722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 84

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LKRAPPALAKGLLQPSSTFQALETNIGDQVR
15 RHSTAVVIREMTSYLISFVLLIGVGCIEKDQSCPVFGGGRKRLHLLFVGGQLRQ
20 VRMLRGELSCACYRPHVQALQLGGCTCF (SEQ ID NO: 357). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the adult pulmonary system.

Therefore, polynucleotides and polypeptides of the invention are useful as
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cystic fibrosis, bronchitis and any pulmonary disorders in general.
30 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
40 pulmonary surfactant, pulmonary lavage/sputum, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene only in the pulmonary system indicates that it plays a key role in the functioning of the pulmonary system. This would suggest
45 that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung and the protein product could be used either in the treatment and/or detection of these disease states. The gene
50

or gene product may also be useful in the treatment and/or detection of pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 621 of SEQ ID NO:94, b is an integer of 15 to 635, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

The translation product of this gene was found to be homologous to CAM proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with CAM proteins. Such activities are known in the art, some of which are described elsewhere herein.

A preferred polypeptide variant of the invention comprises the following amino acid sequence: MLCPWRTANLGLLLILTIFLVAEAEAGAAQPNNSLM LQTSKENHALASSSLCMDEKQITQNYSKVLAENVTSWPVKMATNAVLC CPPIALRNLIITWEIILRGQPSCTKAYKKETNETKETNCTDERITWVSRPDQ NSDLQIRTVAITHDGYRCIMVTPDGNFHRGYHLQVLVTPEVTLFQNRNRITA VCKAVAGKPAAHISWIPEGDCATKQEYWSNGTVTVKSTCHWEVHNVSTV NCHVSHLTGNKSLYIELLPVPGAKKSSKLYIPYIILTIILTIVGXIWLLKVNG CXKYKLNKPESTPVVEEDEMOPYAFYTEKNNPLXXTTNKVKASEALQSEV

DTDLHTL (SEQ ID NO:208). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 271 - 287 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 288 to 348 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 208 as residues: Asp-53 to Tyr-61, Pro-105 to Ile-128, Arg-133 to Leu-140, Gln-182 to Ala-188, Pro-205 to Asn-218, Gly-259 to Ala-264, Asn-290 to Ser-302, Glu-307 to Tyr-314, Tyr-317 to Lys-332. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities,

immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product is applicable in conditions of general microbial infection, inflammation or cancer. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3784 of SEQ ID NO:95, b is an integer of 15 to 3798, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VIKLICPAAFPVYFQDMARGCVCSLCASVCIFLS SLFPLLPSVHSVNIISCLLLSKCFEGLELMCEHL YQLSQLHVLHHIFS YLLCTP (SEQ ID NO: 358). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in embryonic tissue and to a lesser extent in in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, cancer and neoplastic states. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, differentiating, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in embryonic tissue indicates that polynucleotides and
polypeptides corresponding to this gene are useful for the diagnosis and treatment of
10 developmental anomalies, fetal deficiencies and pre-natal disorders, as well as
abnormal cell proliferation and/or differentiation, neoplastic states and cancer.

5 Moreover, the expression within embryonic tissue and other cellular sources marked
by proliferating cells indicates this protein may play a role in the regulation of cellular
15 division, and may show utility in the diagnosis, treatment, and/or prevention of
developmental diseases and disorders, including cancer, and other proliferative
conditions. Representative uses are described in the "Hyperproliferative Disorders"
20 and "Regeneration" sections below and elsewhere herein. Briefly, developmental
tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
25 death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
15 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
potential roles in proliferation and differentiation, this gene product may have
30 applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
20 polynucleotides and polypeptides of the present invention are useful in treating,
35 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
40 degenerative or proliferative conditions and diseases. The protein is useful in
25 modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
45 protein may also be used to determine biological activity, to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
30 interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
50 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2669 of SEQ ID NO:96, b is an integer of 15 to 2683, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

The translation product of this gene shares sequence homology with inter-alpha-trypsin inhibitor which is thought to be important in inhibition of trypsin and other serine proteases (See Genbank Accession No. pirlS30350IS30350; all references and information available through this accession are hereby incorporated herein by reference; for example, Eur. J. Biochem. 179 (1), 147-154 (1989), J. Biol. Chem. 264 (27), 15975-15981 (1989), and J. Biol. Chem. 266 (2), 747-751 (1991)).

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes, and to a lesser extent, other immune and/or hematopoietic cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the

5 following amino acid sequence: YXIPGSTHASGRQRGSGRGEDDSGPPSTVINQ
NETFANIIFKPTVVQQARIAQNGILGDFIIRYDVNREQSIGDIQVLNGYFVHYF
10 APKDLPLPKNVVFLDSSASMVGTKLRQTKDALFTLHDLRPQDRFSIIGFS
NRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTDINGVLQRAIRLLNKYVAH
5 SGIGDRSVSLIVFLTDG KPTVGETHTLKILNNTREAARGQVCIFTIGIGNDVD
FRLEKLSLENCGLTRRVHEEEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVVQ
15 ATKTLFPNYFNGSEIIAGKLVDRKLDHLHVEVTASNSKKFIILKTDVPRPQK
AGKDVTSRPGDGEDXNHIERLWSYLTTKELLSSWLQSDDEPEKERLRQ
RAQALAVSYRFLTPFTSMKLRGPVPRMDGLEEAHGMSAAMGPEPVVQSVR
20 GAGTQPGPLLKKPYQPRIKSKTSVDGDPHFVVDFFLSRLTVCFNIDGQPGDIL
RLVSDHRDSGVTVNGELIGAPAPPNGHKKQRTYLRITITILINKPERSYLEITPS
RVILDGGDRLVLPQNQSVVVGSWGLEVSVSANANVTVTIQGSIAFVILHLYK
25 KPAPFQRHHLGFIYANSEGLSSNCHGLLGQFLNQDARLTEDPAGPSQNLTHP
LLLQVGEGPEAVLTVKGHVPPVWVKQRKIYN GEEQXDCWFARNMPPN
15 (SEQ ID NO: 359). Polynucleotides encoding these polypeptides are also provided.

30 This gene is expressed primarily in placenta and adipose tissue and to a lesser extent in several other organs and tissues including cancer.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of developing organs and metabolic diseases, in addition to
35 vascular diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
40 identification of the tissue(s) or cell type(s). For a number of disorders of the above
25 tissues or cells, particularly of the developing systems and metabolic systems, expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, vascular, and cancerous and wounded
45 tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative
30 to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 210 as residues: Lys-5 to Lys-10, Asn-33 to Lys-39, Asp-48 to Lys-54, Pro-62 to Asp-67, Asn-116 to Arg-123, His-157 to Ala-162, Val-242 to Lys-249, Val-251 to Asp-264. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in placenta, combined with the homology to inter-alpha-trypsin inhibitor and the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of developing and metabolic systems. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease,

5 vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery
disease, arteriosclerosis, and/or atherosclerosis. Polynucleotides and polypeptides of
10 the invention are also useful for the treatment, detection, and/or prevention of
inflammation, tumor invasion and metastasis, wound healing, liver disease,
5 disseminated intravascular coagulation, alzheimer's Disease, ophthalmic disease,
apoptosis, tissue remodeling, intrauterine growth retardation, preeclampsia,
15 angiogenesis, cell migration, fetal development, trophoblast implantation, ovulation,
pemphigus and psoriasis, and antiviral therapy. Furthermore, the protein may also be
used to determine biological activity, to raise antibodies, as tissue markers, to isolate
20 cognate ligands or receptors, to identify agents that modulate their interactions, in
addition to its use as a nutritional supplement. Protein, as well as, antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy targets
for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:97 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 2167 of SEQ ID NO:97, b is an
35 integer of 15 to 2181, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

40 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 88

The translation product of this gene was shown to have homology to the
human colon carcinoma antigen NY-CO-7 (See Genbank and Geneseq Accession
45 Nos. gblAAC18038.11 (AF039689) and WO9904265; all references available through
this accession are hereby incorporated herein by reference; for example, Int. J. Cancer
30 76 (5), 652-658 (1998)).

50 This gene is expressed primarily in breast and breast cancer and to a lesser
extent in several other organs and tissues including cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of reproductive organs and the gastrointestinal system, including cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, breast milk, chyme, bile, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 211 as residues: Gly-22 to Gly-28, Leu-71 to Phe-77, Asn-101 to Val-108, Pro-122 to Ser-127, Arg-149 to Pro-154, Gly-191 to Phe-196, Pro-199 to Thr-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast and breast cancer tissue, combined with the homology to a colon cancer antigen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the reproductive systems and cancers. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

5 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
10 also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
5 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
15 differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
20 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
15 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:98 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
35 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1943 of SEQ ID NO:98, b is an
40 25 integer of 15 to 1957, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 89

30 The translation product of this gene shares sequence homology with the amino
acid and protein sequence of a *Xenopus* transmembrane protein of unknown function.
The very 5'-end of the contig is identical to the mRNA for the human LGN mosaic
50 protein. Based on the sequence similarity, the translation product of this gene is

5 expected to share at least some biological activities with LGN mosaic proteins. Such activities are known in the art, some of which are described elsewhere herein.

10 Preferred polypeptides of the invention comprise the following amino acid sequence:

PRVRPPTKALAVTFTTFVTEPLKHIGKGTGEFIKALMKEIPALLHLPVLIIMAL
5 AILSFCYGAGKSVHVL RHIGGPEREPPQALRPDRRRQEEIDYRPGGAGDAD
FHYRGQMGPTEQGPYAKTYEGRREILRERDVDLRFQTGNKSPEVLRAFDVPD
15 AEAREHPTVVPSHKSPVLDTKPKETGGILGEGTPKESSTESSQSAKPVSGQDTS
GNTEGSPAAEKAQLKSEAAGSPDQGSTYSPARGVAGPRGQDPVSSPCG (SEQ
ID NO:339). Polynucleotides encoding such polypeptides are also provided.

20 10 The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

25 This gene is expressed primarily in small intestine and adipocytes and to a lesser extent in various other normal and transformed cell types, mostly of endocrine origin.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, conditions of growth and metabolism. Similarly, polypeptides and
20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, gastrointestinal, and
35 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, bile, chyme, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

40 25 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 212 as residues: Pro-40 to Gly-68, Gly-79 to Arg-93, Phe-106 to Glu-114, Pro-122 to His-129, Thr-143 to Gly-149, Gly-155 to Ala-168,
45
50
55

Val-171 to Gly-182, Ala-195 to Pro-207, Pro-214 to Val-220. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in small intestine indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of disorders of growth and metabolism as well as endocrine abnormalities. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:99, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

The translation product of this gene shares sequence homology with IgE receptor beta chain which is thought to be important in immune function.

This gene is expressed primarily in kidney medulla tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and renal diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and renal systems,

expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, renal, urogenital, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in kidney renal medulla tissue, combined with the homology to the IgE receptor beta chain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of immune and renal disorders. The protein product of this gene could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Alternatively, this gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the

protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 873 of SEQ ID NO: 100, b is an integer of 15 to 887, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 100, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

The translation product of this gene shares sequence homology with Diff 40 gene product (See Genbank Accession No. gh|AAC51134.1; all references and information available through this reference are hereby incorporated herein).

Preferred polypeptides of the invention comprise the following amino acid sequence: PRVRSIKVTELKGLANHVVVGSVCETKDLFAALPQVVAVDIN
DLGTIKLSLEVTWSPFDKDDQPSAASSVNKASTVTKRFSTYSQSPDTPS
LREQAFYNMLRRQEELENGTAWSLSESSDDSSSPQLSGTARHSPAPRPLV
QQPEPLPIQVAFRRPETPSSGPLDEEGAVAPVLANGHAPYSRTLHISEASVNA
ALAEASVEAVGPKSLSWGSPPTHFAPTHGKHPSVPPALDPGHSATST
LGTTGSVPTSTDPAHLDVHKSTDGSELPGPTHTTTGSTYSAITTTHS
APSPLTHTTTGSTHKPIISTLTGPTLNIIGPVQTTTSPHTMPSPSSHNSPQ
YVDFCSSVCDNIFVHYVIGIFFHTLYSSKTL (SEQ ID NO: 360), and/or PRVRS
IKVTELKGLANHVVVGSVCETKDLFAALPQVVAVDINDLGTIKLSLEVTWSP
FDKDDQPSAASSVNKASTVTKRFSTYSQSPDTPSLREQAFYNMLRRQEELE
NGTAWSLSESSDDSSSPQLSGTARHSPAP RPLVQQPEPLPIQVAFRRPET

PSSGPLDEEGAVAPVLANGHAPYSRTLSEASVNAALAEASVEAVGPKSL
SWGSPPTHPAPTHGKHPSVPPALDPGHSATSSTLGTTGSVPTSTD (SEQ ID
NO: 361). Polynucleotides encoding these polypeptides are also provided.

Polypeptides of the invention do not consist of the primary amino acid sequence
shown as Geneseq Accession No.W69430, which is hereby incorporated herein by
reference.

This gene is expressed primarily in liver and to a lesser extent in gall bladder
tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, metabolic and endocrine diseases and/or disorders, particularly hepatic
and gall bladder disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the metabolic and endocrine systems, expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., hepatic, metabolic, gall bladder, gastrointestinal, and cancerous and
wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, bile, synovial
fluid and spinal fluid) or another tissue or cell sample taken from an individual having
such a disorder, relative to the standard gene expression level, i.e., the expression
level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 214 as residues: Val-9 to Cys-14, Pro-42 to Thr-47,
Thr-56 to Ala-64, Asp-88 to His-98, Cys-128 to Ser-136, Arg-153 to Trp-161.
Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in liver and gall bladder, combined with the homology
to the diff 40 gene product indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the study and treatment of endocrine and
metabolic disorders. polynucleotides and polypeptides corresponding to this gene are
useful for the detection and treatment of liver disorders and cancers. Representative
uses are described in the "Hyperproliferative Disorders", "infectious disease", and

"Binding Activity" sections below, in Example 11, and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1234 of SEQ ID NO:101, b is an integer of 15 to 1248, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 3 - 19 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in fetal brain and to a lesser extent in pancreas tumor, melanocyte and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly neurodevelopmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are

5 useful in providing immunological probes for differential identification of the
tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
10 particularly of the central nervous system, expression of this gene at significantly
higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural,
5 developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph,
serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue
15 or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

20 The tissue distribution in fetal brain tissue indicates that polynucleotides and
polypeptides corresponding to this gene are useful for diagnosis and treatment of
developmental disorders of the central nervous system. Representative uses are
described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in
25 Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not
15 limited to the detection, treatment, and/or prevention of Alzheimer's Disease,
Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,
encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,
30 congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms,
hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
20 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,
and altered behaviors, including disorders in feeding, sleep patterns, balance, and
35 perception. In addition, elevated expression of this gene product in regions of the
brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,
40 25 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
45 identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
30 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1827 of SEQ ID NO:102, b is an integer of 15 to 1841, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 93

The translation product of this gene shares sequence homology with a probable membrane protein YGL054c -yeast (*Saccharomyces cerevisiae*). Moreover,

The translation product of this gene also have homology to the human and mouse cornichon protein which is known to be necessary for both anterior-posterior and dorsal-ventral pattern formation in conjunction with the EGF receptor signaling process (See Genbank Accession Nos. gblAAC98388.11 (AF104398), and spIP52159; all references and information available through these accessions are hereby incorporated herein by reference: for example, Cell 81 (6), 967-978 (1995)).

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 57 - 73, and 121 - 137 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 - 14 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: YGCEKTTEGRRRRRRMEAVVFVSLDDCCAL IFLSVYFITLSDLECDYINARSCCSKLNKWWIPELIGHTIVTVLLLSLHWF IFLNLVPATWNIYR YIMVPSGNMGVFDPTFIHNRGQLKSHMKEAMIKLGFH LLC FMYLYSMILALIND (SEQ ID NO:362). Polynucleotides encoding these polypeptides are also provided.

5 The gene encoding the disclosed cDNA is believed to reside on chromosome
1. Accordingly, polynucleotides related to this invention are useful as a marker in
10 linkage analysis for chromosome 1.

This gene is expressed primarily in activated T-cells and to a lesser extent in
5 endometrial tumor, T cell helper II cells, microvascular endothelial cells, Raji cells
treated with cyclohexamide and umbilical vein endothelial cells.

15 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, immune, hematopoietic, and vascular diseases and/or disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
25 immune system, expression of this gene at significantly higher or lower levels is
15 routinely detected in certain tissues or cell types (e.g., immune, hematopoietic,
vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell
30 sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
20 individual not having the disorder.

35 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 216 as residues: Ser-39 to Asn-45, Asn-103 to Ser-
109. Polynucleotides encoding said polypeptides are also provided.

40 The tissue distribution in activated T-cells indicates that polynucleotides and
25 polypeptides corresponding to this gene are useful for diagnosis and treatment of
immune disorders involving activated T-cells. Representative uses are described in
the "Immune Activity" and "infectious disease" sections below, in Example 11, 13,
45 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene
product indicates a role in regulating the proliferation, survival, differentiation, and/or
30 activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or

5 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

10 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
5 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
15 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
20 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
25 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
15 in the differentiation and/or proliferation of various cell types. Moreover, the protein
is useful in the detection, treatment, and/or prevention of a variety of vascular
30 disorders and conditions, which include, but are not limited to microvascular disease,
vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery
20 disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be
used to determine biological activity, to raise antibodies, as tissue markers, to isolate
35 cognate ligands or receptors, to identify agents that modulate their interactions, in
addition to its use as a nutritional supplement. Protein, as well as, antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy targets
40 25 for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:103 and may have been publicly available prior to conception
of the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO: 103, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 103, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 94

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARAPAPSLPPLPSPAPALAPAHSLGLLLGRMS
10 GSSLPSALALSLLL VSGSLLPGPGAAQNVRVQSGQDQ (SEQ ID NO: 363).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in dendritic cells and to a lesser extent in healing abdomen wound, and pancreas islet cell tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly wound healing disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
20 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or
40 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 217 as residues: Gln-34 to Lys-40. Polynucleotides
45 encoding said polypeptides are also provided.

The tissue distribution in dendritic cells and early healing wound indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating
50

wounds to enhance the healing process. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27; and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

5 cumbersome. Accordingly, preferably excluded from the present invention are one or
10 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1154 of SEQ ID NO: 104, b is an
integer of 15 to 1168, where both a and b correspond to the positions of nucleotide
5 residues shown in SEQ ID NO: 104, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 95

Contact of cells with supernatant expressing the product of this gene has been
shown to increase the permeability of the plasma membrane of aortic smooth muscle
20 cells to calcium. Thus it is likely that the product of this gene is involved in a signal
transduction pathway that is initiated when the product binds a receptor on the surface
of the plasma membrane of both smooth muscle cells, and in other cell-lines or tissue
cell types. Thus, polynucleotides and polypeptides have uses which include, but are
25 not limited to, activating smooth muscle cells. Binding of a ligand to a receptor is
known to alter intracellular levels of small molecules, such as calcium, potassium and
sodium, as well as alter pH and membrane potential. Alterations in small molecule
concentration can be measured to identify supernatants which bind to receptors of a
30 particular cell.

This gene is expressed primarily in pancreatic carcinoma, gall bladder and
20 primary dendritic cells.

35 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, metabolic and immune diseases and/or disorders, particularly cancers,
40 such as pancreatic carcinoma and gall bladder tumor. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the immune system, expression
45 of this gene at significantly higher or lower levels is routinely detected in certain
tissues or cell types (e.g., metabolic, immune, hematopoietic, and cancerous and
30 wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid
and spinal fluid) or another tissue or cell sample taken from an individual having such
50

a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 218 as residues: Lys-34 to Ile-41. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pancreatic carcinoma and gall bladder indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancer, such as pancreatic carcinoma and gall bladder tumors.

Representative uses are described here and elsewhere herein. Alternatively, the detected calcium flux biological activity indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1161 of SEQ ID NO: 105, b is an integer of 15 to 1175, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 105, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 10 - 26 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 27 to 48 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed primarily in osteosarcoma, wilm's tumor, ovarian cancer and in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory diseases and cancers, such as osteosarcoma, wilm's tumor and ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., skeletal, renal, reproductive, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 219 as residues: Ser-30 to Pro-35. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of inflammatory conditions and cancer, such as osteosarcoma, wilm's tumor and ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases

5 and disorders, including cancer, and other proliferative conditions. Representative
10 uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and elsewhere herein. Briefly, developmental tissues rely on decisions
involving cell differentiation and/or apoptosis in pattern formation.

15 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
20 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
25 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
30 modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
35 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

40 Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:106 and may have been publicly available prior to conception
of the present invention. Preferably, such related polynucleotides are specifically
45 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
30 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1007 of SEQ ID NO:106, b is an
50

integer of 15 to 1021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 106, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSKDCVLYAFLDPGMAVPLFLYIFTLLPLLPFLLSLCFSPLTVKRSSSESSEKSSL (SEQ ID NO: 364). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial amniotic fluid, fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level; i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 220 as residues: Thr-28 to Ser-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in ovarian tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing cancer, e.g., ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of

developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 816 of SEQ ID NO:107, b is an integer of 15 to 830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 98

This gene is expressed primarily in macrophages and breast cancer tissue and to a lesser extent in osteoblasts and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system dysfunction; inflammation; breast cancer; cancer; osteoporosis; osteopetrosis; peristaltic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and skeletal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 221 as residues: Glu-16 to Ala-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. Expression in macrophages and other hematopoietic cell types indicates that this gene product is involved in the regulation of hematopoietic cell survival, proliferation, differentiation, or activation. It is involved in the control of such processes as immune surveillance, antigen presentation, T cell activation, cytokine release, and inflammation. Expression in breast cancer tissue may possibly correlate with the diagnosis and differentiation of cancerous tissue from normal breast tissue.

5

10

Expression in osteoblasts and osteoclasts may implicate this gene product in the process of bone turnover, and target it as a likely candidate for the treatment of osteoporosis and/or osteopetrosis. Finally, expression in smooth muscle may indicate an involvement in the normal function of numerous internal organs and in the function of the digestive system.

15

20

25

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1287 of SEQ ID NO: 108, b is an integer of 15 to 1301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 108, and where b is greater than or equal to a + 14.

30

35

40

45

50

55

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq.	Start Codon	Signal Pep	5' NT of First AA of Signal	AA SEQ ID NO	First AA of AA of	Sig of AA of	First AA of AA of	Last AA of AA of	ORF
1	HDPK41	209965 06/11/98	pCMVSPORT 3.0	11	1564	1	1564	39	39	124	1	26	27	369		
2	11FXGT26	209965 06/11/98	Lambda ZAP II	12	1757	1	1757	13	13	125	1	22	23	85		
3	HLTGX30	209965 06/11/98	Uni-ZAP XR	13	1373	1	1373	13	13	126	1	41	42	43		
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	14	3740	1908	3740	50	50	127	1	1	2	319		
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	109	1932	98	1932	313	313	222	1	35	36	42		
5	HNTMZ90	209965 06/11/98	pSPORT	15	1196	1	1196	282	282	128	1	21	22	45		

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of 3' NT of Clone Seq.	5' NT of 5' NT of Start Codon	5' NT of First AA of Signal	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted	Last AA of ORF
6	HP1BX03	209965 06/11/98	Uni-ZAP XR	16	2209	1	2178	81	129	1	29	30	709
7	H6EDY30	209965 06/11/98	Uni-ZAP XR	17	1774	1	1774	321	130	1	29	30	414
8	HAMGR28	209965 06/11/98	pCMVSPORT 3.0	18	1674	47	1674	98	131	1	18	19	242
8	HAMGR28	209965 06/11/98	pCMVSPORT 3.0	110	1534	1	1534	40	223	1	18	19	203
9	HAPNZ94	209965 06/11/98	Uni-ZAP XR	19	2018	255	2018	287	132	1	36	37	312
10	HATCP77	209965 06/11/98	Uni-ZAP XR	20	2098	1	2098	37	133	1	21	22	182

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HDABR72	209965 06/11/98	pSport1	21	1746	1	1746	28	134	1	29	30	146
12	HDPKB18	209965 06/11/98	pCMVSPORT 3.0	22	2876	1	2876	98	135	1	21	22	122
12	HDPKB18	209965 06/11/98	pCMVSPORT 3.0	111	2871	1	2871	87	224	1	21	22	42
13	HEQCC55	209965 06/11/98	pCMVSPORT 3.0	23	1052	30	1052	62	136	1	27	28	112
13	HEQCC55	209965 06/11/98	pCMVSPORT 3.0	112	1037	1	1037	57	225	1	27	28	155
14	HETIDE26	209965 06/11/98	Uni-ZAP XR	24	1541	1	1541	205	137	1	29	30	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HOEDH84	209965 06/11/98	Uni-ZAP XR	25	2079	1	2079	256	256	138	1	20	21	404
16	HPIBT55	209965 06/11/98	Uni-ZAP XR	26	1947	129	1947	253	253	139	1	30	31	95
17	HSLCS05	209965 06/11/98	Uni-ZAP XR	27	3379	1	3354	168	168	140	1	23	24	239
18	HDPDD03	209965 06/11/98	pCMVSPORT 3.0	28	2006	1	2006	233	233	141	1	21	22	53
19	HDPDI66	209965 06/11/98	pCMVSPORT 3.0	29	3070	1	3070	93	93	142	1	45	46	66
20	HDTDQ23	209965 06/11/98	pCMVSPORT 2.0	30	2227	1	2206	148	148	143	1	20	21	108

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of 3' NT of Clone Seq.	5' NT of 3' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HDTDQ23	209965 06/11/98	pCMVSPORT 2.0	113	2214	1	2206	148	148	1	20	21	73
21	HE2PY40	209965 06/11/98	Uni-ZAP XR	31	1288	1	1288	147	147	1	22	23	83
22	HEONM66	209965 06/11/98	pSPORT1	32	3280	1	3280	89	89	1	24	25	166
22	HEONM66	209965 06/11/98	pSPORT1	114	3300	1	3300	98	98	1	20	21	166
23	HKAEG43	209965 06/11/98	pCMVSPORT 2.0	33	1297	1	1297	32	32	1	29	30	70
23	HKAEG43	209965 06/11/98	pCMVSPORT 2.0	115	1286	1	1286	21	21	1	29	30	70

Genc No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	Signal Pep Y	AA SEQ ID NO	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	34	2184	1	2184	19	19	147	1	19	20	412
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	116	2189	1	2189	26	26	229	1	21	22	272
25	HLMDO03	209965 06/11/98	Uni-ZAP XR	35	949	1	949	72	72	148	1	45	46	84
26	HMAGK93	209965 06/11/98	Uni-ZAP XR	36	3338	162	1884	164	164	149	1	30	31	153
27	HMEAL02	209965 06/11/98	Lambda ZAP II	37	1563	1	1563	237	237	150	1	33	34	129
28	IIMKCH52	209965 06/11/98	pSportI	38	1048	1	1048	53	53	151	1	17	18	61

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal	AA SEQ ID NO	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HCEFB69	209965 06/11/98	Uni-ZAP XR	39	1430	1	1430	188	188	152	1	24	25	224
30	HNFFC43	203027 06/26/98	Uni-ZAP XR	40	2103	209	2058	488	488	153	1	15	16	68
31	HSPMG77	203027 06/26/98	pSport1	41	2349	1	2349	130	130	154	1	46	47	83
32	HSQAC69	203027 06/26/98	Uni-ZAP XR	42	1559	1	1559	146	146	155	1	21	22	60
33	IISTBJ86	203027 06/26/98	Uni-ZAP XR	43	1766	1	1766	120	120	156	1	24	25	83
34	HLDQR62	203027 06/26/98	pCMVSPORT 3.0	44	2572	427	2572	520	520	157	1	18	19	161

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total Clone Seq. NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of First AA of Signal Pep	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
35	HUVD143	203027 06/26/98	Uni-ZAP XR	45	526	69	89	89	158	1	31	32	146
36	H/ADCP14	203027 06/26/98	pSport1	46	1032	1	35	35	159	1	20	21	142
37	HBXCF95	203027 06/26/98	ZAP Express	47	2680	1	118	118	160	1	22	23	50
38	HFOBU15	203027 06/26/98	pCMVSPORT 3.0	48	1730	1	56	56	161	1	26	27	64
39	HIL1BD22	203027 06/26/98	Uni-ZAP XR	49	1275	1	53	53	162	1	39	40	58
40	HOEU24	203027 06/26/98	Uni-ZAP XR	50	1762	1	113	113	163	1	21	22	374

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of 5' NT Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HOEU24	203027 06/26/98	Uni-ZAP XR	117	1763	1	1763	113	230	1	21	22	81
41	HITBR96	203027 06/26/98	Uni-ZAP XR	51	2059	1	2059	96	164	1	26	27	63
42	HWHQS55	203027 06/26/98	pCMVSPORT 3.0	52	3282	1	3282	169	165	1	26	27	742
43	HCEEK50	203027 06/26/98	Uni-ZAP XR	53	1860	1	1860	233	166	1	17	18	213
44	HCWBU94	203027 06/26/98	ZAP Express	54	770	1	770	109	167	1	26	27	212
45	HE2NR62	203027 06/26/98	Uni-ZAP XR	55	1093	1	1093	145	168	1	38	39	74

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal	First AA of Signal	Y	First AA of Signal	First AA of Signal	Last AA of Signal	ORF
46	HHS GH19	203027 06/26/98	Uni-ZAP XR	56	632	1	632	291	291	169	1	15	16	47	
47	HDP GT01	203027 06/26/98	pCMV Sport 3.0	57	2687	138	2687	8	8	170	1	28	29	87	
48	HOBA F11	203027 06/26/98	pBluescript	58	619	153	579	166	166	171	1	30	31	41	
49	HOHCA35	203027 06/26/98	pCMV Sport 2.0	59	1378	1	1378	153	153	172	1	15	16	47	
50	HPMGP24	203027 06/26/98	Uni-ZAP XR	60	1126	1	1126	215	215	173	1	33	34	232	
51	HSDIE16	203027 06/26/98	Uni-ZAP XR	61	2078	1	2078	182	182	174	1	29	30	44	

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
52	HSOBK48	203027 06/26/98	Uni-ZAP XR	62	762	1	762	433	433	175	1	16	17	84
53	HTADH39	203027 06/26/98	Uni-ZAP XR	63	1094	1	1094	173	173	176	1	24	25	65
54	HUSGT36	203027 06/26/98	pSport1	64	1361	1	1361	112	112	177	1	16	17	54
55	HVA/LE95	203027 06/26/98	pSport1	65	947	1	947	325	325	178	1	14	15	82
56	HHEAH25	203071 07/27/98	pCMV Sport 3.0	66	1376	1	1376	43	43	179	1	31	32	330
56	HHEAI125	203071 07/27/98	pCMV Sport 3.0	118	1375	1	1375	43	43	231	1	31	32	71

Gene No.	cDNA Clone ID	ATCC Deposit No. and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	Signal Pep	AA SEQ NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
57	HBJIY92	203071 07/27/98	Uni-ZAP XR	67	2434	487	2366	548	548	180	1	29	30	40
58	HCLCW50	203071 07/27/98	Lambda ZAP II	68	1086	1	1086	255	255	181	1	17	18	51
59	HDRMF68	203071 07/27/98	pSport1	69	1262	1	1262	309	309	182	1	22	23	54
60	HOUUG12	203071 07/27/98	Uni-ZAP XR	70	1642	35	1642	116	116	183	1	22	23	61
61	HEEAQ11	203071 07/27/98	Uni-ZAP XR	71	921	1	921	213	213	184	1	28	29	147
62	HEEAZ65	203071 07/27/98	Uni-ZAP XR	72	906	1	906	182	182	185	1	19	20	160

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	NT SEQ ID NO: NT Seq.	5' NT of 3' NT of Clone Seq.	5' NT of 3' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
63	HEGAN94	203071 07/27/98	Uni-ZAP XR	73	680	1	680	133	186	1	23	24	121
64	HPXBL33	203071 07/27/98	Lambda ZAP II	74	1633	1	1633	152	187	1	24	25	162
65	HLIBD68	203071 07/27/98	pCMV Sport 1	75	1022	1	1022	186	188	1	35	36	50
66	HLTCO33	203071 07/27/98	Uni-ZAP XR	76	1184	1	1184	80	189	1	18	19	64
67	HL YAC95	203071 07/27/98	pSport1	77	312	1	312	92	190	1	16	17	46
68	HNFGF20	203071 07/27/98	Uni-ZAP XR	78	1370	38	1370	206	191	1	45	46	143

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq	5' NT of Clone Seq	3' NT of Clone Seq	5' NT of Start Codon	5' NT of First AA of Signal Pep	First AA of ID NO: Y	First AA of Sig Pep	Last AA of Secreted Portion	Last AA of ORF	
69	HNHKS18	203071 07/27/98	Uni-ZAP XR	79	368	1	368	125	125	192	1	36	37	81
70	HSLJW78	203071 07/27/98	Uni-ZAP XR	80	1088	1	1088	159	159	193	1	20	21	44
71	HHFHD01	203071 07/27/98	Uni-ZAP XR	81	1862	1	1862	177	177	194	1	16	17	41
72	HLWAE11	203071 07/27/98	pCMVSPORT 3.0	82	1618	1	1618	85	85	195	1	27	28	259
73	HCYBN55	203071 07/27/98	pBluescript SK-	83	2034	1	1984	341	341	196	1	19	20	117
73	HCYBN55	203071 07/27/98	pBluescript SK-	119	1022	78	1022		3	232	1	1	2	225

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of 5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted	Last AA of ORF	
74	HEONX38	203071 07/27/98	pSport1	84	2240	5	2240	23	23	197	1	23	24	698
74	HEONX38	203071 07/27/98	pSport1	120	2311	1	2311	24	24	233	1	23	24	314
75	HLDQU79	203071 07/27/98	pCMVSPORT 3.0	85	1488	1	1488	99	99	198	1	23	24	348
76	HSYBK21	203071 07/27/98	pCMVSPORT 3.0	86	3174	1	1466	119	119	199	1	29	30	401
77	HELBC12	203071 07/27/98	Uni-ZAP XR	87	2780	2110	2738	120	120	200	1	30	31	324
78	HTHDS25	203071 07/27/98	Uni-ZAP XR	88	1061	1	1061	70	70	201	1	15	16	90

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of 5' NT of Start Codon	Signal AA of NT	Y	AA SEQ ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
79	HFIHO70	203071 07/27/98	pSport1	89	1342	1	1271	141	141	202	1	30	31	243	
79	HFIHO70	203071 07/27/98	pSport1	121	1286	1	1279	131	131	234	1	30	31	93	
80	HPME186	203071 07/27/98	Uni-ZAP XR	90	770	40	770	50	50	203	1	30	31	75	
81	HSOBV29	203071 07/27/98	Uni-ZAP XR	91	1570	207	1570	244	244	204	1	24	25	248	
82	HWABY10	203071 07/27/98	pCMVSPORT 3.0	92	2950	78	2914	263	263	205	1	22	23	168	
83	HACCI17	203071 07/27/98	Uni-ZAP XR	93	1722	336	1714	461	461	206	1	24	25	218	

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of 5' NT of Clone Seq. Codon	5' NT of First AA of ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Purtion	Last of ORF	
83	HACCII7	203071 07/27/98	Uni-ZAP XR	122	1380	12	1380	135	235	1	24	25	72
84	HAPQT22	203070 07/27/98	Uni-ZAP XR	94	635	1	635	132	207	1	17	18	72
85	HDPBO81	203070 07/27/98	pCMVSPORT 3.0	95	3798	1	3798	265	208	1	26	27	348
85	HDPBO81	203070 07/27/98	pCMVSPORT 3.0	123	3793	1	3793	255	236	1	26	27	348
86	HDPGI49	203070 07/27/98	pCMVSPORT 3.0	96	2683	1	2640	266	209	1	29	30	72
87	HDTBV77	203070 07/27/98	pCMVSPORT 2.0	97	2181	1	2181	326	210	1	22	23	608

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal	NT of AA of ID NO: Y	First AA of Sig. Pep	Last AA of Sig. Pep	First AA of Secreted Portion	Last AA of ORF
88	HFIUE82	203070 07/27/98	pSport1	98	1957	1	1957	24	24	211	1	23	24	251
89	HHEND31	203070 07/27/98	pCMV Sport 3.0	99	1112	1	1112	109	109	212	1	25	26	225
90	HKMND01	203069 07/27/98	pBluescript	100	887	1	887	23	23	213	1	26	27	50
91	HLDB184	203069 07/27/98	pCMV Sport 3.0	101	1248	1	1248	50	50	214	1	35	36	171
92	HLTEK17	203069 07/27/98	Uni-ZAP XR	102	1841	1	1841	112	112	215	1	13	14	47
93	HEBEJ18	203069 07/27/98	Uni-ZAP XR	103	685	7	649	51	51	216	1	15	16	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq.	Start Codon	Signal Pep	5' NT of First AA of Signal	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
94	HMEAI48	203069 07/27/98	Lambda ZAP II	104	1168	1	1168	95	95	217	1	29	30	40	40
95	HNHGN91	203069 07/27/98	Uni-ZAP XR	105	1175	161	1175	184	184	218	1	24	25	51	51
96	HODAE92	203069 07/27/98	Uni-ZAP XR	106	1021	1	1021	123	123	219	1	29	30	48	48
97	HODDF13	203069 07/27/98	Uni-ZAP XR	107	830	1	830	46	46	220	1	27	28	41	41
98	HCDCF30	203027 06/26/98	Uni-ZAP XR	108	1301	102	1301	151	151	221	1	14	15	40	40

5
10
15
20
25
30
35
40
45
50
55

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization

5 probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the
cDNA contained in the deposited clone. These probes will also hybridize to nucleic
10 acid molecules in biological samples, thereby enabling a variety of forensic and
diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID
5 NO:Y may be used to generate antibodies which bind specifically to the secreted
proteins encoded by the cDNA clones identified in Table 1.

15 Nevertheless, DNA sequences generated by sequencing reactions can contain
sequencing errors. The errors exist as misidentified nucleotides, or as insertions or
deletions of nucleotides in the generated DNA sequence. The erroneously inserted or
20 10 deleted nucleotides cause frame shifts in the reading frames of the predicted amino
acid sequence. In these cases, the predicted amino acid sequence diverges from the
actual amino acid sequence, even though the generated DNA sequence may be greater
than 99.9% identical to the actual DNA sequence (for example, one base insertion or
25 deletion in an open reading frame of over 1000 bases).

15 Accordingly, for those applications requiring precision in the nucleotide
sequence or the amino acid sequence, the present invention provides not only the
generated nucleotide sequence identified as SEQ ID NO:X and the predicted
30 translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of
plasmid DNA containing a human cDNA of the invention deposited with the ATCC,
20 as set forth in Table 1. The nucleotide sequence of each deposited clone can readily
be determined by sequencing the deposited clone in accordance with known methods.
35 The predicted amino acid sequence can then be verified from such deposits.
Moreover, the amino acid sequence of the protein encoded by a particular clone can
also be directly determined by peptide sequencing or by expressing the protein in a
40 25 suitable host cell containing the deposited human cDNA, collecting the protein, and
determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID
45 NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be
isolated in accordance with known methods using the sequence information disclosed
30 herein. Such methods include preparing probes or primers from the disclosed
sequence and identifying or amplifying the corresponding gene from appropriate
50 sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of

these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95%

"identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence

that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.

5
10
These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

15
20
25
30
35
40
45
50
55
As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

20
25
30
35
40
45
50
55
If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and

C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence, which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an

organism. (Genes II. Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic

activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln; replacement of

the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is

1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the

invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

5 In the present invention, "epitopes" refer to polypeptide fragments having
antigenic or immunogenic activity in an animal, especially in a human. A preferred
10 embodiment of the present invention relates to a polypeptide fragment comprising an
epitope, as well as the polynucleotide encoding this fragment. A region of a protein
5 molecule to which an antibody can bind is defined as an "antigenic epitope." In
contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an
15 antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA
81:3998-4002 (1983).)

Fragments which function as epitopes may be produced by any conventional
20 means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985)
further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at
least seven, more preferably at least nine, and most preferably between about 15 to
25 about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including
15 monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson
et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according
30 to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et
al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et
20 al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes
the secreted protein. The immunogenic epitopes may be presented together with a
35 carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or,
if it is long enough (at least about 25 amino acids), without a carrier. However,
immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to
40 be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes
25 in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is
45 meant to include intact molecules as well as antibody fragments (such as, for
example, Fab and F(ab')₂ fragments) which are capable of specifically binding to
30 protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear
more rapidly from the circulation, and may have less non-specific tissue binding than
50 an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these

5 fragments are preferred, as well as the products of a FAB or other immunoglobulin
expression library. Moreover, antibodies of the present invention include chimeric,
10 single chain, and humanized antibodies.

5 **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion
15 proteins. For example, the polypeptide of the present invention, when fused to a
second protein, can be used as an antigenic tag. Antibodies raised against the
polypeptide of the present invention can be used to indirectly detect the second
20 protein by binding to the polypeptide. Moreover, because secreted proteins target
cellular locations based on trafficking signals, the polypeptides of the present
invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present
25 invention include not only heterologous signal sequences, but also other heterologous
functional regions. The fusion does not necessarily need to be direct, but may occur
15 through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics
30 of the polypeptide of the present invention. For instance, a region of additional amino
acids, particularly charged amino acids, may be added to the N-terminus of the
20 polypeptide to improve stability and persistence during purification from the host cell
or subsequent handling and storage. Also, peptide moieties may be added to the
35 polypeptide to facilitate purification. Such regions may be removed prior to final
preparation of the polypeptide. The addition of peptide moieties to facilitate handling
of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and
40 specifically epitopes, can be combined with parts of the constant domain of
immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins
facilitate purification and show an increased half-life in vivo. One reported example
45 describes chimeric proteins consisting of the first two domains of the human CD4-
polypeptide and various domains of the constant regions of the heavy or light chains
30 of mammalian immunoglobulins. (EP A 394,827; Trautnecker et al., Nature 331:84-
86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the
50

IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem, 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others; many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral

5
10
vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

15
The polynucleotides may be joined to a vector containing a selectable marker
5 for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the
15 vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

20
The polynucleotide insert should be operatively linked to an appropriate
10 promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The
25 expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding
15 portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

30
As indicated, the expression vectors will preferably include at least one
selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin
20 resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin
35 resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as
40
25 CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

45
Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-
9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,
pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and
30 ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1

5 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available
10 from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

10 Introduction of the construct into the host cell can be effected by calcium
phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated
5 transfection, electroporation, transduction, infection, or other methods. Such methods
are described in many standard laboratory manuals, such as Davis et al., Basic
15 Methods In Molecular Biology (1986). It is specifically contemplated that the
polypeptides of the present invention may in fact be expressed by a host cell lacking a
recombinant vector.

20 A polypeptide of this invention can be recovered and purified from
recombinant cell cultures by well-known methods including ammonium sulfate or
ethanol precipitation, acid extraction, anion or cation exchange chromatography,
phosphocellulose chromatography, hydrophobic interaction chromatography, affinity
25 chromatography, hydroxylapatite chromatography and lectin chromatography. Most
15 preferably, high performance liquid chromatography ("HPLC") is employed for
purification.

30 Polypeptides of the present invention, and preferably the secreted form, can
also be recovered from: products purified from natural sources, including bodily
fluids, tissues and cells, whether directly isolated or cultured; products of chemical
20 synthetic procedures; and products produced by recombinant techniques from a
prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,
35 insect, and mammalian cells. Depending upon the host employed in a recombinant
production procedure, the polypeptides of the present invention may be glycosylated
or may be non-glycosylated. In addition, polypeptides of the invention may also
40 25 include an initial modified methionine residue, in some cases as a result of host-
mediated processes. Thus, it is well known in the art that the N-terminal methionine
encoded by the translation initiation codon generally is removed with high efficiency
from any protein after translation in all eukaryotic cells. While the N-terminal
45 methionine on most proteins also is efficiently removed in most prokaryotes, for some
30 proteins, this prokaryotic removal process is inefficient, depending on the nature of
the amino acid to which the N-terminal methionine is covalently linked.

5
10
15
20
25
15
30

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

30 Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

35
40
25
The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

45
30
50
55

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids

containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or

translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

5 The polynucleotides are also useful for identifying individuals from minute
biological samples. The United States military, for example, is considering the use of
10 restriction fragment length polymorphism (RFLP) for identification of its personnel.
In this technique, an individual's genomic DNA is digested with one or more
5 restriction enzymes, and probed on a Southern blot to yield unique bands for
identifying personnel. This method does not suffer from the current limitations of
15 "Dog Tags" which can be lost, switched, or stolen, making positive identification
difficult. The polynucleotides of the present invention can be used as additional DNA
markers for RFLP.

20 10 The polynucleotides of the present invention can also be used as an alternative
to RFLP, by determining the actual base-by-base DNA sequence of selected portions
of an individual's genome. These sequences can be used to prepare PCR primers for
amplifying and isolating such selected DNA, which can then be sequenced. Using
25 this technique, individuals can be identified because each individual will have a
15 unique set of DNA sequences. Once an unique ID database is established for an
individual, positive identification of that individual, living or dead, can be made from
extremely small tissue samples.

30 Forensic biology also benefits from using DNA-based identification
techniques as disclosed herein. DNA sequences taken from very small biological
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen,
etc., can be amplified using PCR. In one prior art technique, gene sequences
35 amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic
biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co.
(1992).) Once these specific polymorphic loci are amplified, they are digested with
40 25 one or more restriction enzymes, yielding an identifying set of bands on a Southern
blot probed with DNA corresponding to the DQa class II HLA gene. Similarly,
polynucleotides of the present invention can be used as polymorphic markers for
45 forensic purposes.

50 There is also a need for reagents capable of identifying the source of a
30 particular tissue. Such need arises, for example, in forensics when presented with
tissue of unknown origin. Appropriate reagents can comprise, for example, DNA
probes or primers specific to particular tissue prepared from the sequences of the
55

present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as

deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

5 A polynucleotide or polypeptide of the present invention may be useful in
treating or detecting deficiencies or disorders of hematopoietic cells. A
10 polypeptide or polynucleotide of the present invention could be used to increase
differentiation and proliferation of hematopoietic cells, including the pluripotent stem
5 cells, in an effort to treat those disorders associated with a decrease in certain (or
many) types hematopoietic cells. Examples of immunologic deficiency syndromes
15 include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia,
dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency,
Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion
20 deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe
combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia,
thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also
25 be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity
(clot formation). For example, by increasing hemostatic or thrombolytic activity, a
15 polynucleotide or polypeptide of the present invention could be used to treat blood
coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet
30 disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other
causes. Alternatively, a polynucleotide or polypeptide of the present invention that
20 can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve
clotting. These molecules could be important in the treatment of heart attacks
35 (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in
treating or detecting autoimmune disorders. Many autoimmune disorders result from
40 25 inappropriate recognition of self as foreign material by immune cells. This
inappropriate recognition results in an immune response leading to the destruction of
the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the
45 present invention that inhibits an immune response, particularly the proliferation,
differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing
30 autoimmune disorders.

50 Examples of autoimmune disorders that can be treated or detected by the
present invention include, but are not limited to: Addison's Disease, hemolytic

anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.

Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae,

Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex-vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

5

10

15

20

25

30

35

40

45

50

55

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

5 of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

10 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

15 20 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

25 Alternatively, the assay can be carried out using cell-free preparations. 15 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

30 20 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

35 All of these above assays can be used as diagnostic or prognostic markers. 40 25 The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

45 30 Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a

candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

5

10

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

15

20

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

25

30

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

35

40

45

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

50

55

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X

5 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by
a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
10 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table
1; which method comprises a step of comparing a nucleotide sequence of at least one
5 nucleic acid molecule in said sample with a sequence selected from said group and
determining whether the sequence of said nucleic acid molecule in said sample is at
15 least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences
comprises determining the extent of nucleic acid hybridization between nucleic acid
20 molecules in said sample and a nucleic acid molecule comprising said sequence
selected from said group. Similarly, also preferred is the above method wherein said
step of comparing sequences is performed by comparing the nucleotide sequence
determined from a nucleic acid molecule in said sample with said sequence selected
25 from said group. The nucleic acid molecules can comprise DNA molecules or RNA
15 molecules.

A further preferred embodiment is a method for identifying the species, tissue
or cell type of a biological sample which method comprises a step of detecting nucleic
30 acid molecules in said sample, if any, comprising a nucleotide sequence that is at least
95% identical to a sequence of at least 50 contiguous nucleotides in a sequence
20 selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X
wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by
a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
35 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table
1.

40 25 The method for identifying the species, tissue or cell type of a biological
sample can comprise a step of detecting nucleic acid molecules comprising a
nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least
45 one sequence in said panel is at least 95% identical to a sequence of at least 50
contiguous nucleotides in a sequence selected from said group.

30 Also preferred is a method for diagnosing in a subject a pathological condition
associated with abnormal structure or expression of a gene encoding a secreted
50 protein identified in Table 1, which method comprises a step of detecting in a

5 biological sample obtained from said subject nucleic acid molecules, if any,
comprising a nucleotide sequence that is at least 95% identical to a sequence of at
10 least 50 contiguous nucleotides in a sequence selected from the group consisting of: a
nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1;
5 and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA
Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit
15 Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of
detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at
20 10 least two nucleotide sequences, wherein at least one sequence in said panel is at least
95% identical to a sequence of at least 50 contiguous nucleotides in a sequence
selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid
25 molecules wherein the nucleotide sequences of said nucleic acid molecules comprise
15 a panel of at least two nucleotide sequences, wherein at least one sequence in said
panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a
sequence selected from the group consisting of: a nucleotide sequence of SEQ ID
30 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence
encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1
20 and contained in the deposit with the ATCC Deposit Number shown for said cDNA
clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA
35 molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence
at least 90% identical to a sequence of at least about 10 contiguous amino acids in the
40 25 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino
acids is included in the amino acid sequence of SEQ ID NO:Y in the range of
45 positions beginning with the residue at about the position of the First Amino Acid of
the Secreted Portion and ending with the residue at about the Last Amino Acid of the
30 Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

5

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

10

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

15

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

20

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

35

40

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

45

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1

50

55

and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is

defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
<u>Plasmid</u>	
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSport 2.0	pCMVSport 2.0

pCMVSPORT 3.0
pCR®2.1

pCMVSPORT 3.0
pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms: SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("on"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSPORT1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lacmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional

5
10
15
20
25
30
35
40
45
50
55

plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982)). The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25

5 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR
(denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1
10 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The
amplified product is analyzed by agarose gel electrophoresis and the DNA band with
5 expected molecular weight is excised and purified. The PCR product is verified to be
the selected sequence by subcloning and sequencing the DNA product.

15 Several methods are available for the identification of the 5' or 3' non-coding
portions of a gene which may not be present in the deposited clone. These methods
include but are not limited to, filter probing, clone enrichment using specific probes,
20 10 and protocols similar or identical to 5' and 3' "RACE" protocols which are well
known in the art. For instance, a method similar to 5' RACE is available for
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et
al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a
15 population of RNA presumably containing full-length gene RNA transcripts. A
primer set containing a primer specific to the ligated RNA oligonucleotide and a
primer specific to a known sequence of the gene of interest is used to PCR amplify
30 the 5' portion of the desired full-length gene. This amplified product may then be
sequenced and used to generate the full length gene.

20 This above method starts with total RNA isolated from the desired source;
35 although poly-A+ RNA can be used. The RNA preparation can then be treated with
phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged
RNA which may interfere with the later RNA ligase step. The phosphatase should
then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order
40 25 to remove the cap structure present at the 5' ends of messenger RNAs. This reaction
leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be
ligated to an RNA oligonucleotide using T4 RNA ligase.

45 This modified RNA preparation is used as a template for first strand cDNA
synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is
30 used as a template for PCR amplification of the desired 5' end using a primer specific
to the ligated RNA oligonucleotide and a primer specific to the known sequence of

the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic PI library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing

individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp^r (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1

5 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

10 Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

15 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

20 The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

25 In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The

origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

5 The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine
10 procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

5 The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue
15 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by
20 gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0
25 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg
15 of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are
30 added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded
20 in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum
35 is added. Cultivation is then continued at 27° C for four days.

40 25 After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of
45 gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell
30 culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a
50 micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then

resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2chr (ATCC 37146), pBC12MI (ATCC 67109),

5 pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used
include human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1,
10 Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO)
cells.

5 Alternatively, the polypeptide can be expressed in stable cell lines containing
the polynucleotide integrated into a chromosome. The co-transfection with a
15 selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification
and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the
20 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing
cell lines that carry several hundred or even several thousand copies of the gene of
interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J.
L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and
25 Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker
15 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279
(1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers,
the mammalian cells are grown in selective medium and the cells with the highest
30 resistance are selected. These cell lines contain the amplified gene(s) integrated into a
chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the
20 production of proteins.

35 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the
expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession
No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et
al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the
40 25 CMV enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,
with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the
cloning of the gene of interest. The vectors also contain the 3' intron, the
polyadenylation and termination signal of the rat preproinsulin gene, and the mouse
45 DHFR gene under control of the SV40 early promoter.

30 Specifically, the plasmid pC6, for example, is digested with appropriate
restriction enzymes and then dephosphorylated using calf intestinal phosphates by
50 procedures known in the art. The vector is then isolated from a 1% agarose gel.

5 A polynucleotide of the present invention is amplified according to the
protocol outlined in Example 1. If the naturally occurring signal sequence is used to
10 produce the secreted protein, the vector does not need a second signal peptide.
Alternatively, if the naturally occurring signal sequence is not used, the vector can be
5 modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

15 The amplified fragment is isolated from a 1% agarose gel using a
commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment
then is digested with appropriate restriction enzymes and again purified on a 1%
agarose gel.

20 The amplified fragment is then digested with the same restriction enzyme and
purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector
are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then
transformed and bacteria are identified that contain the fragment inserted into plasmid
25 pC6 using, for instance, restriction enzyme analysis.

30 Chinese hamster ovary cells lacking an active DHFR gene is used for
transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of
the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo
contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme
that confers resistance to a group of antibiotics including G418. The cells are seeded
20 in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are
trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha
minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml
G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well
35 petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM,
100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of
methotrexate are then transferred to new 6-well plates containing even higher
concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same
40 procedure is repeated until clones are obtained which grow at a concentration of 100 -
200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-
45 PAGE and Western blot or by reversed phase HPLC analysis.
30

50 Example 9: Protein Fusions

5 The polypeptides of the present invention are preferably fused to other
proteins. These fusion proteins can be used for a variety of applications. For
10 example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG
domains, and maltose binding protein facilitates purification. (See Example 5; see
5 also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to
IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization
15 signals fused to the polypeptides of the present invention can target the protein to a
specific subcellular localization, while covalent heterodimer or homodimers can
increase or decrease the activity of a fusion protein. Fusion proteins can also create
20 chimeric molecules having more than one function. Finally, fusion proteins can
increase solubility and/or stability of the fused protein compared to the non-fused
protein. All of the types of fusion proteins described above can be made by
modifying the following protocol, which outlines the fusion of a polypeptide to an
25 IgG molecule, or the protocol described in Example 5.

15 Briefly, the human Fc portion of the IgG molecule can be PCR amplified,
using primers that span the 5' and 3' ends of the sequence described below. These
primers also should have convenient restriction enzyme sites that will facilitate
30 cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion
20 can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be
destroyed. Next, the vector containing the human Fc portion is re-restricted with
35 BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated
by the PCR protocol described in Example 1, is ligated into this BamHI site. Note
that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will
40 not be produced.

25 If the naturally occurring signal sequence is used to produce the secreted
protein, pC4 does not need a second signal peptide. Alternatively, if the naturally
occurring signal sequence is not used, the vector can be modified to include a
45 heterologous signal sequence. (See, e.g., WO 96/34891.)

30 Human IgG Fc region:

5 GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTTCCCCCAAAA
10 CCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
5 ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
15 GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
20 GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATAAGACCACGCCT
CCCGTGTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
25 TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
15 GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

30 The antibodies of the present invention can be prepared by a variety of
methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a
20 polypeptide of the present invention is administered to an animal to induce the
production of sera containing polyclonal antibodies. In a preferred method, a
35 preparation of the secreted protein is prepared and purified to render it substantially
free of natural contaminants. Such a preparation is then introduced into an animal in
order to produce polyclonal antisera of greater specific activity.

40 25 In the most preferred method, the antibodies of the present invention are
monoclonal antibodies (or protein binding fragments thereof). Such monoclonal
antibodies can be prepared using hybridoma technology. (Köhler et al., Nature
45 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.
Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell
30 Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures
involve immunizing an animal (preferably a mouse) with polypeptide or, more
50 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in

any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced

using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^4 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45

minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; 4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319

mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mM glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six

members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

325

5

10

15

25

30

35

40

45

50

55

		<u>JAKs</u>				<u>STATs</u>	<u>GAS(elements) or ISRE</u>
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN- α /B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >> Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	

326

5

PRL	?	+/-	+	-	1,3,5
EPO	?	-	+	-	5

GAS(B-CAS>IRF1=IFP>>Ly6)

10

Receptor Tyrosine Kinases

5	EGF	?	+	+	-	1,3
	PDGF	?	+	+	-	1,3
15	CSF-1	?	+	+	-	1,3

GAS (IRF1)

GAS (not IRF1)

20

25

30

35

40

45

50

55

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCGAAATGATTTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2- (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCGAAATGATTTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTAACTCCGCCAGTTCGCCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTATTTATGCAGAGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTGGAGGCCTAGGCTTTTGCAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1 ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 μ l of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 μ l samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing

10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄·7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

5 The EGR1 gene expression is activated during this treatment. Thus, by stably
transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP
reporter, activation of PC12 cells can be assessed.

10 The EGR/SEAP reporter construct can be assembled by the following
protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene
6:867-871 (1991)) can be PCR amplified from human genomic DNA using the
following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCGGATCCGCCTC-3' (SEQ ID NO:7)

10 Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified
product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector
using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the
EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1
promoter.

15 To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30
dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter
sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and
allowed to air dry for 2 hr.

20 PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker)
containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-
inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and
100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is
done every three to four days. Cells are removed from the plates by scraping and
resuspended with pipetting up and down for more than 15 times.

25 Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine
protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by
growing the cells in 300 ug/ml G418. The G418-free medium is used for routine
growth but every one to two months, the cells should be re-grown in 300 ug/ml G418
for couple of passages.

30 To assay for neuronal activity, a 10 cm plate with cells around 70 to 80%
confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ μ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating diseases. For example, inhibitors of NF- κ B could be used to treat those

diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8). 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site: 5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2- (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCTCCGCCCCTATGGCTGA
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGAAAAA
GCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,

the NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sall and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5

WO 00/06698

PCT/US99/17130

5

336

10

15

20

25

30

35

40

45

50

55

13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml; and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order: First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive

incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for

precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

5 Add 75 μ l of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl
phosphate (NPP) substrate solution to each well and incubate 1 hour at room
10 temperature. Measure the reaction by a microtiter plate reader. Prepare a standard
curve, using serial dilutions of a control sample, and plot polypeptide concentration
5 on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).
Interpolate the concentration of the polypeptide in the sample using the standard
15 curve.

Example 23: Formulating a Polypeptide

20 The secreted polypeptide composition will be formulated and dosed in a
fashion consistent with good medical practice, taking into account the clinical
condition of the individual patient (especially the side effects of treatment with the
secreted polypeptide alone), the site of delivery, the method of administration, the
25 scheduling of administration, and other factors known to practitioners. The "effective
amount" for purposes herein is thus determined by such considerations.

15 As a general proposition, the total pharmaceutically effective amount of
secreted polypeptide administered parenterally per dose will be in the range of about 1
30 μ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will
be subject to therapeutic discretion. More preferably, this dose is at least 0.01
20 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for
the hormone. If given continuously, the secreted polypeptide is typically
35 administered at a dose rate of about 1 μ g/kg/hour to about 50 μ g/kg/hour, either by 1-
4 injections per day or by continuous subcutaneous infusions, for example, using a
mini-pump. An intravenous bag solution may also be employed. The length of
40 25 treatment needed to observe changes and the interval following treatment for
responses to occur appears to vary depending on the desired effect.

45 Pharmaceutical compositions containing the secreted protein of the invention
are administered orally, rectally, parenterally, intracisternally, intravaginally,
intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal
30 patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier"
refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or
50 formulation auxiliary of any type. The term "parenteral" as used herein refers to

5 modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

10 The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-
5 permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R.
15 Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al.,
20 Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent
25 cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

35 For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and
40 concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

45 Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both.
50 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

5 solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl
oleate are also useful herein, as well as liposomes.

10 The carrier suitably contains minor amounts of additives such as substances
that enhance isotonicity and chemical stability. Such materials are non-toxic to
5 recipients at the dosages and concentrations employed, and include buffers such as
phosphate, citrate, succinate, acetic acid, and other organic acids or their salts;
15 antioxidants such as ascorbic acid; low molecular weight (less than about ten
residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
20 polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or
arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose
or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar
alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic
25 surfactants such as polysorbates, poloxamers, or PEG.

15 The secreted polypeptide is typically formulated in such vehicles at a
concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of
about 3 to 8. It will be understood that the use of certain of the foregoing excipients,
30 carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile.
20 Sterility is readily accomplished by filtration through sterile filtration membranes
(e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are
35 placed into a container having a sterile access port, for example, an intravenous
solution bag or vial having a stopper pierceable by a hypodermic injection needle.

40 Polypeptides ordinarily will be stored in unit or multi-dose containers, for
25 example, sealed ampoules or vials, as an aqueous solution or as a lyophilized
formulation for reconstitution. As an example of a lyophilized formulation, 10-ml
vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution,
45 and the resulting mixture is lyophilized. The infusion solution is prepared by
reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

30 The invention also provides a pharmaceutical pack or kit comprising one or
more containers filled with one or more of the ingredients of the pharmaceutical
50 compositions of the invention. Associated with such container(s) can be a notice in

the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

5
10
15
20
25
30
35
40
45
50
55

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

5
10
15
20
25
30
35
40
45
50
55

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodek 3 microcarrier beads.

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The

polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Feigner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland; and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely

differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 μ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A

time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 28: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., *Appl. Microbiol. Biotechnol.* 40:691-698 (1994); Carver et al., *Biotechnology (NY)* 11:1263-1270 (1993); Wright et al., *Biotechnology (NY)* 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., *Cell* 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol. Cell. Biol.* 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (*see, e.g.*, Ulmer et al., *Science* 259:1745 (1993)); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., *Cell* 57:717-723 (1989); *etc.* For a review of such techniques, *see* Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse

transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 29: Knock-Out Animals.

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in

the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and

5 Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

10 When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which
5 prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing
15 for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include,
10 but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in
20 ameliorating such conditions and/or disorders.

25 It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above
30 teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent
20 applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples
35 is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both
40 incorporated herein by reference in their entireties.

WO 00/06698

357


PCT/US99/17130

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
--	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>259</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>July 27, 1998</u>	Accession Number <u>203070</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer  Yvette E. Simms PCT International Division	Authorized officer

Form PCT/RQ/134 (July 1992)

5

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

10

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

15

A. The indications made below relate to the microorganism referred to in the description on page <u>260</u> line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>July 27, 1998</u>	Accession Number <u>203069</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

50

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer <u>Yvonne E. Simms</u> PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

55

5

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
--	----------	-------------------------------	------------

10

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

15

A. The indications made below relate to the microorganism referred to in the description on page <u>253</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203071
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

30

35

40

45

50

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>[Signature]</i> Yvette E. Simms PCT International Division	Authorized officer

55

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
--	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>249</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution: American Type Culture Collection	
Address of depositary institution (including postal code and country): 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit June 26, 1998	Accession Number 203027
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer: Yvette E. Stumms PCT International Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer:

WO 00/06698

361

PCT/US99/17130

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>243</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>June 11, 1998</u>	Accession Number <u>209965</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer <u>Yvette E. Simms</u> PCT International Division	Authorized officer

Form PCT/RQ/134 (July 1992)

Claims

5

10

15

20

25

30

35

40

45

50

55

5

What Is Claimed Is:

10

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

15

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

20

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

25

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

30

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

35

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

40

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

45

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

50

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

55

5

10

15

20

25

30

35

40

45

50

55

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

5

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

20

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

25

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

30

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

35

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

40

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

45

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

50

16. The polypeptide produced by claim 15.

55

5

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

15

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

20

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

25

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

30

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

35

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

40

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

45

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

50

(d) identifying the protein in the supernatant having the activity.

55

5

23. The product produced by the method of claim 20.

10

15

20

25

30

35

40

45

50

55

<110> Human Genome Sciences, Inc.

<120> 98 Human Secreted Proteins

<130> PZ031.PCT

<140> Unassigned

<141> 1999-07-28

<150> 60/094,657

<151> 1998-07-30

<150> 60/093,486

<151> 1998-08-05

<150> 60/095,455

<151> 1998-08-06

<150> 60/095,454

<151> 1998-08-06

<150> 60/096,319

<151> 1998-08-12

<160> 364

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttctctt	tcgcccaaaa	acccaaggac	accctcatga	120
tctcccgga	tcttgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gacctgagg	180
tcaagtccaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	acccccatcg	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccgagaaac	acaggtgtac	accctgcccc	420
catcccgga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctgggc	aaaggctctt	480
atccaagcga	catcgccgtg	gagtgaggga	gcaatgggca	qccggagaac	aactacaaga	540
ccacgcctcc	cgtcctggac	tccgacggct	cttcttctct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcac	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	lytctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser
1 5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct ttttgcaaag cctaggc 27

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
gcccctaact ccgcccagtt ccgcccattc tccgcccacat ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctatc cagaagtaqt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc

12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gaggcctcga ggggaatttc cgggggactt tccggggact ttcggggact ttccatcctg
ccatctcaat tag

60

73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgaaggga ctttccgggg gactttccgg ggactttccg ggactttcca tctgccatct
caattagtca gcaaccatag tcccgccctt aactccgccc atcccgcctt faactccgcc
cagttccgcc cattctccgc cccatggctg actaattttt ttattttatg cagaggccga
ggccgcctcg gcctctgagc tattccagaa gtatgagga ggcttttttg gaggcctagg
ctttgcaaa aagctt

60

120

180

240

256

<210> 11

<211> 1564

<212> DNA

<213> Homo sapiens

<400> 11

gaggacgggt ggctgtgcaa ccttccctcc tttcttaaat gcttggggca tttgtctggc
cttccctttt actgctggct gctgctgca tctgtctctt aaccttcatt aactgtgctt
atgtcaaatg gggaaacctg gtacaagata tttcaccta tgcataagta ttggcactga
tcggcggtcat cgttcaggc attgttagac ttggccaggg agcctctact ctttttgaga
attctcttga gggttcatca tttgcagtgg gtgacattgc cctggcactg tactcagctc
tgttctccta ctcaggctgg gacacccca actatgtcac tgaagagatc aagaatcctg
agaggaaact gccctctctc attggcatct ccatgcccac tgtcaccatc atctatatcc
tgaccaatgt ggcctattat actgtgttag acatgagaga catcttggcc agtgatgctg
ttgtctgtgac ttttgcagat cagatatttg gaattattta ctggataatt ccactgtcag
ttgcattatc ctgttttggg ggcctcaatg cctccattgt ggcctgctct aggettctt
ttgtgggctc aagagaaggc catctcctg atgccatct catgatccat gttgagcggg
tcacaccagt gccctctctg ctcttcaatg gtatcatggc attgatctac ttgctgtggg
aagacatctt ccagctcatt aactactaca gcttcagcta ctggctcttt gtggggcttt
ctattgtggg tcagctttat ctgcgctgga aggagcctga tgcacctcgt cccctcaagc
tcagcgtttt cttcccgatt gtctctctgc tctgcacct cttcctgggt gctgttccac
tttacagtga tactatcaac tccctcatcg gcattgccat tggcctctca ggcctgccct
tttacttct catcatcaga gtgccagAAC ataagcgacc gctttacctc cgaagatcgt
ggggtctgcc acaaggatcc tccaggtctt gtgtatgtca gttgctgcag aaatggattt
ggaaagatga ggaagatgc ccaagcaacg ggaaccaag tctaactaaa caccatctgg
aatcctgatg tggaaagcag gggtttctgg tctacgggt agagctaagg aagttgaaaa
ggaaagctca cttcttttga ggcacctgtc cagaagcctg gcctaggcag cttcaacctt
tgaaacttact ttttgaaatg aaaagtaatt tatttgtttt gctacatact gttccagact
tttaaggggg acaatgaagg tgactgtggg gaggagcatg tcagggttgg gcttgggtgt
tttagaagca cctgggtgtg cctacctact cctcttttct tttaaaaggg cccacaatgc

60

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

1020

1080

1140

1200

1260

1320

1380

1440

tccaattttcc tgtctccttt agagagacat gaaactatca cagggtgctgg atgacaataa 1500
aagttttatgt tcttaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagggcggc 1560
cccc 1564

<210> 12
<211> 1757
<212> DNA
<213> Homo sapiens

<400> 12
ggcacgaggt agatgggttt ttggtgtgga tgtctttttt gtttgttagt tgtccttcta 60
acagacagga ccttcagctg cagggtctgtt ggagtacctt gcaatgtgag gtgtcagttt 120
gcccctgctg gaggtgtcct cccagtttagy ctgctcgcgg gtcagggggc agggaccacac 180
ttgaggaggc agtctgcccg ttcacagatc tccagctgca tgcctgggaga accactgttc 240
tcttcaaaagc tgtcagacag ggacatttaa gtctgcagag gttactgctg tctttttgtt 300
tgtctgtgcc ctgccccagc aggtggagcc tacagaggca ggcaggccctc cttgagctgt 360
gggtgggtcc acccagttcg agcttcccgg ctgctttgtt tacctaagca agcctgggca 420
atggggggcg cccctccccc agtctcctg cgccttgcga gtttgaatc agactgctgt 480
gctagcaatc agcgaagact cctggggtag gacctctga gccaggtggg ggatataatc 540
ttgtgggtgc ccatttttta agcccgtcg aaaagcgcag tattcagggt ggagtgaacc 600
gattttcccg attttccagg tgcctcctgt catccctttc tttgattagg aaagggaact 660
ccctgacccc ttgcgcttcc cgagtggagc aatgccttgc gctgctttgg ctctgtcatg 720
gtgctgtcac ccactgacct gcgccactg tctggcactc cctagtga tgaacccggt 780
acctcagatg gaaatgcaga aatcacccgt cttctgcgtt gctcaggctg ggagctgtag 840
accagagctg tctctattcc gccatcttgg ctctccccc acccccgc caatcctaag 900
tttatctctt aacaaagtaa atactgcaca cgtatttaca tgttttaaa tattgtttat 960
ggagcaetta ctatgtgttt tacgggtccaa gtactttata ttattcaatg actctttata 1020
gcaactctat aacatattaa tagattgtct caatttcact gatgacaaaa ctggcagctt 1080
agtaactaat gagtaacaat accagccctt aaaacctagg gtctttccac tacagcacac 1140
ctgactgac attgcctttg ttacagacac gcaactctca cctagaaaaa gatggagagc 1200
tagaaaagtg ttttcttttt caagttgttc ccattcatca atattctatc aagatatatg 1260
gaagagttat tttctaggtc ttccagaagg ggctgcgac acttgggaat tcaaaaataat 1320
tactccagag ggaatgtgg gcatagaaac tttttaaaaa ctgaattttc ccgatctaat 1380
atcggtctcc acatacagta tattatttct taaaaatcag ccagaaatgc acctgcagtt 1440
ttatctactg gatttttctt tcccagcccc attcttcttt aagtagtttt ttttccccat 1500
tttataaaag aaaagcatac ctcccacctg tagcttccct ccttatggta tattatctca 1560
ggggataact tgaatatttg cttagacac aattctcatt aagaaataaa ctttcagggt 1620
gggtgcagtg gctcacactt gtaatcccag aactttggga ggccaaggcg ggggaggatc 1680
cctgaaggcc aagagttcaa gaccagcctg gaatatatac caagatcccc tctccacaaa 1740
aaaaaaaa aaaaaaa 1757

<210> 13
<211> 1373
<212> DNA
<213> Homo sapiens

<400> 13
gtgaaatgaa acatgtatc caaaacacat aaatttaagt ttataaattt tctttctttg 60
tggatctgga aaattttctt tctgtgtgtt ttcattctga tagttgtttt ggcttttcct 120
attccctgcc tttccatatt ttgaaatgtt ttggtcaaat ttttccctgt tgagtgtgca 180
gtatgttttg attgttaatt ttattgacca tcatctcagt ggattattta ttgaaactt 240
tctgttttcc tgttctggaa tgtttcttgc tctggaagcc atattttaac tgtatactga 300
tccagcttta ttatctttaa gtatttttac aattatttta ctgataatat ataactagg 360
ataatcactc taqtcagtga aatcaaaactg ataacacaaa atgatgctgc tegaaaatt 420
agcctgaaaa ggatcagagg aagcactttt tagtctaagt agtcaagatc aataaactta 480
gaatgagagt ttgtattat ttagccttgt gatagaagga aaaagtacag ttattgaatc 540
tgtatattaa ttatgcaaaa atacacacat tatctttcca ttaacacagt agtatgacat 600

```

acagttttat caccactgga ttcatgtatg cttaaaaatga aaatgaaagg aacacacagg 660
aaagtagctt cttatcttcc cagatacagc ctccaagagt gccctcgtcg tgtactggag 720
tgagtttgaa gaagttcagg taatcctctc ctaaccagca gcttaactta aagtgcactc 780
tcatttttgt cctaccacta aaagcttgct tattgacctc cttcttttct gtctcctaaa 840
ttgtgactgg cttccagtta gacttgcatc tgttgctatt tgtagcagca attgcaggat 900
tcatttgctt tttctcttgc agtgtatttc tgaatgtttt ataactctgg gtatgcataa 960
tgtagctata tgcatatcca tatggtcaag agttttcaga attctttgtt tgaataatga 1020
atgtgtgtat tccctacccc ttgttltgct ctgtcttaac attcaagctt tgccttataa 1080
aattgtattg ttttaagtct ttctctttag attgtaagct cttcatgggc agtggctcaga 1140
tatctgtat ttgttaacttc cggagaatct agtattttat catgtacata atgaacatag 1200
aatagtattg attggaagga cagtgaagta caaatgaga ttctaaaaat acattttcat 1260
tagggctcac aagtgtataa gaagtatccc tttcctattt ttttgtttta tacttttaga 1320
gctattacat taaaaaagct attctcatta aaaaaaaaaa aaaaaaaaaa aaa 1373

```

```

<210> 14
<211> 3740
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (957)
<223> n equals a,t,g, or c

```

```

<400> 14
actctctaaag gctttttttg actcaccana caggctctct gcagtggaga tgaatacaga 60
tcactttaagg ttgactgtgc caaatggcat aggggcccctg aagctaaggg aaatggaaca 120
ctacttctca cagggcctgt cagttcagct gtttaatgat ggggtccaagg gcaaaactcaa 180
tcattttatgt ggagctgact ttgtgaaaag tcatcagaaa cctccacagg gaatggaaat 240
taagtccaat gaaagatgct gttcttttga tggaga-gca gacagaattg tttattacta 300
ccatgatgca gatggccact ttcattctcat agatggagac aagatagcaa cgttaattag 360
cagtttccctt aaagagctcc tgggtggagat tggagaaagt ttgaatatgt gtgtttgaca 420
aactgcatac gcaaatggaa gttcaacacg gtatcttgaa gaagttatga aggtacctgt 480
ctattgcact aagactgggtg taaaacattt gcaccacaag gctcaagagt ttgacattgg 540
agtctatttt gaagcaaatg ggcattggcac tgcactgttt agtacagctg ttgaaatgaa 600
gataaaaaca tcagcagaac aactggaaaga taagaaaaga aaagctgcta agatgcttga 660
aaacattatt gactttgtta accagggcagc tgggtgatgt attcttgaca tgcctgggat 720
tgaagcaatc ttggctctga agggcttgac tgtacaacag tgggatgctc tctatacaga 780
tcttccaaac agacaactta aagttcaggt tgcagacagg agagttatta gcaactacera 840
tgctgaaaga caagcagtta cacccccagg attacaggag gcaatcaatg acctgggtgaa 900
gaagtacaag ctttctcgag cttttgtccg gccctctggt acagaagatg tgcgtccngag 960
tataatgcaga agcagactca caagaaagtg cagatcacct tgcacatgaa gtgagcttgg 1020
cagtatttca gctggctgga ggaattggag aaaggcccca accaggttct tgaagataat 1080
tttcatattc ctgagaaact ggacttttta caagtcttta caaaactgtc aataataatg 1140
gcaqtactaa gagatttata atcataatgt ttacaatgca gccctactgga ttgtctctag 1200
atctgttttt cttaaacact aacagaataa ttctttataa ataggttaagc cttacacttg 1260
ttaaagaaat ttacctclaa tttcagcttc actaatgtaa aatactggga ctttaagtata 1320
caattcagtc actaactgta cagttttatg tggggaacaa ttcatgcagg ctactggaaa 1380
attaaatctt attaccaact ccttgatgata tctttgccat caccatcaca tgagcaagat 1440
gatgttttgc agcattcccc attgtgtata caaatggaga gggcagagaa gactttatc 1500
aaccagtttt tccattgcag agtcttaaga aagattatta gatgacttac ctatatgact 1560
aatgccatca ggaactcaga ggtatgaata ggggggtgtc catccctctt ccatactgag 1620
gtggagatgc tcatgcaata cttttaagga tgcattgtcc agccttcagt tattcttcac 1680
tgctcttggt gaaggtatgt gggagaaaaa ctaattataa tacgtttccc agcctctgat 1740
ggagangaa caccattctg ataccagaac atggttataa aggaaaagag aaaaatcccc 1800
aaccaatctt aattgaacca agtctgaaac caatggaaaa aaaaatgggg tagtgtatat 1860
tttgcagggt taagacaac- caggacaata aaaacaaagg accttacctg tgtatatata 1920
tagctctctt aggcaccata atcagtatga gccacaata tttaaacttg attcaggcca 1980

```

cattcagaca tttgctccta tatacaaata tttaaattaa atacaatctg aaatgtgttc 2040
tggtacatac aaaaaaggaa aaactatata acgcagagca gtgtgtgtgt tttaaataat 2100
tacatttaca tgtaagctaa atggaaccag caatgggtgt caagttttta tcatcccttc 2160
cagaaaaatc tttcttacca tctcttctat tttttgcttg gctttgtctg aacarggttt 2220
gtgtgtctcc agtttcatgt ccttattagg gaaggcattt gaggtaggga taggactccc 2280
tgagtgtcct ccacatcggc ttgtgacttt gctgttgaag acttgactga gcacattgaa 2340
gaacggcagg agctgctcca tactgcgcac ggtgcagatg gtgaqcaqca agtgcctctg 2400
ctcccaaccc aatgttcttc ctgagttlyc ttcccttggg tttttctgca gaaaacaaaa 2460
agtgaactgg tattaatata acagacaatg tgggtatgta gaaaaattaa aaatatataa 2520
actttggcaa ttggtcaaga aatgaatata aatgacatta agtttctaac tcttgactct 2580
atcaaaaccc ttggtgcttc tgagaccttt tactgccatt tattagtctt acatggagca 2640
gtctaacatt gtagtaatat tcccaacta gaatgcgcag ataagcttag ttaacagaaa 2700
tagctttgaa caggaaataga gtcaaacata aaagttttat gttgtgcttt gtatttacte 2760
aaaaagctcc caggtttctg aaccttctact actgtaacca aggactagggt cacaataata 2820
ctacagaaaa aaggaaacaa gtgctttata catctcataa tatatccctt tttattataa 2880
ttagttaatt cctttttatc taaatggcct aaatttgcca tgatggtagc agtgtccaaa 2940
gtgaataatt actgtcagta ctgcatcaca gagaaggaa gggatccctc aggagacact 3000
gctgtctcct tctgggttgt gctaaacaac atagggagga aagctggacc tggagtcaaa 3060
ggaattgagt tagtgtgctg gctctgccat acttacggca cctttgggca ggatatacaa 3120
aggttcccca cttataaaat qqqacagtct aaaactacct ttttagtagag aagtcaaatg 3180
agaaggtatg tgaaaactct gtcaactaaa tataaagact aataatttgg gtattaagag 3240
gctagtttga gaagccacct gaattacaca aacacagcta cagacatcat tctgtctaga 3300
gaaagataag agagaacagg ttggtgaac ttgggcagaa tcacagatac aattccacac 3360
taaagaatga aaataagcaa tgaactagac agaaggaaga aatcatgaag acttaggaag 3420
cagaattaca atctgtcata ttaacaaatg gagtttgcct tctaaagatca gatgttgcct 3480
agaaacttcc attgtttacc taataattta atatcactag ttctctagtg ggtcaagcag 3540
atgcaaaatc cagcttatct tcttctatgt gctctcaagc ttattgctta ttttaaagta 3600
aaatcctgaa aaaggaaaaat attaggttgg tgcacacgta attgcggttt ttgcatttgt 3660
gaaatttggc gttttatatt ggagtacatt cttaaataaa tgtggttatg ttatacaaaa 3720
aaaaaaaa aaactcgag 3740

<210> 15
<211> 1196
<212> DNA
<213> Homo sapiens

<400> 15
ccacgcgtcc ggtgaatctg gatgatctat ttatgtcatt tatctatgtg tctcttctta 60
tgccagtacc ccactgtctt gattattgtg gctttatggt gtcttgaat taagtattgt 120
taagctttgc aatcttttcc aagattgttt tggctatagg tcttttcttt ataaagttta 180
tattaagctt ctccattttt cttaagaaa aaatctgctg gaatggcact gaatttttag 240
gtcgatttgg gaagaattga caataatgaa cctttcaatc gatggacatg gtatgtttct 300
gcatttattt gggcctttta aaatttatct cagcaatatt ttgtagtttt agtgaagaag 360
tcttgtatat atcttttgtt aaatgtattc ctaaatattt tgtggaaatg ttactgtaaa 420
tagtacttta atttcaatrr faagtttatt gctcggtac agaaatatgt ttattttttg 480
taatatggac ttttatattc tgtaatttta tttaaattca cttagtccag tagtagttct 540
tatttttatt ttattgcaag tgccttaggg ataccttgtg tacacaaatc atgtcatata 600
tgaataacca acaggtttac cttttgtttc ttcttgtttt gtcgtaaagg ctaggacctt 660
ccaacctaaa tggttgaata gaagcgtgtg gtgagtttat tactctgtgc ttattctcaa 720
cagcagagga tagcgtctag tttttcacta ttaaaatatg tttagctatg gttttttccg 780
tttcatgttc ttatcagatt gaagatccct tttatctcta ttttgcctag agtgtcatga 840
atgcattgtg aatttcacca agtacttttt cctgcatctg ttgagagaat cttgactttt 900
ctcttttatt ttgttaatgt agattcttta atgttaact gatcttgcac tcttgatata 960
aacatacttt agtcatgata tgttatcccc ttlatataat gctggattcg gtttgcaaat 1020
attttgtttg atttttgcat ctatgctcat gagacagatt ggtctgtgat tttcttttct 1080
tgtaagtctt gtcaggtgtc agggcttggg taattttgac acatttaca acatatattt 1140
ttaagataaa aataaacttc aaaaaaaaaa aaaaaaaa aaaaaaaa aaaaaa 1196

<210> 16
<211> 2209
<212> DNA
<213> Homo sapiens

<400> 16
gagctgagcc gggtctgggc gcttggggcc gccgtctccc accgtcggtt tccccaccga 60
ggccgagggc tcccggagtc atggccgggc tgaactgagg ggtctctatc gcactgtctag 120
gggtctctgct gctgggtgag gcgcgcctgc cgccgggggc agaagctttt qagattgctc 180
tgccacgaga aagcaacatt acagttctca taaagctggg gaccccgacc ctgctggcaa 240
aacctctgta catcgtcatt tctaaaagac atataaccat gttgtccatc aagctctggag 300
aaagaatagt ctttaccctt agctggcaga gtcttgagaa tcaactttgt atagagatcc 360
agaaaatat tgactgtatg tcaggcccat gtcccttttg ggaggttcag cttcagccct 420
cgacatcggt gttgcctacc ctcaacagaa ctttcatctg ggatgtcaaa gctcataaga 480
gcacggtgtt agagctgcag ttttccatcc ctgcctgag gcagatcggt ccggg-gaga 540
gttgcctcaga cggagtcact cactccatca gccggccgaat cgtgcccacc gtggtcagga 600
ttggaacatt ctgcagcaat ggcactgtgt cccggatcaa gatgcawgaa ggagtgaana 660
tggtcttaca cctcccatgg ttccacccca gaaatgtctc cggcttcagc attgcaaac 720
gctcatctat aaaacgtctg tgcacatcg aqtctgtgtt tgagggtgaa ggtcagcaa 780
ccctgatgtc tgccaactac ccagaaggct tccctgagga tgagctcatg acgtggcagt 840
ttgtctgttc tgacacattg cgggccagcg tctctctct caacttcaac ctctccact 900
gtragaggaa ggaggagcgg gttgaatact acatcccggy ctccaccacc aaccccgagg 960
tgttcaagct ggaggacaag cagcctggga acatggcggy gaacttcaac ctctctctgc 1020
aaggctgtga ccaagatgcc caagtcagc ggatctctcg gctgcagttc caagttttgg 1080
tccaacatcc acaaaatgaa agcaataaaa tctacgtggt tgacttgagt aatgagcag 1140
ccatgtcact caccatcgag ccagggcccg tcaaacagag ccgcaagttt gtcctctggt 1200
gtttcgtgtg tctagaatct cggacctgca gtacaaact caccctgaca tctggctcca 1260
aacacaaaat ctctctctct tctgatgatc tgacacgtct gtggatgaat gtgaaaaam 1320
ccataagytg cacagaccac cgttactgcc aaaggaaatc ctactcacty caggtgcccc 1380
gtgacatctc vcamctgcct gtggagctgc atgacttctc ctggaagctg ctggtgcccc 1440
aggacaggct cagcctgggt ctggtgccag ccagaaagct gcagcagcat acacacgaga 1500
agcctcgcaa caccagcttc agctacctcg tggccagtgc cataccagc caggacctgt 1560
acttcggctc cttctgcccc ggaggctcta tcaagcagat ccaggtgaag cagaacatct 1620
cggtgaccct tcgcaccttt gcccccagct tccgacaaag qccctccagg cagggtctga 1680
cgggtgtctt tataccttat ttcaaaagg aaggcgtttt cagggtgacc cctgacacaa 1740
aaagcaaggt ctaccgagc acccccaact gggaccgggy cctgccatcc ctacactctg 1800
tgtctggaa catcagcgtg cccagagacc aggtggcctg cctgactttc ttaaggaggc 1860
ggagcggcgt ggtctgccag acagggcgcg cattcatgat catccaggag cagcggaccc 1920
gggttgagga gatcttcagc ctggacgagg atgtctctcc caagccaagc ttccaccatc 1980
acagcttctg ggtcaacatc tytaaytgma gcccacgag cggcaagcag ctgacctgc 2040
tcttctcggt gacacttacc ccaaggactg tggacttgac tgtcatctc atcgacgcyg 2100
tggtgaggtg agtcttactg ctgtctgccc tggggtcat catttctgt gtgaaaaaa 2160
aaaaaarama aacaaggggc cccgtctggt gtatctacaa tggcaacat 2209

<210> 17
<211> 1774
<212> DNA
<213> Homo sapiens

<400> 17
taggcacccc aggtctttac actttatggt cgggttcgta tgttgtgtga attgtaaccg 60
gataccaatt tcacacaagg aaccagctta tgaccatgat tacgccaaag tctgaaattaa 120
ccctcactaa agggaaacaaa agctggagct ccaccgctgt ggccggcgt ctagaactag 180
tggtaccccc gggtctcagg aattcggcac gagcggtgc gggcgcgagg tgaggggcgc 240
gaggttccca gcaggatgcc ccggtcttgc aggaagctga agtgagaggg ccggagaggg 300
cccagccgc ccggggcagg atgaccaagg cccgctgtt cggctgtggt ctggtgctgg 360
ggtcgggtgt catgatctcg ctgatcatg tgtactgga cagccaggg gccgcgact 420

```
tctacttgca cacttcttct tetagggcgc acacgggggc gccgtgccc acgcccgggc 480
cggacaggga cagggaagctc acggcgact ccgatgtcga cagatctctg gacaagtctc 540
tcagtgtctg cgtgaagcag agtgaccttc ccagaaagga gacggagcag ccgctctcgc 600
cggggagcat ggaggagAAC gtgagaggct acgactggtc cccgcgcgac gcccggcgca 660
gccagacca gggcggcag caggcggagc ggaggagcgt gctgccccgc ttctgcgcca 720
actccagcct gcccttcccc accaaggagc gcgcattcga cgcattcccc aactcggagc 780
tgagccacct gatcgtggac gaccggcagc gggccatcta ctgctacgtg cccaaggtgg 840
cctgcaccaa ctgggaagcgc gtgatgaltc lcttgagcgg aagcctgctg caccgcggtg 900
cgccctaccg cgaccgctg cgcattccgc gcagacagt gcacaacgcc agcgcgcacc 960
tgaccttcaa caagttcttg cgcgctacg ggaagctctc ccgccaectc atgaaggtca 1020
agctcaagaa gtacaccaag ttctctcttc tgccgcgacc ctctgtgcgc ctgatctccg 1080
ccttcgcgag caagtctgag ctggagaacg aggaattcta ccgcaagtcc gccgtgcccc 1140
tgctgcccgt gtacgcaac cacaccagcc tgcccgccctc ggcgcgcgag gccttccgcg 1200
ctggcctcaa ggtgtctctc gccaaactca tccagtacct gctggaccgc cacacggaga 1260
agctggcgcc cttaacgag cactggcggc aggtgtaccg cctctgccac ccgtgccaga 1320
tcgactacga ctctgtgggg aagctggaga ctctggacga ggcgcgcgcg cagctgctgc 1380
agctaactca ggtggaccgc cagctccgct tccccccgag ctaccggaac aggaccgcca 1440
gcagctggga ggaggactgg ttgcgcaaga tccccctggc ctggaggcag cagctgtata 1500
aactctacga ggcgcacttt gttctctctc gtaaccccaa gcccgaaaac ctctctcgag 1560
actgaaagct ttccgcttgc ttttctctgc gtgcttggaa cctgacgcac gcgcactcca 1620
gtttttttat gacctacgat ttgtcaatct gggcttcttg ttactccac tgcctctatc 1680
cattgagtac tgtatcgata ttgtttttta agattaatat atttcaggtt ttaaatcaga 1740
aaaaaaaaa aaaaaaaccc gaggggggggc ccgg 1774
```

```
<210> 18
<211> 1674
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1649)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1663)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1665)
<223> n equals a,t,g, or c
```

```
<400> 18
caagttggga cgcctgcagg tacgggtccg gaattcccg gtgcaccac gcgtccggtc 60
gaagataggt tcgagacggt ggatgttgca gctgatcatg cagttgggtt cgggtgctgtc 120
cacacgctgc cctttttggg gctgcttcag ccagctcatg ctgtacgtg agagggtcga 180
ggcacgcccg aagcccgcaca tcccagtgcc ttacctgtat ttgcacatg gggcagccgt 240
gctgtgcgct agtttcatgt cctttggcgt gaagcggcgc tggttccgcg tgggggcgcg 300
actccaattg gccattagca cctacgcgcg ctacatcggg ggctacgllc actacgggga 360
ctggctgaag gtccgtatgt actcgcgcac agttgccatc atcggcggtt ttcttgtgtt 420
ggccagcggg gctggggagc tgtaccgcgc gaaacctcgc agcgcctccc tgcagtccac 480
cggccagggt ttccctgggta tctacctcat ctgtgtggcc tactcactgc agcacagcaa 540
ggaggaccgg ctggcgatc tgaacctct cccaggaggg gacgtgatga tccagctgtt 600
cttcgtgctg tatggcatcc tggccctggc ctttctgtca ggctaactac tgacctctgc 660
tgcccgatc ctggctgtac tgcgcgcccc tgctatgctg ctcatgtatg gcaatgttgc 720
ttactggcac aacacgcggc gtgttgagtt ctggaaccag atgaagctcc ttggagagag 780
```

tgtgggcac	ttcggaactg	ctgtcactct	ggccactgat	ggctgagttt	tatggcaaga	840
ggctgagatg	ggcacaggga	gccactgagg	gtcaccctgc	cttctctctt	gctggcccag	900
ctgctgttta	tttatgcttt	ttggctgttt	tgcttgatct	tttgcttttt	taaaattgtt	960
ttttgcagtt	aagaggcagc	tcatttgccc	aaatttctgg	gctcagcgct	tgggagggca	1020
ggagccctgg	cactaatgct	gtacaggttt	ttttctgtt	aggagagctg	aggccagctg	1080
ccactgagt	ctccgtctcc	tgaagaaggga	gtatggcagg	gctgggatgc	ggctactgag	1140
agtgggagag	tgggagacag	aggaagggaag	atggagatcg	gaagtgagca	aatgtgaaaa	1200
attctctctt	gaacctggca	gatgcagcta	ggctctgcag	tgctgtttgg	agactgtgag	1260
agggggtgtg	tgtgttgaca	catgtggatc	aggcccagga	agggcacagg	ggctgagcac	1320
tacagaagtc	acatgggttc	tcagggtatg	ccaggggcag	aaacagtacc	ggctctctgt	1380
cactcacctt	gagagtagag	cagacctctg	tctgctctgg	gctgtgaagg	ggtggagcag	1440
gcagtggcca	gctttgccct	tcctgctgtc	tctgtttcta	gctccatggt	tggcctgggt	1500
gggggtggagt	tcctctccaa	acaccagacc	acacagtcct	ccaaaaataa	acattttata	1560
tagamaaaaa	aaaaaaaaaa	aagggcggcc	gctctagagg	atccctcgag	gggcccgaagc	1620
ttacgcgtgc	atgcgacgtc	atagctctnt	ccctatagaa	gtngnaaagg	gttc	1674

<210> 19
 <211> 2018
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2010)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2012)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2014)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2016)
 <223> n equals a,t,g, or c

<400> 19						
cagcaatgaa	atcctgcttt	cttttctcca	gaactactat	attcagtggc	taaatggctc	60
cctgattcat	ggtttgtgga	atcttgcttc	cttttttccc	aacctttggt	tatttgattt	120
gatgcccttt	gcctttttct	ttctggaaac	agaaggcttt	grrggcctga	aaaagggaaac	180
ccgagccccc	atttttagaga	ctttggctat	gcttctctct	cttgccgtac	tcattcttgg	240
gatagtgtgg	gtagcttcag	cactcattga	caacyatgcc	gcaagcatgg	aatctttata	300
tgatctctgg	gagttctatc	tacctatatt	atattctctg	atatcattga	tgggatgttt	360
gttactttct	ttgtgtacac	cagttggcct	ttctcgtatg	ttcacagtga	tgggtcactt	420
gctagtgaag	ccaacaattc	ttgaagaacct	ggatgaacaa	atttatatca	ttaccttaga	480
ggaagaagca	ctccagagac	gactaaatgg	gctgtcttcc	tcgggtggaat	acaacalaat	540
ggagtgtgaa	caagaacctg	aaaatgtaaa	gactcttaag	acaaaattag	agaggcgaaa	600
aaaggcttca	gcattgggaaa	gaaatttggg	gtatcccgcct	gttatgggtc	tccttcttat	660
tgagacatcc	atctcgggtcc	tcttgggtggc	ttgtaatatt	ctttgcctat	tgggttgatga	720
aacagcaatg	ccaaaaggaa	caagggggccc	tggaaatagga	aatgcctctc	tttctacgtt	780
tggttttgtg	ggagctgcgc	ttgaaatcat	ttgatttttc	tatcttatgg	tgtctctctg	840
tgctggcttc	tatagccttc	gattttttgg	aaactttact	cccaagaaaag	atgacacaac	900
tatgacaaag	atcattggaa	attgtgtgtc	catcttgggt	ttgagctctg	ctctgcctgc	960

gatgtcgaga	acactgggaa	tcactagatt	tgatctactt	ggcgactttg	gaagctttaa	1020
ttggctggga	aatttctata	ttgtattatc	ctacaatttg	ctttttgcta	ttgtgacaac	1080
atttgtgtctg	gtccgaaaaat	tcacctctgc	agttcgagaa	gaacttttca	aggccctagg	1140
gcttcataaa	cttcacttac	caaatacttc	aagggtatca	gaaacagcca	agccttctgt	1200
aaatgggcat	cagaaaagcac	tgtagagcgc	acagacggcg	tcttctgcca	ccaagagacc	1260
cgagaactcc	agattcacga	cattcctgtc	ccatgtagaa	gcatttccat	tcaaccgtgg	1320
cccccttca	gaacctagac	ctatcagtgc	catttttttt	tcataatcta	cgaagaactt	1380
ggctatggct	gatctttttt	aaatttaact	ttctgtatga	ccctgtagtt	cccagttaag	1440
tgagatttcc	ttacagacat	atagaacagc	gcattcttct	gtagacattt	gctcatgttg	1500
gtaaatacaa	tcacccatct	gaaaaaattg	ttttcacctg	atatgaaaat	gttagaaaag	1560
gcaaacctcg	ggacttctaa	agatttactt	aaatcccat	atgtacttta	ttcagaatgt	1620
agaagctgac	ttgaaaggca	tccttgggtac	taagtgaagc	ttattcagaa	aatgcatttt	1680
tcaaatgcaa	tggaactgac	ttgtagatat	catttttgca	gtgtatgttg	gagctgtaat	1740
gggtgcaatt	atgtttctta	tttctctaaa	agcaaaaagc	gtagtctctg	atttatgtta	1800
tagaatgata	ctgatttagac	tttgagccaa	ggggaaaata	ctaaattctt	ttaaacctgg	1860
agccttagag	agccacagga	atatcttctg	ttgtacagtc	taataagctg	tggttaggaag	1920
tatcatgtaa	tcacagttaa	atgacagttt	atgtatatat	ataattcagt	attccctcga	1980
ggggggggccc	gggtacccaat	tcgcccgaag	tnancnag			2018

<210> 20

<211> 2098

<212> DNA

<213> Homo sapiens

<400> 20

ggcacgaggg	accgagctat	tctcctggga	ctggctatga	tggtgtgtgc	catcatgatg	60
tattttctgc	tggaatcac	actcctgggc	tcatacatgc	agagcgtgtg	gaccgaagag	120
tccaatgca	ccttgctgaa	tggtccatc	acggaaacat	ttaatgtctc	cttcagctgt	180
ggctccagact	gctggaaact	ttctcagtac	ccctgcctcc	aggtgtacgt	taacctgact	240
tctccgggg	aaaagctcct	cctctaccac	acagaaagaa	caataaaaaat	caatcagaag	300
tgctcctata	tacctaaatg	tggaaaaaat	tttgaagaat	ccatgtccct	gggtgaatgt	360
gtcatggaaa	acttcaggaa	gtatcaaac	ttctcctgct	attctgaccc	agaaggaaac	420
cagaagagtg	ttatcccaac	aaaactctac	agttccaaag	tgctgttcca	ttcactcttc	480
tgcccaacct	gtatgatggc	tggtgggtgtg	gcaattgttg	ccatgggtgaa	acttacacag	540
tacctctccc	tactatgtga	gaggatccaa	cgatcaata	gataaatgca	aaaatggata	600
aaataatttt	tgtaaagct	caaatactgt	ttcttttcat	cttccaccaa	agzaccttaa	660
gtttgtaacg	tgacgtctgt	tatgagttcc	ctaataatatt	cttatatgta	gagcaataat	720
gcaaaagctg	ttctatatgc	aaacatgatg	tctttattat	tcaggagaaat	aaataactgt	780
ttgtgtgtg	ttggtgggtt	tcataatctt	atttctgtac	tggaactagc	actttctctc	840
ctcattccgc	caaaaacagg	ctcagttatt	catttgccaa	gcttcgtgga	ggaatgtagg	900
tgacatcaat	gtgataaagt	ctgtgtctcg	agttgtcaga	tctcttgaag	acaatatctt	960
tcacacactta	ttgtttacta	aagctacagc	caaaaatatt	tttttttctt	attctaaact	1020
gagccctata	gcaagtgaag	ggaccagatt	tcctaattaa	aggaagctag	gtactttttc	1080
tgtaattttt	accatattac	tgtaagaag	aggggaaacc	cagccagcta	ctttttttca	1140
tcacttttta	ttcataactt	cagatttgta	aaactaattt	ccaaaatata	agctgttttc	1200
attagccagt	tctataatat	cttccgtgta	tttatgtaga	aaatgaacac	accccttttc	1260
catttaagac	cctgctactg	tgtagagaga	tgatacttac	aaggagtgtc	altacctgtg	1320
agctgactga	atgttggttag	gtgctccatt	acaatccagg	aaagtctgtg	ttactgatat	1380
ttgttggtgaa	atctttatct	cacttcaatt	taaccattag	atggtaaaat	taagatgcta	1440
ctgtgtggtta	aaaattgggtg	gactgttttc	aatgggtaaa	tgtgtgtgtg	caaattaatg	1500
tggtggaata	ttgtctcttg	tgaatttgtg	cttaagtcga	tgaatgtgta	gtatctctct	1560
ctgacaagca	ttccctattg	ggatttttaa	gctatgtgca	cagaatatta	gtctcttcta	1620
catgttttat	ttttctattt	ataattccct	ttttgtgtgt	tatattttat	acacagatac	1680
gatctttttt	ctaacacata	tttgaaactga	ataacagact	ttaaagaaagc	ctttgtttac	1740
attgctattt	acttttgtgt	ttgggggaaa	atacagagga	ttgattttaa	ataaaaaaca	1800
ttccatcttt	catttaatat	caatatcaaa	agaagaagac	aaacatctat	cttctctctc	1860
tatatttaag	tacctttttg	caatgtagta	tcaaaagtct	ttaggtaagc	caaaatttta	1920
caaatcattt	gtggaatgaa	tggtaaaact	aatctgacga	aatggaaaat	tattctgcaa	1980

tattgtaatt catagtctga cttttcataa gcaaaataat ccctaggtatg taatcaggac 2040
ttcaaatgtg taattcaaat tttttaaaaa aaatctaaaa aaaaaaaaaa aaaaaaaa 2098

<210> 21
<211> 1746
<212> DNA
<213> Homo sapiens

<400> 21
gcgttcgcgc acctccagct cgggcccgatg tggaaagcttt ggagagctga agaggcgcg 60
gcggcgctcg gcggcgcgct ctctctgctg ctcttcgcgc taggggtccg ccagctgctg 120
aagcagaggc ggcgcgatgg ctctcccccgg ggcgcgcggg ggctgccatt tatcggaac 180
atctattccc tggcagcctc atccgagctt ccccatgtct acatgagaaa gcagagccac 240
gtgtacggay aggtacagcc ccgacgggccc cggggcaggg agggccgcca ggctggccc 300
ggctggccag gcccttccctg gttggactta tggccqcccc tgggcccact agtcgggacc 360
tctccgtgtg cgggctgccc tttagaggac acccgcttcc cgggtctgga agggagaagt 420
cctcgacgcc gtgcccctt gcagggggag ccccgccct gccggtgacc cactccgggc 480
cgaggtcccg aggcgatcca gtccgtatlt tcccgctacc gctcgagctc ttgctcctgc 540
gcctgcgcgg tttggctcgc cagccgcgcc gccacttcag gtccagggtg cagcagctgc 600
ctcaggtgcg ggcgtcttgc gactcggcct cgcagctctg tggaaagctg acgcggtctg 660
tgggaaaatc aagggcttct gacttctaga tggtaaatag caggctcttc ggtgtctgca 720
gtcgacgaac gactggtgta ggcgtttgct gtgagaatgg agaattgcagg ggaacgcccc 780
tgactgagaa gcgggcccctg ggaacgatt gtgaacgct gaataaattg a-gactaaaa 840
tccgtcggg gggctctaca gccagatgg taatgccgt ctgactggct ggaacggca 900
ccttagcaga tacttaaaag gcgccttctg tgtgccactg tccactgcaa cttggtgact 960
catttaaaac tcataaccag ccggtgaggt cggtaactcg ctccctctca ttctgaggag 1020
gggaaagcag caggaaaatg ccctgtgact ggcagcgga aaggcgacca ccgcttgtgt 1080
gtgggtgtcc cgacgtccgg agggggcagg agttttccac ggtctcggga cagagctcac 1140
ctgttttgit ttgaattaca ctattttata tgcactaca ggcctgacgc tagcggtgaa 1200
gaaggcagat acagcccttt aaggagttgg cagatgagt ggagagagaa aactaatctc 1260
attatccggc acaggctgtg gtcagtgttt tgaaggaaaa gtacagggat gtttggaac 1320
tgtgttatt caggtttgac cttaaatcct tacttaaac agtttttaca aggattggtc 1380
tagg-gcccc ggcgcggtgc tcacgcctat aatcccagca ctttgggagg ccgaggcggg 1440
cggatcacga aatcaggaga tcgagaccgt cgtggctaac acggtgaac cccatctcta 1500
ctaaaagaat acaaaaaatt ggcggggcgt ggtggcgggc acctgtgtc ccagctatc 1560
gggaaggctg ggcaggagag tggcgtgaac ccgggaggcg gacttttcag tgagccgaga 1620
tcgcgccact gcactccagc ctggggcaaa gagccagact ccgtctcdaa aaaaaaaaaa 1680
aaaaagggcg gccgtcttag aggatccaag cttacgtacg cgtgcagcg acgtcaatag 1740
ctcttc 1746

<210> 22
<211> 2876
<212> DNA
<213> Homo sapiens

<400> 22
ccacgcgtcc ggcggcgagg gcgcgggtgt ggcctgagctc gtggtggcag aggcgaaggc 60
gacagctcta ggggttggca ccggcccccga gaggaggatg cgggtccgga tagggctgac 120
gctgctgctg tgtgcggtgc tgcctgagctt ggcctccggc tccctcgatg aagaaggcag 180
ccaggatgaa tccrtagatt ccaagactac tttgacatca gatgagtcag taaaggacca 240
tactactgca ggcagagtat ttgctggtca aatattttct gattcagaag aatctgaatt 300
agaatcctct attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac 360
agaagatata agctttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa 420
gaaagtcagg aaaccaggta gtctggacat ttccttgcct ttttgattta tttaggggac 480
aactgaaaat ttttaagctaa tgaataaaga ggctgaagaa gactggcttc actgattatt 540
accacacaaat aatatatgga gtgtagtttg gagagaattt ctgattttta atataccaaa 600
gttattcact taacagattt gacccaagtt acataagctg aattccatag atgagattgc 660

atttatcttt ttattaatat cctgacgttt ctttttggaa tcaagtatgt aaataccttt 720
ctcactgaga aatttataaa aataatatgt cagggttagca tacaatacag aaacttagga 780
agaactgtct aacatgccac tatggttatt tttaggtatg tggtaggatt attactacaa 840
taactctgtc gatcatccta gglaatttga tttaggtgtt tatccctcag ctgacgcttg 900
tggctacttc catcctatct taactttcac aactttgaaa cctctacttt tcaatttaaa 960
acttgacctt ttccacaata gtctctcaaa tattaatcct tttaaaaaatt attaatgtat 1020
gcattctacc atgtcttgtt gccctctgt catttattat ttcaatgatc actgccttat 1080
ctgtttatta ttccattact aaccactctc aggaactgat ccaaatggga acttttttaa 1140
aaaatagaat ttctttttac tacaatatata ccattctcat gaatagaaaa ctatttttaa 1200
aaaattaaaa gtacatgaat ccctatcaact agaaataaca gctgctcaca tcatggagaa 1260
tattctctca ggattttttt aggtgtatca gtatgtttta gaaaagttaa ttgggtcaaa 1320
atgtgtatct tatgttgtag cctgcatttt gcacttaaca gtttaccatg aatgtttttc 1380
catgtcattt agcttatctt caatttgata gttaatggct ataaaaaatt ttatttgtaa 1440
atatatggta ccataaacca aaacgtttat gttttgctgg gagatcattt tagatgtatc 1500
tttgtgccta tctgtgaaaa ttctcttaga attcttaaaag taaatttgc gaattggatg 1560
taaaagttaa aaagacaqta gatacacatt gttaaattgt tcttcagana agtgattctg 1620
tttacttctt ctgaaaaaac ctctttccct gtacctcacc caagtgtgta ttaccatttt 1680
aaaattttta ctaaatataa ttttaattcat tcttcatttt ttaattaggg attttttttt 1740
ttttttttta gtttttata ttttagagac atggctctac tctgtcactc aggtctggag 1800
gcagtggcac gatcatagtt cactgcagcc ttgaactcag gtgatctccc tctttggcct 1860
cccaaagtgc tgggattaca ggcattgagc actacatcaa gcctgggaaa tttttaaaca 1920
tgcatataag tagagggtaa aatgacaccc ctaccacacc ctcactcagc ttcaataaac 1980
atcaacattc tgcgtgtctt tcatcttta ctacctaca cacatttgcc ctttttttct 2040
ttcttagaat attttaaggc aaattccgca tgtgttttta catctctgtg tctctctcta 2100
gtaagaattg tcttttcagc aaaatcacag aattagccat tactctctta ttacctata 2160
ccagactgt ttaatttttc tagttgtctc aagtgtctgt ttacaattta tttgtttgaa 2220
ttcatttcta agtactcag gaggtgagt caggagaatt gcttgaaccc aagggcaga 2280
gggtgcagt agctgagac gtgcccctgt actccagcct ggggtgacaa gtgagactcc 2340
atgtcaaaac aaacaaaaac aaacaaaaac aaacaaaaac aaacaaaca attgaataat 2400
atccctcagt tattatttag agaagagatg actcaatata aatgtaatat gtgactcatt 2460
gttcacagaa tgaattcagc tcatgtctta ggtaagcctg gtaaaaaaaa aaaaaacgg 2520
gattccatga ttagtgtgtt gaaaaggggg tggccaaagt gtaacagaca gagccgggtg 2580
cagtggctca cgcctgtaat cccagaactt tggggggcca aggcaggcgg atccaggagt 2640
caagagattg agacaatcct ggccaacatg gtgaagccct gtatcaacta aaaatacaaa 2700
aacaattagc tgggctgtgt gacatgtgcc tgtagtccca gctactcagg aggcagggc 2760
aggagaattg cttgaacctg ggaggcggag gctgcagtga gctgagattg ctccactgca 2820
ctccagcctg gccacagagt gagatccat ctcaaaaaaa aaaaaaaa aaaaaa 2876

<210> 23
<211> 1052
<212> DNA
<213> Homo sapiens

<400> 23
tcgaaccacg cgtccgccca cgcgtccgcc cagcgtccg ggcgggcgca ggaagtgcac 60
tatggctcgg ggtcgcgcgc gccggttgcg gcggctctct gtgcggggc tctggctggc 120
gttgcctgcg tccgtggcgc gggagcaagc gccaggcacc gccctctgct cccgcggcag 180
ctcctggagc gggacctgg acaagtgcac ggactgcagc acctcctgcc ccttccggc 240
tgctttggcc catccttggg ggcgtcttga gctgacctt cgtgctgggg ctgctttctg 300
gcttttttgt ctggagacga tgcgcagag agagaagtt accaccccca tagaggagac 360
ggcgggagag ggtgcccag ctgtggcgt gatccagtga caatgtgcc cctgccagcc 420
ggggctcgcc cactcatcat tcattcatcc attctagagc cagtctctgc ctccagacg 480
ggcggggagc caagctctct caaccacaag gggggtgggg ggcgtggaat cactctcag 540
gcttgggccc agggttcagg ggaaccttcc aaggtgtctg gttgcccctg ccttggctcc 600
agaacagaaa gggagctca cgtggctca cacaacacag ctgacactga ctaaggact 660
gcagcatttg cacaggggag ggggtgccct ccttccctaga ggcctgggg gccaggctga 720
cttggggggc agacttgaca ctaggcccca ctcaactaga tgcctgaaa ttccaccacg 780
ggggtcacc cgggggttta gggacctatt ttttaacta gggggctggc ccactaggag 840

```

ggcggccct aagatacaga ccccccaac tccccaaagc ggggaggaga tattttatatt 900
gggggagatt tggaggggag ggtggggggg gggaaaaaaa aataaaaaaa aaaattttta 960
atttttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1052

```

```

<210> 24
<211> 1541
<212> DNA
<213> Homo sapiens

```

```

<400> 24
ggcacgagct tccctgatcc tactctgtct cttcttgttt tggagaagtt caatttacca 60
gctggatatt tgggactagt attcctgggt atggcactgt cctatgccat ctcttcacca 120
ctatttgggc tcctaagtga caaaaggcca cctctaagga aatggcttct ggtgtttggc 180
aacttaataca cagccgggtg ctacatgctc ttagggcctg tcccaatctt gcataataaa 240
atgcagctct ggtgctggtt gctgatatta gttgtaagt gcctctctgc tggaaatgagt 300
ataattccaa ctttcccgga aattctcagt tgcgacatg aaaatgggtt tgaagaggga 360
ttaagtacac tgggactctg atcaggtctt tttagtcaa tgggtcaat tgggtctttt 420
ttgggaccaa cgctgggtgg atttctgtat gagaaaattg qttttgaatg ggcagcagct 480
atacaaggtc tatgggctct gataaagtga ttagccatgg gcttgtttta tctactggag 540
tattcaagga gaaaagggtc taaatctcaa aacatctcca gcacagagga ggaacgaact 600
actctcttgc ctaatgaaac ctagtccgat ggatccctga ttgatacaag gttgagaaat 660
gaatgctctt ggccttaaac atcaccttag gaagggtttt taaaatttta cgcgcaaac 720
tccgtggacc ccgtgccagt gtcttgggaag tgcacaactg tttttggatg atcctgtatt 780
ggcctgtact tactgtgata ctgaaaagct gtctgtctga agcagctata tttgaaatat 840
taagtatgaa aggagttaatt aaaaacaagc aaaaacaaac aagacttagt ttttaaatga 900
ccaaacttgt ccttaagat gttgttatta actcgagtta gttcttattt cctctgttta 960
ttttttattc taagtagact gattctgtga atgtacctt tttattacac agggaaagaa 1020
atgaattaat ttgatatgct ctaaatacat aaaggtgctt caaaatatgt agaaacatta 1080
ctatgaaatc agtttttaaa agatataact tctcttctgc ctgagggttt tctgtcttgt 1140
tcaaaaggaa gaattcttgc ctgccatata gaaactctct agcactccct gaccttaagc 1200
ttttctaaaa attctgtttg tgtgaaaagt acaagataaa caatacttac aacttccatt 1260
tttgtaacct acgttcactt atgatctgga ttataaaca ttacttggtg taactgtttt 1320
catttctctt aatgtctctg tcttttggct ctaccatctg ttttgttttt gtttttatct 1380
atatcttgtt agatgtattt catccttaga gcaggtcagc etccttcccc taatgccaat 1440
gcttgttttg ttagggaagg gcttctctca actcgtgtg aaattgtgat gttgaagcga 1500
ataaatgtct attgtgtaac aaaaaaaaaa aaaaaaaaaa a 1541

```

```

<210> 25
<211> 2079
<212> DNA
<213> Homo sapiens

```

```

<400> 25
ggcacgaggg aggcgcggct gggggacctg actagattct acgacaaggt actttctttg 60
catgaggatt caacaacccc tgtggctaac cctctcttly cattactct catcaaacgc 120
ctgcagctct actggaggaa tgtgggtacat agtctggagg ccagttagaa catccgagct 180
ctgaaggatg gctatgagaa ggtggagcaa gacctccaq cctttgagga ccttgaggga 240
gcagcaaggc cctgatgctg gctgcaggac gtgtacatgc tcaatgtgaa aggcctggcc 300
cgagggtgtc ttcagagagt cactggctct gccacactg acctgtacag ccccaaacgg 360
ctcttttctc tcacagggga tgaactgttc caagtggca aggtggccta tgacatgggg 420
gattattacc atgccattcc atggctggag gaggctgtca gtccttctcg aggatcttcc 480
ggagagtggg agacagagga tgaggcaagt ctagaagatg ccttgatcca cttggccttt 540
gcttatttcc gggcaggaaa tgtttctgtg gccctcagcc tctctcggga gtttcttctc 600
tacagcccag ataataagag gatggccagg aatgtcttga aatatgaaag gctcttgcca 660
gagagcccca accacgtggt agctgaggct gtcattcaga ggcccaatat accccacctg 720
cagaccagag acacctacga ggggctatgt cagacctgg gttccagcc cactctctac 780

```

```

cagatcccta gctctactg ttccatgag accaattcca acgctacct gctgctccag 840
cccatccgga aggaggccat ccacctggag ccttacattg ctctctacca tgcctctgct 900
agtgactcag aggtctcagaa aattagagaa cttgcagaac catggctaca gaggtcagtg 960
gtggcatcag gggagaagca gttacaagtg gagtaccgca tcagcaaaag tgcctggctg 1020
aaggacactg ttgacctaaa actggtgacc ctcaaccacc gcattgctgc cctcacagge 1080
cttgatgtcc ggcctcccta tgcagagtat ctgcaggtgg tgaactatgg catcggaqga 1140
cactatgagc ctcactttga ccattgctacg tcaccaagca gccccctcta cagaatgaag 1200
tcaggaaacc gagttgcaac atttatgato tatctgagct cgggtggaagc tggaggagcc 1260
acagccttca tctatgcca cctcagcgtg cctgtggtta ggaatgcagc actgcttttg 1320
tggaaacctgc acaggagtgg tgaaggggac agtgacacac ttcattgctgg ctgtctgttc 1380
ctggtgggag ataagtgggt ggccaacaag tggatacatg agtatggaca ggaattccgc 1440
aqacctgca gctccagccc tgaagactga actgttggca gagagaagct ggtggagttc 1500
tgtggtttc cagagaagcc aggaaccaaa agctggggta ggagaggaga aagcagagca 1560
gctctctgga agaagggcctt gtcagctttg tctgtgcttc gcaaatcaga ggcaaggagc 1620
aggttgttac caggggacac tgagaatgta catttgatct gccccagcca cggaaagtcag 1680
agtaggatgc acagtacaaa ggagggggga gtggaggcct gaaggggaag ttcttgaggt 1740
tcagatactc tctgttggga acaggacatc tcaacagctc caggttcgat cagtgggttc 1800
tttggactt tgaaccttga ccacagggac caagaagtgg caatgaggac acctggcagg 1860
ggggctagcc tgactcccg aacttlaaya ttcttcccc actgctctct gctgcagccc 1920
aagcagggag tgtccccctc ccagaagcat atccagatg agtggtagat tatataagga 1980
ttttttttaa gttgaaaaca actttctttt ctttttgtat gatggttttt taacacagtc 2040
attaaaaatg tttataaatc aaaaaaaaa aaaaaaaaa 2079

```

<210> 26

<211> 1947

<212> DNA

<213> Homo sapiens

<400> 26

```

tgtaaacaga ttggagaatc tagcaataag attcaaaqct aatctggagc ataaaggcac 60
agttcagaga cagaataaca gggatcacaa gcatgaatta aaaggaattt atttgcctca 120
agttcctaga tacaaccttc ccattgctga cctctccact gtcggagcac gttccgaaaa 180
acagaatgcc ttgatccctg gttgggtgca aggcagttgt tagggatggc aggcatttgt 240
gggctccaaa agatgaaggc cccacacaca ggtgtgctgc atttgggagc tgtgtgggtg 300
tttcttggac cctttcttct gggagtgggg tacacactaa cgtttaatcc gctgtctggg 360
tgcatgtcca cagtacggtg gctaaactgc aacatcactg caaataggac gctgagcagg 420
tcctgtctgc atgtacgccc actgcacagg tccttgtccc caccagcagg ggagtacttg 480
cgtcagatgt tattgaatag ctgctctcgg gcaggggaag cggggagtgg gggatattaa 540
ttgggggttt taattctatt atcattgtcag ctgacattat gactatataa tgtagttaga 600
gacaattttt atcttgcctt tagtaaaagt tcagcctgcc aattgtaaat cattctaatt 660
tggcaggctt atttttgaca ttggaaaagg cagaaaagca tttgcccagc tagtgttaaa 720
ggagtatatg accagaggct gaaacccaaa ctatataaaa aggaattcag tggagggggc 780
tttgtaatct ccattaatlt gtgttgctac ttccaggatc accaaaaat acatgtaatt 840
ttacatgtta aacacattga aacataacct atgtttataa agcataacgg gcttccttcc 900
cagaagctct cctgcttctc atgaagtgaq aacaatqaaa agtcatagca gatactcagt 960
ttaactctgt gtagaacctt gtagtggttg agctgttatt cagatttgaa ttccagactgt 1020
gtgttggttg cttatggaga ctgctgtgct ttctgtcact gttaaattaa tgaagtctata 1080
aggtttttct tccagaggcc atagggtgaca tcaactaaaat tgcagataaa attgtaattc 1140
ttgctgctgc tgcactcccc aacctctccc ccaccccccg tgggtgctg ctttcttagat 1200
gagcgtgttt tggagcaggg ccactctggga cactctatgc ttccaccaag gaagtgcgat 1260
ctgagcagcc acaatccagc caaaaagagg tegttagatat ttgctctgat caactagatg 1320
aaaatatagc agaattggat tagcccaact ctctgtttta tccaactgag tctcagacca 1380
gcaatttggt cataattatt acagcaaaag ttaagaaatg aaactgtagc aattatgtaa 1440
atgaatgtgt tggcctctta atacctgtta ctagtggact tctgtgagg aagttagttt 1500
tttgttttga tgaatgctt tctgttttta aatcttaatt ctgctgtcca catctccca 1560
aagtgtgctt acttcatttg ttaatttaa atgaacttcc ctcttcttat gtagagggtg 1620
acttggggg tgggggtgggt ggttttgggt ttgtgttttt tctttcttta gggcatctgc 1680
aggcctcaaa ggacctctcc tttaggtcat attcctcaga aagcttcaa tcttcccttg 1740

```

tttttgtttg	tttgtttttc	ttaaagaata	ttttcaaagc	ttaaatttgt	atattaattt	1800
aggactat	agaagtata	gctgtcgttg	gcccgcagcag	tatatcttga	aactgtctcat	1860
agatatatat	ttttgaataa	agatggctgt	gttgaacaaa	aaaaaaaaaa	aaaaaaaaac	1920
tcgagggggg	gcccgggtacc	caatttcg				1947

<210> 27

<211> 3379

<212> DNA

<213> Homo sapiens

<400> 27

atgatattca	agtcgaattc	ccctcactaa	agggaaaaaa	gctggagctc	caccgcgggtg	60
gcggccgctc	taaacctact	ggatcccccg	ggatgcagga	attcgggcagc	aggtctcggc	120
tcctctccgg	accgcgccgg	cccggctcgt	cccggctcct	cccggccatg	gggagctcgg	180
cgccggctgt	gctgtctctg	ggctgcacgg	tgggtggcgc	aggactgagt	ggagtagctg	240
gagtgtggtc	ccgctgtgaa	aaagccctga	accctcggat	gggaaatttg	gctttggggc	300
gaaaaactct	ggcagacacc	acctgcggtc	agaatgttac	cgaactgtac	tgcttctaca	360
gtgagaacac	ggatctgact	tgctgggcagc	ccaaatgtga	caagtgcaat	gctgcctatc	420
ctcacctggc	tcacctgcca	tctgccatgg	cagactcacc	cttcgggttt	cctgcacatc	480
gggtggcagtc	tgccggaggat	gtgcacagag	aaaagatcca	gttagacctg	gaagctgaat	540
tctacttcac	tcacctaat	gtgatgttca	agtcctccag	gcgggtgccc	atggctgtgg	600
accgctccca	ggacttttgg	aaaacatgga	agccttataa	gtacttttgc	actaactgct	660
cgcctacatt	tgccctggaa	gatgatgttg	tcaagaaagg	cgctatttgc	acttctaaat	720
actccagttc	ttttccatgc	actggaagga	aggttatttt	caaagctttg	tcaccacatc	780
acgatacaga	gaacccttac	agt-gccaaag	ttcaggagca	gctgaagatc	accaacctcc	840
cgcgtgcagc	tctgtaaacg	acagttctgt	ccctgtcaga	gaatgacctc	gaacgaagag	900
cctcaacatt	ttacacacta	tgccatctat	gatttcattg	tcaaggcgag	ctgctctctg	960
aattggccacg	ctgatcaatg	catacctgtt	catggcttca	gacctgtcaa	ggccccagga	1020
acattccaca	tggtccatgg	gaagtgtatg	tgtagcaca	acacagcagg	cagccactgc	1080
cagcactgtg	ccccgttata	caatgaccgg	ccatgggagg	cagctgatgg	caaaacgggg	1140
gctcccaacg	agtgcagaac	ctgcaagtgt	aatggggcatg	ctgataacctg	tcacttcgac	1200
gttaactgtg	gggaggcatc	agggaaatcg	agtgggtggg	tctgtgatga	ctgtcagcac	1260
aacacagaag	gacagtattg	ccagagggtgc	aagccaggct	tctatcgtga	cctgcggaga	1320
cccttctcag	ctccagatgc	ttgcaaacgg	tggttctgtcc	atccagttagg	atcagctgtc	1380
cttctctcca	actcagtgac	cttctgcgac	cccagcaatg	gtgactgccc	ttgcaagcct	1440
gggggtggcag	ggcgacgttg	tgacaggtgc	atgggtgggat	actggggctt	cggagactat	1500
ggctgtcgac	catgtgactg	tgccaggagc	tgtagcccta	tcaccggagg	ctgcacagc	1560
agccacacag	acatagactg	gtatcatgaa	gttctctgact	tcctgtccctg	gcacaataag	1620
agcgaaccag	cctgggagtg	ggaggatgcg	cagggttttt	ctgcacttct	acactcaggt	1680
aaatgcgaat	gtaaggaaaca	gacattagga	aatgccaaagg	cattctgttg	aatgaaatat	1740
tcatatgtgc	taaaaataaa	gattttatca	gctcatgata	aaggtaactca	tggtgaggtc	1800
aatgtgaaga	ttaaaaagggt	cttaaaatct	accaaactga	agattttccg	agggaaagcg	1860
aacattatat	ccagaatcat	ggccggacag	aggatgcact	tgctccaatcc	tcaatccttg	1920
tttggaatac	cttgtagcag	gacatgagga	tataagaaca	ggcaaaactaa	ttgtgaatat	1980
gaaaagcttt	gtccagcact	ggaaaccttc	tcttggaaaga	aaaagcatgg	atattttaaa	2040
aagagagtgc	aagtagcatt	aagatggata	gcacataatg	gcacttggct	atgtccaaaa	2100
cacaaacttt	agagcaagaa	gacctcagac	aggaactggg	aatttttttaa	agtgccaaaa	2160
catatagaaa	tggttgaaatg	catgggtctt	tatctaattt	atctcttctg	gacccatggt	2220
taaatacagt	tttatttcac	gaagagaaat	gaaaaccctt	acactgatat	ctgttttcta	2280
tgggactgat	tctgaaatcc	ttaactatta	agaatatctt	aatagcagca	tgacattttg	2340
cagttaatcca	ttaagggcag	tacctctaac	aaggacgcct	tccagcttca	gctatgttac	2400
ttacgtttga	tgctacttaa	agtaatgaat	gacgttttaa	ggaatcccta	accctactat	2460
cagaaaagggt	gtttgtttaa	gagcctcttc	ttgtgtgtta	cgcataaact	ttgctctgta	2520
gggtgtttaa	ggacctcttc	catgtgtata	tagtatttcc	ttgtataaag	cacttttacta	2580
cctaccacttt	gtgtttgtaa	cttttgggtga	ctgctgttga	aagaaggaaa	aggggtgtgtg	2640
agaaaagccta	ctgaagcagc	agcactgcca	ctacatgttg	acaaaagtga	acataaaaaa	2700
gaagtgtgtc	tatttaactc	tgaatacttg	gagaaactag	gtgaagatgc	aaccagaaag	2760
gagaataatgt	atgcgltgaa	lctcagcttt	gagctggagg	ctagattcca	agatgacagc	2820

```
catgatgaaa ctttttaaaa aactaaacca gaagagactt taaaataaga gaaagaaatc 2880
ataaatgtag acatatgtct ggctaaaagg gaaatggact ttaaatttta aagagctcat 2940
ttgcaatgca cttgtatata cttcaaaaat tattgttagc acagaatttg ttatattttt 3000
gtgcttagta tttaaacctg aacattgaaa cagttttcct ccttgctttt ctttaacagta 3060
atagtcatta tttttacctg ttttttaaca caatgtatgt gatagtcaaa aaatcacagt 3120
ttttcattat tattcatctt ctgtaccacac gcataaccac tatacatagt ttcttttgta 3180
cttgaatata caaaacatga acacagtgcc atatgaataa tttcacatac agaacccttt 3240
ttctcttgaa gtctgttgga cttgcaataa tatatatata ttgctttgtt aatttgtttt 3300
tatatttcat atatgtaata aaggaatatg atctgaaaaa aaaaaaaa aaaaactcga 3360
ggggggggcc gtacccaaa 3379
```

<210> 28
<211> 2006
<212> DNA
<213> Homo sapiens

```
<400> 28
cccacgcgtc cgcggacgcg tgggattttc tcttaagaaa aaaaaaggaa gacgttttaa 60
taggaaaaga aaaacaagaa gcagtagcag ctaggtaatt taaacgtctt cctttttttt 120
tcttaagaga aaatggaaca tttaggttaa atgtctttta attttaccac ttaacaaacac 180
tacaagccca taaaatatac ccagtcagta ctgtatttta aaatcccttg aaatgatgat 240
atcagggtta aaattacttg tattgtttct gaagtttgct cctgaaaact actgttttgag 300
cactgaaacg ttacaaatgc ctaataggca ttgagactg agcaaggcta ctgttatctt 360
catgaaatgc ctgttgccga gttattttga atagaaatat tttaaagtat caaaagcaga 420
tcttagttta agggagtttg gaaaaggaaat tatattttct tttttcctga ttctgtactc 480
aacaaatctt gatggaatta aaataactct ctttattctg gtgagcctgc tagctaatat 540
aagtattgga cgggtaataa tttgtcatc ttaatttag taaaatgaat taagatatta 600
taggattaaa cataatttta tacgggttagt actttatttg ccgacctaaa tttatagcgt 660
gtggaaattg agaaaaatga agaaacagga cagatatatg atgaattaaa aatatatata 720
ggtcaatttt ggtctgaaat ccctgagggt tttttaacct cctacactaa ttgtacact 780
aatttatttc tttagtctag aaatagtata ttgtttgcaa gtcaactaata atcattagat 840
aaattatttt cttggccata gccgataatt ttgtaatcag tactaagtgc atactgtatt 900
ttgccacttt ttcttcagat gattaaagta agtcaacagc ttatttttag aaactggaaa 960
agtaaatagg aaagagattt cactatttgc ttcatcagtg gtaggggggc ggtgactgca 1020
actgtgttag cagaaattca cagagaatgg ggatttaaag ttacagagaa aacttgaaa 1080
gtctctgttc aggatcttgc tggcagaatt aactttttgc aaaaagttta tacacagata 1140
tttgatttaa atttggagcc atagtcagaa gactcagatc ataatgggtt tatttttcta 1200
tttccgtaac tattgtaatt tccacttttg taataattt gatttaaaat ataaatttat 1260
ttatttattt ttttaatagt caaaaatctt tgctgttgta gtctgcaacc tctaaaatga 1320
ttgtgttgct tttaggattg atcagaagaa acactccaaa aattgagatg aaatgttggt 1380
gcagccagtt ataagtaata tagttaacaa gcaaaaaaag tgcgtccacc ttttatgatg 1440
attttctaaa tggagaaaca tttgggtgca tccacataga cctttatgtt ttgttttcag 1500
ttgaaaactt gcctcctttg gcaacattcg taaatgaagc agaatttttt tttctctttt 1560
ttccaaatat gttagttttg ttcttgtaag atgtatcatg ggtattgggt ctgtgtaatg 1620
aacaacgaat ttttaattagc atgtggttca gaatatataa tgttaggtt ttaaaaagta 1680
tcttgatggt tcttttctat ttataatttc agactttcat aaagtgtacc aagaatttca 1740
taaatgtgtt ttcagtgaac tgctttttgc tatggtaggt cattaaacac agcacttact 1800
cttaaaaatg aaaatttctg atcatctagg atattgacac atttcaattt gcagtgtctt 1860
tttgactgga tatattaacg ttctctgaa tggcattgat agatgggtca gaagagaaac 1920
tcaatgaaat aaagagaata ttattcaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa 1980
aaagggcgcc cgtcttagag gatccc 2006
```

<210> 29
<211> 3070
<212> DNA
<213> Homo sapiens

<400> 29
 gttggagcct tagaccttcg aagtgcaccta tagaaggtag gcctgcaggt accgggtccgg 60
 aattcccggg tcgacccacg cgtccgcaac gtaggaggag tctgatttct ccacatcctt 120
 gtcaacattt gttgttgggt ttgttttgaat tttagctatc ctagttagatg 180
 tgaagtggta tctcgtgctt ttattttgca ttctctaat gactagttag gttgaacatc 240
 ttttcatgtg cttgttggcc attcgtatat ctctctggag aaatgtctat taagtccctt 300
 gcccaatttc aaattggcct gctctttgtg taggttataa ccattgaatt ttaattgctg 360
 taaaacactc catgagtaca tctagcatgc actcaataac tattagctaa tactatagtt 420
 gtaattattt ttgccacatg tggcctgaat tggaaagaaa ttgcccagtt ttccaagta 480
 ggagtggaga tgaacaaaaa cctgtattta aggccataaa agatttgact ctgtcagttg 540
 tgatactttg cttttaattg atgctcccaa atcaagaaat tagaaacgtg tatacataag 600
 aatcagttta tcttggcag aaatcagtat attatcaatg tttaattaat tccaaagaat 660
 taatggcaat agtgcctcta gtttttagct agatttagat catcttctt cattctgccc 720
 tgttatgcga catttgctat aaatgccaca atgagaattt ttgaaacct gggtcagaga 780
 agcctacttt ctatatttaa taagtatgtg attgatgtat tatcattggg ttatgcttat 840
 tgcactcttg ttttatgggg tgttcaaaaag aagatagatg agaataagggt atccaaaagta 900
 atttagaatt ttatcctcca gttgggaact aacctcttg aactgatgaa tatattctac 960
 caggtttata ggtagatatg ccgtttcact atatcggtag ttggagtgga gacagtagct 1020
 ttaacgcaga caacacagcca tatgtlaaglc laaatttggg tattttcttt gaataagcaa 1080
 tggaaactgt atgcattcag gaactgtgtg ttccagatate ttctgaaggc cctctctccc 1140
 ctgtgctccc acagcttttg tctgaactc tctgtctcc ttgcgatgcc tctgtgcta 1200
 tacctatttt gtgaactctg cctgcgaatgc cgtcccaagt cagttggtag cctctcaaac 1260
 ctcaactgaag tcttccgggg tggattcaaa tgcgtctttt agccattaaa atctgttaca 1320
 tctgttacat actttcacaa tagcacttat cctagttagt ttttaaaaat gcacttaaaa 1380
 atttttaag cagtgcacgc atgcagtaaa caaaattgga cagtacagaa ataatgggt 1440
 aagacagctt cccagttttt tcccccatgg atagcacttt ctctttttta tctttcaaaa 1500
 qatattttgt gctgatacaa gaatttttat accgtatgaa gtgcttattc atcttacttt 1560
 ttacttcagg gtaatttatg agtaaatgaaa aaattcaagc attacaaaaa tgtagagttg 1620
 gtgaagcaaa aggttccccct tactttgatc cctaacacta gccctttcca aataacactg 1680
 tcttaattaa cactcctctc tccagaagta acctctgta taagccttgt ctgtgccttc 1740
 agattgttct gcttacactt atatgcctat ttaaaagtgt atatttttgt attttgtttg 1800
 tttgtttgtt tgagacagag ttctcgtctt gttgcccagg ctgaagtga atggcactat 1860
 ctctgtcac tacaacctgt gtctcctggt tccaagtgt tctcctggct cagcctctg 1920
 agtagctagg attacaggcg cagccacca tggccggcta attttgtat ttttagtaga 1980
 gatggagttt caccatgtgt gccaggctgg tcacgaactc ctgacctcag gttatccacc 2040
 caccctggcc tttaaaactg ctgggattac aaggcatgag ccactgtgcc cggccaagaa 2100
 tttttttatc gataccatag tgagctctct gcctcttcgg aacgatgtcc accttgctta 2160
 tgatcaacc cagcaggact ctctctctcc tggagccttc tcccttggtc tggaaatcttc 2220
 cagttctgcc agaattggcc ttctccagat gctgcaact tccagttgaa ccccttttc 2280
 tgtgtggccc ctggggctgc gagaccaaaa tccatgagtt ctgtgtaccc tagaccttg 2340
 gaaggtgaga gcagggccct gagaaaaggc aaaacgcctc ctctccctga tgataccctt 2400
 acccgcccta ctctcacca gaattgtcag tggcctttca ccacagtggt ccttctctgc 2460
 tgagccctgc actgtccag accacacaga agtctggta cctctggggc cctgggatgg 2520
 tcaccgnaa gaagcacgct gtccccgtct tctcctggct tctgccagaa aatcgaacaa 2580
 gtgcaattaa cacactgtta ctgccgaagc ctgaaactcc caggacttgt ccttgatcct 2640
 tccagaaacc accaggtccg gcacttggag ccccccgag agggacctcc cagccgagct 2700
 ctcaagaac tccatgaaat caggaactgc ttgatgaaat gtatctctt gtacctggaa 2760
 gatgaagccc aaacaccacc acctctgtct cccccaggc tgggatgtc tccagcagct 2820
 cggccacgca gcttcccagg tgggctcggg gaggtgggag cagggaccat ctctgtccc 2880
 tccacctca ctccatccac ctccggagacc acctctccc agccagatag ggaataaac 2940
 tacagacgca gaaaaaaaaa aaaaaaaaaa gggcgccgc tctagaggat cctctgaggg 3000
 gccccagctt acgctgcat gcgacgtcat agctctctcc ctatagtgag tctattata 3060
 agggagcaaa 3070

<210> 30
 <211> 2227
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (289)
 <223> n equals a, t, g, or c

<400> 30

```

cggacgctg ggtcagccca cgcgtccggg aaaaarggaa aaratgccgt gtaaaatctc   60
gttctgtgtc tgaattgccg taggctcaga ccttcatttg aggttctgtg tctgaattgc   120
cgtaggctca gatcttcatt tgaggttatg ttctataagt taacgttgat cttgtgtgag   180
ctttcggtag ctggagtaac acaggcggcc tcacagcgac ctctccagcg ccttccaagg   240
cacatctgca gccagcgtaa tcctcctggg aqatqcctcc tcaaggccnt gctccagacc   300
acgtggggar ggctgacac ccaattccca ggetgtcccc acccttgrag agtgacccta   360
aacgctagac agatggggaa tgggaaagaa aagaagctg cagacctcaa gttaaaaattc   420
cctcaaaaac gtttllaltt atctgtttt tctgaaagga taaaggctt ttgaaaatta   480
ttttctaaca aataacatga acacttctag aaaccctaga aaaacacaaa gtattcaaaa   540
tagaagaaa aattaccat tactctttaa gccagcatta tccattgagg tgcctttgga   600
gttggtgtag gccgtagcct ctgccagtc aaggagcccg gtggtggctg tggcattcct   660
gcagggttgt tttttttct ttgagatgga gtctcactct tgtcacccca gctggaatgt   720
ggtggtgtaa acagctcact gcagccttga cctgagggt caagcgatcc tctgccttg   780
gcctcctgag tagctgggat cccaggcgag agtcaccaca cctgtccat gttcctgcag   840
gtcttgatat gcgaggacgc tgtgtcttcc ctgccacatt ttctcttct tcttgagac   900
agacctctgc tccatcacc cggccagagt gtggtsgtgc gaacacggct cactgcagcc   960
tcgacctca ggcctcagcg atcctcagc ctcggacccc caaagtgtg ggtacacagg   1020
cgagagtcac catgctggcc tgaattctca gggtaattta cggttgaagt gtcacttact   1080
tarccatccc tgtttcaaga gtgtaggtgg tcacctgtc tctgycgctg acctggcctg   1140
gacctctggc tgtgaaggg aqqqgtggc tgggctggag gaacctraag cctcctgtat   1200
gtcacaagcc catctggctg gccatccct gctgtctct gagctgcaca tgcctcaggt   1260
ggcccccaca gcagaggcga gccactgrag ggtgragggc tcccacggac ggtcttcagg   1320
ggragaagaa gggcccagc ccccaggaga ctccaggagc cagagcctgg ggtcaggggc   1380
tyagcagggg ctarccagg gctggatgtc cggagccagc cccmagccc tkgktcttt   1440
gttcttcgca ctcccacgt cctgttgaa agctccagcc ccacctgcgc ctcctgtgc   1500
tgggtccat cagggagccc agaagacgtg tgtgtctct aaattgggtc cctacatgcc   1560
tttgcctcag tgcacctgc tccttccatt tactatcgag atttaaatgc ctgtttctc   1620
cccagaggtt gacgatatata ttacagctt acgacacgga tcaggacggc tggattcagg   1680
tgtctgtaga acagtacctg tccatggctc tcagtatcgt atgacctgg cctctcgtga   1740
agagcagcac aacatggaaa gagccaaaat gtcacagtgc ctatctgtga gggaaatggg   1800
cacaggtgca gttagatgct gttcttctt tagattttgt cagtgggga cccagcgtg   1860
catatgtgga taagctgatt aatggttttg caactgtaat agtagctgta tgcctcaat   1920
gcagacattg gatttgggga ctgtctcatt gtgccatgag gtaaatgtaa tgtttcaggc   1980
attctgcttg caaaaaaatc tatcatgtgc tttcttagat gtctcgggt ctatagtcca   2040
aatgtttta ttagecaata ggaattttta aataacatgg aacttacaca aaaggctttt   2100
catgtgcctt acttttttaa aaaggagttt attgtattca ttggaatatg tgacgtaagc   2160
aataaaggga atgttagacg tgtaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa   2220
aaaaaa

```

<210> 31
 <211> 1288
 <212> DNA
 <213> Homo sapiens

<400> 31

```

ccccgggt gcaggaaattc gccacgagcc tgacctcccc agctcatct ctccctctc   60
tgctctgcc ctctgtgtc cagccaaagt ggcctgtcac tctccacct gccatactgt   120
cctgacctca ggcctttgcc tgtgtatgg cctctgttg aacctcttt gtctctcccc   180
tgctgtgtct gctaattccc actcgtgtca gtgatccatg gctgcagAAC acaccactcc   240
atccatggaa aacaatcaca atcattgatt actatctct cctgggcttc ctggggtgga   300
ctgggctcag ctgggtggtt cactttgggg cctcagcagl calyggcaaa cagtggctgg   360

```

ggctactgca	aagactcccc	tgcattctctg	gcagttgatg	ctggctgcca	tctgagacac	420
ctaccagggg	cctctccctg	gggcctgggc	tcttgcttag	cttgggttggg	aggctccaag	480
accaacatcc	caagaaagat	gagacagaag	ccagatcacc	tttttgggccc	tggcttcaga	540
agtcacccag	cattacttct	gctgcattta	ttctttaaia	cacaaatate	aaaccccatc	600
tcttgatggg	agggggcctc	atgggttcta	aactgtttct	aaactccact	ctgcccggcc	660
ttggcccaac	gtgtctggta	atgtgtgggc	tgtgaggctc	cccgaacgta	gacctcagac	720
tgcaacgctg	gccgttacag	gctctggcac	acgggcccac	gtcaggccca	tccccacagt	780
gatggttgtt	ctgtgactgt	ttctgggtggc	ctctgctcca	caactcagge	tgacgtctg	840
ccccctccac	tgggaccctc	gggtggcttc	catgcacttg	tgccttaaat	cctgctccta	900
gactaaactt	catctcctgt	gttctcatte	tgcagcatyg	ctgttaggga	acctgacct	960
ctgcagcgcy	tctcggtggc	aagggtataat	gtcagtgcct	cccttcagtg	gctcccatgt	1020
cacagaattg	tcttgacgce	ctggcacatg	tgtgccatgt	gggagctggg	gcaggctctc	1080
tttcatctctg	tggctccgag	ggagggggcc	gctcctctcc	cagttctctac	cctgactctg	1140
ccctcgctct	gcagccactc	agagagcacg	atggagctgg	agcttcagtt	ttgaccaaat	1200
gggtgtcgcc	ggcttttg-g	tgtgtgtgty	lytyacagag	ccagaccctg	tctttaaaaa	1260
aaaaaaaaa	aaactcagg	ggggggccc				1288

<210> 32

<211> 3280

<212> DNA

<213> Homo sapiens

<400> 32

gggtccggtg	agaggcaagg	acttttcatc	tttagggcat	tctgaccacg	tcttgcttca	60
gagagattgt	tcccgccgtc	tcagtgtctat	ggggagcagg	tccctcctgg	tcttgctctc	120
aggtctcact	gtcttacttg	ctctgccagg	atcaaaqccc	aagaattctg	gagcttctctg	180
tcttccatgc	cctaaatatg	ccagctgcca	caacagcacc	cactgtactt	gtgaagatgg	240
cttccggccc	aggtctggca	ggacatactt	tcatgattcc	tctgagaagt	gtgaagatat	300
taatgaatgt	gaaaccgggc	tggcaaatg	caagtataaa	gcataattgta	ggaataaagt	360
tggaggttac	atctgtagct	gtttggtaaa	atatacttta	ttcaacttcc	tggctgggtat	420
tatagattat	gatcatccgg	attgttatga	gaacaatagt	caagggaaga	cacagtcaaa	480
cgtggatatt	tgggtgagtg	gggtgaagcc	tggatttggg	aaacagctgg	tacgtataac	540
tatgccatct	tcttacccaa	acattaacat	gtcttctctg	gatttttagg	gtagggtagt	600
tctatccagg	ggtaattttg	tctctgtctc	caagggtcatc	tgtcaatgac	tggggacact	660
tttgggttgc	ataccttggg	ggtgatgtgt	gtgactggca	tctggtggat	ggagaccagg	720
gatacagctc	aacatccctc	agtgcaccag	acagctctcc	acaatcaaga	agtgccctagt	780
gccatattgc	catagagata	gagaaataca	agtgtagggg	gaaagtgcct	cagctggca-	840
tcaaagacct	acatcaagca	cctagattct	caatgccaca	cgcaccttgt	agcaccctaa	900
taaatatcgt	tgccttctgg	gctccccact	ccaacacttg	tgcataatcc	ctatttttta	960
catttcagta	agagtcaatc	taattagctt	aatttttttg	gaaggaaaaa	ctgagaagaa	1020
atggaagcag	agaggacttt	gcaagaaggg	ctactcaact	aattcaaaag	gtggagttag	1080
gcattctgaa	tgcgagtttt	gcttctccag	gaaagggtca	aatttctgaa	tttgatatag	1140
tctatgaaac	caagagggtg	aatgagacaa	gggagaatgc	tttctggaa	gctggaaata	1200
acaccatgga	tatcaactgt	gctgatgctt	taaaaggaaa	cctaagagag	agcactgcag	1260
ttgccctatc	acttatcaat	ctcttgggga	tattctgaat	gcatectttt	ttagtaaacg	1320
aaaagggatg	caggaagtaa	aactgaactc	ttacgttgtg	agcggcacca	tgggtttgaa	1380
qqaataaatt	tccctctctg	aacctgtgtt	ctgactttt	cggcataate	agcctgggtg	1440
caagagaaca	aaacatatct	gtgtctactg	ggagggaatc	gaggggaggc	gctgggtccac	1500
ggagggtctg	tctcatgtgc	acagcaacgg	ttcttacacc	aaatgcaagt	gcttccatct	1560
gtccagcttt	gccgtctctg	tggctcttgc	ccccaaaggag	gacctgtgct	tgacctgat	1620
cacccagggtg	gggctgacca	tctctctgct	gtgctctctc	crggccatcc	tcaccttct	1680
cctgtgccc	cccatccaga	acaccagcac	ctccctccat	ctagagctct	ccctctgct	1740
cttctggccc	caactctctg	tcttgacggg	catcaacaga	actgagcttg	aggtgctgtg	1800
ctccatcatt	gcagggtctg	tgcacttctc	ctacctggct	tgttccacct	ggaatgctct	1860
ggaagggtctg	caactctctc	tcacgtctag	gaacctcaag	gtggccaaact	acaccagcac	1920
gggcagattc	aagaagaggt	tcatgtaccc	tgtaggctac	gggatccag	ctgtgattat	1980
tgtgtgtca	gcaatagttg	gaccccaaaa	ttatggaaca	tttactcact	gttggctcaa	2040
gcttgataaa	ggattcatct	ggagcttcat	ggggccagta	gcaglcatta	tcttgataaa	2100

```

cctgggtgttc tacttccaag ttctgtggat tttgagaagc aaactttcct ccttcaataa 2160
agaagtttcc accattcagg acaccagagt catgacattt aaagccattt ctcaqctatt 2220
tatcctgggc tgttcttggg gccttggttt ttttatggtt gaagaagtag ggaagacgat 2280
tggatcaatc attgcatact cattcaccat catcaacacc ctccaggagg tgttgctctc 2340
tgtgtgtacac tgtctcctta atcgccaggt tcgaaaggaa tataaaaagt ggtttagtgg 2400
gatgcggaag ggggtagaaa ctgaaagcac tgagaagtct cgctcacta cccaacacaa 2460
aacggaagaa gtgggggaagt cctcagaat ctctcataaa ggaggcactg catcatcatc 2520
tgcagagtca accaagcaac cgcagccaca ggttcatctc gtctctgctg ctctgctaaa 2580
gatgaactga cctggcaagt gccatggcaa tgaccggaa gttacccctc ctctcgttt 2640
gtctacagcg cccctgtggt cacacataga ttggacaaat gccactattt ctactttcc 2700
tgtgaaaagt ctaggctcat tcacctattt tggcttttta tgttcacaga aagaacaaga 2760
catttgggag aattcttaga tccagagtcc agtagtgtgg cacgtgcaat gaagtgtcgg 2820
aaggatgcat tttaaagatg gcggggcgga gaagtggatt ttcttcttgc agctactgcc 2880
acctgcccag aaactcacta actggcatct ggattcagct catagtccct tttctggcct 2940
ctcgcctgta ttttatgctc ccaagatct tacattaaca ctccacattc acataattca 3000
acaattttca tatggatcag tattaaagag ggtgttgcat ttgcaatac aaaaatgcat 3060
tatcagtgct tggagagat gtggagaaat aggaacactt ttactctgtt ggtgggactg 3120
taactagtct caaccattgt ggaagtcatg gtggcgattc ctgaggatc taggactagg 3180
aatccattt gacacagcta tccattact ggggtatata cccaggggct ataatcalt 3240
ctgtatataa gacacatgca cacgtaaaaa aaaaaaaaaa 3280

```

<210> 33
 <211> 1297
 <212> DNA
 <213> Homo sapiens

```

<400> 33
ccacgcgtcc ggactgcttt acggacattg gatgaagcgg aagcatttag aatggtgcct 60
ggcacacagt tgggtcgtga tatggttaag ctttgtgtcc ccaccacat ctcatcttga 120
atgtgacggt ttcccgcgtt cctcctgccc gccatgtgaa gaaggctcgt gcttcccctt 180
caccttccac caccatgatt gccatggatg ctcccactc caaagcagcc ctggacagca 240
ttaacgagct gcccgagaa acctcgtctg agctgttcac gcacgtgccg gcccgccagc 300
tgtgtgtgaa ctgcccgtg gtctgcagcc tctggcggga cctcatcgac ctcatgaccc 360
tctggaacg caagtgcctg cgagagggtt tcatcacaa ggactgggac cagcccgttg 420
ccgactggaa aatcttctat ttctacgga gcctgcatag gaacctcctg cgcaacctgt 480
gtgctgaaga ggtatgttt gcatggcaaa ttgatttcaa tgggtgggac cgctggaagg 540
tggagagcct cctggagccc cccgggacag attttcctga ccccaaagtc aagaagtatt 600
ttgtcacatc ctacgaaatg tgcctcaagt cccagctggt ggaccttgta gccgagggct 660
actgggagga gctactagac acattccggc cggacatcgt ggttaaggac tggtttgcgt 720
ccagagccga ctgtggctgc acctaccaac tcaagtga gctggcctcg gctgactact 780
tcgtgttggc ctcttccag cccccacctg tgaccatcca acagtggaa aatgccacat 840
ggacagaggt ctctacacc ttctcagact acccccggg tgtccgtac atcctcttcc 900
agcatggggg cagggacacc cagtactggg caggctggta tgggccccga gtcaccaaca 960
gcagcattgt cgtcagcccc aagatgacca ggaaccaggc ctctccgag gctcagcctg 1020
ggcagaagca tggacaggag gaggtgccc aatcgcccta ccgagctgtt gtccagattt 1080
tctgacagct gtccatcctg tgtctgggtc agccagaggt tctccaggc aggagctgag 1140
catgggggtg gcagtggagt cctgttacca gcgactcctg ccccggttca acctaccag 1200
cttgtggtaa cttactgtca catagctctg acgttttgtt gtaataaatg ttttcaggcc 1260
gggcacaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1297

```

<210> 34
 <211> 2184
 <212> DNA
 <213> Homo sapiens

```

<400> 34
ggcacgaggg gcccgaggat gtgcgtctgg ccgctgctcc tgcgtgggg gctgctcccc 60

```

```

gggacggcgg cgggggggctc gggccgaacc tatccgcacc ggacctctcc ggactcggag 120
ggcaagtact ggctgggctg gagccagcgg ggcagccaga tcgccttccg cctccaggtg 180
cgcatcgag gctacgtggg cttcggcttc tgcgccaccg gggccatggc gtcgccgac 240
atcgtcgtgg gcgggggtggc ccacggggcg ccttaccctc aggtattatt tacaattgca 300
aatagagagt tgaaaaaaga tgcctcagca gattaccatc tagaatatgc catggaaaat 360
agcacacaca caataattga attaccaga gagctgcata catgtgacat aaatgacaag 420
agtataacgg atagcactgt gagagtgtc tgggcctacc accatgaaga tgcaggagaa 480
gctgggtccc agtaccatga ctccaatagg ggcaccaaga gtttgcgggt attgaatcct 540
gagaaaacta gtgtgctatc tacagcctta cctactttg atctggtaaa tcaggacgtc 600
cccatcccaa acaaagatc aacatattgg tgccaaatgt ttaagattcc tgtgttccaa 660
gaaaagcctc atgtaataaa ggttgagcca gtgatacaga gaggccatga ggtctgtgtg 720
caccacatcc tgcctctatc gtgcagcaac aactttaacg acagcgttct ggagtccggc 780
cacgagtgtc atcaccctca catgcccgat gcattctcca cctgtgaaac tgtgattttt 840
gcctgggcta ttgggtggaga gggcttttct tatccacctc atgttggtt atccctggc 900
actccattag atccgcatla tgtgctccta gaagtccatt atgataatcc cacttatgag 960
gaaggcttaa tagataatc tggactgagg ctattttaca caatggatat aaggaaatat 1020
gatctgggg tgaattgagg tggcctcttg gtagcctct tccataccat cctccaggg 1080
atgcttgagt tccagctga ggtcactgc actttggagt gcctggaaga gctctggaag 1140
ccgaaaagcc aagtggaaat catgtgtttg ctgttcttct ccatgctcac tlygctggca 1200
gagcatcagg ctgcgtcatt ttcgaaaagc gaaggaaatg aaattacttg cctatgatga 1260
tgattttgac ttcaatttcc aggagtttca gtatctaaag gaagaacaaa caattcttacc 1320
aggagataac ctaattactg agtgctcgta caacacgaaa gatagagctg agatgacttg 1380
gggaggacta agcaccagga gtgaaatgt tctctcatac ctctcttatt acccaagaat 1440
taattctact cgatgtgcaa gtattccaga cattatggaa caactcagt tcatgggggt 1500
taaggagatc tacagaccag tcacgacctg gcctttcatt atcaaaaagtc ccaagcaata 1560
taaaaacctt tctttcatgg atgctatgaa taagtttaaa tggactaaaa aggaaggtct 1620
ctccttcaac aagctggctc tcaacctgcc agtgaatgt agatgttcca agacagacaa 1680
tgctgagctg tgcattccaa ggaatgacag cattacctcc agatagataa agacctata 1740
aagccagaac cctttgggtg gtggcagctc tcttccctc tccctctgcc acagagattt 1800
ctcccatcca acttgcttgt ttgccttctg ctaactcagc tgcacgctga gcaccaagag 1860
cttgatgata aaattctgtt ggacttgaca atgttttcta tgatctgaac ctgtcatttg 1920
aagtacaggt taaagactgt tccactttg ggcataaga gtgtggagac ttttcttccc 1980
cattttccct ccttcttctt tcttttccat gttacatgag agacatcaat cagggtctct 2040
tctcttctt agaaaatact gatgttatat atactgggc aataaataa aactggcctg 2100
acttaagata accattttta aaaattgggc tgcctatgtg gaataaaga attctttctt 2160
tcttaaaaaa aaaaaaaaaa aaaa 2184

```

<210> 35

<211> 949

<212> DNA

<213> Homo sapiens

<400> 35

```

ggcaccagct cccattgacc ttattgctca gagtgcagta ttagggcaag gtttcgccac 60
tgctctccct catgaatgta tttctccctc ctgccttggg gacatgggga gtggcccttt 120
tctttcccca tctagtccca gaaagatggg gtttggtttt ctgttcttgg attttttttt 180
tttttttttt tttttgcacc aaagtggcaa ctaggtcagt gttgggggat caagctggcc 240
tcgggggtgg gggcccccac ctgcctctcc ctggttccca cagtgttagc gtccctgaaa 300
agacaatatt ctctctaaag caataagggg tgacggggcg gggggagtgt ttgctgctgc 360
tgccccccag ctcccttccc ctgccaggtg tgggggagac tctgtttgtg actgaatgta 420
acccccccac ccttgcgcga gccaatgcag gggaaggggg acactcttcc tgtctcttct 480
ccccagctaa agagactttg gacttagggg gcccatgagc ctggagaggg cttaacctct 540
tgagggaagta tagggggagc cctctccccc ccccatcccc ttctgagagt ggtcaatgtt 600
tacaagcccc tgagcccccc tgcccaggga ctacagcccc gttgctgtcc tttcccgccc 660
ccggtcttcc tgggccctcg ctgctctctc qccctttctg gggttggggt ggggtcaggg 720
gtcacctgtt tctctgtctg ccttgtaccc acagtctccc cgcctctctt ccacctgtg 780
tgacttccct ctctttttacc tgcctctgta aatactccct tctcccaata aaacttggtg 840
tgtgttctcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900

```

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

949

<210> 36
<211> 3338
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2861)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3328)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3330)
<223> n equals a,t,g, or c

<400> 36
taccgggaca ttctggagtc cgagaagtca acggcgcggt tgctgcggcc gccgcgctcc 60
ccggcccagag gcgatggaga acggagcggg gtacagcccc actacggagg aggacccggg 120
ccccgccaga ggcgcccgga gcggcctcgc tgccactttt ttcattggcc ggctcccat 180
gtcccgcgcg gtccccaagg gcttgacgt gttgctgtct ctgctggcct tcatctgtga 240
agaagtgtga tcacaatgta ctttatgtgg aggaactttat ttttttgagt t-gtaagctg 300
cagtgccctt cttctgagtc cctttatact gattgtgtat tgcactccat tttatgagag 360
agttgatacc acaaaagtaa aatcctcgga tttttatatt actttgggaa caggatgtgt 420
gtttttgttg gcatccatca tttttgtttc cacacatgac aggaacttcag ctgagattgc 480
tgcaattgtg tttggattta tagcaagtct tatgttctta cttgacttta tcactatgct 540
gtatgaaaaa cgacaggagt cccagctgag aaaacctgaa aataccacta gggctgaagc 600
cctcactgag ccacttaatg cctaaagact ctggggagca gatgttacct aaggtagrga 660
ccttgcatgg tgggtccctga gccctggcag aagctcttgt aaaatttgtt aattgtttaa 720
accactttct tgggagagca aggggaaggt caagaaggca gttttatcaa tattgtgtca 780
gtcaccacaa agtagggcag ataggttaaa aaaaattttt ttttaataaa taattgaaac 840
ttatctcaaa tggagatttt ggtgggagga ggagaaaaca attgttttta aatcacacag 900
ctcaacggtt gataaatgat tctgtcattc tgttacaggt cattctttta ctaggcttag 960
cttccaaatt atgctttata gc-tgtataaa catcgtgat atattcatct acctagaaat 1020
tgttttatat ttaaatattt ttgcttagct gtttgttttg atgcttagat tatgttctgt 1080
taatgggaat ttaacatatt taagaaacca atatttaaaa tgttggctta ggtttttttc 1140
cttaacatat attaccaggc tttactgtat ttcactcagc cttaaatgct ataattttt 1200
tggataacgg ttattaattc tttgagacct tcgtatagcc tataaaatgt atgggagatg 1260
ttggatattt atgtgtataa aagcaacaat atcagcaact tcgtgtttat actgcacctt 1320
ggttgttgat gtcaagtaaa aaaaagattg ttttgttaaa cataaaaaaa tggaaagaaac 1380
tgataccaca cctaaggacc aaagataaga aagacttttt gcccaagaca gtgaagataa 1440
ttataaaaaa aagctttgac cacttaccaa gtatc-gaay agataggttc atactatgat 1500
ttagaaagtg gtcaattcc cctgttgcca tatgattatc tttactaaaa ttaatacagc 1560
tctgtgggtc ttccttagtg tttctttga agccaatctg ttttttttag gacaccagcc 1620
tttggttttt catctgttcg agatggcctc tctctgtctc cttatcagat agaaatggag 1680
tcatgtgtgt ctgttctatc tagcagaggt tggcctctgg ctctgacact tttgtcag- 1740
tgtctctagg tggctctgaa tcttgggccc ttttgattgt gaatactgtg tagcaggatc 1800
ttgagagtcc ttgttcttac ataggcattg ctctagtttg tctttggcaa aaaaaaaa 1860
aaaaaaaaag aaatatccag ggaacctcgc ccagactaat actgttggtg gcataagaga 1920
atcaagccat tctcaagaga taacttcata accagaattg tctgttggtc agcagcgtc 1980
acagataggc agggcacttg ggatattgac tttctgtcca ggtgattcac agactagacc 2040
ttctctatcc tctcctaga gttttgactt gggactctag tgctaagatg atgagcccg- 2100

gcatcaggtc cttctgcact ttgggtggaag tctcccaggg taggtttcct atttgaacaa 2160
gtggaatcat gtttccagtg ataaagtcta atgacctcat cctttttttt ttttctcacc 2220
tgccatttgt gtgtcttaga tgggttttaa ttgcatgaat gggctaatg tggttctcag 2280
aaattgggtca gtatggccc acatagcttc tgctctgtct tactgactca atacctttag 2340
gatttgatc agagtctgga tactagtgtt agtgggtggg tcaccactac ttaattggga 2400
gataatgaaa ccaatcargg atgctgtttt tattgggcat gtcactcaag agaggagaaa 2460
tagctgggtt ttgggtctaa ttatgaataa ggactgattc agaaaacgag tttatggtag 2520
gtagactaaa gtllcacatc agactgtacc attgtgattt agacctatct aaaattcaga 2580
gcataatc cgggctacct cagggtcacc acccatgtat tgggcttagt caggattgac 2640
agatacatc tcagctggcc tctcatataa aacatactgt catgagctt aaqctccgtc 2700
tgtctcgagg ttccacctcc atgtgtttca ttgggtcaaa agtggatctc ttagttggtc 2760
acttaattct tcttttttca gaaagatagt atgttccacty gtatatattg tcaactcttag 2820
aaccttctct cactttgttt tttatgggac ccatgaatgg nttagcctt cttttctatt 2880
gtagaaggaa ataaatagga gtaaaaagac cattgttagta aataagttca aggggaactt 2940
gggaccagaa accactgtta tgtacaaaaa aatggcaaat tcaataaact caaattttaa 3000
ataattttta aattaacagt tatgataaat tttatatttt atacaaatag attgtcttaga 3060
atggttctca agaattataa gagaatgaa ctcacagtac aaaaatttta taattactat 3120
acttggtttt tgtttggggg ctgggaaatg tatttttaca ttgtagccaa tcattttata 3180
tttgccaatt taaattctat gggctctttt ttttttatct ctcttgatgt cagattttat 3240
agtcttttta aataaatcca ttaattttaa acgttaaaaa aaaaaaaa aaaaaaaa 3300
ggcgggccgc tctggaatct agaactangn cccacgcg 3338

<210> 37

<211> 1563

<212> DNA

<213> Homo sapiens

<400> 37

cggcacgagg aaaaaaggac tcagaccttc cagattggct ccagaaggca gctgctgtca 60
gtgattttcc ttacagacca ttgcagccac ctaccttgcc ccattggccc gayacagcat 120
ggcgtcttcc cccacacgga cctgcagggtg gcctcttagg agctttctcg ctgaaggagg 180
tcacccctct tagtcacacc tgagcagcac tcacttaggc ctgcggcccg agggctcatgc 240
gggggacact ggccgggttc ccggctctgt ctgggtctggc atctgtctgc ctttgggcta 300
ccttttcggc acagctccct ggccctgtgg ctgtacaag ctggactcca gctccctgg 360
gctgcagtgc tgcctgcagt ggtccagaaa agaggctggg cacagcggct cctggctcag 420
cagcatectt ggccagggtt ggcccaggag ctccgtgcag ggtgctgcca gttgacccag 480
ccccggctgc actcaatgtc cgagaaccgg gctggctggg gggccctctt gacggagctt 540
tactccaagt cttgctgaat ttcttgagga aaagcactga tgttctcatg gacacaaggg 600
aggcagaatc tcttgaagta gaataaactg cactccttcc cagtcttctt tctcagctt 660
ctcctggacc gccagctcct ccattgcgct cagacactcc caacgcgcga ctgcgggggt 720
tcttcccgcc ctggcccatc tcattccctt tggctgttga tacagctccc ctgtgtgcat 780
gtcgcctgtt ggcagatgct cagggacttc tcagactcca ggaactccc gaqtacactg 840
accacacagc ctgctgcaca aactgcagcg ccagctaaag accaggaatc tgacattgtc 900
ggaggtgaaq ggaatccttg tgacatagct ttctccagg aggaacctcc actgggtgtc 960
gggggagctt ctgccccaaq tagcaggagg gagctgtcaa ggcgtggagt tcacactcaa 1020
acactcccag aggcaggcac tctgcatggg acgccatcca gctccttga ctgtggaatc 1080
aagtacatta tcagctggcc cctggctcct ggctgtgacc tccctctcgt tgaactgagc 1140
cttgtgtgta agggcgatc aaqttgtatg ggcttcgccc ctgggtgacc ccaaatgcaa 1200
ctccaggaag catgggttac caatgactaa ggtaacgat cagctgggag cggctgtgac 1260
gctgttaato ccagcacttt gggaggtcga ggcgaatgga tcacagagtc aggaagtcaa 1320
gaccagcctg gccaacatgg tgaaaccccc atcttacta aaaaataaaa aattagccgg 1380
gcgtgggtggc gggcgctctg agtcccagct actcaagagg ctgaagcagg agaactcggc 1440
gaactcggga ggcgcagctt gcagtgaagt gagatctcgc ccgtgcaact ccagcctggg 1500
cggcagagcg agactccgtc tcaaaaaaaa aaaaaaaa aaaaaaact cgaggggggg 1560
ccc 1563

<210> 38

<211> 1048
<212> DNA
<213> Homo sapiens

<400> 38
cccggtcga cccacgcgtc cgacaaaaa caaggatgt gtgtgcctt ggatgctttt 60
ctgggcttac cccatctgtg tcttcataga ttctctgtcc tggcagccat gtctttggtc 120
cacaggagcc acttcccact tcaactctcc cacaacctcc ccaactgtta ctctcttcat 180
gccctgtgct cttgccccaa atcccttcac ccaattggga aaactggatg atagataagt 240
agtctcttat ttacatgcat ttctctggaa attaaagtgt ctctccagct agtatttctt 300
cacgtcggaa gcattgttaa aataacacat ggaaactatt tccacctggc acataagaaa 360
aaaagggtct gcctatattg taactgact ctacactttg catgttttag tctgaccac 420
aatTTTTTTT tttggatagt tgaagtaaaa aacgtgggtt caagatgact aaagtttggc 480
ctacaatttc ctgtttggac aacaggaaga attgtgcagt gttttgcaac aqactaatt 540
ctagattctc actgccctta aagataacta gagggaaaagg gtcttctctt tcttttcat 600
ttattaaaga tacttaacagg ttcttcagaa gaagtgtagg gtctcttagg taatgaaata 660
ggtgttgatg gtgttatggg tgatgatgta actggtggcg gctgtataaa gtcttcaccc 720
ttaaacatca gaactgagag tgggttact gatttaaaag aaaatgtgta ttaattcaca 780
gtccactacc ttgactacca ggaacttgc acaactacct catatcctgg cacaggattc 840
aaaaggcaaa atctggaacc taattacgtg tagccaaata ttaagcttcc tcttagatca 900
aacagtacaa taaatatccc ttattaaaga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaagg gcggccgc 1048

<210> 39
<211> 1430
<212> DNA
<213> Homo sapiens

<400> 39
cggcacgagg agcagctgag tcccttccct gtctttcact ctctcggcat cgggtggtttt 60
acttctcga ttgaacctgt ctctctcgac cccctcggga ggccgccttc ttcaggcgcc 120
tccctctctt ccacgagctc gctctgacag ctgaggaact ggcaagatcc tgcctaccag 180
aggggtgaatg ggtatctttc ccggaataat cctaattttt ctaagggtga agtttgcaac 240
ggcggccgtg attgtaagcg gacaccagaa aagtaccact gtaagtcag agatgtctgg 300
tctgaattgg aaaccttttg tatatggcgg ccttgccctc atcgtggctg agtttgggac 360
tttccctgtg gaccttacca aaacacgact tcagggtcaa ggccaaagca ttgatgccc 420
tttcaaagag ataaaaata gagggatgtt ccatcgctgt ttctgcactc gtaaaaggga 480
aggtgtattg gctctctatt caggaaattgc tccctcgctt ctaagacaag catcatatgg 540
caccattaaa attgggattt accaaagctt gaagcgctta ttcgtagaac gtttagaaga 600
tgaaactctt ttaattaata tgatctgtgg ggtagtgtca ggagtgatat cttccactat 660
agccaatccc accgatgttc taaagattcg aatgcaggct caaggaagct tgttccaagg 720
gagcatgatt ggaagcttta tcgatataa ccaacaagaa ggcaccaggg gtctgtggag 780
ggttaagtact cttttcctgc tattatecta cactctcagt tectacaatt tgcagagaat 840
ttttttttat ataaagacat aaaatcgtga attataatcc aaaaactaag gtaagaaact 900
cctcatctcc cttgaaaggc ccaaaactta tcattggcct ttattttctg cataatgttt 960
ggggattata taggtgggga aagtatttac attatttgag atggctgttt cgatcatatt 1020
cacagtgaat gtagtgttc agtgtatttt ttgcaagtt ctgtactaac acgatgatgt 1080
atgtctttgt agtgcttatg ttcaaaagct gttaccggct gtgtgctgtg gctcatgctt 1140
gtagtcccg cactttggga ggccaacgcg ggtggatcac ttgaggtcag aagttaaga 1200
ccagcctggc caacctggtg aaacctccat tcaactagaa atacaaaaat tagccaggca 1260
tgggtggtga tggctgtgtg cacagctact caggaggctg aggcgggaga atgttttgag 1320
ccctggaggt ggaggttqca gtgagccaaq atcatgccac tgcactccag cctgggtgac 1380
ggggcgagac tctgtctcaa aaaaaaaaaa aaaaaaaaaa aaaactcgag 1430

<210> 40
<211> 2103

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2101)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2102)
<223> n equals a,t,g, or c

<400> 40
ttcctcgtag cgagcctagt ggcgggtgtt tgcattgaaa cgtgagcgcg acccgacctt 60
aaagagtggy gagcaaaagg aggcacagac cctttaaacc gaggcgggtg gtgcctgccc 120
ctttaagggc ggggcgtccg gacgactgta tctgagcccc agactgcccc gagttctgt 180
cgcaggctgc gaggaaggc ccttaggctg ggtctgggtg cttggcggcg gcggcttcct 240
ccccgcctgt cctccccggg ccacagaggca cctcggcttc agtcatgctg agcagagtat 300
ggaaagcact gactacgaat gctatccgtg cgagaacagc tattccacga gaggatccgc 360
gagtgtatta tatcaacact tctgttttga acactgtaca tccctctgcca catcttctctg 420
accgccttca agaagcctgc tgagttcacc acagggtgtc ctgggcggcg tctmtgagac 480
agtgggtgatg ttgatgctcc tcactctgct gg-gctaggt atgggtgtgg tggcatcagc 540
cattgtggac aagaacaagg ccaacagaga gtccactctat gacttttggg agtactatct 600
ccccacctc tactcatgca tctccttctc tggggttctg ctgctcctgg ctgctggaag 660
acctggagga gcagctgtac tgctcagcct ttgaggaggc agccctgacc cgcaggatct 720
qtaactctac ttctcgtctg ctgccttttag acatggagct gctacacaga caggctcctgg 780
ctctgcagac acagagggtc ctgctgggta tgtggcttcg tagggcttgg gatacctggg 840
ttcccccaag gagagtagcc cctgggttcca ggtgcttgcg gacagcctcc catccctgca 900
cagagaagag gcggaaggct tcagcctgkc aacggaacct gggctacccc ctggctatgc 960
tgtgcttgcg ggtgctgacg ggcctctctg tgctcattgt ggcctatcac atccrggagc 1020
tgctcatcga tgaggctgcc atgcccgcag gcctgcaggg tacctcctta ggcaggtct 1080
ccttctccaa gctgggtccc ttgtgtgccc tcattcaggt tgactcatc tttaccta 1140
tggtgtcttc agttgtgggc ttctatagct ctccactctt ccggagcctg cggcccagat 1200
ggcacgacac tgccatgacg cagataattg ggaactgtgt ctgtctcctg gtccctaaagt 1260
cagcacttcc tgtcttctct cgaacctctg ggctcactcg ctttgacctg ctgggtgact 1320
ttggacgctt caactggctg ggcaatttct acattgtgtt cctc-acaac gcagccttg 1380
caggcctcac cacactctgt ctgggtgaaga ccttcactgc agctgtgcgg gcagagctga 1440
tccgggctct tgggctggac agactgcgc tgcccgtctc cgggtttcccc caggcatcta 1500
ggaagaccca gcaccagtga cctccagctg ggggtgggaa ggaaaaaact ggaactgccc 1560
atctgctgcc taggcctgga ggaagccca aggtacttg gacctcagga cctggaatct 1620
gagaggggtg gtggcagagg ggagcagagc catctgcact attgcataat ctgagccaga 1680
gtttgggacc aggacctcct gcttttccat acctaacctg ggcctcagca tggggtaggg 1740
ctgggtgact ggytctagcc cctgatecca aatctgttta cacatcaatc tgccctactg 1800
ctgtttctgg ccacccccat agccatgttt acatgatttg atgtgcaata ggggtgggta 1860
ggggcaggga aaggactggg ccaqggcagc ctcgggagat agattgtctc ctttgcctct 1920
ggcccagcag agcctaagca ctgtgctatc ctggaggggc tttggaccac ctgaaagacc 1980
aaggggatag ggaggaggag gcttcagcca tcagcaataa agttgatccc aggggtttgct 2040
ttgt-ttttt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100
nna 2103

<210> 41
<211> 2349
<212> DNA
<213> Homo sapiens

<400> 41
tcgaccacg cgtccgctca tttctgtgta tgtatgtatg ggaatgtgct gattgtgtgt 60

ctgtggtgta	tttctgtgtc	tgtatgtatg	gggtgtgtgt	gattgtgtgt	gtgtctggtg	120
tatctctgta	tgtatggggg	gtgtctgtgt	gtgatgtgt	gtgtgtctgg	tgtatctctg	180
tgtctgtatg	tatgggggtg	gtctgtgtgt	gattgtgtgt	ctgtgtttat	gtgtgtgtgt	240
ctttgtgtga	ttttttgtgt	atgtggcaaa	cccagaacag	aacattatca	ctcacctcac	300
ctggcaaaac	aaaadgcttt	cagagagatg	tgtggccgtc	atgatgtctc	agctgcaggc	360
atctttccaaa	gttatgtttg	atgcagctgg	cacctttctt	ctcggggaca	aatgtgactt	420
ttgatcattg	agttgagaat	gagtttactc	aataatttta	aaatgcctcg	gtgtgagagg	480
atgggctgct	agtaaacatt	tgtggcaaat	atgcgttgcc	ttttctctct	tcaagtgcac	540
ggggcaggct	gcttctctgc	acgtccatct	g-ggggtcagt	ctgtcctgcc	acctcctttg	600
ccccagggct	tagtgccctg	tgtggatcac	ggctgcccc	gggatgctgg	ggaaggattc	660
agcccaacaa	atagattcgt	tgacgtcttc	tcaacgaatg	tgtgctttta	aaaatgtctt	720
taattttgca	ctccatttca	tacaacaggt	gcacatttaa	aacattttat	tttaaacagc	780
tctgtcttct	cagcactgca	gactatttct	cgctcacttg	acaggcagac	gt-gggacta	840
tgtttctttc	ctgccaaaga	tccatcagcc	ccccaatgcc	tgacactcga	gtccagactc	900
cttagcgttg	cgttgggacg	taattccccg	ttagcatccc	cagccccctc	tccccctgtg	960
agccagcctg	gggtctcttt	ttttctcttt	cttccctggt	ttccttcttt	cttttttggg	1020
tttgtataaa	gtaatacaca	gtcttgtggt	taagaaatca	aaataataaa	gaagatacgg	1080
cttagaggatt	cttgcctctc	actggtcctt	ccgccaggac	ctggtgcgtc	ccccaaaggg	1140
gccttgccat	gtgcgagctg	agacacatgt	tcacactttc	ctcctttttt	gtacaaaagg	1200
tagcacatgg	taaatagcgt	ctgcacgctt	ctccccctgc	tctgtcttcg	ggactactcc	1260
acatccatga	agaagcagca	tccttattct	cttgccacag	gggcagtggt	tacactgtat	1320
tcactcgtct	ctgctgatgg	gcactattgt	agtgggtgcaa	ttagttaacct	agtatacatg	1380
cccttcagcg	tgtgtactgg	tgtatggatc	tcacattccc	agaggctgag	tgaagaataa	1440
aaggcttttt	gacagtattc	ctcaggtact	cacacactcg	ctctgtgagc	cagtgatcac	1500
tgggaagcgc	tccttcgaga	gggtctctga	gggagaggct	gatgtccttg	tctgatgggt	1560
gtcctcaacct	gagaatgggt	agctgctctc	ccaatgcaga	ctttctatcac	ttgcactcca	1620
tgcgtgaagt	tgaactgctt	ctcattttatg	ttttctctct	tgtttgccca	tatttttagct	1680
gggtgtgctaa	tcttttaagt	ttttctaggg	gcttttcata	aattagggag	tttagctgta	1740
gtgatgtgag	ttgaaagtat	tttttcaaat	cgctcattgtc	ttgactttcc	tttttttttt	1800
ttcttttgcca	cttaaaatat	gtagttgaat	ctcagtattt	gggggcttct	ggattttgag	1860
togtagttga	aaaggctctt	ctattctgag	gttatcacgg	aattcaccca	tttttttctt	1920
aatattttat	ttccatttaa	acttttgacc	cactttgact	gattttgttg	tatggtgtca	1980
agtatgggtc	caagtttgct	ttcttgacct	ggggatccca	acatcgttca	tcaaaatctc	2040
catgttgccc	ggcgctgggt	gc-caaagcct	gtaatcccaa	cactttggga	ggctgagggtc	2100
ggtggatcac	aaggtcagga	gatcgagacc	accttggtca	acacgggtgaa	atcctatctc	2160
tactaaaaat	acaacaaatt	agccgggtgt	ggtggcaggc	acctgtagtc	ccagctactc	2220
aggaggctga	ggcaggagaa	tcgcttgaa	ccgggaagcg	gaggttgtag	tgagctgaga	2280
ttgcgccact	gcactccagc	ttgggtgaca	gagcaagact	ctgtctcaca	aaaaaaaaaa	2340
aaaaagggc						2349

<210> 42
 <211> 1559
 <212> DNA
 <213> Homo sapiens

<400> 42						
attcatgcca	aaacataggc	tttcagtgcc	tattacatat	ggctttcagc	tctctctact	60
gagggatgta	ggagtttatt	tctgaggtct	gagcctcttt	tcctttactt	cccttactct	120
ttcctaagcc	ttctttataa	aaactatgca	tgttctattg	ttttcctttt	tgattccctt	180
tcttttatta	ccccagtag	gagtgacttg	taattctcat	atgttagaaa	ggcaggtctc	240
ctgggtgaag	aaaagatcca	cccaagcaag	tcagcagttt	aataaaattt	tgagggggat	300
ctcaaatgtg	ggaaggattg	ttatataaga	caaccaaatt	atgacatgag	acaataaatt	360
ctataggaat	tatggaggaa	taattagcta	tttattttct	tggttaggga	agagataata	420
ttagttgtag	aagtaattac	taacttctac	attttttatt	gtggaaatca	aaaatatata	480
tatgaaaata	aaatgttata	attgacttca	gtgtcccata	aaccagcttc	caacaattac	540
caaatgtga	ccaatccctt	acacacatgc	acaggtgtcc	ctccagttat	tgtggggcat	600
tggttctagg	accacttatg	gataccaaca	tctatggatg	ctcaagtccc	tgatataaaa	660
tgggtgacta	tatgcataata	accctgtgac	gtccccgatt	aaccaaatcc	ttccctagatc	720

acttacaaca	cgtaacacaa	tctaaatgcc	acgttaacaa	cgttcatact	gtattaagcg	780
aataaccccg	ccaaaaatgt	acttctctca	gtccagacgc	cttttttttt	tgtgtgtgga	840
atatcccgag	ccccaaagtc	ccctcaaccc	cctggcacat	aggaggctga	ctgcgtgtgt	900
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgcatac	agacacacat	atctctgaaa	960
gttaaatatt	ctctctttta	aaaaattatt	atcacagcta	aacaaattac	cagtaattct	1020
cttatcctca	tatacccggt	qttcagattt	tctagatrrg	ctcttaattt	ttttacagat	1080
tatttgaatc	tgattcaatt	catgtactgt	aatgtttgat	aacttaagta	ccctttatag	1140
gttcccttta	ccacttcttt	attaaattcc	ttgtaatttg	ttgtactaaa	tggattgtct	1200
tccatagaat	tctgttagtc	tgaattatgt	ggtaattgt	cacatgttcc	agtgtcctct	1260
tatttctctg	gagttggtag	ttagatctag	aagcttgatt	aaattcagat	tttctctctt	1320
tagatcatca	acttttagatc	atcaacttgg	atcattttgt	tcattttgct	tttgatatgt	1380
tgttttttag	aattacctct	taaaattttg	atttaatttt	ataaccatgt	aaaatgttta	1440
taaaatttcca	aattcagatc	agcaaacac	aataaaattct	attcagagaa	ggcaaaaaaa	1500
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1559

<210> 43

<211> 1766

<212> DNA

<213> Homo sapiens

<400> 43

cggcacgagg	agcactgaag	tattcactac	atgaagtata	ttttgcaatg	tggacacaaa	60
ttagaaaaat	tgcaagtagt	ggtatatgtt	atttggcatg	cactatatga	gcagagtcaa	120
tgtgtctcct	tgtagaatat	tctctgtatg	tactcactat	tatccccctt	ctgtctaatg	180
ttgttctgtg	tctgaagggc	ataaagcatg	gaaactacat	ttttcagact	ccattaccag	240
aaggatctgg	ttggatttca	gcaatgagtg	ggctttgcat	aaaatttggg	agacgaaaga	300
gaagaaaaac	ctggctgctg	caggttggaa	cactggcaac	aatagatacg	gagtttgcaa	360
gaagctgcta	agcttctctc	ggaaaaattat	ttgtttcaat	atttctggca	tatgggatca	420
tcaattattg	ttttcagtg	ttctgggtga	aaatttggtc	aattcttcta	tctgagaatt	480
gttcatttct	gtgcttcagg	aaactaagac	catcactggc	agtttttggg	gagggatcct	540
tgtgcattca	tttttctctc	aaacagcctt	cctaactttt	actccccag	cctctatggt	600
tgtgtaagtc	tttaattctt	agagttaacat	ttctcttact	cagtatatcc	tagtgcggtc	660
tctgttttcc	agacccaacc	ctgactgata	tagtctccat	gtgtttcaga	tgggtgggata	720
gtttggatat	ttgtccctgc	ccaaatttca	tgttgaactc	taatccccag	tgtgttaggt	780
ggggcccaat	gggaggtgtt	cggatcatgg	gggcagatcc	ctcacggctt	ggtgctgtct	840
tsgtgatagt	gagttctctg	aagatctggt	catttttaag	tgtttggcac	ttgtaccatt	900
tcactgtgtc	ttgctcctgc	tttcaccalg	tgaagtgcct	gtctccagct	cactttttac	960
catgatttca	aacttctctg	ggcctcccta	gaagccaagc	agatgccatc	accagggttc	1020
ctgtaaagca	tgcaagaactg	ttagccaatt	atacctcttt	tctttacaaa	ttaaaaacct	1080
ctttctctta	caaaatggaa	agaataaaagg	tatttcttta	tagcaatgca	agaacggcct	1140
aatacagatg	gctctgccat	tagtgagaaa	attgagacgc	ttttcttaga	tggcaaaaaa	1200
gttgtaaaaa	taaaaggaaa	ttattaacat	accgtctatt	gtgatcattt	actaagttaa	1260
gcatalctatt	aagaagacaa	gcataagttt	aacacaattt	ggcaatgaat	aaaattgaag	1320
gagagagagc	atatgtttgc	ttgtctctgt	gaaactcaaa	tgaatgggtc	acctgttcta	1380
gcagctcatg	aaaaattctg	catgtttcat	tatgtgtcag	gatcaacctt	aaattcagtt	1440
ataaaaagtt	tgatgattac	aaaaaaaagg	gaagcactaa	gtaatatagg	tacagagagg	1500
gaagagtgtc	aaatagaatt	ttcaatctgt	gtataaggat	acttaagcat	ttt-taagga	1560
aagcagaaag	aagcatgaga	aagctctaca	tgacatctat	gtcaatataa	caagctggat	1620
atttagagaa	gaaactcttg	attaaatact	ttttatgata	tgaacacaca	catataatat	1680
gacatgactg	tgttcatgga	acataaagaa	attcctctga	ccaaagagaa	ctggaaaaaa	1740
aaaaaaaaaa	actcgagggg	gggccc				1766

<210> 44

<211> 2572

<212> DNA

<213> Homo sapiens

<220>
<221> SITE
<222> (2527)
<223> n equals a, t, g, or c

<400> 44
aattcggcac gagtctggac cttcttagmt tgcttgatat caggctgttt ttgtagccat 60
tttgettca agtcaccttg aatgccggga gcccttgct atcccgatcc tctccttgta 120
catggygcga cttgtgctgt gcaccacct gtgctgggc tactacaaga acattcacga 180
catcatccct gacagaagt gcccgaact ggggggagat gcaacataa gaaagatgct 240
gagcttcttg tggccttttg ctctaattct ggcacacag agaatcagtc ggcctattgt 300
caacctctt gttccccggg accttggtgg cagttctgca gccacagagg cagtggcgat 360
tttgacagcc acataacctg tggtcacatg ccatacggct ggttgacgga aatccgtgct 420
gtgtatcctg ctttcgacaa gaataacccc agcaacaaac tggctgagcac gagcaacaca 480
gtcacggcag cccacatcaa gaagttcacc ttctgtctga tggctctgtc actcacgctc 540
tgtttctgta tgttttgga acccaacgtg tctgagaaaa tcttgataga catcatcgga 600
gtggactttg cctttgcaga actctgtgtt gtcccttgc ggaatcttct cttcttccca 660
gttccagtea cagtgggggc gcattctacc ggttggtgta tgcactgaa gaaaaccttc 720
gtccttgccc ccagctctgt gctgcggatc atcgtctca tgcgcagcct cgtgttccca 780
ccctacctgg ggtgcacgg tgcgacctg ggtgtgggt cctcctggc gggctttgtg 840
ggagaatcca ccattggtcgc catcgctgct tgcctatgct accggaagca gaaaaagaag 900
atggagaatg agtcggccgc ggagggggaa gactctgcca tgcagagcat gcctccgaca 960
gaggaggtga cagacatcgt ggaaatgaga gaggagaatg aataaggcac gggacgccat 1020
gggcactgca gggacagtca gtcaggatga cacttcggca tcatctcttc cctctcccat 1080
cgtattttgt tccctttttt ttgtttgtt ttgtaatga aagaggcctt gatttaaagg 1140
ttctggtca attctctagc atactgggta tctctacact gacgggggga cctagtgaat 1200
ggtctttact gttgctatgt aaaaacaaac gaaacaactg acttcatacc cctgcctcac 1260
gaaaaccaa aagacacagc tgcctcacgg ttgacgttgt gtctctctcc cctggacaat 1320
cctctcttgg aaccaaagga ctgcagctgt gccatcgcc ctcggtcacc ctgcacagca 1380
ggccacagac tctctgtcc ccttctatcg ctcttaagaa tcaacagggt aaaaactcgc 1440
ttcctttgat ttgrrtccca gtcacatggc cgtacaaga gatggagccc cgtgggctc 1500
ttaaatttcc cttccgccc ggagttcgaa acctctact ccacacatgc aggaggcggg 1560
tggcagctg cagcccgag tcccctca cactgaggaa cggagacctg tgaccacagc 1620
aggctgacag atggacagaa tctcccgtag aaaggtttgg tttqaaatgc cccgggggca 1680
gcgaactgac atggttgaat gtagcattt cactctggtt tctcctagat ctgagcaagc 1740
tgtcagttct cacccccacc gtgtatatac atgagctaac ttttttaagt tgcacaaaa 1800
gcgcatctcc agattccaga ccttgccgca tgacttttcc tgaaggcttg cttttccctc 1860
gcctttctg aaggtgcct tagagcgagt cacatggagc atcctaactt tgcattttag 1920
ttttttagt gaactgaagc tttaagtct atccagcatt ctaatgccag gttgctgtag 1980
ggtaacttt gaagtagata tattacctg ttctgtatc cttagtcata actctcggtt 2040
acaggtaatt gagaatgtac tacggtaact cctcccca ccatacgata aagcaagaca 2100
ttttataacg ataccagagt cactatgtgt tcttccctga aataacgcct tcgaaatcca 2160
tgcagtgac tatatttttc taagttttgg aaagcaggt ttttcttca aaaaaattat 2220
agacacggt cactaaattg atttagtcag aattcctaga ctgaaagaac ctaaaacaaa 2280
aaatatttta aagataataa tatatgctg atatgttat taattattt taggctataa 2340
tacatttctt attttcgcat ttcaataaa atgtctctaa tacaatacgg tgalgtgtg 2400
tgtgctcaac atacctgcag ttgaaacgta ttgtatcaat gaacattgta ccttattggc 2460
agcagtttta laaagtcctg catttgcatt tgaatgtaag gctcagtaaa tgacagaact 2520
atttttncat tatgggtaac tgggggaata aatggggtca ctgggagtag gg 2572

<210> 45
<211> 526
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (66)

<223> n equals a.t.g. or c

<220>

<221> SITE

<222> (106)

<223> n equals a.t.g. or c

<220>

<221> SITE

<222> (484)

<223> n equals a.t.g. or c

<400> 45

ctctgacagc	ttctctcttg	gccaaagccct	gcctctgtac	agcctcgagt	ggacagccag	60
aggtcnagac	tggagcccag	agcccaagat	ggagcccag	ctgggnccctg	aggtgccgc	120
ctctccgccct	ggctggctgg	ccctgctgct	gtgggtctca	gcccctgagct	gttctttctc	180
cttgccagct	tcttcccttt	cttctctggt	gcccacagtc	agaaccagct	acaatttttg	240
aaggactttc	ctcggctcttg	ataaatgcaa	tgccctgcatc	gggacatcta	tttgcaagaa	300
gttctttaaa	gaagaaataa	gatctgacaa	ctggctggct	tcccaccttg	ggactgcttc	360
cggattccct	ttgttttctt	atccttgcaa	attactccar	atgattycca	aaactctggg	420
sccttgtgga	ratcttttaa	ctgttcagca	awtwtcaaac	gaaatctcca	aacaggaaat	480
cttntgcttc	ctgcatccac	ccccaaagaa	cttgacatt	gaugtt		526

<210> 46

<211> 1032

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (974)

<223> n equals a.t.g. or c

<400> 46

gtaaaattgt	caaacattta	tttttaaaaa	taaaatgttg	tgggcgggta	tgggtggagt	60
tattgggtcc	tggctgtcgc	cactgagcat	tgctgaatgt	tgtcatgact	tgtggacttc	120
tcagagctgc	gagcatgcgg	gtgctctttg	tggagatttg	ctctgtgccc	gtaggaaagg	180
gggtgtgtgg	tgtgcattgc	agcaacattg	gtggaacaga	tgtgtgtgcc	cccattgctgt	240
catcagggtt	cattgcacag	gagcctcata	cacactacag	aaaatatgct	cttgttaacc	300
caagttcatg	gggaggcatc	cacacagatg	gcagcagatc	aggaaatgct	ctcagccagt	360
cctcaggggc	agtagggcag	ccttcactct	ggtgcgcttg	gcagccctga	actttatctc	420
ttcttttctg	tgtatttctt	taatatctta	ttcagcattt	tagtttcttt	agttggatga	480
gtttgttcagt	gtctttgtac	tgtacagttc	tectgtgctg	ttggaatgga	cgtcatgggc	540
tatgttactc	ttttgaaata	caaatttctc	tttagaagtt	ttggaaaatc	tgttagagga	600
ggagtctctg	gaatatgaga	agactctctg	ccacatagtt	gtgcccggcc	gatgtatttt	660
tccaaaaaaa	ttgaagggtga	acctgtttga	agctcagttc	tgagtttaac	tgactacttt	720
gcagagacac	aacactctct	ttstaggcatg	tcccttgga	gaaaataggc	tggtgcttgg	780
gtggtgatca	gaactggcag	ttattctagg	cctaaaacag	tttgccaata	aaataagaaa	840
aagggggcac	atgtgtgtgc	tcattgctta	atccccacac	tttgagaggc	tgaggcaggg	900
ggattgcgtg	aagccagcct	gggcaacata	aaatttaaaa	attagccaga	catggtggca	960
tgtgcctgtg	ggtncagcaa	cttgggtggc	taagaccgaa	ggatcacttg	agcccaggaa	1020
gtcaaggctg	ta					1032

<210> 47

<211> 2680

<212> DNA

<213> Homo sapiens

<400> 47
ggcagcagtc ttacagcaag tacttaacaa acttagattt ccataatcag atttatctca 60
aaccgcaaaa aaagctgat ttattatgt taaactgata ggagattttt atgagagatg 120
aaagtaagcg attttaactt ttaattttt ttaattttt ctctgtttct cacacttgag 180
gcttttctga aattcaccaa aagagttttg gtagttgttg ggaatttacc agaaccctcc 240
attattaaaa caattggttc ctatatttaa aatcatcaga caggttttgt gtacacagac 300
atttatgtta agccactgga tagaactaaa ctgtgtgtag gaacctgttt tctctaagaa 360
aggacctctt tgagttctgt aggatattgt cttaaagggt tctctgtgtca agctatttta 420
tgaaataaaa ttttacaac aatgaagctt cattttcaca cgttgatttt gttaaagca 480
gacttggcct atacaggttt ttgaaattaa gggtttttcc cgtaaaacta gcttaggagt 540
ttaatgagtc actgtgtctc tcacctctgt aggatgagca cagagatcac atttgagaag 600
cagggtgtgg tgtttctgtc tgggtacgtc tctctgtcct ctcctctggc tcagcagtta 660
cttttctca gtcattgggg ctgcattcag ctgcgagcc agcattaggg ccaagctctc 720
ccgttctgt gacgttttat tacacgtact ctctatcagt agtagctgcc attccctgag 780
tgttctctcc accgtgcact gagaagggtc gaggatttcc gaacatcaac ctcctctaac 840
cctctgtatg ggaatttagat ttttatcacc ctgactgttg gggctttcta gagctcaggc 900
aacttgcccc tggcgggat ggagctgcc tggggggagt gtgaatgagg ctctctgtgt 960
ctgtggtctg gctctctgtg gttggaaact tcagaagcag tagattccag gtgcaacatt 1020
tgggtcccg acaagtgtt aaacctgacc ttggggaggg ccttcaactgg cagccagtgt 1080
ccacctgtga gcccggtgag cacagcgtt agagccaggg ccggcggtt cagaggttgg 1140
agccggggac cagtgggttc agaggtcgga gccggggacc agtgggtca gaggctggag 1200
ccatgtccct gccgtgaagc tctgaggtt ggtggtgaca tcggggcgat tgtggcatcg 1260
cgattgtggt gtcttggctg cctttggccg gcgtgtccac tgcctgtgtt tcatgacgta 1320
ggcaccacat ggtctgtgt tgtctcact acggctccac tctgtgttt tctctacttg 1380
ctcacccttg agataaact ctatttcatt ttcatttcgg ttatattgtg ggtttcttc 1440
caggctctgat gtttaagccta taattttgca atgtgatgt ttgaagttaa ygtgtaatag 1500
agccagtga ccaagggttc acacccagt gaaatacaaa tattcagaat tgagccactg 1560
tgttgccata ctgattatgt aatgtgtgat taacaagtat aatgtgtcac tttcaacatc 1620
agtttcatgc caaagtgtca ttttattaga ttatttggga gttcactttg ggcccaagg 1680
ctcgtgtcta cataataata acttatgatt ttctttttt tctttgttt attttttgtt 1740
ttgtgttttt tctttctag accatgccag agtaatctca gctttcttta gttactggat 1800
cacacatct cttcttgaga agagcagtga ctaaaatgga atatctcttt aagaacagct 1860
cctcttttaac aaaaaaactt aaagacaaa tgtgagatgg gcttagagtt agttctctgg 1920
gaacttgaag gacatttatg ccatattatt tattcactgt ttgttctctg gtgggcaaga 1980
tgccatctga ggttccagat gagaatttgg ggtaaaatgg aaatttttca cttatttgca 2040
attatatata tcttgaaata ctacataaaa cttgattctg tttctctact tattgtaaaa 2100
attgaaaatg gacattctgt taagttaaat gtatagtttg aagctcata atttttatga 2160
agttttgaat cacttctat ctgaaagtct ctgctttaag aatgctttct gggattataa 2220
atgttctagt ttaagtattt tgaatatagt tgagttttt tctctctctc tactttgtga 2280
atcatatcag gtacctgtt tctctgttct gattttcttt tctgtgatag aagcagtcgt 2340
cagttctctg tattactaag tgttaaaagc atcagtcagg ccgggtgagg tggctcagc 2400
ctgtaatcct ggcacttttg gagaccgagg caggcgagtc acaacgtcag gagatcgaga 2460
gcattccggc taacacgtg aaaccccatc tctattaaaa atacaaaaaa ttagccgggc 2520
gtggtggcgg gcgctgtat tcccagctac tctggaggct gaggcaagag aatggcatga 2580
acctggggagg cagagtttgc agtgagctga gatcgacca ctgactgca gcctgggcga 2640
cagagcgaga ctccagctca aataaaaaaa aaaaaaaaaa 2680

<210> 48
<211> 1730
<212> DNA
<213> Homo sapiens

<400> 48
cccacgcgtc cgggggcttg tggcggagtc cagagggaac taggcccgtc tcgggatggt 50
gtggagcgct gctctctgcc cctgttgcct cctcggggtc ctggggctgg tccagggtgt 120
ggggggccaa gccgtgggccc cctggacggc tccagcgtgt ttgggggcag ctcaggctca 180
gccctgcagg ccttcgaagg agagctctct gaqcttatcc tcagcttcag ctccctcaat 240

```
gactcactga atgagctcca gaccactgtg gagggccagg gcgctgatct ggctgacctg 300
ggggcaacca aggaccgtat catttctgag attaacaggc tgcagcagga ggccacagag 360
catgctacag agagtgaaga gcgcttccga ggcctagagg agggacaagc acaggccggc 420
cagtgtccca gcttagaggg gctgattggc cgtcttgagg gtgtctgtga acggttgga 480
actgtggctg ggggactgca gggcctgccc gagggccttt ccagacacgt ggctgggctc 540
tgggctgggc tccgggaac caacaccacc agccagatgc aggcagccct gctggagaa 600
ctggtcgggg gacaggcggg cctgggcagg cggctgggtg ccttaacag ctccttgca 660
ctcctggagg accgtctgca ccagctnagc ctgaaggacc tcactgggccc tgcaggagag 720
gctgggcccc cagggcctcc tgggtgagc ggacccccag gccctgctgg acctccagga 780
tcaccaggca aggacgggca agaggcccc atcgggccac cagctcctca aggtgaacag 840
ggagtggagg gggcaccagg agccccctgt ccccaagtgg cactttcagc cgtctcag 900
ttgccccgg ctgaaccagg caggttccc ttcqacagag tctgtctcaa tgatggagg 960
tattatgac cagagacagg cgtgttccca gtcccccact gctggagcct acttgctgag 1020
cgcggtgctg actgggcacc ggcacgagaa agtggaggcc gtgctgtggc cgttcaaac 1080
agggcgtggc cggcgtagac tccgggctgg tacgagcctg agggctcggg gaataagccg 1140
gtggccgaga gccagccagg cccgggcacc ctgggctgct tcagcctcat cctgccgctg 1200
caggccgggg acacgggtct cgtcgacctg gtcatggggc agctggcgca ctccggagg 1260
ccgctcacca cttcagcgg ggccctgctc tatggggacc cagagcttga acacgcgtag 1320
actgggttcc cgcccgacgt gtctacgtcg gctgaagaga cagcgggggc ggcgggctcc 1380
tggggctcgc cctgagacgg ggcacctagc cctgggcgag cgcgcaccc gggcccgag 1440
cggcaccggc cccagagcgg cctctcccca cgcccggggc ggcgcggctc agggagctc 1500
ggggccgccc atgcagactt ttggcctggc gcgatcccc aagaaacctt ccaggccggg 1560
cctgcccagg agccgatcct cgcacctctc gctccctcca ctggccctcc aggtcgattc 1620
cctgggtccc aggtctcccc gcgcggggcg cgcacccgc cactataaac gatcgaggaa 1680
taaagacact tggtttttct aaaaaaaaaa aaaaaaaaaa aaggggcccg 1730
```

<210> 49

<211> 1275

<212> DNA

<213> Homo sapiens

<400> 49

```
ggcagagacc agctcctctt ccaagatgtc ctcccttaac ttgcccagtg aaatggagaa 60
gtacgtttg gggataata tctttcaag gttttgctta tttttgataa tgctcctgca 120
catccttctt tttttgggta ccttcattca agctcacact gttgtctctc tctccagca 180
ccaccccttt gttccaaacta atggatcaaa gagtatatgc agcttttaag gcttgattac 240
tacctgagga ggaacctttg ctaggctatt gctgcaata agaaagatcc tttttaaca 300
cactggtgca attctggaag gattacaaca tctatggcag catcaacaac cttggttaag 360
ttgggggtga agtcaccaag gagtgtgtaa atgctatctg ggaagagata ttgaagacat 420
ttgtccatga ctcaaaaaca ttgctaagga tgaggatgtt gcaaaaaaaa aatattcaca 480
agggctttagt tgaatgggca aacaacttta agctggatgt ggaaggagat gatattgagg 540
aggtcacaga tgtggtcact gaggaattga ctaatgacga gttactggaa ccagaacaga 600
aatgcatagc aagaggaaag gaaactacag gaaaaaaa gaaaagcccc caaggatatt 660
cacagtgatg ggtttaggca gaegcttttg cagacctcaa caaactcctt aaaaagtgtg 720
aaaaatgttg ctccaacatg aatgattttt cattagtaga gaggaatgtt catcgtgcat 780
tatctattta caagcaaatc tatgatgaat aaaaagaaca aaccaaacaa accaccatga 840
acacatttct gaaaagagtg acatctcaag aagagctca ggcagggtct tcaggaggta 900
tcccagaaga agaaggcatt gttatcacag gacatgacag ctccctgggt gttattgccc 960
ttaaaggcct tccagtagga taagggtgtg agatggaagg tgcgatttt tatgatcctg 1020
acccatcata ggtctaggct aatgggtaat ggtgtgtttg tgccttagtt tttaaagaaa 1080
aatgtaaaaa gtaaaaaata aaaaataact taatataggt aaaagttaa agaataagga 1140
tataaggaga gaaaaaaatt atcttctctc gtatttgtgt ttcaagctgt gttactacaa 1200
aagaataaaa aagttaagag aaattgtttt laaagtaaaa tagttacaat aatctaaaaa 1260
aaaaaaaaaa aaaaaa
```

<210> 50

<211> 1762

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (447)
<223> n equals a.t.g. or c

<400> 50
ggtggcctag agatgctgct gccgcgggtg cagttgttgc gcacgectct gcccgcacgc 60
ccgctccacc gccgtagcgc ccgagtgctg gggggcgcac ccgagtcggg ccatgaggcc 120
gggaaccqcg ctacaggccg tgcgtctggt cgtgctgctg gtggggctgc gggccgcgac 180
gggtcgccctg ctgagtgggc agccagcttg ccggggaggg acacagaggg cttgttataa 240
agtcaattac tcccatgata cttctcgaag actgaacttt gaggaagcca aagaagcctg 300
caggagggat ggaggccagc tagtcagcat cagatctgaa gatgaacaga aactgataga 360
aaakttcatt gaaaacctct tgcctctga -ggtgacttc tggattgggc tcaggaggcg 420
tgaggagaaa caaagcaata gcacagnctg ccaggacctt tatgcttggg ctgatggcag 480
catatcacaa tttagggaact ggtatgtgga tgagccgtcc tgcggcagcg aggtctgcgt 540
ggtcactgac catcagccat cyycacccgc tggcatcgga gggccctaca tgttccagtg 600
gaatgatgac cgggtgcaaca tgaagaacaa tttcatttgc aaatatcttg atgagaaacc 660
agcagttcct tctagagaag ctgaagggtg ggaacacag ctgacaacac ctgtacttcc 720
agaagaaaca caggaagaag atgcacaaaa aacattttaa gaaagtagag aagctgcctt 780
gaatctggcc tacatcttaa tccccagca- tccccctctc ctccctcttg tggtaaccac 840
agttgtatgt tgggttttgg tctgtagaaa aagaaaacgg gagcagccag accctagcac 900
aaagaagcaa cacaccatct ggcctctctc tcaccaggga aacagcccg accctagagt 960
ctacaatgtc ataagaaaac aaagcgaagc tgacttagct gagaccggc cagacctgaa 1020
qaatatctca ttcctgagtg gttcgggaga agccactccc gatgacatgt cttgtgacta 1080
tgacaacatg gctgtgaacc catcagaag tgggtttgtg actctgggtg gcgtggagag 1140
tggatttttg accaatgaca tttatgagtt ctccccagac caaatgggga ggagtaagga 1200
gtctggatgg gtggaaaatg aatatatggt ttattaggac atataaaaaa ctgaaactga 1260
caacaatgga aaagaaatga taagcaaaaal cctcttattt tctataagga aaatacacag 1320
aaggtctatg aacaagctta gatcaggtcc tgtggatgag catgtgtgcc ccacgacctc 1380
ctgttggacc cccacgtttt ggctgtatcc tttatcccag ccagtcaccc agctcgacct 1440
tatgagaagg taccttgccc aggtctggca catagttagg tctcaataaa tgtcacttgg 1500
ttgggtgtat ctaactttta agggacagag ctttacctgg cagtataaaa gatgggctgt 1560
ggagcttggg aaaccacctc tgttttcttt gctctataca gcagcacata ttatcacata 1620
gacagaaat ccagaaatctt ttcaaacccc acatatggta gcacaggytg gcctgtgcat 1680
cggcaattct catatctgtt ttttttaaa aataaaatca aataaagagc aggaaaaaaa 1740
aaaaaaaaa aaaaaactcg ag 1762

<210> 51
<211> 2059
<212> DNA
<213> Homo sapiens

<400> 51
cggcacgagg tttggtctaa gagtgagcag aactgtgttg ayatgggagc acatttggtt 60
gtgttcaaca cagaagcaga gcagtggag gaggcagca tccccagctg ataccttgg 120
ttattgctgt agttttctac ttacttctcg gtgtctgttt tattgcaagt tgttttggta 180
ctcatcacaa cttttcacgc tgtaagagag gcacaggagt gcacaagtta gagcaccatg 240
caaaagctca atgcatcaaa gagaatcag aactgaaaag ttgctgaagg gagcaccctg 300
aactgttgc ctattgactg gagaaccttc cagttccaac tgctatttct ctcttactg 360
acaacaagac gtgggctgag agttgaaagg aactgttcag ggtggggggc ccatctgatg 420
accatcagca cggaagctga gcagaacttt attattcagt ttctggatag acggctttcc 480
tatttctctg gacttagaga tgagaatgac aaaggtcagt ggcgtttgggt gggaccagac 540
gccatttaac ccacgccaag gtattctggc ataagaatga acccgacaac tytcaggagg 600
aaaactgtgt tgttctgtgt ttataaccaa gataaatggg cctgggaatga tgttcttgt 660
aactttgaag caagtaggat ttgtaaaaa cctggaacaa cattgaacta gaaactcaga 720

aagtcgctct	tgtgatggaa	agagaaaaga	aaaaccaatt	agaataaggc	agaatgtacg	780
tcggtcactg	gaacacagaa	aacatgctgg	ttcatacagc	gttttttagtc	ataatggtct	840
tttttatttt	gtttgattca	ttcgagacaa	catgtgtgta	tgtgtgtgtg	tgtgtgtgta	900
gataattgtg	tttttctatg	gtgtttgatg	gaaggaataa	tctttctttg	ctttcttagt	960
agtatttcaa	gggttttact	tttcaattgg	tgtgcactga	atgcatgtat	ggaagaatag	1020
cgtgaataat	gcaatctctt	tgctattttt	tcccctttct	cagactctta	gctcttaaaa	1080
ttcaaaagat	gggatattct	aactggtagt	gggtcatcat	ttttaaccct	aattattgcaa	1140
gcacttttaa	gatttgaaac	cacattttta	ttgtttgatg	tttcailltc	agacttttta	1200
atgtcagtoa	ttacaattac	attgcatgag	gaaaattttt	ccagaacaac	agtgtggaat	1260
agttctgaat	tatgctgttc	tacagatgga	aaaaagtcca	aatgccttta	aaaattttact	1320
ttctactcca	cccaacaggt	ttttgcaaa	caagaagtct	ttgtaagaca	ccttaaacaa	1380
agtccttcaa	ttctacagca	gaggaaataa	aatccccag	aagccaaagg	gctcaccttc	1440
acattgttag	ttcatgacag	accaggtgtg	gcttcattag	agataacata	cattcccttt	1500
ggatocacag	gaagtactct	gggattactc	gacctcatta	cttagctaac	gactggataa	1560
aattttctaa	ttgtttgaag	taacattgta	ttcgtgtttg	cattattaat	ttgaatagaa	1620
aataatcaca	ttttcaaccc	atttatacaa	attgttaatg	ttctcttaga	gctgtataac	1680
tatagtttga	actagcaagg	aagttattgt	tttgacaacc	agaaattatg	ctttctcggt	1740
gcattgaaaca	ctaattgcaa	agggcagtc	catccaaact	taataaaata	tgggtggtct	1800
ttttaaattt	ttcaatttgc	taatttttcc	tggaaacct	actttcttac	tactactttt	1860
aaaagcagta	tttattttgt	aaattagcta	ctgatatttt	qqttttgaaa	tactggtgtt	1920
tgatttgtgt	gtggtgtgtg	tgggtgatga	tgcgtgtagc	tgtgttaaaa	gctgataact	1980
ttagctgaaa	tgggtctaaa	taaatttgac	tgtgtttgcc	atactcacta	aaaaaaaaaa	2040
aaaaaaacta	gagggggggg					2059

<210> 52

<211> 3282

<212> DNA

<213> Homo . sapiens

<400> 52

cccacgcgtc	cgacttaaaa	gagaagcttt	agctgcaaaa	gattgggaaa	gggaaaggac	60
aaaaaagacc	cctgggctac	acggcgtagg	tcagggtttt	cctactgctg	ttcttttatg	120
ctgggagctg	tggctgtaac	caactaggaa	ataacgtatg	cagcagctat	ggctgtcaga	180
gagttgtgct	tcccaagaca	aaggcaagtc	ctgtttcttt	ttcttttttg	gggagtgctc	240
ttggcagggt	ctgggttttg	acgttattcg	gtgactgagg	aaacagagaa	aggatccttt	300
gtggtcaatc	tggcaaaagg	tctgggacta	gcagaggggg	agctggctgc	aaggggaaac	360
aggggtgttt	cgatgataaa	caaaacaatac	ctgctcctgg	attcacatac	cgggaatttg	420
ctcacaaatg	agaaactgga	ccgagagaag	ctgtg-ggcc	ctaaagagcc	ctgtatgctg	480
tattttccaaa	tttttaattgga	tgatcccttt	cagatttacc	gggctgagct	gagagtcagg	540
gatataaatg	atcacgcgcc	agtattttcag	gacaaagaaa	cagtcttaaa	aatatcagaa	600
aatacagctg	aagggacagc	attttagacta	gaaagagcac	aggatccaga	tggaggactc	660
aacggtatcc	aaaactacac	gatcagcccc	aactcttttt	tccatattaa	tatttagtggc	720
ggtgatgaag	gcattgatata	tccagagcta	gtgttggaca	aagcactgga	tgggaggag	780
cagggagagc	tcagcttaac	cctcacagcg	ctggatgggt	ggtctccatc	cagggtcggg	840
acctctactg	tacgcatacgt	tgtctttggac	gtcaatgaca	atgccccaca	gttgccag	900
gctctgtatg	agacccaggc	tccagaaaaa	agccccattg	ggttccttat	tgttaaggta	960
tgggcagaag	atgtagaccc	tggagctcaac	gcggaagtat	cctatttcatt	ttttgatgcc	1020
tcagaaaaata	ttcgaacaac	ctttcaaatc	aatccttttt	ctggggaaat	ctttctcaga	1080
gaattgcttg	attatgagtt	agtaaatctt	tacaaaaaa	atatacagggc	aatggacggt	1140
ggaggccttt	ctgcaagatg	tagggtttta	gtggaagtat	tggacaccaa	tgacaatccc	1200
cctgaactga	tcgtatcatc	attttccaac	tcgttgctg	agaattctcc	tgagacgcgg	1260
ctgggtgttt	ttaagattaa	tgacagagac	ctggagaaaa	atggaaagat	ggtttgctac	1320
attcaagaga	atctgccatt	cctactaaaa	ccttctgtgg	agaattttta	catectaatt	1380
acagaaggcg	cgctggacag	agagatcaga	gccgagtaca	acatcactat	caccgtcact	1440
gactttggga	caccagggrr	gaaaaccgag	cacaacataa	ccgtgctggg	ctccgacgtc	1500
aataacaacg	ccccgcctt	cacccaaccc	tcctacaccc	tgttctccg	cgagaacaa	1560
agccccgccc	tgcacatcgg	cagcgtcagc	gccacagaca	gagactcggg	caccaacgcc	1620
caggttcact	actcgtcgtc	gccgccccaa	gaccgcgacc	tgcctctcgc	ctccccggtc	1680

ccatcaacg	cggaacaacg	ccacctgttc	gccctcaggt	cgctggacta	cgaggccctg	1740
caggctttcg	agttccgcgt	gggcccacac	gaccgcggct	ccccgcgct	gaacagcgag	1800
gcgtgggtg	cgctgtgctg	tgctggacgc	caacgacaac	tcggcccttcg	tgctgtaccg	1860
gctgcagaac	ggctccgcgc	cctgcaccga	gctgggtccc	cgggcgggcg	agccgggcta	1920
cctggtgacc	aaggtggtgg	cggtggacgg	cgactcgggc	cagaacgcct	ggctgtcgta	1980
ccagctgctc	aaggccacgg	agcccgggct	gttcggtgtg	tgqccgcaca	atggggaggt	2040
gcgcaccgcc	aggctgctga	gcgagcgcga	cgagcccaag	cacaggctgg	tggtgcttgc	2100
caaggacaat	ggcgagcctc	ctcgtctggc	caccgcaccg	ctgcacgtgc	tcctggttga	2160
cggtcttccc	cagccctacc	tgctctctcc	ggaggcgccc	ccggcccgag	ccaggccga	2220
cttgctcacc	gtctacctgg	tggtggcggt	ggcctcgggt	ttctcgtctc	tcctctcttc	2280
ggtgctcctg	ttcgtggcgg	tgcggtctgt	caggaggagc	agggcgggct	cggtgggtcg	2340
ctgctcgggt	cccgagggtc	cttttccagg	gcctctgggt	gacgtgaggg	gcgtgagac	2400
cctgtcccg	agctaccagt	atgaggtgtg	tctgacggga	ggccccggga	ccagtgagtt	2460
caagtctctg	aaaccagtta	tttcggatac	tcaggccacag	ggccctggga	ggaaggggtg	2520
agaaaattcc	accttccgaa	atagctttgg	atttaaatat	cagtaaaagt	cggttttagt	2580
ttcatatact	tttgggtgtg	tacatagcca	tgtttctatt	agtttacttt	taaatctcaa	2640
atttaagtta	ttatgcaact	tcaagcatta	ttttcaagta	gtataccctc	gtggttttac	2700
aatgtttcat	catttttttg	cattaataac	aactgggttt	aatttaatga	gtattttttt	2760
ttaaatgata	gtgttaaggt	tttaattctt	tccaactgcc	caaggaatta	attactatca	2820
ttcttcatta	cagaaatcgg	aggttttgat	tcatttcaga	gcttgcatct	catqattcta	2880
atcacttctg	tctatagtgt	acttgcctca	tttaagaagg	catatctaca	tttccaaact	2940
cattctaaca	ttcta:atat	tcgtgtttga	aaacca:gtc	atttattttt	acatcatgta	3000
tttaaaaaga	aatatttttc	tactactatg	ctcatgacaa	aatgaaccaa	agcatattgt	3060
gagcaatact	gaacatcaat	aataccctta	gtttatatac	ttattatttt	atctttaagc	3120
atgctacttt	tacttggcca	atatttttct	atgttaactt	ttgctgatgt	ataaaacaga	3180
ctatgcctta	taattgaaat	aaaatcataa	tctgcctgaa	aatgaataaa	aataaacat	3240
tttgaatttt	gtgaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa		3282

<210> 53

<211> 1860

<212> DNA

<213> Homo sapiens

<400> 53

aattcggcac	gagcagcagg	gagaagagga	tgatgagcat	gccaggcccc	tgcccgagtc	60
cctgctcctg	gccattgctg	acctgctctt	ctgcccgac	ttcacgggtc	agagccaccg	120
gagggagcact	gtggactcgg	cagaggacgt	ccactccctg	gacagctgtg	aatacatctg	180
ggaggctgggt	gtgggcttcg	ctcactcccc	ccagcctaac	tacatccacg	atatgaaccg	240
gatggagctg	ctgaaactgc	tgctgacatg	cttctccgag	gccatgtacc	tgccccagc	300
tcgggaaagt	ggcagaccca	acccatgggt	tcagttcttt	tgttccacgg	agaacagaca	360
tgccctgccc	cccttcacct	ccctctcctc	caccgtgtgt	gcctatgacc	ctg-gggcta	420
cgggatcccc	tacaaccacc	tgctcttctc	tgactaccgg	gaacccctgg	tgaggagggc	480
tgcccagggt	ctcattgltc	ctttggacca	cgacagtgcc	agcagtggca	gccccactgt	540
ggacggcacc	accactggca	ccgccatgga	tgatgccgat	cctccaggcc	ctqagaacct	600
gtttgtgaac	tacctgtccc	gcattccatg	tgaggaggac	ttccagttca	tcctcaaggg	660
tatagcccg	ctgctgtcca	acccccctgt	ccagacctac	ctgcctaact	ccaccaagaa	720
agatccagtt	ccaccaggag	ctgctagtgc	ttttctggaa	gctctgcgac	ttcaacaaga	780
aattctctct	cttcgtgctg	aagagcagcg	acgtccctaga	catccttgte	cccatctct	840
ttcttctcaa	cgatgcccgg	gcgatcaggt	gtaagaccag	ggtaggggtg	ggatgctggg	900
ggctttcctg	gcggcgaggt	ggagggtcgt	ctatctgccc	tgactcccag	gagctcagcc	960
tggaactctg	acctcc:agg	agggaggcct	ccaaaatggg	cactgcctgg	gccccctctt	1020
ccccctccca	cccgagtgc	ccctccccag	ccacctggcg	cagctcgggt	gggcttgatg	1080
caacattgggt	tttcatctt	gctgcttctg	agcggggagc	ggaacttcgg	ggtagggctg	1140
aaacaaacct	actcaatccg	cgtgcccctg	gacatcccag	ttttcacagg	gaaccacgcc	1200
gacctgtcca	ttgtgtgtgt	ccacaagatc	atcaccacgc	ggcaccagcg	gttcgacccc	1260
ctcttcgact	gcctgtctac	catcgtcggt	aacggtaggg	gcccggagct	tgcaactccc	1320
gcgtccacca	ccaggtgggt	tcagccacag	gccaacctgc	cacttgctcc	aggtttcaag	1380
ccccctcagc	ccacagaaag	aacgcaagct	tgtgtaccct	tcatagtagc	cacattaaaa	1440

aaaaagggg	acaacaattg	aataaatatgt	tttatctatc	atcatctcaa	catgtagcca	1500
atatgaaaat	tactaatgag	atatttaata	ttcccttctc	acactcagtc	ttgtcgccca	1560
ggctggagtg	cagtggcacc	atctcagctc	actgcaacct	cgcccccttg	ggttcaagca	1620
attctcatgc	ctcagcctcc	tgagttagtg	ggattacagg	cgtgtgccac	cacacctggc	1680
taatttttgt	atcttttagta	gagacgggg	tttgccatgt	tgccagggt	ggtctcgaac	1740
tcctgacctc	agatgatatg	cccacctcag	cctcccaaa	tgctgggatt	acaggcatga	1800
gccactgcat	ctggcctttt	taaaaaaaa	aaaaaaaaa	actcgagggg	gggcccggta	1860

<210> 54
 <211> 770
 <212> DNA
 <213> Homo sapiens

<400> 54						
aattcggcac	gagccgaggg	gcgaatccat	acatccgtcg	tgtggactcg	ccctgacatc	60
ccctcaacgc	ttagactcgg	cattcttttc	attgcctgat	gccgtttcat	gccttctttg	120
cgtttctctg	ctctggccct	cctgctggcc	atccttcccg	cacttcccaa	cgccccatgcc	180
gcgcggggga	ttggcgccct	gatcgcgccg	ggctcccagg	cctcagccaa	yyaagagccc	240
cagagcaacg	cgcaacccag	cgccgatgag	cgcaaacac	gactgctcag	ccaggcctgag	300
gaaacccggc	agcgcttgac	cgatctcaag	gccgaactcg	ccggcgacc	caaggagatc	360
agcgagggcc	agcgtacgct	ctccaaactg	gtgagcgagg	acaacagcga	tctgcccagag	420
cgctctccca	agctttcggt	gccggtaactg	gagcaacgcc	tgggggcccg	cgtggacgag	480
ctcgccctct	ggcaacaagc	gctcagcgcg	gccaacagca	tgctcatcag	cgcgagagcc	540
cgccccgagc	gcgccagggc	cgatatcagc	aagaaccagt	tgccgatcga	cgagatcaac	600
ggcctgctga	aaagcggtcg	ggagaacaac	aagccgctga	cggacgaacg	tcggcgcgctg	660
ctcgagagta	cttctagagc	gcgccggggc	ccatcgattt	tcaccccggt	tggggtacca	720
ggtaagtgtg	cccaattcgc	cctatagtag	gtcgatttac	aattcactgg		770

<210> 55
 <211> 1093
 <212> DNA
 <213> Homo sapiens

<400> 55						
cagattcggc	acgaggtttt	ttttaagatt	tattttttta	aaattatttt	tgtggacttg	60
ggatccaatg	atggcaccta	cttttgggaa	ctctagctg	tgctttgaga	attgcatcag	120
gtcatgtgtt	gcaccgtttc	ctgtatgttt	acgtcccttg	gactggcttc	tcccaggatt	180
ctttctgttt	tttgtttttt	tgatttgggc	tttatttttt	tctgtgtact	gtactatatt	240
gtaaaaggga	ttttagcaga	gacttttagtc	tttggggcaa	gaggagaaca	ggaatgctgg	300
gctgtttact	ttaggcggag	aacctatctt	cagacctttg	gactattttc	tttcaactgc	360
agtgtataga	aaaaccaaac	tacgacctca	gagcagagta	ttaatgaaaa	gcacaaaaaa	420
aggaaactaag	ttcagcgagg	ggtgggggga	ggggggagat	tttctttttg	aaaaataaatg	480
actcttagga	catttgtttt	tcagtccaag	tgctcttcag	cactgtcttg	tctcccaata	540
taccaacca	ctggacattt	tttctctctg	tttctctctc	cgattttgct	ctgtctctcc	600
agtttaagtgt	ttccttctct	tgtgcccccc	gctggtgacc	ctctgtctcc	ctctctcttt	660
ccctttggca	gctgcaatac	acagtgttat	tttggggaaa	taaatctagc	aaagcctcgc	720
cttccatgcc	gagcgtcttc	ttggctctga	gagggaaaag	tctgtctctg	ggatgccttc	780
tggtcttttt	tccccctaag	ctttctctct	tcccatcata	cccttccctg	cccaccttgt	840
tttctgtctc	ctttttatta	ggaattccca	agtqaatttt	attaatgtgg	gagtggaaac	900
gatgctaaaa	gctatccagg	attttggttc	tgtttgtttt	aaattttgtg	gttctcttcc	960
tttctctccc	ctcccatcg	taagacgttc	tggtgaacct	ccattaaatt	tggtacaaaa	1020
ccactcgcca	gagctgtggt	gtcagaaaaa	taaaatatat	tgtttcttam	aaaaaaaact	1080
aaaaaaaact	cga					1093

<210> 56
 <211> 632

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (46)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (94)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (162)
<223> n equals a,t,g, or c

<400> 56
cgcaactaat gtgagttagc tcaactcatna ggcaccccag gctttncact ttatgctttc 60
cggtcgtat gttgtgtgga attgtgacgg atancaattt cacacaggaa acagctatgc 120
catgattacg ccaagctcga aattaacctt cactaaaggg ancaaaaagct ggagctccac 180
cgcggtggcg gccgtctcag aactagtggg tccccggggc tgcagggaatt cggcacgaga 240
ctatgtatat atgtttaata tctgtctttt gaaatgcaga aatagtttaa atgtttcttt 300
gtctattttt cttttttttt aatgctacc agggaaatat ttccatatca tttttaagtg 360
gectgcctea atgtatatat attttctttt aaacaaaaag gttctggaaa ctgtttttct 420
gtagctttaa atgaataggt gagcaaaatc tatatgggat gtaatttttt tgttcagttc 480
cttaaaaaat actttgtttt ggtacatttg gttgtgcttg tggggaaaat aaaaacgcag 540
agatccctat atatttatgt caaagtaata ttttattatc tacataaaac agaaatgcac 600
aataaaaaaa aaaaaaaaaa gctcgagggg gg 632

<210> 57
<211> 2687
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1614)
<223> n equals a,t,g, or c

<400> 57
gtacaccatg ggcctccacc tccgccccta ccgtgtgggg ctgctcccg atggcctcct 60
gttctctttg ctgctgctea tgcgtgctgc ggacccagcg ctcccggcg gacgtcacc 120
cccagtgggt cctgctccctg gtgatttggg taaccaactg gaagccaagc tggacaagcc 180
gacagtgggt cactacctct gctccaaqaa gaccgaaagc tacttcacaa tctggctgaa 240
cctggaactg ctgctgctcg tgcattcatt actgctggat tgacaatate aggtctggtt 300
acaacaaaac atccagggcc acccagtttc cggatgggtt ggaatgtacgt gtccctggct 360
ttgggaagac cttctcactg gagttccctg accccagcaa aagcagcgtg ggttctatt 420
tccacaccat ggtggagagc cttgtgggct ggggctacac acggggtgag gatgtccgag 480
gggtcccta tgactggcgc cgagcccaa atgaaaacgg gccctacttc ctggccctcc 540
gcgagatgat cgaggagatg taccagctgt atgggggccc cgtgggtgctg gttgccaca 600
gtatgggcaa catgtacacg ctctactttc tgcagcggca gccgcaggcc tggaaargaca 660

agtatatccg	ggccttcgtg	tcactgggtg	cgccctgggg	gggctggcc	aagacctgc	720
gcgtcctggc	trcaggagac	aacaaccgga	tcccagtcac	cgggcccttg	aagatccggg	780
agcagcagcg	gtcagctgtc	tccaccagct	ggctgctgcc	ctacaactac	acatgggtcac	840
ctgagaagg	gttcgtgcag	acccccacaa	tcaacacac	actgcgggac	taccgcaagt	900
tctccaggga	catcggcctt	gaagatggct	ggctcatgcg	gcaggacaca	gaagggtctg	960
tggaagccac	gatgccacct	ggcgtgcagc	tgactgcct	ctatggtact	ggcgtcccca	1020
caccagactc	cttctactat	gagagcttcc	ctgaccgtga	ccctaaaatc	tgctttggtg	1080
acggcagatg	tactgtgaac	ttgaagagt	ccctgcagtg	ccaggccttg	cagagccgcc	1140
aggagcacca	agtgttgctg	caggagctgc	caggcagcga	gcacatcgag	atgctggcca	1200
acgccaccac	cctggcctat	ctgaaacgtg	tgctccttgg	gccttgactc	ctgtgccaca	1260
ggactcctgt	ggctcggccg	tggaacctgt	gttggcctct	ggggctgtca	tggtccacgc	1320
gttttgcaaa	gtttgtgact	caccattcaa	ggccccgagt	cttggactgt	gaagcatctg	1380
ccatggggaa	gtgctgtttg	ttatccttcc	tctgtggcag	tgaagaaggga	agaaatgaga	1440
gtctagactc	aagggaacact	ggatggcaag	aatgctgtg	atggttgaac	tgctgtracc	1500
ttaggactgg	ctccacaggg	tggactggct	gggcccgtgt	cccagtcctc	gcctggggcc	1560
atgtgtcccc	cctattcctg	tggtgttttc	atacttgctc	actgggccc	ggcncsgcag	1620
ccttcctatg	agggatgtta	ctgggtgtg	gtcctgtacc	cagaggctcc	agggatcgcc	1680
tcctggcccc	tcgggtgacc	cttcccacac	accagccaca	gataggcctg	ccactggcca	1740
tggttagcta	gagctgtctg	cttccctgtg	gcttagctgg	tggtcagcct	gactggcttc	1800
ctgggcgagc	ctagttagctc	ctgcaggcag	gggcagtttg	ttgcgttctt	cgtggttccc	1860
aggccctggg	acatctcact	ccactcctac	ctcccttacc	accaggagca	ttcaagctct	1920
ggattgggca	gcagatgtgc	ccccagtcce	gcagctgtgt	tccaggggcc	ctgatctcct	1980
cggatgtgct	attggcccca	ggactgaagc	tgctcccttc	cacctggga	ctgtggttcc	2040
aaggatgaga	gcaggggttg	gagccatggc	cttctgggaa	cctatggaga	aagggaatcc	2100
aagggaagcag	ccaaggctgc	tcgcagcttc	cctgagctgc	acctcttctt	aaccccacca	2160
tcacactgcc	accctgcccc	aggtgtcac	tagtaccacg	tggttcagca	cagggtcgag	2220
gatggggctc	ctatccaccc	tgccagcac	ccagcttag	gctgggacta	gcccagaaac	2280
ttgaatggga	ccctgagaga	gccagggttc	ccctgaggcc	ccccagggg	cttctgtctt	2340
gccccagggt	gtcccatgga	tctccctgtg	gcagcaggca	tggaagtgca	gggtgccttc	2400
catggcagta	ggcttcaagt	gggtgactgg	ccacaggccg	agaaaaaggt	acagcctcta	2460
ggtggggctc	ccaaagacgc	cttcasgctg	gactgaactg	ctctccaca	gggtttctgt	2520
gcagctggat	ttctctgttt	gcatacatgc	ctggcatctg	tctccctgtt	ttcttgagtg	2580
gccccacatg	gggtctctgag	caggctgtat	ctggattctg	gcaataaaaag	tactctggat	2640
gctgtaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	ggcggcc		2687

<210> 58
 <211> 619
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (526)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (619)
 <223> n equals a,t,g, or c

<400> 58						
tcacagctt	tcacctgga	tatcgtgaca	gcctcctact	gcttctctat	catgtggcca	60
gagctatctt	cctaaaatgc	attgcatagt	tgatcaagtc	actctctggc	ctaaaacctt	120
ccttggctcc	ctgctgccct	caggataaag	tctggacccc	tcagcatggc	ttgtgagact	180
catgtgtctc	ttgtccctgc	tcacctctct	ggtctatcca	cttgccctct	tgcatctctg	240
gtcccagcct	cctgtatcca	gagatgcagt	ggctctccat	tgccactctg	attctctctt	300
tcttttggct	acagagaaaag	ggtaactctt	ctgtcaaatc	tcaacttaga	cttgacttcc	360
tccaaggagc	tttggctata	ctctctcttc	ccgaccccca	ccctggcata	ctacacagat	420

cactctgggc	tcacttgcct	gcctaattggt	catctcccca	gtagactgta	agctccttga	480
gggcaaggat	tgtgtggaa	ttttgtatt	aacagtgcct	ggcttngtgc	ctggcaccta	540
gaaagcactc	aataaatggt	tgtttaatga	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	600
aaaaaaaaaa	aaaaaaaaaa					619

<210> 59
 <211> 1378
 <212> DNA
 <213> Homo sapiens

<400> 59	
tcgacttctg	ggatgtagat
ttattttttt	cacactgtat
cttccctgcc	aggattggaa
taattacagg	cttggcagaa
aaatacaact	gtcctctaca
gattaggttc	atactttggt
gtgcagcttc	attaaaggggt
tcctatgttt	tactctccca
ttctcctctc	tctctgatta
cagcgtcttc	cttcttcagt
catcatttaa	aaattctcct
ctcccttagc	tggaggtggt
tgtgggtttc	tccagtttct
gttgatattt	agattcaaat
ctttgatgct	ctcttcacag
agggaaattt	cgcaaaaaaa
tttcaaatac	catatttgcc
gttcttctaa	atttgttaat
tattcatttg	cagttggatg
ctacaggtaa	ttttcggaca
taatctctac	aggatcatgg
aaattcacagg	ctcattaac
ccccgggtcg	acgagctcac
	tagtcggcgg
	ccqctctaga
	ggatccctcg
	aggggcac
	60
	120
	180
	240
	300
	360
	420
	480
	540
	600
	660
	720
	780
	840
	900
	960
	1020
	1080
	1140
	1200
	1260
	1320
	1378

<210> 60
 <211> 1126
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (21)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (35)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (49)
 <223> n equals a,t,g, or c

<220>
 <221> SITE

<222> (99)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1012)
<223> n equals a,t,g, or c

<400> 60
tccggcttcg taatgtgggt ngaaattgta acggmataac aatttcacnc aqqaaccagc 60
tatgcccattg attacgcca gttcgaatt aaccttcant aaaggaccaa aagtgaagtt 120
ccaccgcggt gccggcccg cctagaaact agtggatccc ccgggctgca ggaattcggc 180
acgagccggc ccgtaccgcc aggcgatccc gctga-gggc gcgctggcag cagcggccaa 240
gaaggtgtgg agcgcggcggc ggctgctggt gctgctgttc acgcgcgtcg cctgctgccc 300
ggcggtcttc gccctccgc ccaaggaagg ccgctgcttg tttgtcatcc tgctcatggc 360
gggtgactgg tgcacggagg cctgcccgt ctcagtgcg gcgctgctgc ccatcgctct 420
gttcccttc atgggcattc tgcctccaa caaggtctgc ccccgatct ccttcgacac 480
caacttcctc ttcctcagtg ggctgatcat ggccagcgcc attgaggagt ggaacctgca 540
ccggcgatc gccctcaaga tcttgatgct tgttgagtc cagccggcca ggctcatcct 600
ggggatgatg gtgaccacct cgttcttgte catgtgctg agcaaccgc cctccactgc 660
catgatgctt cccattgcc aigccatcct gaaaagtctc tttggccaga aggaggttcg 720
aaaggacccc agccaggaga gtgaagagaa cacaggata gaacccaata ctttctcttc 780
tgaggaaagg ctgaaacttc aagctcccct tgtgalaaga cttggtcaga taactgagtc 840
tggtcaatgg aatatgagtg gaaatgatgt gtgcaacttc cgggttctgt ccttctctgc 900
gggtggaatg tgaatatgat ggcacctggg acccaagagc aggagccaca tcttgagaga 960
tagatggcag atctgcccct gtggcttgg atcatttacc tcagtgaaca cnacaagcat 1020
tatccatgaa accataggtt ttgtgtgcta gttctagttt ttaaaatatg aattaaatta 1080
aatacgtatc tgttaaaact taasaaaaaa aaaaaaaa ctcgag 1126

<210> 61
<211> 2078
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (337)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (492)
<223> n equals a,t,g, or c

<400> 61
gattattttc aatagattgt caataaatta tcaaatatg gaaatatcct ttagattcct 60
gtgataatgc ttgtgtcatg tttcttatta tttagaaaat gaaaacagca gtcatttgac 120
cagccatgtt atgacaccag ataattattc gcaaggatct tccaaacagg gagaaactgc 180
aatgggaaca atctttggat atctacattg tgtcaaatgt tatgtgcttt atttcatttt 240
catacttata acagctgtat atcacagttt ttattatoca cattatagag gcaaggcact 300
gatatacagga acttgagtaa ttggcttaca cagcaantgt agttgaaata gaagccagga 360
ctgtctgatt cccaagacag tgttcttgta ctgcaggtaa gcctgggtgt gctgggkttc 420
cctagcactg agtatgcag aaatcggag atttatttac tcagggtgaat gatgaagcag 480
aatcttttatt tngcttttta aattatkgtat gggkckgag ttaagctagt tcaccaatga 540
gtctcaaaagg gtgaagaact ggcctgtgta gttttaaaac aaagcagcag ttttctctat 600
ttgtagatat tatatttaat ttactcttga tttccaatag cattaatat tagaagcgta 660
taagcttttt ctttttatgc ctaggggata tggcttaaca ctgagaaaca cttgagaaac 720
actgccacat tctaaggaac aaccaataat aagaaaaatt atttcataata aaaggatgca 780

gcttgcatat	aaaatgctga	attcaactga	agttcattat	gctgccttta	tgtgagctca	840
ggggtgacct	tcattgctctg	gactctttaa	ggatccagtg	tcggatacag	ctctgccatt	900
ggagcaatgt	gttcataaac	taggggtgcc	caagtataac	ctctctctcg	ktatctatag	960
ttttcttcta	aagggtgtgc	tttcaaaaca	tgatgttatt	tcataatcmt	atatatatat	1020
atgcacacat	acataatacmt	catgcatgka	tcataatgt	gtgtgtatgt	atgtatctat	1080
cttcaatctt	tcaggaaaagt	ttgtaaaawa	tagccctaaag	tagaattatg	gggaacaggt	1140
tcagaaactg	ctgaaattgg	ctcagatgaa	aaggaaaagag	caaaaatcta	ggttattcac	1200
aggaagttag	tccagctgtg	ctttgcgagg	catgaaacag	gctgaatcag	agcaagaaca	1260
ggttgcaatc	ctagggtcaca	tggcaattaa	attccagcta	tagaataattg	aagacatgta	1320
agtgcttaat	ttaaggatta	ttcaatgcag	tgaataaatt	tatatcattc	ccaaaagtat	1380
gcacatcaga	taatgagtta	actgcattga	acttgaaaac	cttaaatatt	taactgaaag	1440
gattttgtgc	atagaaagat	gtcttagtca	atgtaaaaat	gccagtgatt	tgtgtagcat	1500
gtcctttgtc	aaaagtcatt	atataaaactg	aagtcactta	ctttgtttc	caatgtgata	1560
atattccaca	tttaacaggt	gataattatt	gaaaatatta	gtttgcctca	ctaataattgt	1620
gtccgagata	ttctagttta	aaccaagtta	ctaatactgt	aaaagaagta	ttccttttat	1680
gaagccagca	ttatcctgat	actagaactg	ggaagagaca	cacacaaaaa	gaaaacttca	1740
ggccaatata	gctgatgaac	atcaatgtga	aaatcttcaa	taaaatactg	gcacaaccgaa	1800
tcacagcagca	tgaggcggtg	ggatcacaa	gtcaggagat	cgagaccatc	ctggctaaca	1860
tggtgaaacu	ccatctctac	taaaaatata	aaaaattagc	cgggcatggt	gatgggcacc	1920
tgtag:ccca	gctactgggg	aggctgaagc	aggagaatgg	cgtgaacctg	ggaggcgga	1980
cttacagtga	gccgagattg	caccactgca	ctccagcctg	ggtgacagag	caagactctg	2040
tctcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aactcgta			2078

<210> 62
 <211> 762
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (10)
 <223> n equals a,t,g, or c

 <220>
 <221> SITE
 <222> (12)
 <223> n equals a,t,g, or c

 <220>
 <221> SITE
 <222> (42)
 <223> n equals a,t,g, or c

 <220>
 <221> SITE
 <222> (219)
 <223> n equals a,t,g, or c

 <220>
 <221> SITE
 <222> (747)
 <223> n equals a,t,g, or c

<400> 62						
cgagtcagtn	ancgagaaa	cggaagagcg	cccaatcgca	anccgcctct	ccccgcgct	60
tgcccgattc	attaatgcag	ctggcacgac	aggtttcccg	actgaaaagc	ggccagttag	120
cgcaacgcaa	ttaatgtgag	ttagctcact	cattaggcac	cccaggcttt	acactttatg	180
cttcgggctc	gtatgttgtg	tggaaattgtg	agcgatatnc	aatttcacac	aggaaacagc	240

tatgaccatg attacgcca	gctcgaatt	aacctcact	aaagggamca	aaagctggag	300
ctccaccgcg gtggcgccg	ctctagaact	agtggatccc	cggggctgca	ggaattcggc	360
acgagcacia atgcttatac	aaaacttttt	tccatgtcct	caatactttg	tatcagatta	420
tctatatttc tcatgggttg	gtttcttttt	cttgccttca	ttttctgaa	ggtaaaagg	480
gattttttcc cccctttct	gatctgtaac	ttgttttga	tttggatgat	tacaggcggtg	540
agccaccgcc tccagccaca	aatacttttt	agtcgccata	agcataatca	agaaatcatt	600
ttgcaaatgg taagcttttc	atgttggtga	ttctttccca	tgattagaga	ggtaaaaagt	660
gscctgggat gcataaagat	gtcgtagacm	tmtgcaatct	gccacattat	ttctttaaaa	720
aaaaaaaaa aaaaactcgag	gggggggacg	gaaccaggcg	cg		762

<210> 63
 <211> 1094
 <212> DNA
 <213> Homo sapiens

<400> 63					
tcggcacgag gtcaatcaag	tgaaatatca	tgtaactgt	ccagcagctt	tgaaagttaga	60
gaatgaacaa gggcccttcc	ccacccaccc	tggtgaaagc	ccgtctgtgt	tggtgtccctc	120
ctggacagcg tcttgccggt	cacctttggc	catctcccgg	tgctgtgttc	agatgtgggt	180
cctgtcttcc tggccctccc	ctctctgtgt	ctgtcctgcc	tctgtgtgtc	cgggccagtg	240
ccttggtggc cagtggagtg	gacaccagct	gagactgtct	gggaggggct	ggcatttgccg	300
ctgccactgc agggcttggg	cggctgacat	gggacgaggg	ttgcacagct	gccagctcct	360
gtctcgtgta ctttttttat	acagttttgt	ctgggccacc	gccttcagtg	ccacggggccc	420
cttgccgttc aggtctgtcc	tcatagatga	acaaggccct	gccccgtgtc	cttacccttt	480
agagctgttt aaattcaaat	gaactgaaac	tgaatatgaa	aaatccaggg	cctcagccgc	540
ccaggccatg fttcaagtgc	tccatggcca	catgtggctg	gtggacagtg	cagctctaga	600
acattccatc accacagagg	gttctgtctg	acagtggcct	tgggggctgt	tttgagggtc	660
cgcctgtcag tctccgggca	tcaaagtcat	tctgccattg	tcaagttaca	gttatcttcc	720
ttttacctcc aagccactat	gtgcgtatgc	tgctatgtgt	ctgtatttcc	cgtctaaactt	780
cctgtcacgg agggaaagggt	gccacagggc	cagctccctg	aggggggttg	gatgtctggg	840
tggggggaag ggtgccacag	gcccagctcc	cggagggggt	ttggatgtct	gggtgggggc	900
cagggcgcca cagttccagc	tccggagggg	ggtttggatg	tctggggcggg	gctttcttca	960
tgttccatgt atgataacgg	tgactggggg	gtttacagag	agagggcatac	aaatagtgtt	1020
ggagtgtgtg tttcgttaat	ataaatgttt	gaataqctaa	aaaaaaaaaa	aaaaaacctcg	1080
agggggggcc cgggt					1094

<210> 64
 <211> 1361
 <212> DNA
 <213> Homo sapiens

<400> 64					
cccgggtcga cccacgcgtc	cgaatttctt	tagtgtattt	tatgtacttt	tgtattaatt	60
acattgggta gactgttcca	taaatgtrga	atagataccta	tttgttgggt	aatgtcattg	120
ttgtgtatcc tgggtatttt	ctgtgtagtt	ggctctacag	ttgttgggag	aagagtgttg	180
aagtctacaa ctataattgt	gtalltgtct	attactcctt	tcagttcttt	cagttccatt	240
tcacatattt tccagctctt	gattgggtga	cattaatgat	tactatgtct	tcttgggtgaa	300
tagaccattt tataatttta	tgatgtacct	ctcttgtcac	tttcttgtct	ctgaagtcta	360
cctgatatta atatagtcac	tctagcttcc	tttggagtaa	tggtagtgtg	atatactttt	420
tttcgtcttt ttacttttaa	ccctatctat	atcattaat	lattttaagt	gagttttttg	480
tagatagcac ttacttgtgt	ctgtcatgtt	tttaaatcca	ctgtacaagt	acaaatctgt	540
ctttattttt cttttttatc	cttattttga	gacagagctc	cacttttgaca	ctcagcctag	600
aatgcagtgg tgtgatctcg	gctcactgca	acctctgcct	ccgaggggtca	agcaatcctt	660
tcacctcagc ctcccaagta	gctgggagta	caggcatgaa	ccaccatgcc	tggtcaattt	720
tttttttttt tttttttgta	gagatgggga	tttaccatgt	tgctgaggct	ggccctggaac	780
ccctggggtc aaacgacctg	cccagctcag	cctcccagag	aaatatgatt	ttaattagca	840
catttagatc atttactttc	aatggaatta	ttgatgtatt	acaattcaag	tctgtcattt	900


```
tatttattgc ctccatttt tccctccgtt ttccatttct gtgctttttt tctttgcatt 960
taaacatgtt ttaggattct gttttgatgt atttagagta ttttttagtg tatcgggtta 1020
tgtagctttt ctagtggatc ctttaagtat tacattatat atacataact aagaagtata 1080
tcagtgtcat cttttacca gttcaagtaa agtacagaaa tctttgtccc ttttacctgt 1140
cctgcttata atgtaaatgt ctttaagatt tccctgacac acatttagaa ccatatcaca 1200
gtgttgtttt tgcctcagtc gtgaaatata atttagaaac tcatgagaat aaaaaccat 1260
tatattttat tataaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa aaaaaaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa agggcggcgc c 1361
```

<210> 65
<211> 947
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> n equals a,t,g, or c

```
<400> 65
ctttctatag ttaaagccgg tacgacctga ggtaccggtc cggaaatccc gggctgaccc 60
acggctnccg tttctgggtt ctaggccctg ctcccttgcc cctttgctgc agaagggcag 120
ctgaaggctc accctagaaa ccgggacctg tgggtcttac ccggctcact cctccctctg 180
tccttacaca tacaggaaga caagacctga gtggtgctgt ctttgtgtcc gtcgtgtatg 240
gtcttccctg tcttcatttc ttctcactct gtcctataac ctctctctct cctccctccc 300
cctcagtaac tttctacag acctatgtgc gtggtccctt ccttctgtcc ttttctctct 360
tcagctctcc ctgctctcca cacacaattt tacatgcccc gaggagccaa gtttgggaca 420
tttaccctcc aggcattctg gtccctctct gaagagaaaa cacacagctt cacacatcca 480
ggcatagggg gcaagctctt ggggcatcag gacctggag caccaggctc tccctggaat 540
attagatcca cctggagcac caggtctctc taagtctcac ctggggaatt cggctccacc 600
tgggtcacca gtccccacct agagcactgt gtccctgccc agagcacaaa gacctgctcc 660
tcccgagact ctctctgact gcagccagc atagtacct tgcctgtgtt tgcctccctg 720
tccacagatt tgggtggctg gcaggtgccc ggacagtgt gaggtcttgc cgccttaact 780
gtccccccca gtcaattctc ccacaggccc agcaggagc agtcctgagg atcagggatt 840
ctacagctgc attaaaatca atcctatcca aaaaaaaaaa aaaaagggcg gccgctctag 900
aggatccaag ctacgtacg cgtgcatgag acatcaagct ctgaaga 947
```

<210> 66
<211> 1376
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> n equals a,t,g, or c

```
<400> 66
ggcgggcgcc gcggaagngg nggckgcgcg gccggggcag ccatgtcgcc attgtctgcg 60
gcgcggggcg cctgcggggt ctacgcggta ggcccgccgg tgatcctggc gcaactgctg 120
cgggcgctgc gcggggcgct cctggagcca gttytcccc caccacctga ccgtgtcgct 180
atagtgcagg gaggagacaga tggcattggc tttctctacg cgaagcatct ggcgagactt 240
ggcatgcatg ttatcatagc tggaaataat gacagcaaa ccaaacaaat tgaagcaaaa 300
ataaaagaag aaactttgaa cgacaaagtg gaatttttat actgtgactt ggcctccatg 360
acttccatcc ggcagtttgt gcagaagttc aagatgaaga agatccctct ccatgtcctg 420
atcaacaatg ctggggtgat gatggctccc cagaggaaaa ccagagatgg attcgaagaa 480
catttcggcc tgaactacct agggcacttc ctgctgacca accttctctt qatcacgctg 540
```

```
aaagagtctg ggtccctctg ccacagtgcg aggggtggta ccgtctcttc tgccacccat 600
tacgtcgtctg agctgaacat ggatgacctt cagagcagtg cctgctactc accccacgca 660
gcctacgccc agagcaagct ggcctcttgc ctgttcacct accacctcca gcggctgctg 720
gcggctgagg gaagccacgt gaccgccaac gtgggtggacc ccgggggtgg caacacggac 780
stccacaagc acgtgttctg ggccacccgt ctggcggaaga agcttctcgg ctggttgctt 840
ttcaagaccc ccgatgaagg agcgtggact tccatctacg cagcagtcac ccagagctg 900
gaaggagtctg gtggccgtta cctatacaac gagaaagaga ccaagtccct ccacgtcacc 960
tacaaccaga aactgcagca gcagctgtgg tctaagagtt gtgagatgac tggggtcctt 1020
gatgtgacct tgtgatctcc tgtctcagga tagctgctgc cccaagaaac acattgcacc 1080
tgccaatagc ttgtgggtct ggaagactg cgggtgttga gtttctcaca cccacctsc 1140
cacagggctc tgcctcttag ttttgagaca gctgcctcaa cctctgcaga acttcaagaa 1200
gccaaataaa cattttggag gataatcacc ccaagtgggc ttcaaccata aactttgtga 1260
ttccaaagtg ccagttgttc acaggtgcca taaataatta cattttccaa cataaaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc ggccgc 1376
```

```
<210> 67
<211> 2434
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (27)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (73)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (75)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (103)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (130)
<223> n equals a,t,g, or c
```

```
<400> 67
ctgggggtan tncagaacc ctctgtngga cttagatgac aagctcttcc ctttgggcag 60
cgtgtttcct tctnecagat agtggtgctgt gtaaaactaaa ttngccggtt cgtcttccat 120
```

```
ttcctgacan ttgagatgga atgccttgac cattgggtgct ctgacagaga agtcatggag 180
tcattgccat ttcctgggtg ccctttttgga atgtgacccct gttagtagag gttttctagc 240
ttctactaag atacttcttt ccctaaccat cctacacttg gcatgtttca tccccatctc 300
ctttcccttc accttaaagg agactacccc ttgtcccccatt attgtcaacc taattttctc 360
tcgtactctc tctagtgaat gatgtgctac caagtatatg ccaggcctgtg agaggattat 420
actgagtagt agaaagaagc taatttgaaa taaaaattat ttgtataatt aagaaagcag 480
attagatgca catggtcaac aggaagttag ctgtatgtct gctagttaga ttcaaacat 540
cataaagatg atagcatgtc aatataattag cctagccatt atgttagcct ttgttaggtg 600
ggcagctttt ctgctttttc ccttctctctg tggtagacaac ggaggaaaata tccaacagaa 660
acagctctaa cagggaaattt gggatcatag ttatatgca tctgatttga aaggagtatt 720
gaggaagggtt ttcatatatg atctatcttt ggattaaaaa gaacatttat gaaatcaagc 780
cttctaacac tagttataat tgagaagcaa cagttaactcc gtggacagca atcaagctta 840
aaattgtaaa taaatatggg gataattcag ttgttgcaaa aaaagggcag aattcagtag 900
aataaagtcc ttttctctta cagggtattaa atgaggacag agaacctcag gtgttcttat 960
gctagtgtct gctgagtgc aactaagaaa gcaattccaa atagatgtat acatctagag 1020
agagtgggtat tagagattca gtgtatgtat ttatttacct gagaggaaac tggaaatata 1080
tcccataaat tattggaata taatcccata aattatcacc ttttatgact ggaaatatt 1140
tgccaatgaa gaaatgggtct gtagggtatt gtcttaagat ttttggctgt ttaataaaaa 1200
tgtaacttta acgggttctt atagttgect ttataaagtg tattgtctaa aatatttttt 1260
tatcatgtgc ctttgaattt tgacagctga ttgggtgttt ggatttctgc ccagccattt 1320
atcagtatta tcaattttat cagttagctg cagggtgtatt agacaaacga gacttaggta 1380
aggaatggaa cctttctctg ggtttgactg cacatcacac cagaagactc cagtatccct 1440
cattccagaa tgaggaaaaa gtattctaca aagaacctaa tcacctctgt gaaatctatg 1500
ggatggaaac agtgtggcct taggagtcac atagtctctg catggtgggg aggatcatga 1560
tggaaatatg gaatttctac ctctagaagt tgtgaaatag gtccctgcact ttgcagaat 1620
gtccttcttt aaacctggct tattccacag ctgtagtgtg taacatgacc tggggcttag 1680
ctgtcttagc cctgggttct tcgaacacct acactgcctg gcccttggcc atccacctaa 1740
ggactgcctg ctttctgttc acatgtggac cttgatacga ctaagcgggt acatatgtg 1800
ttgtgcaaaa gctttctgtt taatgcctag tgttaccgat ttacatcttg gttttcagtg 1860
gcactatgtc taggaggcaa tatcctttta aacagtgtt tggctaagat agatatttgt 1920
gaatcaaaag tagcacagaa atgaactaag tatatccat ttggaattat attttgatac 1980
tatttataat ggtttcacct gttaaagggc caacgaacct cttgggtttta cttttgtaat 2040
tactgtacag aaattttcaa gagtgtttga gtgctgtgca tcagggtgtt tcccttaata 2100
gtaggatgat gatcatttac aggaattata tatgaaaaaa gtttttgaaa tgtatttttg 2160
tgatgtgcta tgttgagggg aaaccaataa tttatgattt taaaacattc gtatgaaac 2220
attgtacaat gtaatatgct caactttctc aattttttgc taatttttct aagatacatt 2280
aaaaatgttt tatatttttt tttaagttaa atggaccag taagaaaaatt aaaaatacca 2340
gaacataaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa 2400
aaaaaaa aaaaaaaa aaaaaaaa aaaa
```

```
<210> 68
<211> 1086
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (77)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1056)
```

<223> n equals a,t,g, or c

<400> 68

ttgaaacacn	cttttgagca	ttaggtccca	gtccaccgc	ggtggcgcc	gctctagaac	60
tagtggatcc	cccgggntgc	akkaattcgy	cacgagcaac	ctgtagttag	ttggctgtca	120
ctcagcagct	ctggaaaatt	acctgtctgc	actgaatttc	ctcatcagta	aaatggaaat	180
gattatagta	ctgacctgtg	aggattatc	taaaaatcag	agaagttcat	gcagcttaga	240
acagtggcag	gcacatggna	aatgctatgg	catacttaag	catcttcttc	tgtggtgcct	300
cgatcatccc	atgtgattgt	gccttgcttg	tccctgttcc	acttttcaga	gggagaaaag	360
tggcccaactt	taagaatcaa	aattctgatg	ttacttcggg	aaatgcatag	agccagagag	420
acacaatttg	acttagtatg	atccacatca	ccccctcagg	ctgaatagtg	gtggcatgca	480
catctatacc	aaaatgtttt	accttttttg	tagaaggaaa	atatttgat	ctctatttcc	540
atatcttaga	tctttataag	agcacttaag	ttcaacctcc	taagaaactg	ccaattttgt	600
tgatcatgat	agtcctgcaca	gattttcgtc	ctatttagtg	ktgggagtg	cttagggacc	660
atcaacaaca	ggsccttctt	tttatccatg	agactactga	ggccttgtag	gttatttgtc	720
catccatggc	gggtgcacrg	ctagaggtta	tctggttagt	agcccaacta	agattagaac	780
ccaggaaattt	tgatttaatc	tcaaatgacc	tcttttattt	ctgcattccg	gaaggagaa	840
aggaaagtaa	acgggaaatt	catgttatct	atggaaaagt	tatcagtttg	atgtttatta	900
aatgatttgt	ttcaggagat	tgtttacaac	ttttatcttc	ctagacaata	attttctgta	960
agagtaaaagt	catgggtcatt	aaggtagtca	tattaatgta	ttcagtaasc	tgtgaagaaa	1020
aatatataatc	aatgttttcc	aatcaaatac	agtgaatacc	tgaaaaaaaa	aaaaaaaaaa	1080
aaaaaa						1086

<210> 69

<211> 1262

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (568)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (639)

<223> n equals a,t,g, or c

<400> 69

ccttctatag	gkmaagctgg	tackcctgca	ggtaccggtc	cggaattccc	gggtcgaccc	60
acgcgtccgc	ttacaacttc	tcttctgttt	ctgtgtttct	tccacaccat	tatggcgat	120
ttactgatct	acaaccgggt	ttaagctagt	tgcttgccta	aaattttctc	atgaattctc	180
attacatttt	caaacaaaa	ccaaagtttt	taccatgacc	ttgtgyatat	ctttctgacc	240
tcatttacta	ctgttatctt	ccttattcat	tccattccac	ccacagtggc	cttcttgcaa	300
gtcagagaat	gcaacaaata	tgctcctgce	ttggggcatt	tgcaattctg	ttcttttggc	360
ctggctcactt	cacctccaca	ttctccattt	tttatgactt	tcttctctata	tttggatctc	420
tgttcamaatg	tcacctctca	aaaaggcctt	caaaactacc	ctatttataa	tagcacctgc	480
cactgccatc	tccataccca	ttttcatttt	tccatagcac	ttatccctac	ttggcattat	540
gttatatatt	tgtttatttg	kttactgmct	gtctcccca	ctggactgta	agctccatga	600
ctgtaagtac	atagatgaat	tacaaaatga	atcaatggng	aawtatccct	gmcatatatt	660
atttaaatgat	tttgmtcca	rttraaagtaa	aaaaaaaata	ccattttttt	cactcttcaa	720
agtgatatag	tttaattctc	taaaactacat	ttttctcatt	tcccgattta	attaaatcag	780
tgatataaaa	aaaagagtga	tggggatatg	tgaaagaaga	ctaaaataga	tgccaggaaa	840
tactaaaaact	gctgaagttt	agtggtatat	tttttcttta	cacacagtat	tatttgagtt	900
actaattgtg	tcactgaatt	acaaataaag	caaaatacta	ggtaaacaga	atcacgcttg	960
ggggctatat	tttgtgtaaa	atttgtgtta	tgcaaaaata	atattaaata	tttaattact	1020
acagttttgt	tatttctctc	ttattttagg	aaatgatttg	cagctgagtg	aatcaggaa	1080
tgacagctgat	gactgaagaa	atatylauet	ataaataaaa	atttatatag	catgtataat	1140

```
ttattttgta ttaacaataa aaattcctaa gactgagggg aatatgtctt aacttttgat 1200
gataaaagaa attaaatttg attcagaaat ttcaaaaaaa aaaaaaaaaa aagggcgggc 1260
gc 1262
```

<210> 70
<211> 1642
<212> DNA
<213> Homo sapiens

```
<400> 70
ggcgcgctgc cgggarctgc ctgggttgcg ctgccggcca cgtcccccgc cggggcctca 60
ggctccttcc tactgtccga gggccaccag gccgcggggg gccctgctgc cccggatgcy 120
tctgttacta gactggagag tctaccttcg cctcacatgt gccacaaagg atggcatggc 180
ccgggagtgc ccaccacgyl ggttttcaac ccttgcaaaag ccagacttcg cccagcgaca 240
cagtgtcaag ccacagctc tccaaggagg aagatgggtcc aggtctgggg catcyctta 300
gcagcagcct ctgatccctt ggcacaagcag gagggaaacca ttagcagcct gaggagctgg 360
ctggctggga gcttcgggga ccgcccgacc ttgctcccag ctcaccaca agatgtggac 420
agctcttggt ctcatttgga ttttctctt gtccttatct gaaagccatg cggcalccaa 480
cgatccacgc aactttgtcc ctaacaaaat gtggaaggga ttagtcaaga ggaatgcac 540
tgtggaaaaca gttgataata aaacgtctga ggatgtaacc atggcagcag cttctcctgt 600
cacattgacc aaagggaattc ggcagcccam ctcaactcta tggaaagtac aacagaggac 660
acaagcagga cagatgtgag tgaaccagca acttcaggag gtgcagctga tgggtgtgac 720
tccattgtct ccacggctgt ggcctccagt acgactgcgc cctccattac gactcgggcc 780
tccagtatga ctgtggcccc cagtgtctcc acgactgcag cctccagtac aactgtggcc 840
tccattgtct ccacgactac agctctcagt atgactgcgc cctccagcac tcccatgaca 900
cttgactctc ccgcgcctac ctccacttgc acagggcgga cccctgccac taccgccact 960
gggcatccat ctctcagcac agcctctgca caagtgcga agagcagcgc gttgccaaga 1020
acagcaaccc tggccacatt ggcacacgt gctcagactg tagcgaccac agcaaacaca 1080
agcagcccca tgagcactcg tccaagtcct tccaagcaca tggccagtga caccgcggca 1140
agccctgtac cccctatgck tccccaagca caaggtccca ttagccaggt gtcagtggac 1200
cagcctgtgg ttaacacaa acataaatcc acamccatgc cctcaaacac aaccmwag 1260
cccctaccc aggcctgtgt agacaaaact cctctctgg tgggtgtgtt actcggggtg 1320
accctttca tcacagctct ggttttgttt gccctgcagg cctatgagag ctacaagaag 1380
aaggactaca ccaggtgga ctacttaac aacgggatgt atgcggactc agaaatgtga 1440
ggggggcggg ggcctggcgg gaggcctggc ccttctctg tctttcctt ttgctttga 1500
gaccaaacca agtgcctcca aattcttttg gtgcaattga ggagatatgc cagatgctta 1560
aacacattta attgctgtca gattaatcc atgatcacta aagagttgct gcttttttca 1620
taaaaaaaaa aaaaaaaaaa gg 1642
```

<210> 71
<211> 921
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (11)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (901)

<223> n equals a,t,g, or c

<400> 71.

gcgnggggna	naggnaagcn	ccccactatt	gggttcaaaa	gctggagctc	caccgcggtg	60
gcggccgctc	tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	aggctctgagc	120
agataagatt	aagggtctgg	tctgtgctca	attaactcct	gtgggcacgg	gggctgggaa	180
gagcaaaagt	agcgggtgct	acagtcagca	ccatgctggg	cctgccgtgg	aaggggaggtc	240
tgctctgggc	gctgctgctg	cttctcttag	gctcccagat	cctgctgata	tatgcctggc	300
atttccacga	gcaaaggagc	tgtgatgaac	acaatgtcat	ggctcgttac	ctccctgccca	360
cagtgagggt	tgctgtccac	acattcaacc	aacagagcaa	ggactactat	gcctacagac	420
tggggcacat	cttgaattcc	tgggaaggagc	agggtggagtc	caagactgta	ctctcaatgg	480
agctactgct	ggggagaact	aggctgtggga	aatttgaaga	cgacattgac	aactgccatt	540
tccaagaaaq	cacagagctg	aacaatactt	tcacctgctt	cttcaccatc	agcaccaggc	600
cctggatgac	tcagtccagc	ctcctgaaca	agacctgctt	ggagggattc	cactgagtga	660
aaccactca	caggcttgct	catgtgctgc	tcccacattc	cgtggacatc	agcactactc	720
tyctgaggac	tcttcagtg	ctgagcagct	ttggacttgt	ttgttatcct	atcttgcatg	780
tgtttgagat	ctcagatcag	tgttttagaa	aatccacaca	tcttgagcct	aatcatgtag	840
tgtagatcat	taaacatcag	cattttaaga	aaaaaaaaaa	aaaaaaaaarct	cgaggggggg	900
nccggtaccc	agggcggaag	a				921

<210> 72

<211> 906

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (833)

<223> n equals a,t,g, or c

<400> 72

ggaaaattctc	cctcactaat	tggaaacaaa	gctngagctc	caccgcggtg	gcggccgctc	60
tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	agggagagag	gaggggaggg	120
tgagcagagg	acaggccggg	agttttccgg	gaacggagga	agagcagtgg	aggctgccag	180
gatgaggctg	ctgtgtggcc	tgtggctgtg	gctctccttg	ctgaaaagtc	tgcaggccca	240
gaccccaacc	ccccctgccac	tcccccccc	gatgcagagc	ttccaaggaa	accagttcca	300
gggggaatgg	ttcgtcctgg	gcctgscggg	caacagcttc	agggccggagc	acaggccgct	360
gctgaacgct	ttcaccgcaa	ctttcgagct	aagtgatgat	ggccgctttg	aygctgggaa	420

```

tgcgatgact cgaggccagc actgtgacac atggtcttat gtgctgatac cggcagccca 480
gcctggggcag ttcaactgtg accacgggtg gggcaggagc tgggtgctgc ctcccgggac 540
gctggaccag ttcatctgcc tgggcagagc tcarggcctc tcggatgaca acattgtctt 600
cccagatgtg actggargtg ccttggacct carcagcctg ccttgggtgg cagccccagc 660
ctgaccactc agacagcgcg ggcceccaag gcctgactct tcttgggtga gggcgaggct 720
ggtcacccca ggccagcgtc tgttgaagga tgaagcagct cctgtccggc ccagccctgc 780
ctcacagctg tgcgagctct gccctctca gctctcaaac ctgaataaat gcnccaagcc 840
cagaaaaaaa aaaaaaaaaa aaaaaaaaaa ctcgaggggg ggcgccgtac ccaattcgga 900
agattg

```

```

<210> 73
<211> 680
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (7)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (16)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (22)
<223> n equals a,t,g, or c

```

```

<400> 73
cactcantng aacannagct cnagctccac cgcgggtggc gccgctctag aactagtgga 60
tccccggggc tgcaggaatt cggcacgaga tatttcgctg gacccataga aagccaccac 120
gacctgtggg ccatgatgct accccaatgg ctgctgctgc tgttccctct cttcttcttt 180
ctcttctctc tcaccagggg ctcaactttc ccaacaaaat acaacctttt ggaactcaag 240
gagtcttgcg tccggaacca ggactgcgag actggctgct gccaacgtgc tccagacaat 300
tgcgagtcgc actgcgcgga gaagggtccg gagggcagtc tgtgtcaaac gcagggtgtc 360
tttggccagt atagagcgtg tccctgcctg cggaacctga cttgtatata ttcaagaat 420
gagaaaatgg ttagcatcgc ctatggccgt tgtcagaaaa ttggaaggca gaagtggct 480
aagaaaaatgt tcttctagtg ctccctcctt cttgctqscd cctctctyct caccctgctc 540
cctccctacc cagagctctg tgtkacnct gtccccaga gcctccacca tgagtggagg 600
gaagtgggga gtgattgaaa taaagagctt tttcaatgaa aaaaaaaaaa aaaaaaaaaa 660
aaactcgagg gggggcccg

```

```

<210> 74
<211> 1633
<212> DNA

```

<213> Homo sapiens

<400> 74

ggcaccgagca	tcagtaagta	ggagctaggg	aagagaaagc	atgcaaaaagg	gcaagaatca	60
ggagaattga	tatagtagct	ggacagaact	ctagatgtgt	gtgtgtgaga	gaaagagagg	120
caggggagaag	gagggaggag	ttaccccccac	gatgacctcc	aactccctt	tctgcacct	180
catccgggg	atagcacagg	ctcaggcctg	ccctgggtgc	cctggcgatt	ggcctggcct	240
gggctcaggg	gtgggggagg	ggctgcacca	cattaggacc	tgccgtactc	caatcccatg	300
cagtcctctct	gctcctgttg	ctgctgtgct	gggctctggt	catgccaggc	ttcctgtgt	360
cctgcgtctg	tggccgggtc	ctgccaacct	gtctagtctt	ttcagggttg	aggccctgca	420
ttgctctttc	tggtcctctc	ccctccttcc	cgctcccat	ctagcctttt	ttgggttccg	480
ggatctgctg	acagacttct	ttcttgctgc	ctgctgtgct	acatttcaga	agacctctct	540
ggaactgccc	atggctgttg	tccacctgct	ggtagcaacg	ccctgttacc	aaatgctaga	600
taactctgcca	ctccctctct	cagccgcca	ctgggtctga	gctgccacct	gttgtctgtt	660
tcacacacct	tgtacactgc	attctgctct	tcactctgga	cagctgcccc	gcagctgcag	720
ctgaggccgt	cctgccagca	cctaccgcag	ccccatgggt	ggctcctgtc	agttccctggc	780
gctcccagcc	tgctctatct	gctgtactta	cagagccaca	tctggttgaa	tacagagctg	840
gggtagcctg	gatgggcccc	tggcacactc	actcccagag	aggcgggcat	cctctctctg	900
gacctctagg	gaagggcagg	gtctggagcc	caataataaa	acacagtaat	gataatcata	960
gctaattgtt	actgagaact	taggatgtga	taggctcaat	gatttaccag	aattactcta	1020
tactgcataa	ctacctctat	aggttaagta	tattaatatc	ccctttccca	catgaagaaa	1080
ctaaggctaa	ccaataqaaa	tgaacctgtc	taattgtcca	tgggcataat	tcattggagcc	1140
aggattcaga	accaggtgct	ttacttcagg	gctgaagctc	ataaccacta	gaccaaagcg	1200
cctctcctgt	gacctctggg	gaaggccag	caacatctct	tattgctgct	aatgacttct	1260
ccctggctct	agatccactg	actcacaggg	gtagggttaa	ggttaaggcc	agagtctcag	1320
ctaaagcttg	gatactttct	tctggatttg	gagaaggctg	gaataactga	atttctgtct	1380
atcttcagga	gcggcctact	agagccacac	atttcccagc	tctctctgtg	tggttcccag	1440
accctctctc	catcgtgtcc	tcctccctag	gctcctggaa	agttttcaga	gagaatcacc	1500
cagtggtaac	attgttaaac	aaaacaggaa	aatgggactt	gtgtgtatat	atgattaaat	1560
tattaattga	tggatctacc	ttcttagctc	gtgccgaatt	cgatatcaag	cttatcgata	1620
ccgtcgacct	cga					1633

<210> 75

<211> 1022

<212> DNA

<213> Homo sapiens

<400> 75

ttcccgggtc	gacccacgcy	tccgcccacy	cgctccggtt	ggggccagca	ccctgtctca	60
aagatggcaa	aatgaggcta	gttctggatg	agctagctgg	tgtgggttcc	aacctagga	120
acacactgat	gctcaaatcc	taaggtgcca	agctctaggg	cctggaggct	ggtagaacag	180
gatctatgcc	tggaaatcctg	gcagggatcc	ctgtcaagga	cttgtgttta	agcctgcttc	240
agggcttcag	gctgtctctg	ctctgtgtct	gcccaggctg	gctgagcgyy	tggatgggtg	300
gacagaaggg	ctcaccacgg	attgtggaca	tagggtaggc	cctggtacca	cgggtttcag	360
gctgttatca	cttcccttgt	aggaacatag	ccagaagcag	atgagccagg	gtagagggt	420
ggcccctcct	ctcactctcc	cttcagttct	aaattgtctc	cagcgatggg	aagaggccag	480
ggactataac	ccttgtgctg	tgtattctct	gagcctctgc	tcactctcag	ggccaagcac	540
ctcccagacc	ggggccctct	ctggccaaa	atctgaggag	cagtctaggt	tacaggcttt	600
ttggtacgta	gggtcttggt	gctgttaaat	gcagttaggg	ccccgatta	ggtacagtga	660
gaaacaagct	agaacaaccc	tggccagaaa	gactgtgcac	tccagcaaga	tccagggatg	720
atagccttgc	agggccactg	ggagttttgt	cccaagnttc	tccctcttct	ctccccaggg	780
ggcactggga	ctggtccctg	ccctcactct	tagcctgggc	cttccccaga	ggatataaag	840
agaagtatga	ttcctctgtc	ttcagttctt	ttcaggggca	tcctgcccac	agtaccaggt	900
tcccaagggg	ccccagtgca	cgtggtgaag	cctagcactc	atgcagctct	tagggaaacca	960
aaaaccagca	ctgaaataaa	gctgaatgac	tgactcaaaa	aaaaaaaaa	aaaggggggc	1020
cg						1022

<210> 76
 <211> 1184
 <212> DNA
 <213> Homo sapiens

<400> 76
 agcaaaaggc gaagagagaa aggaagcttt ttctctaaaa atggtgcagc tatcctctga 60
 accaatttcc ttccggtttaa tctacctgta tcttgggggt tttttccact taatttatcc 120
 tggagctctt tccataacaa cacttggaaa gcactctcat ccttttttca ctgctgaaca 180
 gaattccact gtgtggatgg aacatactct atttcaccag tccctctgtag ccagtcactt 240
 ggtttgttcc caatcttttg ctllttcaga gtaataacct tgtatgtcta tcatttgtta 300
 tgcatacagg ttatatgtta ggaataattt cttagagtagg attgctggac caatggataa 360
 aagtatattg tggacagaca atgccaaatt gccctttcaga gactgtggcc ctgtgcaccc 420
 catcaggcat gtgtgactac caaagctcct gtcagctgtt ttattttatc tctttccag 480
 tctcaggctc aatgcagAAC tttgaggtaa gcttttctaa aatgtaggct cctaaacgcc 540
 acagccagct ctgccacatg aaggagagc: caaatgagac agaaacagcc tctgggcagg 600
 atttctatcc tgcacagata tattttccac attctgggaa accgtgaagc ttccagagcc 660
 acaattcccc agaaacacat cccctgctg gtacagccaa gccccagaac aagctgtgct 720
 tgcctggcag ctcaagcca agcaccatgg atgccacttg ccatgggtgc ctgcaatttc 780
 aaataatgag aaataagaaa tttcagcttc tcagtccttc tagccaacat ttcagggtga 840
 tgaacgcttc aggtggcagc cagctactct gccggacagg gcagaagatg gaacacccca 900
 tccctgggga agatcacgag gtcaggagat caagaccatc ctggctaaca caatgaaacc 960
 ccgtctctac tgaaataaca aaacattagc tgggtgtggt ggcaggcacc tgtagtccca 1020
 gctactcagg aggctgaggc aggagaatgg cgtgaacctg ggaggtggag gttgcagtga 1080
 gccaaagatg cgcactgca ctccagcctg gcaacagagt aagactccat atcaaaaaaa 1140
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1184

<210> 77
 <211> 312
 <212> DNA
 <213> Homo sapiens

<400> 77
 aattcccggg tcgacccacg cgtccgtgat gaggggattt gtactcttac ccaggtcctg 60
 agggccagcc caccagcat ccccaccct gatgacgctg tccctacaac tggctgaact 120
 ggtgcatctt gtgtgtgctt tccagagcca gtggactggt gtgtatccaa tgaatgcacc 180
 tctgaaacct acagaaccac ta-gctttgc atgtgtaccc tgcagggtct gaggggcagg 240
 ctgtctggta gctctgtcc tgggtgacag agcaagactc tgtctcaaaa aaaaaaaaaa 300
 agggcgggct ct 312

<210> 78
 <211> 1370
 <212> DNA
 <213> Homo sapiens

<400> 78
 tgggttaaaga gtacgacatt ttagtcaggc ctgagcacag cgcctgggctg aggagtgcct 60
 ttatatgtcc ttggaagtat atggggactc catttctgtc actgtggcga ttcacttat 120
 gcattcacca tgcgaatcca aggcagctga tggcttagga aagtcagaga ctgagatgtt 180
 aaaaatcctt gggctatcta ccaacatgtc tccattccac ctgttagggt taaaggtttt 240
 tctaaccttg gccctgacct tagcacagat ctgcctatat ttttttgaag ttcagccac 300
 tggactatta gccctaaact ttttctgtac tgcactgca gggctgaagg agctttgcat 360
 gcacccacca agtctggctt tcacacctga atttcacacc tgcctttcac ccttagctat 420
 tccatcttct tgtggaacat cagtgtcact tagcaatagc catacaatcc cattatcctt 480
 atacctacct ttcccttcaa agtcctggat gctgataca ttgcacctgc tagtgcatte 540
 actcccatta gtacactccc aagtccttcc agtgaaagat gtaacaattg aatggccact 600
 ttgccaaggy tgcctgggct ctacctgcca ccagtgtgg ggtcctcaca gccacccag 660

```

tggtgtatca tccatttcca aaaccatctc amtgcctggt ttcttggacc actcctggca 720
tcaactgttt cagggttagag tgaactgaaa ttggggttat aagatattta ttagagatca 780
atatctatta aaaaatgcaa aggaagcagg attktgtctga ggaagaagat aacaacaaag 840
ataccacaat gtcagcccat caaagccttt ggccaacca gcaaaaaaat ctggagcagg 900
tgtayctttt tcagagtctc cccagttagg tcaaaatgtg cgcctttaca cccgcacttc 960
cctcaatcac gggtttcagg ctgtcctggg catgacctca gatgaagcgg ctccacacgc 1020
tgaggctaac gttgtgggag ctgacagctg aaagccgttt gctgaccaca ctcccacagc 1080
cgagcagcat gcccttgctt ggaggagat ttggatgaca cagctctatg tctgccgtat 1140
tttgggggtc acatttctca caccagctc tgccctaaa ggcaacattg acaaaaaattc 1200
attccagttg caaaccaatt gtagaatact ataaaaccag agtacaagtc taatagcata 1260
aatctcctcc taagtggaaa agaaagggtc atttattcac acatttttgg ggaaaaaaaa 1320
acaaccttgg ctatgtcttt attacaacac ggatactcac aaaaaatagt 1370

```

```

<210> 79
<211> 368
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (13)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (351)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (367)
<223> n equals a,t,g, or c

```

```

<400> 79
aatgnaactc tcnttactaa ttggaaccaa agctngagct ccaccgcggc ggccggccgct 60
ctagaactag tggatccccc gggctgcagg aattcggcac gaggtccagg tgtctttatt 120
tcagatgttc tgttttttct ctattttctg ctccatgaa catacacact tgccaggcac 180
attctggctt ttcttatttc tctttctgat ttgctctct tcctgccctt gttttcttcc 240
cttttctctg gctatagaaa ctgtcagggt gccctgctgg catcatccta cctcttttga 300
actgtgttac ccaggaaact ccatttatta tgccctcagg gggggcccg nacccaattc 360
ggaagant 368

```

```

<210> 80
<211> 1088
<212> DNA
<213> Homo sapiens

```

<220>
<221> SITE
<222> (1)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (11)
<223> n equals a,t,g, or c

<400> 80
nttnnaacng naaatctccc ctactatttg ggaacaaaq ctggagctcc accgcggttg 60
cgcccgctct agaactagt gatccccgg gctgcaggaa ttcggcaega gattccccag 120
aattgggtca tcttgggaaa ggaaggccta ggaagctgat gacctacttg ttttgttcat 180
ccatttctct actgcttctt aaagtgcact caagcggta ccaggacatc agaaaagcca 240
aatccaaggt cccaaggctc ttgatcatcc agtgcacaca acagagggag taagctagac 300
ggagaagctg aagtgaagga ggaagagag aaggggtgc ctgttccacc ccttctctag 360
cagctgcctc tgtgggctcc ataatccca tgcctctcc cccacccac cctcggccg 420
mccacctctc ctccaccac cccattcatc agtaggggg cactgtatca gcacagcctt 480
tcaaggcctg acagtttctt tctgggtgcc cccacatgt aacctctaa cccccagcac 540
aaagggccag cctgaatggg ctggagccg gtgctctgt cgraggggga ggctcaata 600
ggatttgggg agctgggtgt ataaaccgct ctgtccagc agcctcaat ggaggagctg 660
gagttggggc atgtgccag gggaggagct cggcagctgc atcccgscce tgaacaatga 720
tttattcatt ctccctggac gcacagagaa gacaggctgg ggaacatgg cccacacaat 780
cgccctcagc ctacagctgat tcccacgga atcattgcag ttcagagtgc cccctccac 840
ttgtaattgt ttgcctcaag ctggccttc ctcttctgg taaggaaagta gactacatta 900
cgggaggcct taagtgcct taaattcagg caagcatcgt tctttgagtt ggttgaccc 960
aaactcaatc tcactctctc aaagctttct ggccagggtt tcttcacaca cccatagaaa 1020
cagatgcaga caaaaaaaaa aaaaaaaaaa actcgagggg gggcccgga cccaattcgg 1080
aagatttg 1088

<210> 81
<211> 1862
<212> DNA
<213> Homo sapiens

<400> 81
ggcacgagct ctgcaagct cctctgctc cagcagctcc tgtattttt caactttgga 60
tgtttgcaca agctattatc ttttgcaaga atgtctgccc cctccctatc catctgtgga 120
agtcaacctt tcttttagggc ccagaggaaa acctatcacc ttctacacct tcccagatgc 180
ccaccatttg ggttaaacctc tgcctccctc aggtttgcca tggcttttcc cctctcttaa 240
agcactgggc ccagcccatg ccaattgtgt tcaccttggc tctgtctcc tactggctgt 300
agatcttttg gaggggagga actgggggaat ttcatcctg gggclatggg atagtgccta 360

ccctaagta taaaaaagc aagaatcctt gaattgaaaa gctccagtga cttgatagct 420
tccaacagcc cctaaagatg gggtagcca ctgctcccta tataggagg aagaggttca 480
cagtcacatg gatttagcag ccttcgtage ctccagatct tccccaatgt cccagttct 540
cctgctgggc cagctgtggc ctctgagaa: gctcagttcc ctgggctagg ctggcttatg 600
gggcccctcc tcctggacct gggctccatg: gaccaagtgg ccagccagcg agagagccct 660
gggtgatgag catctggaag tcagcttgct tgtctgacct aatcacagcc ctgggctcta 720
ccctcaagta cctactcac atgggtccaag agggaccac tctctgtgca tccctccccc 780
ttctgctcct catctacccc acccagctgt tctgggcaag atcctgtggg catgatggaa 840
tctcccttt tctctacat ccatcccttt gatcacctaa tctctcact gccctccaac 900
caagggtgttc tttctatacc aaaaaatctg atcaggccat cactcctctg tttaaaacca 960
ttcaacggct acccactgcc ctccaggataa aaactaaaat tcttaacagg atttacaat 1020
tcttcacctg gcccttttga gataagagga tttataatct tttcaagcc acaagcate 1080
ctgagacaat cttaattttt gcagctgtcc aagctattta agattgatga ggtctgcamt 1140
aagtgtttaa atgggtgatta atttatctgg cctgaatggc akgtgaattc caaggggatc 1200
atttttctct acccttcttg ctgcacattg ggacacagca agggcaggac acccttytta 1260
gggtactgsg taaccagggt cattaaagca gtcagcgagc agaagaagca aaaaatgggg 1320
aggagttgtg taatatgaat tgccgataat accaaaggaa ccccaagaga ggttcagctc 1380
cccacaatt gcagctttgc tgcaacatgc cagggtggga caggggtagg tttggatctg 1440
ggctgctttg cmttggaagt ggggttacag ggcagggaga ggcctaccat cactgagcat 1500
ctttaattga ctttgtcatt tcastgagaa cttaacaatt gagctattct tcatggagt 1560
atatttgga gcaaggttcaa tacataatc agtctccct ctagaatttc tgctttatgt 1620
ccacgtgatg caqctgttgc atttctgaat tctttttaa gacaaaaaca tttggaagga 1680
atgtaaagac tcaaaaaggg gatggcatgt aaactatagt tggacaata tgtggccatt 1740
taaaagaagt gttgtccagg aggtggagggt tgcaagtgc tgagattgca ccactgcact 1800
ctagcctggg ccatagaatg agactccttc tcaaaaaaaa aaaagaaaa aaaaaactcg 1860
ag 1862

<210> 82
<211> 1618
<212> DNA
<213> Homo sapiens

<400> 82
ccacgcgtcc gcaaggagcc agaggccatg cagtggctca ggggtccgtga gtcgctggg 60
gagggccacag gacacagggc caccatgggg acagccgcc tgggtccctg ctgggcagcg 120
ctcctgctct tctcctgat gtgtgagatc cctatgggtg agctcacctt tgacagagct 180
gtggccagcg actgccaacg gtgctgtgac tetgaggacc ccttggtacc tggccatgta 240
tctcagcct ctctctccgg ccgccccac gccctgcctg agatcagacc ctacattaa: 300
atcacccatcc tgaagggtga caaaggggag ccaggcccaa tgggcctgcc agggatcatg 360
ggcaggggagg gtccccaagg ggagcctggc cctcagggca gcaagggtga caagggggag 420
atgggcagcc ccggcgcccc gtgcccagaag cgtttcttcg cttctcagc gggccgcaag 480
acggccctgc acagcggcga ggacttccag acgctgctct tggaaagggt ctttgtgaac 540
cttgatgggt gctttgacat ggcgaccggc cagtttgctg ctcccctgct tggcatctac 600
tctctcagcc tcaatgtgca cagctggaat tacaaggaga cgtacgtgca cattatgcat 660
aaccagaaag aggtgtcat cctgtacgag cagccagcg aqcgagcat catgcagagc 720
cagagtgctga tcttggaact ggcctacggg gaccgctct ggggtcggtc cttaagcgc 780
cagcgcgaga acgcatctca cagcaacgac ttcgacacct acatcacctt cagcggccac 840
ctcatcaagg ccgaggacga ctgagggcct ctgggccacc ctcccggctg gagagctcag 900
ctgatacggc atcctgagag aagacctgcc ctctcactg ggtcccctt cctgctcct 960
cccagggtc tgccagggtc ttgctcaatc ccttcacca aagtcactg aacttccgtt 1020
tcccagggtc tccagctgcc ctccagacct gatgtctgt cccagggtct ctctgcccc 1080
catgcccctc tcaacggccc agtgcgccga ctctcagggc tttatcaagg tgcataaggc 1140
cgggtgggca gctcctcgtc tcagagccct cctcggcct ggtgctgctt ttcaaacac 1200
ctgcaggaga agggccacgg aagccccagg ctttagagcc ctccagaggt ctggggagct 1260
agagcaagg agggacctca gcccttccgt ttctcttccc aggggtgggt ggcctggtg 1320
tcccctagcc ttccaaaccc aggtggcctg ccttctccc cagagggagg cggcctccgc 1380
ccattgggtc tcatgcagac tctgggctg aggtgcccc gggggtgatc tctggtgctc 1440
acagtcgagg gagccglyc tccatggcca gatgacggaa acaggggtctg accaagtgc 1500

aggaagacct gtgtataaa ccaccctgcc tgatcctgcc cctgcctgac ccgcctacgc 1560
cctgcctgcc agcatgatta aagaatgctg tctcctcttg gaaaaaaaaa aaaaaaaa 1618

<210> 83
<211> 2034
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (382)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1999)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2027)
<223> n equals a,t,g, or c

<400> 83
actcactaag ggancaaagc tggagctcca ccgcggtggc ggccgctcta gaactagtgg 60
atccccccggg ctgcaggaat tcggcacgag atctaccggg agakggaytc tgaaggggcc 120
ccggccagcg tccttgagac gccaacggca gtcaactgcc cccattccag ctccctgggat 180
acgtactatc agccccgtgc cctggagaaa catgctgaca gcattcctggc actggcttca 240
gtattctggg ccattctcta ttactcctct cccctcgccct tcttctactt gtacaggaaa 300
ggttacttga gtttgtccaa agtggtgccg ttttctcact atgctgggac attgtctgta 360
cttctggcag gtgtggccctg cntccgaggc attggccgct ggaccaacce ccagtaccgg 420
cagttcatca ccattcttga agcaacacat cggaaaccagt cttcagaaaa caagaggcag 480
cttgccaaact acaactttga cttccggagc tyggccagtcg acttccactg ggaagaaccc 540
agcagccgga aggagtctcg agggggccct tccccccggg gtgtggccct gcttcgcccc 600
gagccctgc accgggggac agcagacacc ctccccaacc gggttaagaa gctgccttgt 660
cagatcacca gctaccctgt ggccgacacc ctaggggccc ggatgctgta tccaggctct 720
gtgtacctgc tgcagaagge cctcatgcct gtgtgtctgc agggccagyc ccgactggtg 780
gaagagtgtg atgggcgcgc ggcaaaaytg ctggcctgtg atggcaatga gattgacacc 840
atgtttgtgg accggcgggg gacagctgag ccccagggac agaagctggt gatctgtctg 900
gaggggaatg ctgggtttta tgaggtgggc tgcctctcca cggcccttga agctggatah 960
tcagtctcgg gctggaatca tccaggcttt gctggaagca cgggggtgccc attccccgag 1020
aatgaggcta atgcatgga tgtgtgtggt cagtttgcca tccaccgctt xggcttccag 1080
ccccaggaca tcattcatca cgcctgtgct atcggcggct tcactgccac gtgggcagcc 1140
atgtcctacc cagatgttag tgccatgac ctggatgcct cctt-gatga cctggtgccc 1200
ttggccttga aggtcatgcc agacagctgg aggggcttgg tgaccaggac cgtgaggcag 1260
catctcaate taaacaagc ggagcagctg tgcagatacc agggctcctgt actgctgac 1320
cggagaacca aggatgagat catcaccacc acggttccct aggacatcat gtccaaccga 1380
ggcaatgacc tctgctgaa gctcctgcag catcggtatc cccgggtgat ggcagaggag 1440
ggtcttccag tggtagggca gtggttggag gcctcctcac agctggaggga agcctcaatt 1500
tatagccgat gggaggttga agaggactgg tgtctgtctg tctcgcctc ctaccaggca 1560
gaacacgggc ccgacttccc ctggagcgtg ggggaggaca tgagtgcaga tggacggcgg 1620
cagctggcct tgttctggc tcggaaagcat ctgcacaact ttgaggccac tcactgcacc 1680
ccactccag cccagaactt ccagatgccc tggcacctct agggaccaac tgggactcat 1740

tatggaagaa	tgggggtgaga	ggagacatga	ggaaagaccc	tcttatttgt	gattctctgt	1800
gttcatgttg	ctgtttatag	tttgtggaaa	gtgggggacc	atcccccttc	tcaccactgt	1860
tcctcttgca	cgtttccctt	cattcatgtg	gctgtactta	accttctcca	acatacatcc	1920
tgcattacat	gaatggatta	ttcttaataa	tttaataaaaa	ggatattttt	ctacaaaaaa	1980
aaaaaaaaaa	aaactccana	attacttcct	aaaaccggcc	cgcggncccc	atcc	2034

<210> 84
<211> 2240
<212> DNA
<213> Homo sapiens

<400> 84						
tcgaccacgc	gtccgcttcc	tcattgtgccc	cgctcgccta	cggttcaggc	tgctgagcct	60
tttctctcgt	ggatccgctc	ccacggcagc	gcgccatggc	ctccggggagc	cgctcctgga	120
gaggagg-gc	gctgcgcgct	cctccttcca	gcactcatcg	agtctgggac	gcagagcttcc	180
ttatgacccc	gtggacacgg	agggctttgg	agaaggtggt	gacatgcagg	agcgttttct	240
gttcccgag	tacatcctgg	atccggagcc	gcaacccacc	cgcgaaaagc	agctgcagga	300
gctccagcaa	cagcaggagg	aggaggagcg	acagaggcag	cagcggcggg	aggagcggcg	360
acagcaaaac	ctacggggcca	ggccccggga	gcacccggtc	gtggggcacc	cggaccgggc	420
attgccgccc	agcggcgctga	actgctcggg	ctcgggggca	gagctgcact	gccaggacgc	480
cggagtgcgc	ggctaccctgc	cccagagaaa	gttctccgc	acggcggagg	cagacggcgg	540
gctggcacgg	accgtgtgct	agcgtctgtg	gctgctgtcg	caccaccggc	gcgtctctacg	600
ctcgagggtg	agcggcgagc	agtacctgga	gctggtgagc	gccgcgttgc	ggcggcccgg	660
ccccctccctg	gtgctctaca	tggtggacct	gctggacctg	cccagcggcc	tgctgcccga	720
cttgcccgcg	ctggtggggc	ccaagcagct	gatcgtgctg	ggaaacaaag	tggacctctc	780
gccccaggat	gctcctggct	accggcagag	gctgccccgg	cgactgtggg	aggactgtgc	840
ccgcgcgcgg	ctcctgcttg	ccccggcca	ccaaggggcca	cagcgccccg	tcaaggacga	900
gccacaggac	ggggagaatc	cgaatccgcc	gaactggtcc	cgcacagtgg	tcaggggacgt	960
gcggctgac	agcgccaaga	ccggctatgg	agtggaaag	ttgatctctg	cccttcagcg	1020
ctcctggcgc	taccgtgggg	acgtctactt	agtggggccc	accaacggcg	gcaaatccac	1080
tctctttaac	acgctcctgg	agtcagatta	ctgcactgcc	aagggtcccg	acgccatcga	1140
cagagccacc	atctccctt	ggccaggtae	tacattaaac	cttctgaagt	ttcctatttg	1200
caaccctaact	ccttacagaa	tgtttaaaag	gcatacaaga	cttaaaaaag	attcaactca	1260
agctgaagaa	gatcttagtg	agcaagaaca	aaatcagctt	aatgtctctca	aaaagcatgg	1320
ttatgtcgtg	ggagaggttg	gaaggacatt	cttgtattca	gaagaacaga	aggataacat	1380
tcccttttag	tttgatgttg	attcacttgc	ctttgacatg	gaaaatgacc	ctgttatggg	1440
tacacacaaa	tccaccaaac	aagtagaatt	gactgcacaa	gatgtgaaag	atgccacttg	1500
gtttttatgac	acccttgga	ttacaaaaga	aaattgtatt	ttaaatcttc	taacagaaaa	1560
agaagtaaat	attgttttgc	caacacagtc	cattgttcca	agaacttttg	tgcttaaac	1620
aggaatggtt	ctgttttttg	gtgctatagg	ccgcatagat	ttcctgcagg	gaaatcagtc	1680
agcttggttt	acagtctgtg	cttccaacat	cctccctgtg	catatcactc	cctgggacag	1740
ggcagacgct	ctgtatcaga	agcatgcagg	tcatacgtta	ctccagattc	caatgggttg	1800
aaaagaacga	atggcaggat	ttcctctctc	tggtgtgaa	gacattatgt	taaaagaagg	1860
actgggggca	tctgaagcag	tgcccgacat	caagttttcc	ctgcaggtt	gggtttcagt	1920
aacacctaat	tttaaggaca	gactgcactc	ccgaggctat	acacctgaag	gaacagtttt	1980
gaccgtccgg	ccccctctct	tgccatatat	tgtaaacatc	aaaggacagc	gcataaagaa	2040
aagtgtgggc	tataaaacca	agaagcctcc	ttcccttatg	tacaacgtga	ggaagaagaa	2100
aggaagata	aatgtatgag	accgaccttg	ttcactccag	atattaactg	tattgaacac	2160
aacaaaatac	attgaatttg	tattaaacat	ataacgcata	aataaagctc	ccattcttac	2220
ccttaaaaaa	aaaaaaaaaa					2240

<210> 85
<211> 1488
<212> DNA
<213> Homo sapiens

<400> 85

cgccaagttt	ccggaggagg	agggtagaaa	ctggaggggg	tggacctgtc	actcacggga	60
ctgagggtcc	ttttctcccg	ctcccaggag	gaacgagaat	gaatatgac	caagcccgga	120
ttctgggtgg	tgcagtgggt	gggttggtgg	ctgtcctgct	ctacgcctcc	atccacaaga	180
ttgaggagg	ccatctggct	gtgtactaca	ggggaggagc	tttactaact	agccccagtg	240
gaccaggcta	tcataatcat	ttgcctttca	ttactacgtt	cagatctgtg	cagacaacac	300
tacaaactga	tgaagttaaa	aatgtgcctt	gtggaacaag	tggtaggggc	atgatctata	360
ttgaccgaac	agaagtgggt	aatatgttgg	ctccttatgc	agtggtttgat	atcgtgagga	420
actatactgc	agatttatgac	aagaccttaa	tcttcaataa	aatccaccat	gagctgaacc	480
agttctgcag	tgcctcacaca	cttcagggaag	tttaccattga	attgtttgat	caaatagatg	540
aaaaactgaa	gcaagctctg	cagaaaagact	taaacctcat	ggccccaggt	ctcactatac	600
aggctgtgcg	tgttacaaaa	cccaaaatcc	cagaagccat	aagaagaaat	tttgagttaa	660
tggaggctga	gaagacaaaa	ctccttatag	ctgcacagaa	acaaaaggtt	gtggaaaaag	720
aagctgagac	agagaggaaa	aaggcagtta	tagaagcaga	gaagattgca	caagtggcaa	780
aaattcgggt	tcagcagaaa	gtgatggaaa	aagaactga	aaagcgcat	tctgaaatcg	840
aagatgctgc	attcctggcc	cyagayaaag	cgaaagcaga	tgtgaatat	tatgctgcac	900
acaaatatgc	cacctcaaac	aagcacaaat	tgaccccgga	atatctggag	ctcaaaaagt	960
accaggccat	tgttctaac	agtaagatct	attttggcag	caacatccct	aacatgtctg	1020
tggactcctc	atgtgctttg	aaatattcag	atattaggac	tggaaagagaa	agctcaatcc	1080
cctctaagga	ggctcttgaa	ccctctggag	agaacgtcat	ccaaaacaaa	gagagccagc	1140
ttgtatgcaa	gaggtggaaa	tgttctccat	atcaagatgt	ggcccaggag	gttaagtggg	1200
aacaatcatt	atacggactc	ttcagattta	cagagaactt	acacttcact	tggtccacct	1260
ctcctgcgat	agtctcgggt	gttccactga	ttggaggata	gagccagctg	tctgacacac	1320
aaatggtctt	ttcagccaca	gtcttatcaa	gtatcctata	tgtattcctt	tctaaactgc	1380
tactcatgaa	tgaggaaagt	ctgatgctaa	gatactgcct	gcactgggaat	gttaaacact	1440
aaatatataa	caagctgtgt	tttcttaagc	tgaaaaaaaa	aaaaaaaa		1488

<210> 86

<211> 3174

<212> DNA

<213> Homo sapiens

<400> 86

gcgagcgtcg	gxcscaaaaca	ctaaggcctg	agcgggtgac	atcgaggcga	gatgatggtc	60
aacagggaat	gcctcgtggg	agaaaaaaga	caattttatt	ctcagcgtcg	attttgagat	120
gatgggcttg	ggaaaacggg	gtcgcagcat	gaagtcgccc	cccctcgtgc	tggccgcctt	180
gggtggcctgc	atcatcgtct	tgggcttcaa	ctactggatt	gcgagctccc	ggagcgtgga	240
cctccagaca	cggatcatgg	agctggaagg	cagggtccgc	agcggggtcg	cagagagagg	300
cgccgtggag	ctgaagaaga	acgagttcca	gggagagctg	gagaagcagc	gggagcagct	360
tgacaaaatc	cagtcacagc	acaacttcca	gctggagagc	gtcaacaagc	tgtaaccagga	420
cgaaaaggcg	gttttggtga	ataacatcac	cacaggtgag	aggtctatcc	gagtgtgca	480
agaccagtta	aagaccctgc	agaggaatta	cggcaggctg	cagcaggatg	tcctccagtt	540
tcagaagaac	cagaccaacc	tggagaggaa	gttctcttac	gaactgagcc	agtgcatcaa	600
tcagatgaag	gaggtgaagg	aacagtgtga	ggagcgaata	gaagaggtca	ccaaaaaggg	660
gaatgaagct	gtagcttcca	gagacctgag	tgaaaacaac	gaccagagac	agcagctcca	720
agccctcagt	gagcctcagc	ccaggctgca	ggcagcaggc	ctgccacaca	cagaggtgcc	780
acaaggggaag	ggaaacgtgc	ttggtaacag	caagtcccag	acaccagccc	ccagttccga	840
agtggtrttg	gattcaaaaga	gacaagttga	gaaagaggaa	accaatgaga	tccaggtggc	900
gaatgaggag	cctcagaggg	acaggctgcc	gcaggagcca	ggccgggagc	aggtgggtgga	960
agacagacct	gtaggctgaa	gaggcttcgg	gggagccgga	gaactgggcc	agacccaca	1020
ggtagcaggct	gcccctgyag	tgagccagga	aaatccagag	atggaggggc	ctgagcgaga	1080
ccagcttgtc	atccccgacg	gacaggagga	ggagcaggaa	gctgcggggg	aaggagagaaa	1140
ccagcagaaa	ctgagaggag	aagatgacta	caacatggat	gaaaaatgaag	cagaatctga	1200
gcagagacaag	caagcagccc	tggcagggaa	tgacayaaac	atagatgttt	ttaatgttga	1260
agatcagaaa	agagacacca	taaatattact	tgaacagcgt	gaaaagcggg	atcatacact	1320
ctgaattgaa	ctggaaatcac	atatttcaca	acaagqccca	agagatgact	ataaaatgtr	1380
catgagggac	tgaataactga	aaactgtgaa	atgtactaaa	taaaaatgtac	atctgaagat	1440
gattattgtg	aaattttagt	atgcactttg	tgtaggaaaa	aatgggaatgg	ctttttaaac	1500
agcttttggg	gggtactttg	gaagtgtcta	ataaggtgtc	acaatttttg	gtagtaggta	1560

tctcgtgaga	agttcaacac	caaaactgga	acatagtttt	ccttcaagt	ttggcgacag	1620
cggggcttcc	tgattcttga	atataacttt	gtgtaaat	acagccacct	atagaagagt	1680
ccatctgctg	tgaaggagag	acagagaact	ctgggtccg	tcgtctgtgc	cacgtgctgt	1740
accaagtger	gggtgccagcc	tgttacctgt	tctcaactga	aagtcctggc	aetgctcttg	1800
tgatgtcact	tctgattctg	acaatcaatc	aatcaatggc	ctagagcact	gactgttaac	1860
acaaacgtca	ctagcaaat	agcaacagct	ttaagtctaa	atacaaaagt	gttctgtgtg	1920
agaatttttt	aaaaggctac	ttgtataata	acccttgta	tttttaagt	acaaaacgct	1980
attaaatggc	ttagaatttg	aaatattgtg	gtctttattt	actttgtctc	gtgtgtgggc	2040
aaagcaacat	cttccctaaa	tatatattac	caagaaaagc	aagaagcaga	ttaggttttt	2100
gacaaaacaa	acaggccaaa	agggggctga	cctggagcag	agcaggtgga	gaggcaaggc	2160
atgagagggc	aagtttgggt	tggaagatc	tggtcctact	ttattactgg	agtaaaagaa	2220
aacaaagtcc	attgatgtcg	aaggatatat	acagtgttag	aaattaggac	tgtttagaaa	2280
acacaggaata	caatggttgt	ttttatcata	gtgtacacat	ttagcttggg	gtaaatgact	2340
cacaaaactg	attttaaaat	caagttaatg	tgaattttga	aaattactac	ttaatcctaa	2400
ttcacataaa	caatggcatt	aaagtctgac	ttgagttggg	tcttagtatt	atttatggta	2460
aataaggtct	taaccacttg	aaataactgg	ccacatcatt	aatgactgac	ttcccagtaa	2520
ggctctctaa	gggttaagta	ggaggtacca	caggatttga	gatgctaagg	ccccagagat	2580
cgtttgatcc	aaccctctta	ttttcagagg	ggaaaatggg	gcttagaagt	tacagagcat	2640
ctagctgggt	cgctggcacc	cctggcctca	caagactccc	cgagttagct	ggactacagg	2700
cacacagtca	ctgaagcagg	cctgttttgc	aattcacgtt	gccacctcca	acttaaacat	2760
tcttcataatg	tgatgtcctt	agtcactaag	gttaaacctt	cccaccacaga	aaaggcaact	2820
tagataaaat	cttagagtag	tttcatactc	ttctaagtc	tcttccagcc	tcacttttag	2880
tcctccttgg	ggttgatagg	aattttctct	tgctttctca	ataaagttct	tattcatctc	2940
atgttttaatt	tgtaacgata	gaattgtctg	gaaataaaat	gttctgttca	acttaaaaaa	3000
cttgtcacag	ctctgttttt	ttgcttttcc	ccttcactct	ctattagatc	cttaagaagt	3060
ccacccctcaa	actgtggact	aaggatggca	gtttgcctta	aaccttctgt	ggaatgagat	3120
gggtctgtcag	gacgtcttca	acccacagta	ccccgaaagc	tttgtgctca	ccac	3174

<210> 87

<211> 2780

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2760)

<223> n equals a,t,g, or c

<400> 87

ggcgccgcgg	gcgggggggc	ccggggccac	gtggacgcgg	acgggtctgg	tctgcggcgt	60
gtggacactg	ccagcggtct	cagccgactt	ggaatgacct	gggagacaaa	tacaacagca	120
tggaaagakc	caaagtctat	gtggctaaag	tggactgcac	ggcccactcc	gacgtgtgct	180
ccgcccaggg	gggtgcgagga	taccccacct	ttaaagcttt	caagccaggg	caagaagctg	240
tgaagtacca	gggtcctcgg	gacttccaga	cactggaaaa	ctggatgctg	cagacactga	300
acgaggagcc	agtgacacca	gagccggaag	tggaaaccgc	cagtgcctcc	gagctcaagc	360
aagggctgta	tgagctctca	gcaagcaact	ttgagctgca	cgttgcaaaa	ggcgaccact	420
ttatcaagtt	cttcgctcgg	tggtgtgtgc	actgcaaaag	cctggctcca	acctgggagc	480
agctggctct	gggccttgaa	cattccgaaa	ctgtcaagat	tggcaaggtt	gattgtacac	540
agcactatga	actctgtctc	ggaaaccagg	ttcgtggcta	tcccactctt	ctcgggttcc	600
gagatgggaa	aaaggtggat	cagtacaagg	gaaaacggga	tttgaggta	ctgagggagt	660
acgtggagtc	gcagctgcag	cgacagagga	ctggagcgac	ggagaccgtc	acgcctcag	720
aggccccggt	gctggcagct	gagccccagg	ctgacaaggg	cactgtgttg	gcactcactg	780
aaaataaact	cgatgacacc	attgcagaag	gaataacctt	catcaagttt	tatgtcccat	840
gggtgtgtca	ttgtaagact	ctggctccta	ctggggagga	actctctaaa	aaggaattcc	900
ctggtctggc	gggggtcaag	atgcgccaaq	tagactgcac	tgctgaacgg	aatatctgca	960
gcaagtattc	ggtacgaggg	taccccagct	tattgctttt	ccgaggaggg	aagaaagtca	1020
gtgagcacag	tggaggcaga	gaccttgact	cgttacacgg	ctttgcctcg	agccaaagca	1080
aagacgaact	ctagggaacac	agttggaggt	cacctctcct	gccagctcc	cgcacctctc	1140


```
gttttaggagt tcagtcaccac agaggccact ggggtccacg tgggtgctgt tcagaaagca 1200
gaacatacta agcgtgaggt atcttctttg tgtgtgtgt ttccaagcca acacactcta 1260
cagattcttt attaagttaa gtttctctaa gtaaatgtgt aactcatggt cactgtgtaa 1320
acattttcag tggcgatata tcccccttga cctctctttg atgaaattta catggtttcc 1380
tttgagacta aaatagcgtt gagggaaatg aaattgctgg actatttgtg gctctcgagt 1440
tgagtgattt tggtgaaaga aagcacatcc aaagcatagt ttacctgccc acgagttctg 1500
gaaaggtggc cttgtggcag tattgacgtt cctcggatct taaggtcaca gttgactcaa 1560
tactgtgttg gtccgtagca tggagcagat tgaaatgcaa aaaccacac ctcgggaaga 1620
taccttcacg gccgctgtg gagcttctgt tgetgtgaat acttctctca gtgagagg 1680
ttagccgtga tgaaagcagc gttacttctg accgtgcttg agtaagagaa tgctgatgcc 1740
ataactttat gtgtcgatag tttgcaaatc agttactgtt caggggagtc ttctgtttct 1800
cacggggtga aacatgtctt taqttctca tgttaacacg aagccagagc ccacatgaac 1860
tgttggtgtt cttctctaga aagggtaggc atggaaaatt ccacgaggct cattctcagt 1920
atctcattaa ctcatgaaa gattccagtt gtatttgcac cctgggggtg caagaccaga 1980
caggctttcc cagggctggg tatccaggga ggctctgcag cctctctgaa gggccctaac 2040
tagagtctta gagtttctga ttctgtttct cagtagtctt tttagaggct tgctatactt 2100
ggctctgttc aaggaggtcg accttcta atctcgaaga tgggatgcat ttgatctcaa 2160
gaccaagac agatgtcagt ggggtgtctt gggcctgggt tgcacggctg tggcagctgt 2220
tgatgccagt gtctcttacc tcatctgttc cttgtgatta aacacctcta tctctcttgg 2280
gaataagcac atacaggctt aagctctaa ataggtgttt gtccttttac catcgagcta 2340
cttcccataa taaccacttt gcatccaaca ctctcacc accctccata cgcaagggga 2400
tgtggatact tggcccaaag taactgtgtg taggaatctt agaaacaaga ccactatac 2460
tgtctgtctg aggcagaaga taacagcagc atctcgacca gccctgtcct taaaggaaat 2520
ctttaataat cacgtatggt tcacagataa ttcttttttt aaaaaaaccc aacctctagt 2580
egaagcacia ctgtcaagag tcttgtacac acaacttcag ctttgcatac cgagtcttgt 2640
attccaagaa aatcaaagt gtacaatttg ttgtttaca ctatgatact ttctaaataa 2700
actctttttt tttaaaaaaa aaaaaaaa aaaaaagggg gggggggggg 2760
ggggccccc ccccccaaa
```

<210> 88

<211> 1061

<212> DNA

<213> Homo sapiens

<400> 88

```
aattcggcac gagagaagga aatacatcaa aatgccacac ttggttatct gtagaggata 60
gaatgaaaaga tggctttatt ctcttgtttg ctcttattaa agcaatcaga tgggtcttct 120
cctgtactca gagccctggc tgcttctctg ctggcctctc ctggggctg ctgttggaac 180
agaaaagcct taaacggaaa tgtgggagag aaggttggat tcactttcat gtcttctccag 240
ggttgtgacc cctcaagtc tgggttgcctt tgcgtttctc tattaccttc aaacagccag 300
ctcgtcttta ttctttttt agttttgtcg gggttggctt gatagatgtt agtccatcat 360
agccagatgt gtctagcctt gtcttttgaa tgcaagattt aggatgtggg tacttagctg 420
ttagtggaca tcagagtcac tagtcaggat gaaagagttc ttggctttaa ctcccagaaa 480
ttctggtaac gtcatgtata gtgacggccg catgtctaac aggtggccag gtaagtcttt 540
tgggggtggc tgtgaatcac agtttgggag acattgacct ttaggggaatc tttcttgaat 600
tcaactagata atagagatat aatacagagc ttgaaagct ggtgtcttga tgacagagcc 660
gtggcaatgg ggaggttga ggaggtggct gttgggctg cctctctgtg agagttgaaa 720
gggcctgaac tcaagcagag gccctcagaa cyaaaggttg tggaaagatg cagcaagagg 780
cgccacacag gagtactctg cgccctggca gggctctaat acacgtggga gtgggtgagag 840
ggagaacttt aagtcagggt ttgtgtcctc atcgacttag tgtggccata tcattagaaa 900
tgtgttgagg ccgggcacag tggctcatgt ctgtaatccc agcactttga gaggtctagg 960
caggaggatg gcttgaggcc aggaatttaa aaccagcctg gacaacatag tgagagcctg 1020
tctctacaaa aaaaaaaa aaaaactcga gggggggccc g
```

<210> 89

<211> 1342

<212> DNA

<213> Homo sapiens

<400> 89

ccacgcgtcc	gggcgcgcgg	gtgaaaggg	cattgatgca	gcctgcggcg	gcctcggagc	60
gcggcggagc	agacgctgac	cacgttcctc	tctcgggtct	cctccgcctc	cagctccggc	120
ctgcccgga	gccgggagcc	atgcgacccc	agggccccc	cgctccccc	cagcggctcc	180
gcggcctcct	gctgctctcg	ctgctgcagc	tgcccgcgcc	gtcgcgcgcc	tccgagatcc	240
cgaaggggaa	gcataagggc	cagctccggc	agagggaggt	ggtggacctg	tataatggaa	300
tgtgcttaca	agggccagca	ggagtgcctg	gtcgagacgg	gagccctggg	gccaatggca	360
ttccgggtac	acctgggac	ccaggtcggg	atggattcaa	aggagaaaag	ggggaatgtc	420
tgagggaag	cttlgaggag	tcctgggacac	ccaactacaa	gcagtgttca	tggagtccat	480
tgaattatgg	catagatctt	gggaaaattg	cggagtgtac	attacaaaag	atgcgttcaa	540
atagtgtctc	aagagtcttg	ttcagtggct	cacttcggct	aaaatgcaga	aatgcattct	600
gtgagcgttg	gtatttcaca	ttcaatggag	ctgaatgttc	aggacctctt	cccatgaag	660
ctataattta	tttggaccaa	ggagacccct	aaatgaattc	aacaattaat	attcatcgca	720
cttctctctg	ggaaggacct	tgtgaaggaa	ttggtgctgg	attagtggat	gttgcctatc	780
gggttgccac	ttgttcagat	tacccaaaag	gagatccttc	tactggatgg	aattcagtct	840
ctcgcatcat	tattgaagaa	ctacccaaat	aatgcttta	attttcattt	gctacctctt	900
tttttattat	gccttggaat	ggttcactta	aatgacattt	taataaagtt	tatgtataca	960
tctgaatgaa	aagcaaaagc	aaatatgttt	acagaccaaa	gtgtgatttc	acactgtttt	1020
ttaatctagc	attattcatt	ttgttcaat	caaaagtggg	ttcaatattt	tttttagctg	1080
gttagaatac	tttttccata	gtcacattct	ctcaacctat	aatttggaat	attgttgtgg	1140
tcttttgttt	ttttctctag	tatagcattt	ttaaaaaat	ataaaagcta	ccaactcttg	1200
tacaatttgt	aaatgttaag	aattcttttt	atatctctta	aataaaaaat	atttccaaaa	1260
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaaaaaaa	aa				1342

<210> 90

<211> 770

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (690)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (762)

<223> n equals a,t,g, or c

<400> 90

ggtagggtcg	ggkcgaccy-	cgcgtccggc	tcttcctcag	gcggcggcca	tggcgggaca	60
ggaggtaccg	gtgcagcggg	agattcacca	ggactgggct	aaccgggagt	acattgagat	120
aatcaccagc	agcatcaaga	aaatgcgaga	ctttctcaac	tcgttcgata	tgtcttgcg	180
ttcaagacct	gcaacactaa	acgagaaatt	gacagccctt	gaacggagaa	tagagtacat	240
tgaagctcgg	gtgacaaaag	gtgagacact	cacctagaac	agtgcctgtc	tgtgtctggg	300
aagttgcttt	acacaacaca	ggccacatgg	gaaaggcccc	agcagccttc	agctccttcc	360
tttctcctta	aagagcaaca	gggcttatcc	ttgtttttct	tttttcaaaa	gtgtggcctt	420
tgggctctgc	catctggggg	gtggtgtggg	atgtgggaag	aagttcagag	gaaccgttgg	480
aaacgacgtt	aggcatttta	ccttttcagt	aacattttat	acatctactt	gtcaatgtat	540
ttgagacatt	cacagccaaa	agcctgggac	tctttgtgaa	ggtctctctc	amctctatct	600
ttctttctct	ctctctcaaa	ctttctctaa	agttctcatt	gccttttgac	tgtctctgtg	660
aacagtcttt	gtctctctcc	cacctttggg	ggaaagtgcg	ggcgaatcct	ggtcaagaca	720
ctcatgcctc	ggcaatgtgg	cctgcagaga	atgtgttgtt	anccaccagt		770

<210> 91
<211> 1570
<212> DNA
<213> Homo sapiens

<400> 91
gatgggtttta ctgaagtgc taaaagttta cagaaaagga agtgcaggaa catttcacaa 60
atctacaatc tgtgagtac acatcctgta tagctgtmaa cactggaata aggaagggtt 120
gatgactttc agaagatgaa ggtaagttaga aaccgttgat gggactgaga aaccagagtt 180
aaaacctctt tggagcttct gaggactcag ctggaaccaa cgggcacagt tggcaacacc 240
atcatgacat cacaacctgt tcccaatgay accatcatag tgctcccatc aaatgtcatc 300
aacttctccc aagcagagaa acccgaacct accaaccagg ggcaggatag cctgaagaaa 360
catctacacg cagaaatcaa agttattggg actatccaga tcttgtgtgg catgatggta 420
ttgagcttgg ggaatcattt ggcatctgct tcttctctc caaattttac ccaagtgaat 480
tctacactgt tgaactctgc ttaccctatc ataggacctt ttttttttat catctctggc 540
tctctatcaa tgcgccaga gaaaaggtr accaagcttt tgggtcatag cagcctgggt 600
ggagcattc tgagtgtctt gtctgccctg gtgggtttca ttatcctgtc tgtcaaacag 660
gccaccttaa atctgcctc actgcagtgt gagtgggaca aaaaataat accaacaaga 720
agttatgttt cttaacttta tcatgattca ctttatacca cggactgcta tacagccaa 780
gccagtctgg ctggawctct ctctctgatg ctgatttgca ctctgctgga atctgccta 840
gctgtgtcca ctgctgtctt gcggtggaaa caggcttact ctgacttccc tgggagtgt 900
cttttctctg ctacagatta catttgtaat tctggcatgt cctcaaaaat gactcatgac 960
tgtggatatg aagaactat gacttcttaa gaaaaaggg agaaatatta atcagaaagt 1020
tgattcttat gataatargg aaaagttaac cattatagaa aagcaagct tgagtctct 1080
aaatgtaagc ttttaaagta atgaacatta aaaaaacca ttatttcaat gtcatttaag 1140
atatgtgttc attggggatc tcttgatttg cctgacattg acttcagcaa aagcacgggg 1200
ctgtaaaatta ccatttacta gattagccaa atagctcga tttccagaaa acaaggcaga 1260
atgatcatte ccagaaacat ttcccagaaa atgtttccca gaaaactaga cagmatgatc 1320
attcaatgga tcacagtga gcaaaggaca caactttta ctgtacctt taattgtcaa 1380
caggagttaa ctgatttgtt gtgggtgtca gacttttta tacagggtgt agtgtttat 1440
cctatgtatt ttaactcatt agtgcataaa ggcaagcccc atataatgaa gtctcagggt 1500
atatgaaagt agctggcttc aaaaataaat ttttgagtgc aaaaaaaaa aaaaataaaa 1560
aaaaaaaaa 1570

<210> 92
<211> 2950
<212> DNA
<213> Homo sapiens

<400> 92
cccggtctcc gccgctccc agccgggccc cccagcggtc ggcgggacgg ctcccggctg 60
cagtctgccc gccgccccg cgcgggggccc gactcgcgaa gcgcgcctgc gaccggcgct 120
ccggggcgcc tggagaggac gcgaggagcc atgaggcgc agctgcgaag gtggcgccgc 180
tgctgtctgg gctgctcttg gagtgcacag aagccaaaa gcattgtctg tatttcgaag 240
gactctatcc aacctattat atatgccgt cctacgagga ctgctgtggc tccaggtgct 300
gtgtgcgggc cctctccata cagaggctgt ggtacttctg ttctctctg atgatggcg 360
tgcttttctg ctccggagcc ggctcttca tccggaggcg catgtacccc ccgcccgtga 420
tcgaggagcc agccttcaat gtgtctaca ccaggcagcc cccaaatccc ggcccaggag 480
cccagcagcc gggccgccc tattacacyg acccaggagg accggggatg aacctgtcg 540
ggaattccat ggcaatggct ttccaggctc caccacact accccagggg agtgtggcct 600
gcccgcctcc tccagcctac tgcaaacgc ctccgcccc gtacgaacag gtagtgaagg 660
ccaagtatgt ggggtccac gtgcaagg agagacagga gagggcctt cctgtgctt 720
tctgtcttct ttgatgttca cttccaggaa cgtctctgt ggctgtctaa ggcagtctct 780
ctgataacct cacagcaagc acagctctct ttccaggctt ccatggagta caatatatga 840
actcacactt tgtctctct gttgtctct tttctgacgc atctgtgctc tcacatggta 900
gtgtgtgtac agtccccgag ggtgacgtc cttacggtg cgtgaccaga tctacaggag 960
agagactgag aggaagaagg cagtgtctga ggtgcagggt gcatgtagag gggccaggcc 1020
gagcatccca ggcaagcacc cttctgccc ggtattanta ggaagcccca gcccggcg 1080

ctcagccgat	gaagcagcag	ccgactgagc	tgagcccagc	aggctcatctg	ctccagccctg	1140
tcctctcgtc	agccttcctc	ttccagaagc	tggtggagag	acattcagga	gagagcaagc	1200
cccttgatcat	gttctctgtc	ctgttcatac	cctaaagata	gacttctctc	gcaccgccag	1260
gaaagggtag	cacgtgcagc	tctccacgca	gatggggcct	agaatcagge	ttgcttggag	1320
gcctgacagt	gatctgacac	ccactaagca	aatttattta	aattcagggg	aaatcacttc	1380
ctgccccaaa	ctgagacatt	gcattttgtg	agctcttggt	ctgattttgga	gaaaggaactg	1440
ttaccatttt	ttttggtgtg	tttatggaa	tgcatgtaga	gcgtcctgcc	ctttgaaatc	1500
agactgggtg	tggtgtcttc	ctggacatca	ctgcctctcc	agggcattct	caggcccggg	1560
ggctctcttc	cctcaggcag	ctccagtggg	gggtctcgaa	gggtgctttc	aaaacggggc	1620
acatctgggt	gggaagtcac	atggactctt	ccaggggag	agaccagctg	aggcgtctct	1680
ctctgaggtt	tggttgggtc	taagcgggtg	tggtgctggc	tcgaaggagg	aggagcttgc	1740
tgggaaaaga	cagggaaggt	actgactcaa	ctgcactgac	catgttgta	taattagaat	1800
aaagaagaag	tggtcggaaa	tgccacttcc	tggaataggaa	tcacagctca	ccccaggatc	1860
tcacaggtag	ctcctctgag	agttgacggc	tagcggggag	ctagtctccg	cgcatagtta	1920
tagtggtgat	gtgtgaacgc	tgactctgac	tggtgcttaa	gagctatgca	gcttagctga	1980
ggcgccctaga	ttactagatg	tgctgtatca	cggggaatga	gggtgggggtg	cttatttttt	2040
aatgaactaa	tcagagcctc	ttgagaaatt	gttactcatt	gaactggagc	atcaagacat	2100
ctcatggaag	tggaatcagg	gtgatttggg	gtccatgctt	ttcactctga	ggacatttaa	2160
tcggagaacc	tcctggggaa	ttttgtggga	gacacttggg	aacaaaacag	acaccctggg	2220
aatgcagttg	caagcagaga	tgctgcccac	agtgctctctg	accaccctgg	tgtagctgct	2280
gactgcccagc	gtggtaacctc	ccatgctgca	ggcctccatc	taaatgagac	aacaaagcac	2340
aatgttcact	gtttacaacc	aagacaactg	cggtgggtcca	aacactctct	ttctccagg	2400
tcattttgtt	tgcattttta	atgtctttat	tttttgaat	gaaaaagcac	actaagctgc	2460
ccctggaatc	gggtgcagct	gaataggcac	ccaaaagtc	gtgactaaat	ttcgtttgtc	2520
tttttgatag	caaatattat	taagagacag	tgatggctag	ggctcaacaa	ttttgtattc	2580
ccatgtttgt	gtgagacaga	gtttgttttc	ccttgaactt	ggttagaatt	gtgctactgt	2640
gaacgctgat	cctgcataatg	gaagtccerc	ttcggtgaca	tttctggcc	attcttgttt	2700
ccattgtgtg	gatgggtggg	tggtcccact	tcctggagtg	agacagctcc	tggtgtgtag	2760
aattccccga	gcgtcctgtg	ttccagatga	acttgaagca	gatctgtgca	tgctttctct	2820
ctgcaacaat	tggtcctgtt	ctcttttttg	ttctcttttg	ataggatcct	gtttctctatg	2880
tggtcaaaat	aaaaataaat	tggtggcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2940
aaaaaaaaaa						2950

<210> 93

<211> 1722

<212> DNA

<213> Homo sapiens

<400> 93

ggcagcagcc	agagcaggct	gctaggcctg	gggccaccac	tgcccctggg	tgctacaccc	60
agtgtgctgg	gtcactggga	acttccctgaa	gtgctgtcac	ctgaactggg	cccccaagga	120
tggggtgctg	gcagracccg	aggaagagga	gcagccccc	tgaagattga	gagctgccag	180
aggctctgtg	attggctcgg	gcacgatgac	ccgcgcacgg	attggctgct	tcgggcccgg	240
gggcccggcc	cgggggacag	aatccgcccc	cgaaccttca	aagaggttac	cccccgccag	300
gagctggcag	accyaggagg	tgccacagac	ccgcggggca	aacggactgg	ggccaaagac	360
cgggagcgcg	ggcgcaaaag	caccaggggc	cgccaggggc	gcccgcgagc	acggcccttg	420
gggttctcgg	ggccttcggg	tgccgcctctc	gcctctagcc	atgggggtccg	cagcgttggga	480
gatccctggg	ctggtgctgt	gcctgggtggg	ctgggggggt	ctgatcctgg	cgtgcgggct	540
gcccattgctg	cagggtgaccg	ccttccctgga	ccacaacatc	gtgacggcgc	agaccacctg	600
gaaggggctg	tggtatgtcgt	gcgtgggtgca	gagcacsggg	cacatgcagt	gcaaaagtga	660
cgactcgggtg	ctggctctga	gcaccagggg	gcaggcggcg	cgggcgctca	cgtgagcgc	720
cgtgctgctg	gcgttcgttg	cgctcttctg	gaccttgccg	ggcgcgagct	gcaccacctg	780
cgtggcccgg	ggcccggcca	argcgctgtg	ggccctcagc	ggaggcgtgc	tcctacctgt	840
ttgcccggctg	ctggcgctcg	tgccactctg	ctggttcgcc	aacattgtcg	tcgcgagtt	900
ttacgacccg	ctgtgctccg	tgctgcagaa	gtacaaactg	ggcgacggcg	tgatcatcgg	960
ctggggcgcc	accgcgctgc	tcattggtagg	cggtgcctc	ttgtgctgcy	gcgctgggt	1020
ctgcaccggc	cgtcccggac	tcagcttccc	cgtgaagtac	tcagcgccgc	ggcgggccac	1080
ggcaccggcg	gactacgaca	agaagaacta	cgtcagagg	cgctgggcac	ggcgggggcc	1140

```

ctctctgscag ccacgcctgc gaggcggttg ataaccttc qagcccccc atggaccgcg 1200
gcttccgcgg ggtagcgccg cgcgcaggct cctcggaacg tccggctctg cccccgacg 1260
cggtctctgg atccgctect cctcgccccc gcagctgacc ttctctctgc actagcccg 1320
ccctgccttt aacagacgga aagaagtctt ctttctctg cgcggcgctg ttcccatagg 1380
cagagcggtt gtcagactga ggatttcgct tccccctcaa gacgctgggg gtcctggctg 1440
ctgctctact tcccagaggc tcttgcctgac ttccgagggc cggatgcaaa qcccagggcc 1500
cccaccgga gatgtgtaca gctggtcttt actccatcgg cagggccga gccagggac 1560
cagtgccttg gcctggacct cccggtctca ctccagctc tcccaggca agccttgctg 1620
gcaccggagc ttgagagagg gcgggagtg gaaggctaag aatctgctta gtaaatgggt 1680
tgaactctca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1722

```

<210> 94
 <211> 635
 <212> DNA
 <213> Homo sapiens

```

<400> 94
gcctaaagag agctccccc yyaccagccc tggccaaggg attgctgcag cctcatcca 60
cctccaaagc actggaaca aacattggag accaagttag gcgtcactca acagccgtag 120
taatcagggg aatgacaagt tacatactga tatccttctg ttgctgatt ggagttgggt 180
qcatgtaaaa agatcagctg tgcccagctg ttggggggaag gaagcgtctt cactgctgtg 240
ttgtggcagg acagttgagg caggtgagga tgctgagagg tgagctcagc tgtgctctgt 300
accgtccaca tgtcaagcc ctccagctcg gtggctgtac ttgttttga gatgcagttt 360
cactcttctc acccaggctg gagtgcattg catgactctg gctcgtctga acatccgctt 420
cccgggttca agcgattctc ctgtctctac taaaaataca aaaattagct ggggtgtgtg 480
gtcgtgctct ttaatccagc ctactcagaa ggcgtgagtg caagaattgc ttgaacctgg 540
gaggtggagg ttgctgtgg ccgagatcac gccaccgac tccagcctag gcaacagagc 600
tagactgtct caaaaaaaaaa aaatgacctc tcgag 635

```

<210> 95
 <211> 3798
 <212> DNA
 <213> Homo sapiens

```

<400> 95
ccacgcgtcc ggggttctat acaggaaatc tattgctgtg tcaagttcca gagaagagct 60
tctgttctgc caagttacta accaggctaa accacataga cgtqaaggaa ggggctagaa 120
ggaaggaggt gccccactgt tgatggggta agaggatcct gtactgagaa gttgaccaga 180
gagggtctca ccattgcgcac agttctctct gtaccagtgt ggaggaaaag tactgagctga 240
agggcagaaa aagagaaaac agaaatgctc tgccttgga gaactgctaa cctagggcta 300
ctgttgattt tgactatctt cttagtgccc gaagcggagg gtgctgctca accaaaacac 360
tcattaatgc tgcdaactag caaggagaat catgctttag ctcaagcag tttatgtatg 420
gatgaaaaac agattacaca gaactactcg aaagtactcg cagaagttaa cacttcatgg 480
cctgtaaaaga tgggtacaaa tctgtgctct tgttgccctc ctatcgcatc aagaaatttg 540
atcataaata catgggaaat aatcctgaga ggcagcctt cctgcacaaa agcctacaag 600
aaagaaacaa atgagaccaa ggaaccaa cgtactgatg agayaataac ctgggtctct 660
agacctgatc agaattcgga ccttcagatt cgtaccgttg ccatactca tgacgggtat 720
tacagatgca taatggtaac acctgatggg aatttccatc gtggatatca cctccaaagt 780
ttagtacac ctgaagtgc cctgtttcaa aacaggaaata gaactgcagt atgcaaggca 840
gttgaggga agccagctgc gcatactctc tggatccag agggcgattg tgcactaag 900
caagaatact ggaacaaagg cacagtgaat gttaaagata catgccactg ggaggtccac 960
aatgtgtcta cctggaactg ccacgtctcc catttgactg gcaacaagag cctgtacata 1020
gagctacttc ctgttccagg tgccaaaaaa tcagcaaaat tatataattc atatatcctc 1080
cttactatta ttattttgac cctgtggga ttcatttggg tgtgaaaagt caatggctgc 1140
agaaaaata aattgaataa acagaatct actccagctg ttgagggaga tgaaatgcag 1200
cctatgcca gctacacaga gaagaacaa cctctctatg atactacaaa caagctgag 1260
gcattctgag cattacaaag tgaagttgac acagacctcc atactttata agttcttcca 1320

```

```

ctctagtacc aagaacaac aacaaacgag atacattata attactgtct gattttctta 1380
cagttctaga atgaagactt atattgaat taggttttcc aaggttctta gaagacattt 1440
taatggattc tcattcctac ccttgataaa ttggaatttt tgattcttag ctgctaccag 1500
ctagtctctc gaagaactga tgttattaca aagaaaatac atgcccatac ccaaatattc 1560
aaatttgcca ggacagttaa taatgaaac caaatttctt caagaaataa ctgaagaagg 1620
agcaagtgtg aacagtttct tgtgtatcct ttcagaatat ttaattgtac atatgacatg 1680
tgtatatgcc tatggtatat gtgtcaattt atgtgtcccc ttacatatac atgcacatat 1740
ctttgtcaag gcaccagtgg gaacaatata ctgcattact gttctataca tatgaaaacc 1800
taataatata agtcttagag atcattttat atcatgacaa gttagagctac ctcaattctt 1860
ttaatgggta tataaaattc cattgtatag ttatatcatt atttaattaa aacaaacct 1920
aatgatggat atttagattc ttttaagttt tgtttatttc ttttaagttt tgtttgtggg 1980
ataaacaata ccacatagaa tgtttcttgt gcatatatct ctttgttttt gagtatattc 2040
gtaggataac tttcttgagt ggaattgtca ggtcaagggt tttgtgcatt ttactattga 2100
tatatatgtt aaatttgttc aaalatatat gtcaaatccc ctccaacatt gtttaaatgt 2160
gcctttccct aaatttctat ttttaataac gtactattcc tgccttctaca gttgccactt 2220
tctcttttta atcaaccaga ttaaatatga tgtgagatta taataagaat tatactattt 2280
aataaaaaag gatttatatt tttgggtcatg tttgtaagag agtgaatgca cgtgtgagaa 2340
cattagcttc tttctgaactc atttatctc cacaaggtgt ttgtacttg atgctaaca 2400
gttttgaga tgtgtctacat tgggaattgt tatttttatg gtgtacattc tattgtgata 2460
tattttatga ataattatg tctattgacc atataagtg cgaaaaaatc accatagagg 2520
acatggggta tttatttaca aactatgagc tacaataaa gcaagtggcc atgggatggc 2580
atgacctccc cctccatatt tttgtggagc aaaatattgg caatgtttat gtaaatcatt 2640
gttaatatca tgaattattt ttttaataaa aacataagtc tatttgtctc atagcagaaa 2700
aaacatgaga agttttttca tcatgataga aattgaaaca aaatatatto attcttcaat 2760
cataccatct gagattttta agacagctat tttgtcttat aagtatatat ttctccctct 2820
agacatttca gttactatgg attttgtcct caaagggacc tttagtctat tttggatgta 2880
aagctaactc aatgacactt ggcacatgat attttgatca agccattttg acttgacca 2940
aaagcagtg ccattagggt tctgcatata aatattacca agcaatgttc acaatagaca 3000
tcttacctc gtccctgaaa tttattaatt cttcatccaa ccctgggtga gctgaggctc 3060
atagttaggt tcaagactat ctgtttaaatt attactgaaa aacaaagtaa gacagtacta 3120
tgcttacctc ttaacttgat aatgtcaaaa caggcatgtt aaatgacac atagaaaaga 3180
cttcaagata atttatagaa gttaaattat attgtacaga aaataattgt atgaaaatct 3240
ctactatggg gctggaacat ggttgaacat tagaatgata taaaaatta tatatattct 3300
ccaaatccac gctagacctg tcaaataga gaactagag attagacctg gcgtgcagc 3360
aaggtcatcc aggaagcaga qgctgagacg gagttaggtg tyattactta catagtcgat 3420
tacattttac aaataacatt ttatatgtct catattactg gctttctccc catcccatct 3480
tgtatctttt cctttgtctt gctagatttg tcaattttct ctctctttct gtctctctct 3540
ctttcaatat ctctaataat ttgaaagtaa ttcatacata ccaaatatct attgggggta 3600
tgcttcaatt acaaaactct gaaaacggct ttactgagat ataattgata tatttaagtg 3660
tacagtttgt taaattttgc acatatttaa aatgtggact ttggtaaatg ttgacatagt 3720
tttcatctg tgaaccatc agcataatca agataataaa cttgtccatc acccccaaaa 3780
aaaaaaaaa aaaaaaaa

```

<210> 96

<211> 2683

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2640)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2676)

<223> n equals a,t,g, or c

<400> 96
acaasgtmac gectgacagg tmaccggacc cgggaattcc cgggtcgacc caccggcgtec 60
gcatttgcaa taacagaaaa ggaattgcat gtatgaagtt tccaatcggt ggcttttctt 120
tggttggggg aggggggtcgg gggatagttt gatttccatt ttctgaaaac gacagacttg 180
gattctgttt gtgtgtgcat attttatcca gccttaagtt ataaagctca tctgtcccgc 240
tgcatccctt gtgtatttcc aggacatggc tegtgggtgt gtgtgttcat tgtgtcgctc 300
tgtatgtatt ttctgtcat cactgttccc tctctcccg agtgcatt cagttaatat 360
aatcagttgc ttgtctcttt caaagtgcct tgaaggtctt gaactcatgt gtgagcatct 420
ttatcaacta cccaatttgc atgttctcca tcacatatcc tcttatttgc tctgtacccc 480
ctgagaatat gttttagaga tatgtgaata aagctgtctg ggtaaggagt aggtcttagcc 540
gacctatgaa taatacactt tagtctagtt ctltattcta aatctggatt gccagtattg 600
tgtattttaa ccaagtctgt gaataccctgc ttttttttgc cacagagtaa caagttttca 660
tgttaagatt tcataccaaa gttaggaagta aaaaatagctt agaaagctct gtcagggtgt 720
ttgtgcagct gacagargta atgtttacat acctaaaaaa gaaagatata cygtcagtta 780
tcctaaaaat aaattgtttg gaaagtacaa tgcaccacat tttgttagaa gtcactatt 840
tgataaacag ttgaaattca agatgtgttt gaccttagt catttttact ctttgggtct 900
gagtatacct attttcttag ttttttttag aattcatgga tcagtctgat ctactcttat 960
gtatgacata ggaaggtcat ttttttttag aattcatgga tcagtctgat ctactcttat 1020
tcataatgga acatgtaac atactgaaa ctgtttttca ggagagaaat atgagttgga 1080
gggaaggaaa agtgggtcta ctaatgttcc aaaaatctca tcagagaagg tatgatattc 1140
tcagggtgtg aaaaattttt ttatgtgatt gagaatgcag gtttaacaga agagataagg 1200
ggcataatga ctgtgtgttt tccagactgg attttctac cgcaactatt aatgttttca 1260
gagtgtatga ggaccacctt tgtgtataca ctgtgtatt taaaccttgc attggttaaca 1320
aatgatcaa ctttaattca ggtagaatcc aagatggctg tacttcagtt gtatgataaa 1380
attaatggtt ctcatgactt gtgtggcatc taaaaataat gtttttatag catctctctg 1440
ccactaaatt gttgacttga atttgggaaa aaaaaaaagt tgggtgtgat atgtatatgt 1500
gtgtgtgtat atatgtattt ataaacaagt gtgtttgagt aacaagttag ttctcatgtc 1560
ttccctctac catgtgtatt ccacacacaa atggctgagt tatagtata aaacaatttg 1620
caataaaaaa aaaacccaaa cagattgtca gtttaaccagg aacaggttaa tgttttttaa 1680
tgaatctggc attatagtga gcaaatgtcg tactaattta ggctaatttc taatactacc 1740
ataatttgg totaatttcc tgttggggtg gaaattacta aaattgtggg gatttttttc 1800
tgatttttac attgttttag gaaacatttt tactaattca gctgtcttag gtaaaatgaa 1860
tagttttctt cctgtttttt tatgtgtcat tgttagtggc ctcaagaattc tgaatcagtaa 1920
ctttgtgtat gatgtgaat tacaaaacctt ttgaatgac cagttgaaaa cgtatccctc 1980
tactttcttc agttgttaga aaggttaatt tccctcagtg tccacatta tacciaacct 2040
agagaagaac aggtatagg gayaaataaa catacggtgg ttccagtggt ttgtgtcatg 2100
tgccacagg agaaactaac catcagttg ttgactttcc aaaaatgtgc attagtaant agttgtcact 2160
gaatttggtt ccatcagttg ttgactttcc aaaaatgtgc attagtaant agttgtcact 2220
ctgtgtgtct catggtcaat atcaatcaga ctttcatgat ctctactaat tattagttaga 2280
gtcctgtact atgtctgtaa ctactaagtt taaagaaaag cacatagtca cttcatctct 2340
ttttttctta gctacgctc actccccaac ccatcccaac attgacatgc tatctgtgga 2400
caaatacgag ttctcagaat ctagtcaagt tgccatcatc ccccttgctt cggccgttca 2460
tagtaggtat gcataatgtt tttctgtac agtactgtgt gtgtgtgtgt atatatatat 2520
acatctgtat gcacacatct ttgataaaat agctatttga ctgacgggt taaagtggct 2580
ttaataact tegtgtgtg tattggatac atcttaaaaa aaaaaaatct ggaccagaa 2640
ccatgccata cttgggttga ctatttttgg gcattnaaaa ttg 2683

<210> 97

<211> 2181

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> n equals a,t,g, or c

<400> 97

gtacnggatt cccgggtcga cccacgctc cggcagcag aggggcagtg ggcggggga 60
 agatgattct gggcctcccc catctactgt cattaaccaa aatgaacat ttgccaacat 120
 aatttttaaa cctactgtag tacaacaagc caggattgcc cagaatggaa ttttgggaga 180
 ttttatcatt agatattgacg tcaatagaga acagagcatt ggggacatcc aggttctaaa 240
 tggctatttt ggcactact ttgtctctaa agaccttctt cctttaccca agaattgtgt 300
 attcgtgctt gacagcagtg cttctatggg gggaaccaaa ctccggcaga ccaaggatgc 360
 cctcttcaca attctccatg acctccgacc ccaggacgtt ttcagtatca ttggattttc 420
 caaccggatc aaagtatgga agggaccatt gatattcagc actccagaca gcattcaggga 480
 tgggaaagtg tacattcacc atatgtcacc cactggaggc acagacatca acgggtctct 540
 gcagagggcc atcaggctcc tcaacaagta cgtggccac agtggcattg gacaccggag 600
 cgtgtccctc atcgtcttcc tgacggatgg gaagccacg gtcggggaga cgcacacctt 660
 caagatcctc aacaacaccc gcagggcgtt cagggctgct ggagaaactg tcgctggaga actgcccctt 720
 categgcaac gacgtggact tcaggctgct ggagaaactg tcgctggaga actgcccctt 780
 caccagggcg gtgcacgagg agggggacgc cggaggccaa gtcgtgcatc tcaccatttg 840
 aatcaggacc ccgctctct ctgacatccg catcgattat ccccccagct cagtgtgtga 900
 ggccaccaag accctgttcc ccaactactt caacggctcg gacatcatca ttgcccggaa 960
 gctggtggac agaaagtctg atcacctgca cgtggaggtc accgccagca acagtaagaa 1020
 attcatcctc ctgaagacag atgtgctgtt gcggcctcag aaggcaggga aagatgtcac 1080
 aggaagcccc aggcctggag ggcagggaga gggggacmcc aaccacatcg agcgtctctg 1140
 gagctacctc accacaaagg agctgctgag ctccctggctg caaagtqacg atgaaccgga 1200
 gaaggagcgg ctggggcagc yggcccaggg cctggctgtg agctaccgct tctcactcc 1260
 ctccacctcc atgaagctga gggggccggg cccacgcalg gacggcctgg agggggccca 1320
 cggcatgtcg gctgcatggg gaccgcaacc ggtgtgtag agcgtgtag gacgtggcac 1380
 gcagccagga cctttgtcca agaagccata ccagccaaga attaaatct ctaaaacatc 1440
 agtggatggt gatccccact ttgtgtgga ttcccccctg agcagactca cgtgtgctt 1500
 caacattgat gggcagcccg gggacatcct caggctgtgt cctgacaca gggactctgg 1560
 tgcacagtg aacggagagt taattggggc acccgccctt ccaaatggcc acaagaaaca 1620
 gcgcacttac ttgcgacta tcacctctt catcaacaag ccagagagat cttatctcga 1680
 gatcacaccg agcagagtca tcttggatgg tggggacaga ctggtgctcc cctgcaacca 1740
 gagtgtgtg gtggggagct ggggkctgga ggtgtccggt tctgccaacg ccaatgtcac 1800
 gctcaccatc cagggtctca tagcctttgt cactctcct cactctcaca aaagccggc 1860
 gcccctccag cgacaccacc tgggtttcta cattgccaac agcgagggcc ttccagcaa 1920
 ctgccacgga ctgtgggllc agttctgaa ccaggatgcc agactcacag aagacctgc 1980
 agggccacgc cagaacctca ctccacctct gctccttcag gtgggagagg ggcctgagc 2040
 cgtcctaaca ctgaaaggcc accaagctcc agtggctctg aagcaaggga agatttaca 2100
 cgggggaagc cagwtagayt gytggtttgc caggaaatg ccgcaaaact gattgacggg 2160
 gagtacagga ttacctggca t 2181

<210> 98

<211> 1957

<212> DNA

<213> Homo sapiens

<400> 98

acgcgtccgg agggggcagg ctcatggcgc cggcgtcgg gtgctccggt ctctggcgcc 60
 tggcggcgtt ggctctaccc ggctccgggg cggagggcga cggcgggtgg cgcggggcg 120
 ggccgggggg cgtgacggag gaggagcgtt gcacgglyga ggtcggggcc gacctcactt 180
 acgaggagtt cgtgcagcag tacgctctcg tcaggcccgat catcctgcag ggactcacgg 240
 acaactcgag gttccgggcc ctgtgtctcc gcgacagatt gctggcttctg ttgggggaca 300
 gagtgttccg gctgagcacc gccaacacct actctacca caaagtggac ttgccccttc 360
 aggtatgtt ggagcagctg ctgnaccccc agggacccac ctccctgggc aatgacaccc 420
 tgtaactctt cgggggacaac aacttcaccg agtggggctc tctctttctg cactactccc 480
 caccctcatt tggcctgctg ggaacgctc cagcttacag ctttggatc gcaggagctg 540
 gctcgggggt gcccttccac tggcaaggac cgggttactc agaagtgate tacggtcgta 600
 agcgtgtgtt cctttaccca cctaaagaag cggcagagtt caaccccaac aagaccagc 660
 tggcctgggt ccgggacaca taccagcct gcacggtctg cagggccttg gattgtacca 720
 tccgggctgt tgaggtgctg acttcccagc cgtgggtggc atgctacgt caaccttgac 780
 accagcgtct tcatctcacc ttctccggct agccaaaca gctggcagga ctgcccgtca 840


```

cacaccagca cgtccacact cgtgctcagc gattttatta cacagatagt ggcggcaatg 900
gcctcagccc agcccacccct cacctgcttt tccagcccac aaagggggac gatcacgggc 960
cagcaaaagc gatgctgaga ggggaaacag tccagagtcc aacagcagaa ctrgggggaa 1020
gcggtcgggg tggccaggaa cataaactat gtataggggc cgggggcttc tggccagggc 1080
tcccctggac caggacgcca ggtaggggag ggaacctcag tagtcctcca cccagccatt 1140
ctcagagatg aatgcgtcaa taacctcctt catagccaag ttggggatga gctgttcttg 1200
ggtcaggggg ctccgggtca cgggggtcaa atgacccaca cgtgcagtg acaagaaggc 1260
cagagggcag tcatggggcc caggaccatg ccactggccc tgetccccc ggcgagggc 1320
tcacctgcag gtgctctctg atgtccttgc ggtcgtaggt gatgccactg ggcgtgatgc 1380
acggctcccg catcagctca aagctgatct tgccacacag gtatcgggg atgtctcgct 1440
tctgtggcac aggggcacac ggtcagaggc tgaaaagggg cactgcacga gcacctgcca 1500
gccatcgcca gcaagcgaca cacactcacc ttctcttct catccacctg aaaaaaagc 1560
tcttccatgt ccccatgtta ctgtctctgt gaagagtga gtgctgtgct tgggggagac 1620
accacacatc cctcctccat ygggcacaga cccaacacaa ggcggggatg ctcccagcc 1680
acgtgcacac acacagaccc acatgtgggt ggggggcacc ctacgtgct tggcctcaat 1740
gcagcgctgc tggggccgga cgtggctgtc gtctctatca ccctcgtggt ttcgctggca 1800
ctcttccagc tccctggggg ttgaccagga gccggtcaga gatggacctg gccagatgtc 1860
tgaccacacc ccaatctcag agctaacatc cacacttccc cacatttctt gcttgccagt 1920
aaagccttcg ataaacaaa aaaaaaaaaa aaaaaaa 1957
```

<210> 99
<211> 1112
<212> DNA
<213> Homo sapiens

```

<400> 99
ccacgcgtcc gccaccacac aaaggcactt gcagttacat tcaccacatt tctaacggag 60
ccattgaagc atattgaaaa aggaactggg gaattttatta aagcactcat gaaggaaatt 120
ccagcgctgc ttcattcttc agtgctgata attatggcat tagccatcct gagtttctgc 180
tatggtgctg gaaaatcagt tcatgtgctg agacatatag gcggtcctga gagagaacct 240
ccccaggcac ttgcggcaag ggatagaaga cggcaggagg aaattgatta tagacctgat 300
ggtaggagcag gtgatgcga tttccattat agggggccaaa tggggccccc tgagcaaggc 360
ccttatgcca aaacgtatga gggtagaaga gagattttga gagagagaga tgttgacttg 420
agatttcaga ctggcaacaa gagccctgaa gtgctccggg catttgatgt accagacgca 480
gaggcacgag agcatcccac ggtggtaccc agtcataaat caccctgtttt ggatacaaac 540
cccaaggaga caggtggaat cctgggggaa ggcacaccca aagaaagcag tactgaaagc 600
agccagtcgg ccaagcctgt ctctggccaa gacacatcag ggaatacaga aggttcaccc 660
gcagcggaaa aggccagct caagtctgaa gccgcaggca gccagaccca aggcagcaca 720
tacagccccg caagaggtgt ggtggacca cgtggacagg atccgggtcay cagccccctgt 780
ggctagagga acaccagcac aaacgacagc ctcaagtcct cttcgagctt tgtaaagtaa 840
tctcacagc tgccaaagaa cacatcccaa gcagtaatca cagatgatga agcaccttac 900
aggacccctc caccctcaaa cgcgatgtc cagagaagta ttaatgcctt aatagactac 960
tgaagggtaa ctatttcat cattctaaaa atattttaag ctgtattaca gtgctataaa 1020
ttctcctttc aaggaaaaaa gtaaatagatt gtttcccttac cgtgtttgaa aggaaaaaaa 1080
ataaatccat agtaactaaa aaaaaaaaaa aa 1112
```

<210> 100
<211> 887
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (303)
<223> n equals a,t,g, or c

<400> 100

ggcagcagag aattataggt gcatgatggy gcttttggag actggcaatg tctgttttg 60
ggctgggta gtggttactt gtgtgtattc actttatgct aactcattga actgtacaga 120
tatggactgt gccctttctt atatgtgtgt aatgcttcaa caaaagtgtc aatagtgtatg 180
catgcacatg tcaaaatttc aaactatatt aaagagtgtg caartaaaag gaagltatcc 240
tctcactcta aagcctatt tccctctctc agtctatcat tactactagt tctagtata 300
tcntttagaa atgkgtgta aaagaacaa gatgtgtatg tctctacagg tatatattta 360
tcttttttgt aaltacaaaa atataaactc actacatatg ttattctacc acatgctttt 420
tttcatgtaa cagtatgtct tagacatctt ttcctattat tgcgtggaag ctatcaacct 480
tattctttgt aatgactcca taaattatto tactgtgaaa acacaccatg ttttaaccagt 540
tctctgttag tgaacattta ggatttttcc agttttttaa tattacagtg acatatttaa 600
cattaaacat atcttttgac acatgtcctt gcacacatgt ataggataga tggactttaa 660
caccctttgg ctagattctt tagcacataa cgtaaatatc ccatagagtc aaaaccaccc 720
ttaaactctc ctacaggaggc tgggtgtggt ggctcaecgc cgtaatccca gcactttagg 780
aggccgaggt gggcggatca egaggtcagg agatcgagac catcctggcc aacatggtga 840
aacctgtct ctactaaaaa taaaaaaa aaaaaaaa actcgta 887

<210> 101
<211> 1248
<212> DNA
<213> Homo sapiens

<400> 101
ccacgcgtcc ggtctattaa ggtgacagaa ctgaagggcc tggccaacca tgtggttgtg 60
ggcagtgtct cctgtgagac caaggacctg tttgcggccc tggcccaggt tgtggtgtg 120
gatatacatg accttggtag catcaagctc agcctggaag tcacatggag ccccttcgac 180
aaggatgacc agccctcagc tgcttctctt gtcaacaagg cctccacagt caccacggc 240
ttctccacct atagccagag cccaccggac acaccctcac ttcgggaaca ggccttctat 300
aacatgctgc gacggcagga ggagctggag aatgggacag catgggtccct gtcacttgaa 360
tcttcagacg actcatccag cccacagctc tcaggcactg cccgccactc accagccctc 420
aggcccttgg tgcagcagcc cgagcccctt cccatccaag ttgccttcgg caggcctgag 480
accccagct ctgggcccctt ggatgaggag ggggccgtgg cccagtcctt gycaaatggg 540
catgcacctc acagtccgac tctgagccac atcagttagg ctagtgtaaa tgcgtccttg 600
gctgaggctt cagtggaggg cgttggccca aaaagcctat cctggggacc tagcccacct 660
acacaccag ctcccaccca tggaaagcac cccagtcctg ttcctctcgc cctggacctc 720
ggccactctg ccacaagctc taccctcggg acaacaggct ctgtccccc acatcacagac 780
cctgcccact ctgcacacct agactcagtt cataagtcca cagactctgg ccttcagaa 840
ctgccaggcc ccacacacac cactacaggg tctacctata gtgccattac cactaccac 900
agtgtccaa gcccctcac tcacactact acaggctcca cccacaagcc cataatctt 960
accttacta ctacaggccc taccctcaat atcataggcc cagtccagac taccacaagg 1020
cccaccaca ctatgccaa ccttctctcc cacagcaata gtccccaata cgtagatttt 1080
tgctcttctg tatgtgacaa catttttcta cattatgtta ttggaaattt ctttcataca 1140
ttatattcct ctaaaactct caaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1248

<210> 102
<211> 1841
<212> DNA
<213> Homo sapiens

<400> 102
ggcagcagct ggtgcaggag ctggagcagt accagtgtgt gccgaagaga ttggactggg 60
agggcaacga gcacaacagg agctacgagg agttggtctt gtccaataag catgtggctc 120
ctgatcatct ttgcaaatc tgcagcgca tgggtcctat ttggataaa gaaattccac 180
ccagtatttc aagatcact tctttacttg gtgcaggaag gcagtccttg ctacgtacag 240
caaaaggtag ctttaattga agaagtgttc tgccttctat taatagccca ataattatta 300
taattgtgaa gtaattgaag catgtggaag aaagggtgaa atgtaactat aaatcatct 360
gtggactata aaattctctg catctagcat agaaccattga attttattac ataagtgttt 420

```
aatgggtccct tctgcattaa aaaagtggat aaagatatag atgttaagct aaaaagcttg 480
aatttattct gagatgttgt ttgagggttt atcaatgga gttcttaatt ttccattttg 540
tagctcactc ataacttcat tgaatgtaat tggatgtgtc taataaaactc tttaaatgct 600
agagggtattt catttgatat tttagcttctg aaagcccttt gttataaagg gaagtgtatt 660
tctaaaatttg gttagcagctt gaaaacaagc accacaaatg taaaattgca tggttctttt 720
tttactaatt taattttttt gccaaagtat gtgctagcaa aatgtttgaa attgctattc 780
tttttctggt agcttgggtat atatgactta gactaagtat atgtatgtga tataatatat 840
gtgtacatgt ggctaaactg ctaatgggca aagattgttg gttcttctga tgctgagtat 900
acatcaagtt catcccatga ttatttttta ttacgagcta ttgctgatgt gatgctactc 960
ttagctgcac caccagtata aagcttaact gagaaagaac acccctccct cttagtccg 1020
tgccagactg gtttggttagc tttagttgtt tcttagtgct ctgcccagtc caccctgtgg 1080
cactaatcag gacactgttt atattcttcc tcttctgtgt cctattccac ttgttaatta 1140
ttctatttta gctgggtata tggtagttaa ttggtagcct gtttccctt gttttcttta 1200
cttgtgtcaa gctccatgtc gtlgtllyl gatgagcagt gatttagaac tggccagacc 1260
ttagaagagt cttcagcaag ctgccctagg gtaggggcat attctctgtt tgtttgttac 1320
tggtaacctc ggaggatgac ttgttaactgc tctttgtgca tgatagtgtt aatgaatcca 1380
ttcatgtaaa atgcaatatg tctgttagtt tggggcaccg gaggtcagt agagggttag 1440
tatgatgctt tccctttctt ctttgagtta tgaagaaact aatttctggc acagtgtgac 1500
tgcttcaaac ctatgttctg ctgctatctc ctatagagga gggcagactt tttttcttta 1560
gtgcatttgc tggtaggtca aggggggatg gactttgaat tagtgtcag agtcacagat 1620
ctcacgtatg tgctcttcaq taqaqaattt tctgtgatcc tacaatgaag ggaagctat 1680
ataattttat ggtacttctt aaagatagag actaaagtca tggtagtatt ggccaaatta 1740
attttaaaac tgaaccaagc atgaatttcc atataaatca aagaactttt tctttataaa 1800
agcttccatt ttgtaaaagt tgaaaaaaaa aaaaaaaa a 1841
```

```
<210> 103
<211> 685
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (678)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (679)
<223> n equals a,t,g, or c
```

```
<400> 103
actacggctg cgagaagacg acagaagggg ggcggcgacg gaggaggagg a-ggaggcgg 60
tgggtgttcgt cttctctctc ctcgattgtt gcgcgctcat cttctctctg gttctactca 120
taattacatt gtctgattta gaattgtatt acattaatgc tagatcatgt tgctcaaat 180
taaacagtg ggttaattcca gaattgattg gccataccat tgcactgta ttactgctca 240
tgtcattgca ctggttcate ttcttctca acttaacctg tggcaactgg aataatatac 300
gatacattat ggtgccagat ggtaacatgg gagtgtttga tccaacagaa atacacaatc 360
gagggcagct gaagtccac atgaagaag ccatgatcaa gcttggtttc cacttgctct 420
gcttcttcat gtatctttat agtatgatct tagctttgat aaatgactga agctggagaa 480
gccgtgggtt aagtcagcct acnctacagt gcacagtga ggagccagag acttcttaaa 540
tcatccttag aaccgtgacc atagcagtat atatttctct cttggaacaa aaaactattt 600
ttgctgtatt ttaccatat aaagtattta aaaaaaca-ga aaaaaaaa aaaaaaaa 660
aaaaaaaa aaaaaanna aaaaa 685
```

```
<210> 104
<211> 1168
<212> DNA
```

<213> Homo sapiens

<400> 104

ggcaccgagcc	cccgccccc	ccctccctcc	cctcccttcc	ccggccccc	ctctggcccc	60
ggcccatteg	ctgttgggtc	ttctgctagg	gaggatgtcg	ggctcgctcg	tgcccagcgc	120
cctggccctc	tcgctgttgc	tggtctctgg	ctccctctc	ccagggccag	gcgccgtca	180
gaacgtgaga	gtacaatctg	gacaggatca	gaagtagaga	atgaagtgtg	aagagaaagg	240
gaaagacaga	agaaaqgctc	cagtagtaca	aggagaaaag	caggatgcaa	gaatgaggaa	300
tgaatcttctg	tttgnggggc	atccggaaaa	ataaagctg	tcagaaaagag	taaataagacc	360
agggacctct	aaagttaaatt	cacacatcaa	agttaaaata	atgttggaga	alcacctctt	420
gtgaaaaall	ggcllagctt	tcagtatgcc	tttttaaaaa	aaacattatc	attttatata	480
aa:tttttaaa	atgttgttca	taatatggag	tttaatttta	agcaccttag	ataatgcatt	540
tgtagctttg	ttcttgaatt	ttttatggat	tttttttttc	aaaattccca	attttagttg	600
gtaaggatta	acttcgggaa	gacaggaaac	ccctccagta	aaattgattg	gttatataatg	660
gttacaatatt	ttaggcttat	atacataaca	aaallctaa	ctgaatttaa	aagtgtatctt	720
gtgtaaaaac	attatcttag	tgatattgat	gtctaaattt	aaaagagtga	atacacaaqt	780
aaaatatatc	tgctttttaa	ggatctatcc	agtttaggaa	ggagagtcac	aatttgattt	840
taatttcaat	ttattatatt	gtctgaaact	gaaagttagc	ctaacctttg	tttgcctttg	900
tgtatgtaca	aaggcaaaac	tttatcaatc	aaactctatt	aatttgagat	tattttgacc	960
tgattgttca	gaacttttgt	ctatctgtat	agaaatgggg	ttttctaaat	attttaagaa	1020
tttctacgt	atgtaaaatt	acttgacac	agtaagttag	gggagacatt	taataatcct	1080
caqataacct	ctgttttctt	gttgtgtttc	tgtttttca	aataaataaa	ctgagtgtta	1140
tctgttcatt	aaaatagaat	gtagtcag				1168

<210> 105

<211> 1175

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (24)

<223> n equals a,t,g, or c

<400> 105

gcattgaaat	atattctata	catnaagtgc	tgtcttgagc	tgtacatwta	gccatattta	60
gratttttatt	argcaggatt	caaggccctc	taaaantgga	tattcagata	tttaaaaaata	120
cactattaag	gaatgcaatg	taaaatcaca	ctaactttg	catagcactt	tatagtttac	180
aaaatgcctt	cacatatacg	agctcattta	ttctctcttc	tcttcttctt	attcatctat	240
caaggaaat	cttctataag	ccaggcatca	ggcttgacac	tgaagacaca	aaatgaaaaa	300
gatatacaag	tctctattct	taaagagttc	gtagtttaat	gaagtgacct	aaaaagttaa	360
cagttgcaat	ataacatgca	aaggagtgtg	atgaaataca	cctagagtac	tatgaaaatg	420
gcataagagg	accaagcctg	taattgaagtc	agagaaaagta	aaagagggtga	agcckgagct	480
aagtttttaaa	ggatgaacaa	aaattgacca	gacaaaggag	ttggagaagt	gggacggtaa	540
agga:aaaag	cttttctaat	ttggggaaat	gtgagtcgtc	gatattagat	gatattatta	600
atagattgtg	cacagagtgc	acatggtaga	gaggtgagag	atgaggtagc	actgttaggg	660
cagataggtg	aattctcaca	gtaaccctgt	gwtgtacmtt	atcatctctc	tctccattat	720
gtagggggaga	acaccaaaag	ccaaagagat	taagtaactt	tccagaattt	tgtattcaaa	780
tcctaagcgt	ttggtagctg	tgtttccctg	catatagctt	gctcaaaag	aaaattttaa	840
gttgattttt	gtattaaatt	taaacaaaata	raggcgggtg	gcagtgyctc	acgcctgtag	900
tcccagcact	ttggtaygcc	aaygtgggag	gatcacctga	ggtcaggatt	tcgagaccag	960
cctggccaat	atggtgaaac	ccatctctta	ctaacaata	aaaattagct	gggcatggtg	1020
gcacatgcct	gtaatcctgg	ctacttggga	agctgaggca	ggaqaatctc	ttganccag	1080
gagggcgagg	ttgcactgag	ccgagattgt	gccactgcac	tacaactctg	acaacagagc	1140
aagattccgt	ctcaaaaaaa	aaaaaaaaaa	ctcga			1175

<210> 106

<211> 1021
<212> DNA
<213> Homo sapiens

<400> 106.
ggcagcgagaa taaaatagat ttagggtatt cgacacattt aatacataat gaacagtgaa 60
tttcttgaat aatataatgc cteaatgtga ctgatatgca aaatatttaa atcccttaca 120
ggatgtgcat ttaccaatca gaacagatgt tggctttact gcttgattta gtttctctgta 180
ttagtttgct tgtattagtt tgctggggca gccataacaa agtaccacag aaatttatat 240
tctcacaatt ctgggggcta gaagactgag ataaagatgt ctgcagggtt ggtttcttct 300
aaggactctc ttgttggctt gtagatgggt gttgtctccc tgtgcttcca cctgcacttc 360
ccctctgtacc tgcctgtatc ttaactctctt cttataagga cagagtcata ttggattagg 420
gcctcacctc aatgacctcc ttttaactta attacctctt tagagactct gtcttcaaat 480
acaggccatc tctgaggtac ttttaaggta gaacttcaac atatgcat tgggaactgggg 540
cataactgag tccatgacac tattggagag ggttctggag ccataacaga tggaaatgaat 600
gggccttggt tggattctaa tttaaataaa ccaactatag aaaaacatgt tttaggcaat 660
cagatttttt gttatgggct aaatatttag aagatgttaa gaaatgttta ttaatttcat 720
taggtaaaat aaagtgtgtg tggttatgta gagtatgact tacgtgcaca gaacagaatg 780
ataagtgctc caggatttgc tttaaaaat tctagatatt tttaaaaggt gagaggaat 840
gacacatgta tctctaaatt ttgatgtgtg ttgaagctgg ctggtaggta cctagtattt 900
cattacactt tttctttgt gtgtttggaa atttttataa taagcaggaa aaataaaagt 960
aagaatatal gtattataga taatttgaaa tatgtagaat catgaaaaaa aaaaaaaaaa 1020
a 1021

<210> 107
<211> 830
<212> DNA
<213> Homo sapiens

<400> 107
ggcagcgagta aggactgtgt tctttatgca tttcttgatc caggcatggc agttcctctt 60
ttcctgtaca tctcacact cctgccactt ctacccttcc tcttatccct ctgcttttca 120
cccttgactg taaaaaqaag tagcagttcc gaaagcaaga gttccctatg aacacggaaag 180
aagacattgg caacttttga gtacaacaac tatatttaat agagtaattt aagaacatca 240
gccagtgaat tttatacaag atagtgaag agaaaaggaa gattaattag gggtagttta 300
ggatgccatt aaatagccta gaattagggg agtagtcgtt gaatagaaag gaggcccaa 360
atttgaggga tataagctaa gaatttgtaa gccaaagaaga aggaaaaggt ttgggcagta 420
aggataatga ggaacaaaat agagaactca gaagcaatat ctgactgtta tcattggang 480
aatTTTTtTg cttgcttgag gctggatatt gaagtggatc aggatacttg agtgactatc 540
tgatgggctt ttggaactag ctctcaagag gtgaaaaatg gctttttttt ctttttcttt 600
cttttttttt tttttttagg caaggtctca ctgttggtga ggcTgaacct cctgggctca 660
agcagttgtc ccattgcagc ctctcagat actctgtaag ccaaggcagg gggaaatatt 720
tgtgtcctag agtttgaggc tgtgttgagc taagatcaca ctgctgtgct cacttcagcc 780
tgggcacac agtgaacccc cgtctccatc tgtttaaaaa aaaaaaaaaa 830

<210> 108
<211> 1301
<212> DNA
<213> Homo sapiens

<400> 108
aagagggtgq ctgcagagtt cttgtttgtc ctgtgctctg agagtgggta gttatggaga 60
cccagggtccc agccccccc dectcagcca ggcttgcaqa ctgacctctg ccttgccccct 120
cagtgcctcg attcatcaag tacacaggct atgggaatgc tgcTggcctt ctggctgcca 180
ggggcctcat ggcaggaggc cggcccaggg gccagtactc agaggatgag gacacagaca 240
cagatgagta caaggaaqcc aaagccagca taaccctgt gaccgggagg gtggaggaga 300
agccgctaa ccttatggag ggcctgacag aggagcagaa ggagcacgag gccatgaagc 360

```
tggtgacccat gtttgacaag ctctccagga acagagtcac ccagccaatg gggatgagtc 420
ccccgggtca tcttaagtc ctcaggagat ccattgtgca gactatggag cagcagctct 480
cctcgggaccc tgactcggac ccctgactgag gatggcagct cttctgctcc cccatcagga 540
ctgggtgctgc ttccagagac ttccctgggg ttgcaacctg ggggaagccac atccactgg 600
atccacaccc gcccccactt ctccatctta gaaacccctt cttctgactc ccgttctgtt 660
catgatttgc ctctggtcca gtttctcctc tctggactgc aacggtcttc ttgtgctaga 720
actcaggctc agcctcgaat tccacagacg aagtaacttc ttttctctgc gccaaaggga 780
atgtgttcag aagctgctgc ctgagggcag gccctacctg ggcacacaga agagcatatg 840
ggagggcagg ggtttgggtg tgggtgcaca caaagcaagc accatctggg attggcacac 900
tggcagaacc agtgtgttg ggtatgtgct gcacttccca gggagaaaac ctgtcagaac 960
tttccatagc agtatatcag aacacaccct tccaaggatg gtatgctctg ttgttctctg 1020
cctgtcttca ctgagcgagc ggcctggagg ctcttagaca ttctccttgg tccctgctca 1080
gctgcccact gtagtatcca cagtccccga gttctcgtg gttttggcaa ttaaacctcc 1140
ttctacttgg tttagactac acttacaaca aggaaaatgc cctctgtgtg accatagatt 1200
gagatttata ccacatacca cacatagcca cagaaacatc atcttgaat aaagaagagt 1260
tttggaacaa aaaaaaaaaa aaaaaaaaaa aaaaaactcg a 1301
```

<210> 109
<211> 1932
<212> DNA
<213> Homo sapiens

```
<400> 109
aatttttttt tttttttttt tttttttgaa aaaaaaatg ggtagtgtat attttgcagg 60
tttaagacaa ctcaggacaa taaaaacaat ggactttaca tgtgtatata tatagctctc 120
ttaggcacca taatcagtat gagccaacaa tatttaaaact tgattcaggc cacattcaga 180
catttgctct tatatacaaa tatttaaaat aaatcacatc tgaatgtgt tctgttacat 240
acaaaaaagg aaaaactata caacgcagag cagtgtgtgt gttttaaaata attacattta 300
catgtaagct aaatggaacc agcaatgggt ctcaagtttt tatcatccct tccagaaaat 360
ctttttctac catctctctt attttttgct tggctttgct ggaacatggt ttgtggtlct 420
ccagtttcat gtctttatta gggaaaggcat ttgagtagag gataggactc cctgagtgtc 480
ctccacatcg gcttgtgact ttgctgttga agacttgact gaggacattg aagaacggca 540
ggagctgctc catactgcgc acgtgcgaga tggtagcag caagtgcctt ggctcccaac 600
ccaatgttct cctctgagtgt tcttctcttg gatttttctg cagaaaaaaa aaagtgaact 660
gggtattaata caacagacaa tgtgggtatgt tagaaaaatt aaaaatataa aaactttggc 720
aattgggtcaa gaaaagaata caaatgacat taagtttcta actcctgacc tgatcaaaac 780
ccttggtgct tctgagacct tttactgcca tttattagtt ttacatggag cagtctaaca 840
ttgtagtaat agttcccaac tagaatgcgc agataagctt agttaacaga aatagctttg 900
aacaggaata gagtcaaaaca taaaagtttt atgttgtgct ttgtatttac tcaaaaagct 960
cccaggttct tgaacctcca ctactgtaac caaggactag gtcacaaaat tactacagaa 1020
aaaaaggaaca aagtgcttta cacatttcat aatatatccc cttttattat aattagttaa 1080
ttccctttta tctaaatggc ctaaaatttg catgatggta gcagtgtcca aagtgaataa 1140
ttactgtcag tactgcatca cagagaaagg aagggatccc tcaggagaca ctgctgtctc 1200
cttctgggtt gtgctaaaca acatagggag gaaagctgga cctggagtca aaggaaatga 1260
gttagtgtgc tggctctgcc atacttacg cacccttggg caggalaatc aaaygttctt 1320
cacttataaa atgggacagt ctaaaactac cttttagtag agaagtcaaa tgagaaggta 1380
tgtgaaaact ctgtcaacta aatataaaga ctaataattt gqgtattaaq aggctagtgt 1440
gagaagccac ctgaattaca caaacacagc tacagacatc attctgtcta gagaaagata 1500
agagagaaca ggttgggtga acttgggcag aatcacagat acaattccac actaaagaat 1560
gaaaaataagc aatgaactag acagaaygaa gaaatcatga agacttagga agcagaatta 1620
caatctgtca tattacaaca tggagtttgc cttctaagat cagatgttgc tcagaaactt 1680
tcattgttta cctaataatt taatatcact agtttctctg tgggtcaagc agatgcaaaa 1740
tccagcttat ttctctctat gtgcctcaca gcttattgct tattttaag taaaatcctg 1800
aaaaagggaa atattaggtt ggtgcaaaag taattgcggt ttttgcatg ttgaaatttg 1860
cgtttttata ttggagtaaa tcttcaataa aatgtgggta tgttatataa aaaaaaaaaz 1920
aaaaaactcg ag 1932
```

<210> 110
<211> 1534
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1212)
<223> n equals a,t,g, or c

<400> 110
tcgaagatag gttecgagcg gtggatgttg cagctgatca tgcagttggg ttcgg-gctg 60
ctcacacgct gccctctttg gggctgcttc agccagctca tgctgtacgc tgagagggct 120
gaggcacgcc ggaagcccca catcccagtg ccttacctgt atttcgacat gggggcagcc 180
gtgctgtgcg ctagtctcat gtccctttggc gtgaagcggc gctgggtcgc gctgggggcc 240
gcactccaat tggccattag cactacgccc gctacatcg ggggctacgt coactacggg 300
gactggctga aggtccgtat gtactcgcgc acagtggcca tcatcggcgg ctctctgtg 360
ttggccagcg gtgctgggga gctgtaccgc cggaaacctc gcagccgctc cctgcagtc 420
accggccagg tgttcctggg tatctacctc atctgtgtgg cctactcact gcagcacagc 480
aaggaggaac ggcctggcgt tctgaaccat ctcnccaggag gggagctgat gatccagctg 540
ttcttcgtgc tgtatggcat cctggccctt ggcctctctg tcaggctact acgtgaccc 600
cgctgcccag atcctggctg tactgctgcc cctgtcatg ctgctcattg atggcaatgt 660
tgcttactgg cacaacacgc ggcgtgttga gttctggaac cagatgaagc tccttgga 720
gagtggtggc atcttcggaa ctgctgtcat cctggccact gatggctgag ttttatggca 780
agaggtgag atgggacag ggaagccactg agggtcaccc tgccttctc ctgtctggcc 840
cagctgctgt ttatttatgc ttttgggtct gtttgttga tctttgctt ttttaaaatt 900
gttttttcca gtttagaggg agctcatttg tccaaatttc tgggcttcay cgttlyggag 960
ggcaggaacc ctggcactaa tgcgtacaa ggttttttct ctgttaggaa gaacttgagg 1020
ccagctgccc actgagctct ctgtccctga agaaagggag tattgggcag ggcttgggat 1080
ccggctactg aagtgaggag agtgggagac agaggaagga agatggagat tggagtgag 1140
caaatgtgaa aaattcctct ttgaacctgg cagatgcagc taaactctgc agtaggttt 1200
ggagactgtg anagggagtg tgtgtgttga cacatgtgga tcaggcccag gaagggcaca 1260
ggggctgagc actacagaag tcacatgggt tctcagggta tggcaggggc agaaacagta 1320
ccggctctct gtcactcacc ttgagagtag agcagacctt gttctgctct gggtgtgaa 1380
ggggtggagc aqccagtgcc cagctttgcc ctctctctg tctctgttct tagctccatg 1440
gttggcctgg tgggggtgga gttccctccc aaacaccaga ccacacagtc ctccaaaaat 1500
aaacatttta tatagacaaa aaaaaaaa aa 1534

<210> 111
<211> 2871
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1234)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1259)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1283)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1284)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1297)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1378)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1912)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1913)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1935)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1947)
<223> n equals a,t,g, or c

<400> 1:1

ggcgcgaggg	ggcggtgggt	gctgagtcgg	tggtggcgaga	ggcggaaggcg	acagctctag	60
gggttggcac	cgcccccgag	aggaggatgc	gggtccggat	agggctgacg	ctgctgctgt	120
gtgcggtgct	gctgagcttg	gctcggcggt	cctcggatga	agaaggcagc	caggatgaat	180
ccttaggatt	ccaagactac	tttgacatca	gatgagtcag	taaaggacca	tactactgca	240
ggcagagtag	ttgctgggca	aatatttctt	gattcagag	aatctgaatt	agaatcctct	300
attcaagaag	aggaagacag	cctcaagagc	caagaggggg	aaagtgtcac	agaagatctc	360
agctttctag	agtcctccaaa	tccagaaaac	aaggactatg	aagagccaaa	gaaagtacgg	420
aaaccaggta	gtctggacat	tttccttgc	ttctgattta	tttaggggac	aaatgaaaa	480
tttaagctaa	tgaatanaa	agctgaagaa	gactggcttc	actgattatt	accacaaa	540
aatatattga	gtgtagtttg	gagagaattt	ctagatttta	atataccaaa	gttattcacl	600
taacagattt	gacccaagtt	acataagctg	aattccatag	algagattgc	atttatcttt	660
ttattaatat	cctgacgttt	cttttggaa	tcaagtatgt	aaataccttt	ctcactgaqa	720
aatttaaaaa	aataatatgt	cagggtagca	tacaaaacag	aaactcagga	agaactgtct	780
aacatgccac	tatggttatt	ttcaggattg	tggtaggatt	attactacaa	taacctgttc	840
gatcatccta	ggtaatttga	tttaggtgtt	tatcctctca	gcttgacgct	tgtgtgtact	900
tccatcctat	tctaactttc	acaatcttga	aaactctact	tttcaattta	aaacttgacc	960
tttttcacaa	tagtctttca	aatattaatc	cttttaaaaa	ttattaatgt	atgcatttca	1020
ccatgtcttg	ttgccctctc	gtcattttat	atttcaatga	tcactgcctt	atctgtttat	1080
ta-tccatta	ctaaccactc	tcaggaactg	atccaaatcg	gaacttttta	aaaaaataga	1140
atTTTTTTTT	actacaaaata	taccattctc	atgaatagaa	aactattttt	aaaaaattaa	1200
aagtacctga	atcccatcaa	ctagaaaata	cagntgctca	catcatggag	aatattctnt	1260
caggattttt	ttaggtgtat	cannagtttt	aaqaaaaqta	aattgggtca	aaatgtgtat	1320
tctatgttgc	agcctgcatt	ttgcacttaa	cagtttacc	tgaatgtttt	tcca-gtmat	1380


```
ttagcttatt ttcaatttga tagttaatgg ctataaaaaa ttttatttgt aaatatatgg 1440
taccataaac caaaacgttt atgttttggc gggagatcat tttagatgta tctttgtgce 1500
tatctgtgaa aatttccctta gaattcttaa agtaaatctg ctgaattgga tgtaaaagtt 1560
taaaagacag tagatacaca ttgttaaatt gttcttcaga aaagtgtatc tgtttacttc 1620
ctctgaaaat acctctttcc ctgtacctca cccaagtgtg tattaccatt ttaaaatttt 1680
tactaaatat aatttaattc attcttcatt ttttaattag ggattttttt tttttttttt 1740
tagtttttat atttttagag acatggcttc actctgtcac tcagggtgga gtgcagtggc 1800
acgacatag ttctactgcag ccttgaactc aggtgatctc cctctttggc ctcccaaagt 1860
gtctgggatta caggcatgag acactacatc aagcctggga aat-tttaaa cnngcataaa 1920
aagtagaggg taaantqcca ccccttneca accctcactc agcttcaata aacatcaaca 1980
ttctgctggt cttttcatct ttactacctt acacacattt gccctttttt tctttcctag 2040
aatattttta ggcataattc gcactgtgct ttacatctct ggtctctctt ctagttaaga 2100
tgctcttttc agcaaaatca cagaattagc cattactctt ttattacctt ataccagac 2160
tgtttaattt ttctagtgtc ttcaagtgtc tgtttacaat ttatttgttt gaattcattt 2220
ctaagctact caggaggctg agtcaggaga attgctttaa ccttagaggc agagggttga 2280
gtgagctgag atcgtgccac tgtactccag cctgggtgac aaagtgtgac tccatgtcat 2340
aacaatacaa aacaaaacaa aacatgacga aacaaaacac acaatgaat aatatcccc 2400
agttattatt tagagaagag atgactcaat ataaatgtaa tatgtgatcc atttggtcac 2460
agaatgaatt tcagtcattg cttaggttaag cctggttaaa aaaaaaaaaa cggqattcca 2520
tgattagtgt gtgaaaaaag gggtrtgcac aaagtgtaac agacagagcc ggtgtcagtg 2580
gctcacgctt gtaatcccag aactttggga ggccaaaggca ggcggatcac gaggtcaaga 2640
gattgagaca atcctggcca acatggtgaa gccctgtatc aactaaaaat acaaaaacaa 2700
ttagtctggc gtggtgaca gtgctgttag tcccagctac tcaggaggct gaggcaggag 2760
aattgcttga acctgggagg cggaggctgc agtgagctga gattgctcca ctgcactcca 2820
gcctggccac agagttagat tccatctcaa aaaaaaaaaa aaaaaaaaaa a 2871
```

<210> 112

<211> 1037

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (936)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (946)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (951)

<223> n equals a,t,g, or c

<400> 112

```
ccggtccgga atccccgggt cgacccacgc gtccggggcg gcgcaggacg tgcactatgg 60
ctcggggctc gctgcgcggt ttctgtcggt tctctgtgct ggggctctgg ctggcggtgc 120
tgccgtccgt ggccggggag caagcccgag gcaccgcccc ctgctccccc ggcagctcct 180
ggagcgcgga cctggacaag tgcatggact gcagcacctc ctgccccctt ccggctgtct 240
tggcccatcc ttggggggcg tctgagcctg acctctgtgc tggggctgct ttctggcttt 300
ttggtctgga gacgatgccc caggagagag aagttcacca ccccataga ggagaccggc 360
ggagagggct gccagctgtg ggcgctgac cagtgaacat gtgccccctg ccagccgggg 420
ctcgcacact cctcattcat tcatccattc tagagccayl ctctgctcc cagacgcggc 480
gggagccaag ctctcccaac cacaaggggg gtggggggcg gtgaatcacc tctgaggcct 540
gggcccaggy ttcaggggaa ccttccaagg tgtctgggtg cctgcctctt ggctccagaa 600
cagaaaggya gcctcacgct ggctcacaca aaacagctga cactgactaa ggaactgcag 660
```

```
catttgcaca ggggaagggg gtgcctcctc tcttagaggc cctggggggc aggctgactt 720
gggggggcaga cttgacacta ggcctccactc actcagatgt cctgaaattc caccacgggg 780
gtcacccctgg ggggttaggg acctattttt aacactaggg ggctggccca ctaggagggc 840
tggccctaag atacagaccc ccccaactcc ccaagcgggg ggggggatat ttattttggg 900
gagagtttgg aggggagggg gatttttttt ttaaangatt ttctantttt naaaaaaaaa 960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaa 1037
```

<210> 113
<211> 2214
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (289)
<223> n, equals a, t, g, or c

```
<400> 113
cggacgcgtg ggtcgaccca cgcgtccggg aaaaarggaa aaratgccgt gtaaaatctc 60
gttctgtgtc tgaattgccc taggctcaga tcttcatttg aggttctgtg tctgaattgc 120
cgtaggctca gatcttcatt tgaggttatg ttctataagt taacgttgat cttgtgtgag 180
ctttcggtag ctggagtaac acagcgggcc tcacagcgac ctctccagcg ccttccaagg 240
cacatctgca gccagcgtam tcttcctggg agatgcctcc tcaaggccnt gctccagacc 300
acgtgggrar ggcctgacaa gccaatcccc aggcgtgtccc cacccttgra gagtgaacct 360
aaacgctaga cagatgggga atgggaaaga aaagaaagct gcagacctca agttaaattt 420
ccctcaaaaa cgtttttatt tatctgcttt ttctgaaagg ataaaggctt ttgaaaaatt 480
attttctaac aaataacatg aacacttcta gaaaccctag aaaaacacaa agtatttcaa 540
atagaaagaa aaattaccca ttactcttta agccagcatt atccattgog gtgcttttgg 600
agttgggtga ggcctgagcc tctgccaaat caaggagccc ggtggtggct gtggcattcc 660
tgcagggttg ttttttttct tttgagatgg agtctcactc ttgtcaccct agctgggaatg 720
tgggtggtga aacagctcac tgcagccttg accctgaggg tcaagcgatc cttctgcctt 780
ggcctcctga gtagctggga tcccagcqa gactcaccac accctgtcca tgttcttcca 840
ggtcttgata tgcgaggagc ctgtgtcttc cctgccacat ttctcttctc ttcttgaga 900
cagacccttg ctccatcacc caggccagag tgtggtsgtg cgaacacggc tcactgcagc 960
ctcgaccctc aggcctcaagc gatcctcacg cctcggaccc ccaaagtgtc gggatcacag 1020
gcgagagtca ccagtctggc ctgaattctc agggattttr cgggtgargt gycattact 1080
tarccatscc tgtttcaaga gtgtagggtg tcaccctgtc tctgccgtg accctggcctg 1140
gacccctcggc tgtgagaggg aggggtgggc tgggctggag gaacctraag cctcgtgat 1200
gtcacaagcc catctggctg gccatccctc gctgtgtcct gactgcaca tgccccaggt 1260
ggccccca gcagaggcga gccactgrag ggtgragggc ttccacggac ggtcttcagg 1320
ggragaagaa gggccacagg cccagagaga ctacaggagc cagagcctgg ggtcaggggc 1380
tmagcagggg ctgarccagg gctggatgtc cggagccagc cccmagcccc tggkktcttt 1440
gttcttcgca ctcccaccgt ccgtgtgaac agctccagcc ccacctgccc ctccctgtgc 1500
tgggtctccat caggagagccc agaagacgtg tgtgtctctg aaattgggtc cctacatgcc 1560
tttgtccag- tgcaccttgc tcttccatt tactatcgag atttaaatgc ctgtttctc 1620
cccagaggtt gaeggatata ttacagcgtt acgacacgga tcaggacggc tggattcagg 1680
tgtctacga acagctaccg tccatggtct tcagtatcgt atgacctgg cctctcgtga 1740
agagcagcac aacatggaaa gagccaaaat gtcacagttc ctatctgtga gggaaatggag 1800
cacaggtgca gtttagatgct gttcttctct tagattttgt cactggggga cccagctgta 1860
catatglgga taagctgatt aatggttttg caactgtaat agtagctgta tegtctcaat 1920
gcagacattg gatttgggtga ctgtctcatl gtgccatgag gtaaatgtaa tgtttcaggc 1980
attctgcttg caaaaaaate tarcattgtc ttttctagat gtctctggtt ctatag-gca 2040
aatgctttta ttagccaaata ggaattttaa aataacatgg aacttacaca aaaggctttt 2100
catgtgcctt acttttttaa aaaggagttt attgtattca ttggaatgtg tgacgtaagc 2160
aataaaggga atgttagacg tctaaaaaaa aaaaaaaa aaag 2214
```

<210> 114
<211> 3300
<212> DNA
<213> Homo sapiens

<400> 114
tcgaccacag cgtccggtga gaggaagga cttttcatct ttagggcatt ctgaccacgt 60
cctgcttcag ayagattgtt cccggcgtct cagtgctatg gggagcaggt tcttctctgt 120
cctgctctca ggtctcactg tcttactggc tctgccagga tcagaagcca aqaattcttg 180
agcttctctgt cctccatgcc ctaaatatgc cagctgccac aacagcaccc actgtacttg 240
tgaagatggc ttctgggcca ggtctggcag gacatacttt catgattcct ctgagaagtg 300
tgaagatatt aatgaatgtg aaaccgggct ggcagagtg aagataaag catattgtatg 360
gaataaagtt ggaggttaca tctgtagctg ttgggtaaaa tatacttta tcaactttct 420
ggctgggtatt atagattatg atcatccgga ttgttatgag aacaatagtc aagggacgac 480
acagtcacac gtggtatatt ggtgagtg ggtgaagcct ggatttggga aacagctggt 540
acgtataact atgccatttt cctacccaaa catttaacatg tcttctctgtg ntctttaggg 600
tagggtagtt ctatccaggg gtaattttgt cctctgtccc aaggtcatct gtcaatgact 660
ggggacactt ttgggtgtca taccctgggg gtgatgtgtg tgaactggcat ctggtggatg 720
gagaccaggg atacagctca acatccctaca gtgccagga cagctcccca caatcaagaa 780
gtgcctagtg ccatatgtcc atagagatag agaaatacaa gtgtaggggg aaagtgcctc 840
agctggcatt caaagacctc catcaagcac ctacattctc aatgccacac gcaccttgta 900
gcaccttaat aatatcgtt gccctctggg ctcctccactc caacacttgt gcatattccc 960
tattcttac atttcagtaa ggtcaactc aattagctta atttttttg aaggaatac 1020
tgagaagaaa tgggaagcaga gaggaacttg caagaagggc tactcaacta attcaagcg 1080
tggagtggag catctggaat gcgagttttg cttctccagg aaaggggtcaa attcttgaat 1140
ttgatatagt ctatgaaacc aagaggtgca atgagacaag ggagaatgct ttctgggaag 1200
ctggaaataa ccccatggat atcaactgtg ctgatgcttt aaaaggaac ctaagagaga 1260
gcactgcagt tgccctatca cttatcaatc tcttggggat attctgaatg catcctttt 1320
tagtaaacga aaagggatgc aggaagttaa actgaactct tacgtttgta gcggcaccat 1380
cggtttgaag gaaaaaattt cctctcttga acctgtgttc ctgacttttc gccataatca 1440
gcctggtgac aagagaacaa aacatatctg tgtctactgg gagggatcag agggaggccg 1500
ctggtccacg gagggctgct ctcatgtgca cagcaacggt tcttacacca aatgcaagtg 1560
cttccatctg tccagctttg ccgctccctg ggtctctgccc cccaaggagg acctctgtct 1620
gaccgtgac acccaggtgg ggtcgaccat ctctctgctg tgccctcttc tggccatcct 1680
caccttctc ctgtgccggc ccatccagaa caccagcacc tccctccatc tagagctctc 1740
cctctgcctc ttctggccc acctcctgtt cctgacgggc atcaacagaa ctgagcctga 1800
ggtgctgtgc tccatcattg cagggtctgt gcacttctc tacttggtt gcttcactg 1860
gatgctctg yaagggctgc acctcttctc caccgtcagg aacctcaagg tggccaacta 1920
caccagcacg ggcagattca agaagaggtt catgtacct gtaggctacg ggtcccagc 1980
tgtgattatt gctgtgtcag caatagtgtg accccagaat tatggaacat ttactactg 2040
ttggctcaag ctgtataaag gatctatctg gagcttcatg gggccagtga cagtcatat 2100
cttgataaac ctgggtgtct acctccaagt tctgtggatt ttgagaagca aactttctc 2160
cctcaataaa gaagtttcca ccatcagga caccagagtc atgacattta aagccatttc 2220
tcagctcatt atcctgggct gttcttgggg ccttgggttt ttatgtgtt aagaagttag 2280
gaagacgatt ggtatcaatc ttgcatactc attcaccatc atcaacaccc ttcagggaat 2340
gttgctcttt gtgtgtacact gtcctcttaa tgcagaggt cgaatggaat ataaaaagt 2400
gtttagtggg atgcggaag ggtcagaaac tgaaagcact gagatgtctc gctctactac 2460
ccaaaccaaa acggaagaag tggggaagtc ctacagaaatc ttccataaag gaggcactgc 2520
atcatcatct gcagagtcaa ccaagcaacc gcagccacag gttcatctcg tctctgtctg 2580
ttggctaaa atgaactgac ctggcaagt ccatggcaat gaccgggaag ttacccctcc 2640
ttctcgtttg tctacagcgc cctgtgtgtc acacatagat tggacaaatg ccatattttc 2700
tagctttctt gtgaaaagtc taggtctatt cactattttt ggttttttt gtccatagaa 2760
agaacaagac atttgggaga attcttagat ccagagtcga gtatgtgtgc acgttcaatg 2820
aagtgtcgga aggatgcat ttaaaagtgg cgggcgggag aagtgtgatt tctcttgca 2880
gtactgcca ccttgccaga aactcactaa ctggcatctg gattcagctc atagtctcct 2940
ttctggcctc tctgtgtat ttatgtctcc caaagatctt acattaacac tccacatcca 3000
cataattcaa caattttcat atggtacagt attaaaggag gtgtgtgatt ttgcaataca 3060
aaaatgcatt atcaggtgct ggagaggatg tggagaaata ggaacacttt tacactgttg 3120
gtgggactgt aaactagtct aaccatcgtg gaagtcagtg tggcgattcc tcagggatct 3180

agaactagaa ataccatttg acacagctat cccattactg ggtatatacc ccaagggcta 3240
 taaatcatgc tgcataaag acacatgcac acgtaaaaaa aaaaaaaaag ggcggccgct 3300

<210> 115
 <211> 1286
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (1149)
 <223> n'equals' a.t.g. or c.

<400> 115
 gactgcttta cggacattgg atgaagccga agcatttaga atggtgcctg gcacacagtt 60
 ggtgcgtgat atggttaagc tttgtgtccc caccacatc tcattctgaa tgtgacggtt 120
 tcccggctc cctcctgccg ccatgtgaag aaggtcgttg cttcccttc accctccacc 180
 accatgattg ccatggatgc tcccactcc aaagcagccc tggacagcat taacgagctg 240
 cccgagaaac tctgctgga gctgttcacg cactgcccc cccgccagct gctgctgaac 300
 tgcgcctgg tctgcagcct ctggcgggga cctcctgac ctcctgaccc tctggaaaacg 360
 caatgcctgc gagagggctt catcaccaag gactgggacc agcccgtggc cgactggaaa 420
 atcttctatt tctacggag cctgcatagg aactcctgag caaccctgt gctgaagagg 480
 atatgtttgc atggcaaat gatttcaatg gtggggaccg ctggaagggt gagagcctcc 540
 ctggagccca cgggacagat tctcctgacc ccaaagtcaa gaagtatttt gtcacatcct 600
 acgaaatgtg cctcaagtcc cagcgggagg accttgtagc cgagggtctac tgggaggagc 660
 tactagacac attccggccg gacatcgtgg ttaaggactg gtttgcctgc agagccgact 720
 gtggctgcac ctaccaactc aaagtgcagc tggcctcggc tgactacttc gtgttgccct 780
 ccttcgagcc cccacctgtg accatccaac agtggaaaca tgccacatgg acagaggctc 840
 cctacacctt ctcagactac ccccggggtg tccgtacat cctctccag catgggggca 900
 gggacaccca gtactgggca ggcgtgtatg ggccccgagt caccacacgc agcatgtcg 960
 tcagccccaa gatgaccagg aaccaggcct cctccgagcc tcagcctggg cagaagcatg 1020
 gacaggagga gctgcccaca tgcacctacc gagctgtgt ccagatttc tgacagctgt 1080
 ccatcctgtg tctgggtcag ccagagggtc ctcaggcag gagctgagca tgggggtggc 1140
 aagtggagnc cctgtacca ggcactctc ccccggttca accctacca gcttggggga 1200
 acttactgca catagctctg acgttttgtt gtaataaatg ttttcaggcc gggcaaaaaa 1260
 aaaaaaaa aaaaaaaa aaaaaa 1286

<210> 116
 <211> 2189
 <212> DNA
 <213> Homo sapiens

<400> 116
 ggaattcggc acgaggcgcc cggagatgtg ctgctggccg ctgctcctgc tgtggggcct 60
 gctccccggg acggcggcgg gggcctcqqq ccqaacctat ccgaccgga cctcctgga 120
 ctcggagggc aagtactggc tgggtggag ccagcggggc agccagatcg ccttccgctc 180
 ccaggtcgac actgcaggct acgtgggctt cggcttctcg cccaccgggg ccatggcgctc 240
 cgccgacatc gtcgtggcgg ggcctggcca cggcggccc tacctccagg attattttac 300
 aatgcaaat agagagtga aaaaagatgc tcagcaagat taccatctag aatatgccat 360
 ggaaaatagc acacacacaa caattgaatt taccagagag ctgcatacat gtgacataaa 420
 tgacaagagt ataacggata gcactgtgag agtgcctgg gctaccacc atgaagatgc 480
 aggaagaagc ggtcccaagt accatgactc caatagggg accaagagt tgcgggtatt 540
 gaatcctgag aaaactagt tgcctctac agccttacca tactttgatc tggtaaatca 600
 ggacgtcccc atcccaaca aagatacaac atattggtg caaatgttta agattcctgt 660
 gttccaagaa aagcatcatg taataaaggt tgagccagtg atacagagag gccatgagag 720
 tctgggtcac cacatcctgc tctatcagt cagcaacaac tttacgaca gcgttctctg 780
 aatccgggca cgaattccca tcaccccaac atgcccgaag ctttctcac ctgtgaaact 840

gtgatttttg	cctgggctat	tgggtggagag	ggctttttct	atccacctca	tggtggatta	960
tcccttgcca	ctccattaga	tccgcattat	gtgctcctag	aagtcattta	tgataatccc	960
acttatgagg	aaggcttaat	agataattct	ggactgaggt	tattttacac	aatggatata	1020
aygaaatata	algclgggyl	gallgaggtt	ggcctctggg	tgagcctctt	ccataccatc	1080
cctccaggga	tgctgagtt	ccagtctgag	ggcactgca	ctttggagtg	cctggaagag	1140
qctctqaaq	ccqaaaaqcc	aaqtggaatt	catgtctttg	ctgttcttct	ccatgctcac	1200
ctggctggca	gaggcatcag	gcgcgctcat	tttcgaaaag	ggaaggaaat	gaattactt	1260
gcctatgatg	atgattttga	cttcaatttc	caggagtttc	agtatctaaa	ggaagaaaca	1320
acaattctac	caggagataa	cctaattact	gagtgctgct	acaacacgaa	agatagagct	1380
gaga-gactt	ggggaggact	aagcaccagg	agtgaatgt	gtctctcata	ccttctttat	1440
tacccaagaa	tlaattctac	tcgatgtgca	agtattccag	acallatgga	acaacttcag	1500
ttcatgggg	ttaaggagat	ctacagacca	gtcacgacct	ggcctttcat	tatcaaaagt	1560
cccaagcaat	ataaaaaact	ttcttctcat	gatgctatga	ataagtataa	atggactaaa	1620
aagggaagtc	tctccttcaa	caagctgggc	ctcagcctgc	cagtgaatgt	gagatgttcc	1680
aagacagaca	atgctgagtg	gtcgattcca	aggaatgaca	gcattacctc	cagatataga	1740
aagacctat	aaagcagaac	cctttggtgt	gtggcacgtc	ttcttctctt	tccttgcaaa	1800
gagatttctc	ccatcaactt	gcttggttgc	cttctgtctac	tcagctgcac	gctgagcacc	1860
aagagcttgt	gatcaaaatt	ctgttggaat	tgacaatgtt	ttctatgac	tgaaactgtc	1920
atttgaagta	caggtttaaag	actgtgtcca	ctttgggcal	gaagagtgtg	gagacttttc	1980
ttccccattt	tcctctcttc	cttttctctt	tccatgttac	atgagagaca	tcaatcaggt	2040
tctcttctct	ttctttagaaa	tatctgatgt	tatatataca	tggtcaataa	aatagaactg	2100
gcctgactta	agataaccat	tttaaaaaat	tgggctgtca	tgtgggaata	aaagaattct	2160
ttcttctcta	aaaaaaaata	aaaaaaaata				2189

<210> 117

<211> 1763

<212> DNA

<213> Homo sapiens

<400> 117

ggtggcctag	agatgctgct	gccgcgggtg	cagttgtctc	gcacgcctct	gccgcgcagc	60
ccgctccacc	gccgtagcgc	ccgagtgctg	gggggcgcac	ccgagtcggg	ccatgagggc	120
gggaaccgcg	ctacaggccg	tgctgtctgc	cgctgctgct	gtggggctgc	gggcgcgcac	180
gggtcgccctg	ctgagtgggc	agccagtcct	ccggggaggg	acacagaggg	cttgataata	240
agtcattttac	ttccatgata	cttctcgaag	actgaacttt	gaggaagcca	aagaagcctg	300
caggagggga	tggaaggccag	ctagtcaacn	tcgagttctg	aagatgaaca	gaaactgata	360
gaaaakttca	ttgaaaacct	cttgccatct	gatggtgag	tctggawtgg	gctcaggagg	420
ctgagggaga	aacaaagcaa	tagcacagct	gccaggacct	ttatgcttgg	actgatggca	480
gcataacaca	atttaggaac	tggtatgtgg	atgagccgtc	ctgcggcagc	gaggctgctg	540
tggtcatgta	ccatcagcca	tcggccaccg	ctggcatcgg	agggccctac	acttccagt	600
ggaatgatga	ccggtgcaac	atgaagaaca	atttcatttg	caaatattct	gatgagaaac	660
caqcaatctc	ttctagagaa	gctgaaggtg	aqgaacaaga	gctgacaaca	cctgtacttc	720
cagaagaaac	acaggaagaa	gatgccaaaa	aaacatttaa	agaaagtaga	gaagctgctt	780
tgaatctggc	ctacatctta	atccccagca	ttccccctct	cctctctctt	gkggcaccac	840
cagttgtatg	ttgggttttg	atctgtagaa	aaagaaaacg	ggagcagcca	gacctagaca	900
caaagaagca	acacaccatc	tggccctctc	ctcaccaggg	aaacagcccg	gacctagagg	960
tctacaatgt	catwagaaaa	caaagccgaag	ctgacttagc	tgagaccggg	ccagacctga	1020
agaatatttc	attccgagtg	tgctcgggag	aagccactcc	cgatgacatg	tcttgtagct	1080
atgacaacat	ggctgtgaac	ccatcagaaa	gtgggtttgt	gactctgggt	agcgtggaga	1140
gtggattttgt	gaccaatgac	atttatgagt	tctccccaga	ccaaatgggg	aggagtaagg	1200
agttctggatg	ggtggaaaaat	gaaatatatg	gttattagga	catataaaaa	actgaaactg	1260
acaacaatgg	aaaagaaaag	ataagcaaaa	tcctcttatt	ttctataagg	aaaatacaca	1320
gaagggtctat	gaacaagctt	agatcaggtc	ctgtggatga	gcattgtggtc	cccacgacct	1380
cctgttggac	ccccacgttt	tggctgtatc	ctttatccca	gccagtcctc	cagctcgacc	1440
ttatgagaag	gtaccttgcc	caggtctggc	acatagtaga	gtctcaataa	atgtcacttg	1500
gttgggttga	tctaactttt	aagggacaga	gctttacctg	gcagtgataa	agatgggctg	1560
tgagagcttg	aaaaccacct	ctgttttctt	tgctctatac	agcagcacat	attatcatac	1620
agacagaaaa	tccagaatct	ttccaaagcc	cacataggtt	agcacaggtt	ggcctgtgca	1680

tcggcaattc tcatatctgt ttttttcaaa gaataaaatc aaataaagag caggaaaaaa 1740
aaaaaaaaaa aaaaaaactc gag 1763

<210> 118
<211> 1375
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> n equals a,t,g, or c

<400> 118
ggcgggccc ggcgaagngg cggckgcgag gccggggcag ccatgtcgcc attgtctgag 60
ggcgggccc cctgcccgtt ctacgcggta ggcggcggc tgatcctggc gcagctcgtg 120
cggcgcctgc gsgggggcctt cctggagcca gtttccccc cagcactga ccgtgtcgct 180
atagtgcagg gaggacaga tggcattggc ttttctacag cgaacatctg gcgagacttg 240
gcattgcatt tatcatagct ggaaataatg acagcaaac caaacaagt gtaagcaaaa 300
taaaagaaga aaccttgaac gacaaagtgg aattttata ctgtgacttg gcttccatga 360
cttccatccg gcagtttctg cagaagtcca agatgaagaa gatcctctc catgtcctga 420
tcaacaatgc tgggtgatg atgtccctc agaggaaaac cagagatgga ttcaagaac 480
atttcggcct gaactaccta gggcacttcc tgctqaccaa ccttctcttg gatacgtga 540
aagagtctgg gtccctggc cagcgtgcga ggggtggcac cgtctcctc gccaccctt 600
acgtcgtga gctgaacatg gatgacctc agagcagtc ctgctaactc cccacgcag 660
cctacgccca gagcaagctg gcccttctc tgttcacctc ccacctccag cggctcgtg 720
cggctgaggg aagccacgtg accgccaac tgggtggacc cgggtggtc aacacggacs 780
cttacaagca cgtgttcttg gccaccctc tggcqaagaa gcttctcgcc tggttgctt 840
tcaagacccc cgtgaagga gcgtggactt ccattctacc agcagtcacc ccagagctgg 900
aaggagttgg tggcgttac ctatacaacg agaagagac caagtcctc cagctcact 960
acacacagaa actgcagcag cagctgtggt ctaagagttg tgagatgact ggggtccttg 1020
atgtgacctt gtgatattct gtctcaggat agctgcgcc ccaagaaaca cattgcacct 1080
gccaatagct tgtgggtctg tgaagactgc ggtgtttgag tttctcacac ccacctgcc 1140
acaggtctct gtcctctagt tttagacag ctgctcaac ctctgcagaa ctcaagaag 1200
ccaaataaac attttggagg ataatacccc caagtgtct tcaaccataa actttgtgat 1260
tccaaagtgc ccagtgtca caggtgccat aaataattac attttccaac ataaaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaggcgc gccgc 1375

<210> 119
<211> 1022
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (937)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (990)
<223> n equals a,t,g, or c

<400> 119
ggcacgagag agccrgcggc ccgagccggg gccatggcga actgctgagc tgcgtcctag 60
gccccggct ctacaaaatc taccgggaga gggactctga aagggccccg gccaccctc 120
ctgagacccc aacggcagtc actgcccccc attccagctc ctgggatacg tactatcagc 180

cccggtgccc ggagaaacat gctgacagca tcttggcact ggcttcagta ttctgggtcca 240
tctcttatta ctctctctcc tctgctctct tctacttgta caggaaaggt tacttgagtt 300
tgtccaaagt ggtgcccgttt tctcactatg ctgggacatt gctgctactt ctggcagggtg 360
tggcctgctc cgaggcattg gccgctggac caacccccag taccggcagt tcatccacct 420
cttgggaagca acacatcgga accagtcttc agaaaacaag aggcagcttg ccaactacaa 480
ctttgacttc cggagctggc cagtgcactt ccaactggaa gaacccagca gccggaagga 540
gtctcgaggg ggcctctccc gccggggtgt ggccctgctt cgcacagagc cctgcaccg 600
ggggacagca gacacccctc tcaacccggg taagaagctg ccttgctaga tcaccagcta 660
cctggtggcg cacacccctg ggcgcgggat gctgtatcca ggctctgtgt acctgctgca 720
gaaggccctc atgctctgtg tctgacagg ccaggcccgga ctggtggaag agtgtaatgg 780
gcgcccggca aagctgctgg cctgtgatgg caatgagatt gacaccatgt ttgtggaccg 840
gcgggggaca gctgagcccc aggcagaaag ctgggagatc gctgctgarg gaatgctggg 900
ttttatgarg tgggctgctg ctccamgccc ctggaanctg gatattcatg ckgggtggaa 960
tcacccagct ttgctggaac acagggggtt ccattcccgc aaaatgaagg ctaatgccat 1020
gg 1022

<210> 120

<211> 2311

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (654)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2293)

<223> r equals a,t,g, or c

<400> 120

tcgaccacag cgtccgcttc ctcatgctgc ccgctcgcct accgttcagg ctgctgaqcc 60
ttttccttca tggatccgct ccacacggag cggcgcctgg cctccgggag ccgctcctgg 120
agaggagggt cgtgcccgc tctctcttcc agcactcacc gactctggga cgcgagcttc 180
cttatgaccc cgtggacacg gagggtcttg gagaagggtg tgacatgcag gagcgttttc 240
tgttcccyya gtacatcctg gatccggagc cgcaacccac ccgcgaaaag cagctgcagg 300
agctccagca acagcaggag gaggaggagc gacagaggca gcagcggcgg gaggagcggc 360
gacagcaaaa cctacgggccc aggtcccggg agcaccgggt cgtggggcac ccggaccggg 420
cattgccgcc cagcggcgtg aactgctcgg gctgcccggc asasctgcac tgcaggagc 480
ccggagtgcc cggctacctg ccccgagaga agttctctcg caccggcgag gcagacggcg 540
ggctggcacg gaccgtgtgc cagcgtgtgt ggctgctgtc gcaccaccgg cgcgtctac 600
gcctgcaggt gagccgcgag cagtacctgg agctgggtgag cgcgcgcttg cggnggcccc 660
gccctccctt ggtgctctac atggtggacc tgcctggacct gcccgacgcc ctgctgcccg 720
acttgcgccg gctggtgggc cccaagcagc tgatcgtgct gggaaacaaa gtggacctcc 780
tgcccagga tgctctggc taccggcaga ggctgcccga gcgactgtgg gaggactgtg 840
cccgcccggg gctcctgctg gccctgggca ccaagggcca cagcgccccg tcaaggacga 900
gccacaggac ggggagaaac cgaatccgcc gaactggtcc cgcacagtgg tcaggagcgt 960
gcggctgac agcgccaaga ccggctatgg agtggaagag ttgatctctg ccttccagcg 1020
ctcttgccgc taccgtgggg acgtctactt agtggggccc accaacgccg gcaaatccac 1080
tctctttaac acgtccctgg agtccgatta ctgcactgcc aagggtctcg agggcactga 1140
cagagccacc atctccctt ggccagggtac tacattaaac cttctgaaat tctctattt 1200
caacccaact ccttacagaa tgtttaaaag gcatcaaaag cttaaaaaag attcaactca 1260
agctgaagaa gatcttagtg agcaagaaca aaatcagctt aatgtctca aaaagcatgg 1320
ttatgtcgta ggaagagttg gaaggacat cttglatcca gaayaacaya aggataacat 1380
tccctttgag tttgatgctg attcacttgc ctttgacatg gaaaatgacc ctgttatggg 1440
tacacacaaa tccaccaaac aagtagaatt gactgcacaa gatgtgaaag atgcccactg 1500
gttttatgac acccctggaa ttacaaaaga aaattgtaatt ttaaatcttc taacagaaaa 1560

agaagcaaat attgttttgc caacacagtc cattgttcca agaacttttg tgcttaaac 1620
aggaatggtt ctgtttttgg gtgctatagg ccgcatagat ttctgcagg gaaatcagtc 1680
agcttggttt acagtcgtgg ctccaacat cctccctgtg catatcact cctgggacag 1740
ggcagacgtt ctgtatcaga agcatgcagg tcatacgtta ctccagattc caatgggtgg 1800
aaaagaacga atggcrggat ttctcctctt tgttgctgaa gacattatgt taaaagaagg 1860
actgggggca cctgaagcag tggccgacat caagttttcc tctgcagggt gggtttcagt 1920
aacacctaat tttaaggaca gactgcactt ccgaggctat acacctgaag gaacagtttt 1980
gaccgtccgg cccctctctt tggcatatat tgtaacatc aaaggacagc gcatcaagaa 2040
aagtgtggcc tataaaacca agaagcctcc ttcccttatg tacaacgtga ggaagaagaa 2100
aggaagata aatgtatgag accgaccttg ttcaactccg atattaactg tattgaacac 2160
aacaataac attgaatttg tattaacat ataacgcata aataaagctc ccattcttac 2220
ccttaaaaaa aaaaaaaag gggcgccgct cttagggatc caagcttacg tacgcgtgca 2280
tgcgacgtca tancctgtct ataggaaactg g 2311

<210> 121
<211> 1286
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1284)
<223> n equals a,t,g, or c

<400> 121
gggcgcgcgg gtgaaaggcg cattgatgca gcttgccggc gcctcggagc gcggcggagc 60
agacgctgac caggttcctc tctcgggtct cctccgcctc cagctccggc ctgcccggca 120
gccggggagc atgcgacccc agggcccccgc cgctcccccg cagcggctcc gcggcctcct 180
gctgctcctg ctgctgcagc tqcccgccgc gtccgagcgc tctgagatcc ccaaggggaa 240
gcaaaaggcg cactccggca gagggaggtg gtggacctgt ataattggaat gtgcttacaa 300
gggccagcag gagtgcctgg tcgagacggg agccctgggg ccaattggcat tccgggtaca 360
cctgggatcc caggtccgga tggattcaaa ggagaaaagg ggaatgtct gagggaaagc 420
tttgaggagt cctggacacc caactacaag cagtgttcat ggagttcatt gaattatggc 480
atagatcttg gaaaaattgc ggaatttaca ttacaaaga tgcgttcaaa tagtgcctca 540
agagttttgc tcagtggctc acttcggcta aaatgcagaa atgcattgtg ccagcgttgg 600
tatttcacat tcaatggagc tgaatgttca ggacctcttc ccattgaagc tataatttat 660
ttggaccaag gaagccctga aatgaattca acaattaata ttcattgcac ttcttctgtg 720
gaaggacttt gtgaagggaat tgggtgtgga ttagtgatg ttgctatctg ggttgccact 780
tgttcagatt acccaaaagg agatgcttct actggatgga attcagtttc tcgcatcatt 840
attgaagaac taccaaaata aatgctttaa ttttcatttg ctacctcttt ttttattatg 900
ccttggatg gttcacttaa atgacatttt aaataagttt atgtatacat ctgaatgaaa 960
agcaaaagcta aatatgttta cagaccaaag tgtgatttca cactgttttt aaatctagca 1020
ttattcattt tgcttcaatc aaaaagtggtt tcaatatttt ttttagttgg ttagaatact 1080
ttcttcatag tcacattctc tcaacctata atttggaata ttgttggtgt cttttgtttt 1140
ttctcttagt atagcatttt taaaaaata taaaagctac caatctttgt acaattctgta 1200
aatgttaaga atttttttta tatctgttaa ataaaaata ttccaacaa aaaaaaaaaa 1260
aaaaaaaaa aaaaaaaaaa aaaaaa 1286

<210> 122
<211> 1380
<212> DNA
<213> Homo sapiens

<400> 122
cagaccgcgc gggcaaacgg actggggcca agacccggga gcgcggggcg aaaggcacca 60
gggcccgcgc agggcgccgc gcacacggcc ttgggggttc tgcgggcctt cgggtgcgcg 120
tctcgcctct agccatgggg tccgcaqcct tggagatcct gggcctgggt ctgtgcctgg 180

tggtctgggg	gggtctgac	ctggcgtg	ggctgccc	gtggcagg	accgccttc	240
tggtaccaca	catcgtgac	gcgcagacca	cctggaagg	gctgtggatg	tcgtgctgg	300
tgacagacac	gggcacatgc	agtgcacagt	gtacgactcg	gtgctggctc	tgagcaccga	360
gggtcaggcg	gcgcggggcg	tcaccgtgag	cgccgtgctg	ctggcgttcg	ttgcgtctt	420
cgtgacctcg	gcggggcgcg	agtgcaccac	ctgcgtggcg	ccgggcccgg	ccaaggcgcg	480
tgtggccctc	acgggaggcg	tgctctacct	gttttgcggt	ctgctggcgc	tcgtgccact	540
ctgctgggtc	gccaacattg	tcgtccgcga	gttttacgac	ccgtctgtgc	ccgtgtcgca	600
gaagtacgag	ctggggcgac	gctgtacatc	ggctggggcg	ccaccgcgct	gctcatggta	660
ggcggctgcc	tcttgtgctg	cggcgcctgg	gtctgcaccg	gccgtcccga	cctcagcttc	720
cccgtaagt	actcagcgcc	gcggcgccgc	acggccaccg	qcgactacga	caagaagaac	780
tacgtctgag	ggcgtctggg	acggccgggc	ccctctctgc	agccacgcct	ggagggcggt	840
ggataagcct	ggggagcccc	gcattggaccg	cggtctccgc	cggttagcgc	ggcgcgagg	900
ccctccggaa	cgtccggctc	tgccgcgcga	cgccgctcct	ggatccgctc	ctgctgcgc	960
ccgcagctga	ccttctcctg	ccactagccc	ggccctgccc	ttacagacg	gaatgaagtt	1020
tcctttctg	tgccggggcg	tgtttccata	ggcagagcgg	gtgtcagact	gaggatttcg	1080
cttccccccc	aagacgctgg	gggtcttggc	tgctgcctta	cttcccagag	gctcctgctg	1140
acttcggagg	ggcggtatgca	gagcccagg	ccccccaccg	aagatgtgta	cacctggctt	1200
ttactccatc	ggcagggccc	gagcccagg	accagtgact	tggtctggac	ctcccggctt	1260
cactccagca	tctccccagg	caaggcttgt	gggcaccgga	gcttgagaga	ggcggggagt	1320
gggaaggcta	agaatctgct	taqtaaatgg	tttgaactct	caaaaaaaaa	aaaaaaaaaa	1380

<210> 123

<211> 3793

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1102)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1132)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1199)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1228)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1229)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1231)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (3176)

<223> n equals a.t.g. or c

<400> 123

ggggcttcat	acaggaaatc	tattgctgtg	tcaagttcca	gagaaaagct	tctgttcgtc	60
caagttacta	accaggctaa	accacataga	ngtgaaggaa	ggggctagaa	ggaagggagt	120
gccccactgt	tgatggggta	agaggatcct	gtactgagaa	gttgaccaga	gagggctcca	180
ccatgcgcac	agttccctct	gtaccagtgt	ggaggaaaag	tactgagtga	agggcagaaa	240
aagagaaaac	agaaatgtcc	tgcccttgga	gaactgctaa	cctagggcta	ctyttgattt	300
tgactatctt	cttagtgggc	gaagcggagg	gtgctgctca	accaaacaac	tcattaatgc	360
tgcaaaactag	caaggagaat	catgctttag	cttcaagcag	tttatgtatg	gatgaaaaac	420
agattacaca	gaactactcg	aaagtactcg	cagaagttaa	cacttcctgg	cctgtaaaaga	480
tggtacaaaa	tgctgtgctt	tggtgccttc	ctatcgcat	aagaaatttg	atcataataa	540
catggggaat	aatcctgaga	ggccagcctt	cctgcacaaa	agcctacaag	aaagaaacaa	600
atgagaccaa	ggaaaccaac	tgactctgat	agagaataac	ctgggtctcc	agaccgatc	660
agaatttcgga	ccttcagatt	cgtaccgtgg	ccatcactca	tgacgggtat	tacagatgca	720
taatggtaac	acctgatggg	aatttccatc	gtggatatca	cctccaagtg	ttagttacac	780
ctgaagtgc	cctgtttcaa	aacaggaaata	gaactgcagt	atgcaaggca	gttgacggga	840
agccagctgc	gcatactccc	tggtatccag	agggcgattg	tgccactaag	caagaaact	900
ggagcaatgg	cacagtgaat	gttaagagta	catgccactg	gaaggtccac	aatgtgtcta	960
ccgtgaactg	ccacgtctcc	catttgactg	gcaacaagag	tctgtacata	gagctacttc	1020
ctgttccagg	tgccaaaaaa	tcacaaaaat	tatatattcc	atatatcttc	cttactatta	1080
ttattttgac	catcggtggg	tcattttggt	tggtgaaagt	caatggctgc	anaaaaata	1140
aattgaaata	accagaatct	actccagttg	ttgaggaggga	tgaaatgcag	ccctatgcnt	1200
tttacacaga	gaagaacaat	cctctctnng	ntactacaaa	caaggtgaag	gcactctgag	1260
cattacaaag	tgaggttgac	acagacctcc	atactttata	agttgttggg	ctctagatcc	1320
aagaaacaac	aacaaacgag	atocattata	attactgtct	gattttctta	cagttctaga	1380
atgaagactt	atattgaaat	taggttttcc	aaggttctta	gaagacattt	taatggattc	1440
tcattcatat	ccttgataaa	ttggaaattt	tgattcttag	ctgctaccag	ctagtctctt	1500
gaagaactga	tggtattaca	aagaaaatac	atgcccata	ccaaatattc	aaattgtgca	1560
ggacagtaaa	taatgaaaac	caaatttctc	caagaaataa	ctgaagaagg	agcaagtgtg	1620
aacagtttct	tggtatccct	ttcagaatat	tttaattgac	atatgacatg	tgatatatgc	1680
tatgttatat	gtgtcaattt	atgtgtccce	ttacataatc	catgcacct	atcttctgta	1740
aggcaccagt	gggaacaata	cactgcatta	ctgttctata	catatgaaaa	cctaataata	1800
taagtcttag	agatcatttt	atatcatgac	aagtagagct	acctcattct	ttttaattgt	1860
tatataaaa	tcatttgat	agttatatca	ttatttaatt	aaaaacaacc	ctaagtgtg	1920
atatttagat	tcttttaagt	tttgtttatt	tcttttaagt	tttgtttgtg	gtataaaca	1980
taccacatag	aatgtttctt	gtgcataat	ctctttgttt	ttgagtatat	ctgtaggata	2040
acttcttga	gtggaattgt	caggtcaaag	ggtttgtgca	ttttactatc	gatataatg	2100
ttaaaattgt	tcaaatatat	atgtcaaatt	ccctccaaca	ttgtttaaa	gtgcctttcc	2160
ctaaaattct	atttttaata	ctgtactatt	cctgcttcta	cagttgccac	tttctctttt	2220
taatcaacca	gattaaatat	gatgtgagat	tataataaga	attatactat	tttaataaaa	2280
tggaattata	tttttggtca	tgtttgtaag	agagtgaatg	cagctgtgag	aacattagct	2340
tcttctgaac	tcatttatat	tccacagagg	tggtgatact	tgatgcctaa	cagttttgca	2400
gatgtgtac	attggaattg	tgatttttra	tggtgtacat	tctattgtga	tatatattat	2460
gaataaataa	tgctctatga	ccatataagt	ggcgaaaaat	gcaccataga	ggacatgggg	2520
tattttattt	caaaactatga	gctacataat	aagcaagtgg	ccatgggatg	gcacagacct	2580
ccccccata	tttttggtga	gcaaaatatt	ggcaatgttt	atgtaaatca	ttgttaatat	2640
catgaaatta	tttttaatta	aaaacataag	tctatttgct	ccatagcaga	aaaaacatga	2700
gaagtttttt	catcatgata	gaaattgaaa	caaaatatat	tcattcttca	atcataccat	2760
ctgagatttt	taagacagct	attttgtctt	ataagtatat	ttttctccct	ctagacattt	2820
cagttactat	ggattttgtc	ctcaaaagga	cylltagtct	aatlttgagg	tgtaaaagcta	2880
atcttaatga	cacttgccac	atgatatttt	gatcaagcca	ttttgacttg	accaaaaagc	2940
agtggtcatt	aggtttctgc	atataaatat	taccaagcaa	tggtcacaat	agacatcatt	3000
acactgtcct	tgaaattttat	taattcttca	tccaacctg	gttgagctga	ggctcatagt	3060
taggtttcaag	actatctgtt	taaatattac	tgnaaaacaa	agtangacag	tactatgtct	3120
acctctaac	ttgataatgt	caaaccaggc	atgttaaatg	acatcataga	aaaganttca	3180
agataaattt	tagaagttaa	atttatattg	acagaaaata	attgtatgaa	aatctctact	3240
atggggctgg	aacatgggtt	aacattagaa	tgatataaaa	aattatatat	atrtctccaa	3300

```

tccacgctag acctgtcaaa ttagagaatc tagagattag acctggcgtg tcagcaaggt 3360
catccaggaa gcagaggctg agacggagtt aggtgtgatt acctacatag tcgattacat 3420
tttacaata acattttata tgtctcattt actgtgcttt ctccccatcc cattttgtat 3480
cttttccttt gctttgctag atttgtcaat ttctctcttc ttctgtcttc tctctcttcc 3540
aatactctta ataatttgaa agtaattcat cataactaaa tatctattgg gggtatgctt 3600
cacttcaaaa cttctgaaaa cggctttact gagatataat rgatatattt aagtgtacag 3660
tttggttaaa ttgtcacata tttaaaatgt ggactttggt aaatgttgac atagttttac 3720
atctgtgaaa ccatcagcat aatcaagata ataaacttgt ccatcaccoc ccaaaaaaaa 3780
aaaaaaaaaaa aaa 3793

```

<210> 124

<211> 370

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (370)

<223> Xaa equals stop translation

<400> 124

```

Met Leu Gly Ala Phe Val Trp Pro Ser Leu Leu Leu Ala Ala Ala
1 5 10 15

```

```

Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala Tyr Val Lys Trp Gly
20 25 30

```

```

Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys Val Leu Ala Leu Ile
35 40 45

```

```

Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly Gln Gly Ala Ser Thr
50 55 60

```

```

His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe Ala Val Gly Asp Ile
65 70 75 80

```

```

Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr
85 90 95

```

```

Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro
100 105 110

```

```

Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr Ile Ile Tyr Ile Leu
115 120 125

```

```

Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met Arg Asp Ile Leu Ala
130 135 140

```

```

Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln Ile Phe Gly Ile Phe
145 150 155 160

```

```

Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser Cys Phe Gly Gly Leu
165 170 175

```

```

Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe Phe Val Gly Ser Arg
180 185 190

```

```

Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile His Val Glu Arg Phe

```

195 200 205
 Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile Met Ala Leu Ile Tyr
 210 215 220
 Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn Tyr Tyr Ser Phe Ser
 225 230 235 240
 Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly Gln Leu Tyr Leu Arg
 245 250 255
 Trp Lys Glu Pro Asp Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe
 260 265 270
 Pro Ile Val Phe Cys Leu Cys Thr Ile Phe Leu Val Ala Val Pro Leu
 275 280 285
 Tyr Ser Asp Thr Ile Asn Ser Leu Ile Gly Ile Ala Ile Ala Leu Ser
 290 295 300
 Gly Leu Pro Phe Tyr Phe Leu Ile Ile Arg Val Pro Glu His Lys Arg
 305 310 315 320
 Pro Leu Tyr Leu Arg Arg Ser Trp Gly Leu Pro Gln Gly Thr Ser Arg
 325 330 335
 Ser Cys Val Cys Gln Leu Leu Gln Lys Trp Ile Trp Lys Met Glu Glu
 340 345 350
 Arg Cys Pro Ser Asn Gly Ile Pro Ser Leu Thr Lys His His Leu Glu
 355 360 365
 Ser Xaa
 370
 <210> 125
 <211> 86
 <212> PRT
 <213> Homo.sapiens
 <220>
 <221> SITE
 <222> (86)
 <223> Xaa equals stop translation
 <400> 125
 Met Gly Phe Trp Cys Gly Cys Pro Phe Cys Leu Leu Val Val Leu Leu
 1 5 10 15
 Thr Asp Arg Thr Leu Ser Cys Arg Ser Val Gly Val Pro Cys Asn Val
 20 25 30
 Arg Cys Gln Cys Ala Pro Ala Gly Gly Cys Leu Pro Val Arg Leu Leu
 35 40 45
 Ala Gly Gln Gly Ser Gly Thr His Leu Arg Arg Gln Ser Ala Arg Ser
 50 55 60

Gln Ile Ser Ser Cys Met Leu Gly Glu Pro Leu Leu Ser Ser Lys Leu
 65 70 75 80

Ser Asp Arg Asp Ile Xaa
 85

<210> 126
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 126
 Met Tyr Thr Lys Thr His Lys Phe Lys Phe Tyr Asn Phe Leu Ser Leu
 1 5 10 15

Trp Ile Trp Lys Ile Phe Phe Leu Leu Phe Phe Ile Leu Ile Val Ala
 20 25 30

Leu Ala Phe Pro Ile Pro Cys Leu Ser Ile Phe Xaa
 35 40

<210> 127
 <211> 319
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (264)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (303)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 127
 Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala
 1 5 10 15

Leu Lys Leu Arg Glu Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val
 20 25 30

Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly
 35 40 45

Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile
 50 55 60

Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile
 65 70 75 80

Val	Tyr	Tyr	Tyr	His	Asp	Ala	Asp	Gly	His	Phe	His	Leu	Ile	Asp	Gly	85	90	95
Asp	Lys	Ile	Ala	Thr	Leu	Ile	Ser	Ser	Phe	Leu	Lys	Glu	Leu	Leu	Val	100	105	110
Glu	Ile	Gly	Glu	Ser	Leu	Asn	Ile	Gly	Val	Val	Gln	Thr	Ala	Tyr	Ala	115	120	125
Asn	Gly	Ser	Ser	Thr	Arg	Tyr	Leu	Glu	Glu	Val	Met	Lys	Val	Pro	Val	130	135	140
Tyr	Cys	Thr	Lys	Thr	Gly	Val	Lys	His	Leu	His	His	Lys	Ala	Gln	Glu	145	150	155
Phe	Asp	Ile	Gly	Val	Tyr	Phe	Glu	Ala	Asn	Gly	His	Gly	Thr	Ala	Leu	165	170	175
Phe	Ser	Thr	Ala	Val	Glu	Met	Lys	Ile	Lys	Gln	Ser	Ala	Glu	Gln	Leu	180	185	190
Glu	Asp	Lys	Lys	Arg	Lys	Ala	Ala	Lys	Met	Leu	Glu	Asn	Ile	Ile	Asp	195	200	205
Leu	Phe	Asn	Gln	Ala	Ala	Gly	Asp	Ala	Ile	Ser	Asp	Met	Leu	Val	Ile	210	215	220
Glu	Ala	Ile	Leu	Ala	Leu	Lys	Gly	Leu	Thr	Val	Gln	Gln	Trp	Asp	Ala	225	230	235
Leu	Tyr	Thr	Asp	Leu	Pro	Asn	Arg	Gln	Leu	Lys	Val	Gln	Val	Ala	Asp	245	250	255
Arg	Arg	Val	Ile	Ser	Thr	Thr	Xaa	Ala	Glu	Arg	Gln	Ala	Val	Thr	Pro	260	265	270
Pro	Gly	Leu	Gln	Glu	Ala	Ile	Asn	Asp	Leu	Val	Lys	Lys	Tyr	Lys	Leu	275	280	285
Ser	Arg	Ala	Phe	Val	Arg	Pro	Ser	Gly	Thr	Glu	Asp	Val	Val	Xaa	Ser	290	295	300
Ile	Cys	Arg	Ser	Arg	Leu	Thr	Arg	Lys	Cys	Arg	Ser	Pro	Cys	Thr		305	310	315

<210> 128'

<211> 46

<212> PRT

<213> 'Homo sapiens

<220>

<221> SITE

<222> (46)

<223> Xaa equals stop translation

<430> 128

Met Asp Met Val Cys Phe Cys Ile Tyr Leu Gly Leu Leu Lys Phe Ile
1 5 10 15

Ser Ala Ile Phe Cys Ser Phe Ser Glu Glu Val Leu Tyr Ile Ser Phe
 20 25 30
 Val Lys Cys Ile Pro Lys Tyr Phe Val Glu Met Leu Leu Xaa
 35 40 45

<210> 129
 <211> SITE
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (189)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (275)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (414)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (438)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (541)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (643)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (696)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (697)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 129
 Met Ala Gly Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu
 1 5 10 15

Leu Leu Gly Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile
 20 25 30

Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr
 35 40 45
 Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His
 50 55 60
 Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe
 65 70 75 80
 Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn
 85 90 95
 Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln
 100 105 110
 Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp
 115 120 125
 Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro
 130 135 140
 Arg Leu Arg Glu Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr
 145 150 155 160
 His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr
 165 170 175
 Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met Xaa Glu Gly Val
 180 185 190
 Lys Met Ala Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly
 195 200 205
 Phe Ser Ile Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu
 210 215 220
 Ser Val Phe Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr
 225 230 235 240
 Pro Glu Gly Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val
 245 250 255
 Pro Ala His Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser
 260 265 270
 Asn Cys Xaa Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser
 275 280 285
 Thr Thr Asn Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn
 290 295 300
 Met Ala Gly Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala
 305 310 315 320
 Gln Ser Pro Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His
 325 330 335
 Pro Gln Asn Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu

340 345 350
Arg Ala Met Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg
355 360 365
Lys Phe Val Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser
370 375 380
Ser Asn Leu Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu
385 390 395 400
Cys Asp Asp Leu Thr Arg Leu Trp Met Asn Val Glu Lys Xaa Ile Ser
405 410 415
Cys Thr Asp His Arg Tyr Cys Gln Arg Lys Ser Tyr Ser Leu Gln Val
420 425 430
Pro Ser Asp Ile Leu Xaa Leu Pro Val Glu Leu His Asp Phe Ser Trp
435 440 445
Lys Leu Leu Val Pro Lys Asp Arg Leu Ser Leu Val Leu Val Pro Ala
450 455 460
Gln Lys Leu Gln Gln His Thr His Glu Lys Pro Cys Asn Thr Ser Phe
465 470 475 480
Ser Tyr Leu Val Ala Ser Ala Ile Pro Ser Gln Asp Leu Tyr Phe Gly
485 490 495
Ser Phe Cys Pro Gly Gly Ser Ile Lys Gln Ile Gln Val Lys Gln Asn
500 505 510
Ile Ser Val Thr Leu Arg Thr Phe Ala Pro Ser Phe Arg Gln Glu Ala
515 520 525
Ser Arg Gln Gly Leu Thr Val Ser Phe Ile Pro Tyr Phe Lys Glu Glu
530 535 540
Gly Val Phe Thr Val Thr Pro Asp Thr Lys Ser Lys Val Tyr Leu Arg
545 550 555 560
Thr Pro Asn Trp Asp Arg Gly Leu Pro Ser Leu Thr Ser Val Ser Trp
565 570 575
Asn Ile Ser Val Pro Arg Asp Gln Val Ala Cys Leu Thr Phe Phe Lys
580 585 590
Glu Arg Ser Gly Val Val Cys Gln Thr Gly Arg Ala Phe Met Ile Ile
595 600 605
Gln Glu Gln Arg Thr Arg Ala Glu Glu Ile Phe Ser Leu Asp Glu Asp
610 615 620
Val Leu Pro Lys Pro Ser Phe His His His Ser Phe Trp Val Asn Ile
625 630 635 640
Xaa Asn Xaa Ser Pro Thr Ser Gly Lys Gln Leu Asp Leu Leu Phe Ser
645 650 655

Val Thr Leu Thr Pro Arg Thr Val Asp Leu Thr Val Ile Leu Ile Ala
660 665 670

Ala Val Gly Gly Gly Val Leu Leu Leu Ser Ala Leu Gly Leu Ile Ile
675 680 685

Cys Cys Val Lys Lys Lys Lys Xaa Xaa Thr Arg Gly Pro Ala Val Gly
690 695 700

Ile Tyr Asn Gly Asn
705

<210> 130

<211> 415

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (415)

<223> Xaa equals stop translation

<400> 130

Met Thr Lys Ala Arg Leu Phe Arg Leu Trp Leu Val Leu Gly Ser Val
1 5 10 15

Phe Met Ile Leu Leu Ile Ile Val Tyr Trp Asp Ser Ala Gly Ala Ala
20 25 30

His Phe Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro
35 40 45

Leu Pro Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser
50 55 60

Asp Val Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln
65 70 75 80

Ser Asp Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser
85 90 95

Met Glu Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg
100 105 110

Arg Ser Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu
115 120 125

Arg Gly Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg
130 135 140

Ala Phe Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp
145 150 155 160

Asp Arg His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr
165 170 175

Asn Trp Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg
180 185 190

Gly Ala Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His
 195 200 205
 Asn Ala Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly
 210 215 220
 Lys Leu Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys
 225 230 235 240
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg
 245 250 255
 Ser Lys Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val
 260 265 270
 Pro Met Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala
 275 280 285
 Arg Glu Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Acn Phe Ile
 290 295 300
 Gln Tyr Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu
 305 310 315 320
 His Trp Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr
 325 330 335
 Asp Phe Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu
 340 345 350
 Leu Gln Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr
 355 360 365
 Arg Asn Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile
 370 375 380
 Pro Leu Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe
 385 390 395 400
 Val Leu Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp Xaa
 405 410 415

<210> 131
 <211> 242
 <212> PRT
 <213> Homo sapiens

<400> 131
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
 1 5 10 15
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
 20 25 30
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
 35 40 45

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
 50 55 60
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
 65 70 75 80
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
 85 90 95
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 100 105 110
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
 115 120 125
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 130 135 140
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 145 150 155 160
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 165 170 175
 Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu
 180 185 190
 Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala
 195 200 205
 Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu
 210 215 220
 Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr
 225 230 235 240
 Asp Gly

<210> 132
 <211> 313
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (313)
 <223> Xaa equals stop translation

<400> 132
 Met Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr
 1 5 10 15
 Ser Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro
 20 25 30
 Val Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys
 35 40 45

Pro Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu
 50 55 60
 Glu Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val
 65 70 75 80
 Glu Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr
 85 90 95
 Leu Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg
 100 105 110
 Asn Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser
 115 120 125
 Ile Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp
 130 135 140
 Glu Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala
 145 150 155 160
 Ser Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu
 165 170 175
 Ile Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg
 180 185 190
 Phe Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys
 195 200 205
 Ile Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro
 210 215 220
 Val Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp
 225 230 235 240
 Phe Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr
 245 250 255
 Asn Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe
 260 265 270
 Thr Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys
 275 280 285
 Leu His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser
 290 295 300
 Val Asn Gly His Gln Lys Ala Leu Xaa
 305 310

<210> 133
 <211> 163
 <212> PRT
 <213> Homo sapiens
 <220>

<221> SITE
 <222> (183)
 <223> Xaa equals stop translation

 <400> 133
 Met Met Val Cys Ser Ile Met Met Tyr Phe Leu Leu Gly Ile Thr Leu
 1 5 10 15
 Leu Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr
 20 25 30
 Leu Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys
 35 40 45
 Gly Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr
 50 55 60
 Val Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu
 65 70 75 80
 Glu Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly
 85 90 95
 Lys Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn
 100 105 110
 Phe Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn
 115 120 125
 Gln Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe
 130 135 140
 His Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile
 145 150 155 160
 Val Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg
 165 170 175
 Ile Gln Arg Ile Asn Arg Xaa
 180

<210> 134
 <211> 147
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (147)
 <223> Xaa equals stop translation

<400> 134
 Met Trp Lys Leu Trp Arg Ala Glu Glu Gly Ala Ala Ala Leu Gly Gly
 1 5 10 15
 Ala Leu Phe Leu Leu Leu Phe Ala Leu Gly Val Arg Gln Leu Leu Lys
 20 25 30

Gln Arg Arg Pro Met Gly Phe Pro Pro Gly Pro Pro Gly Leu Pro Phe
 35 40 45
 Ile Gly Asn Ile Tyr Ser Leu Ala Ala Ser Ser Glu Leu Pro His Val
 50 55 60
 Tyr Met Arg Lys Gln Ser Gln Val Tyr Gly Glu Val Gln Pro Arg Arg
 65 70 75 80
 Ala Pro Gly Arg Glu Gly Arg Gln Ala Gly Pro Gly Trp Pro Gly Pro
 85 90 95
 Ser Trp Leu Asp Leu Trp Pro Pro Leu Gly Arg Leu Val Gly Thr Ser
 100 105 110
 Pro Cys Ala Gly Cys Pro Leu Arg Asp Thr Arg Phe Pro Gly Leu Glu
 115 120 125
 Gly Arg Ser Pro Arg Arg Arg Ala Pro Leu Gln Gly Glu Pro Arg Pro
 130 135 140
 Cys Arg Xaa
 145

<210> 135
 <211> 122
 <212> PRT
 <213> Homo sapiens

<400> 135
 Met Arg Val Arg Ile Gly Leu Thr Leu Leu Cys Ala Val Leu Leu
 1 5 10 15
 Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
 20 25 30
 Leu Asp Ser Lys Thr Thr Leu Thr Ser Asp Glu Ser Val Lys Asp His
 35 40 45
 Thr Thr Ala Gly Arg Val Val Ala Gly Gln Ile Phe Leu Asp Ser Glu
 50 55 60
 Glu Ser Glu Leu Glu Ser Ser Ile Gln Glu Glu Glu Asp Ser Leu Lys
 65 70 75 80
 Ser Gln Glu Gly Glu Ser Val Thr Glu Asp Ile Ser Phe Leu Glu Ser
 85 90 95
 Pro Asn Pro Glu Asn Lys Asp Tyr Glu Glu Pro Lys Lys Val Arg Lys
 100 105 110
 Pro Gly Ser Leu Asp Ile Phe Leu Ala Phe
 115 120

<210> 136
 <211> 112
 <212> PRT

<213> Homo sapiens

<400> 136

```

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
 1           5           10           15
Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
          20           25           30
Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
          35           40           45
Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
          50           55           60
Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
          65           70           75           80
Leu Phe Gly Leu Glu Thr Met Pro Gln Arg Glu Lys Phe Thr Thr Pro
          85           90           95
Ile Glu Glu Thr Gly Gly Glu Gly Cys Pro Ala Val Ala Leu Ile Gln
          100          105          110

```

<210> 137

<211> 140

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (140)

<223> Xaa equals stop translation

<400> 137

```

Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys Ser Gln Leu Trp
 1           5           10           15
Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser Ala Gly Met Ser
          20           25           30
Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala His Glu Asn Gly
          35           40           45
Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser Gly Leu Phe Ser
          50           55           60
Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr Leu Gly Gly Phe
          65           70           75           80
Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala Ile Gln Gly Leu
          85           90           95
Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe Tyr Leu Leu Glu
          100          105          110

```


Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile Leu Ser Thr Glu
115 120 125

Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr Xaa
130 135 140

<210> 138
<211> 404
<212> PRT
<213> Homo sapiens

<400> 138
Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val Lys Gly Leu Ala Arg
1 5 10 15

Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile Thr Asp Leu Tyr Ser
20 25 30

Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp Cys Phe Gln Val Gly
35 40 45

Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His Ala Ile Pro Trp Leu
50 55 60

Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr Gly Glu Trp Lys Thr
65 70 75 80

Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp His Leu Ala Phe Ala
85 90 95

Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu Ser Leu Ser Arg Glu
100 105 110

Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met Ala Arg Asn Val Leu
115 120 125

Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn His Val Val Ala Glu
130 135 140

Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu Gln Thr Arg Asp Thr
145 150 155 160

Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln Pro Thr Leu Tyr Gln
165 170 175

Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn Ser Asn Ala Tyr Leu
180 185 190

Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His Leu Glu Pro Tyr Ile
195 200 205

Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu Ala Gln Lys Ile Arg
210 215 220

Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val Val Ala Ser Gly Glu
225 230 235 240

Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys Ser Ala Trp Leu Lys
 245 250 255
 Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn His Arg Ile Ala Ala
 260 265 270
 Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala Glu Tyr Leu Gln Val
 275 280 285
 Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro His Phe Asp His Ala
 290 295 300
 Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys Ser Gly Asn Arg Val
 305 310 315 320
 Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu Ala Gly Gly Ala Thr
 325 330 335
 Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val Val Arg Asn Ala Ala
 340 345 350
 Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu Gly Asp Ser Asp Thr
 355 360 365
 Leu His Ala Gly Cys Pro Val Leu Val Gly Asp Lys Trp Val Ala Asn
 370 375 380
 Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg Arg Pro Cys Ser Ser
 385 390 395 400
 Ser Pro Glu Asp

<210> 139
 <211> 96
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (96)
 <223> Xaa equals stop translation

<400> 139
 Met Lys Ala Pro His Thr Gly Val Leu His Leu Gly Ser Val Trp Val
 1 5 10 15
 Phe Leu Gly Pro Phe Leu Leu Gly Val Gly Tyr Thr Leu Thr Phe Asn
 20 25 30
 Pro Leu Ser Gly Cys Met Ser Thr Val Arg Trp Leu Asn Ser Asn Ile
 35 40 45
 Thr Ala Asn Arg Thr Leu Ser Arg Ser Val Cys His Val Thr Pro Leu
 50 55 60
 His Arg Ser Leu Ser Pro His Asp Gly Glu Tyr Leu Arg Gln Met Leu
 65 70 75 80

Leu Asn Ser Ser Ser Arg Ala Gly Glu Ala Gly Ser Trp Gly Tyr Xaa
85 90 95

<210> 140
<211> 240
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (240)
<223> Xaa equals stop translation.

<400> 140
Met Gly Ser Cys Ala Arg Leu Leu Leu Leu Trp Gly Cys Thr Val Val
1 5 10 15

Ala Ala Gly Leu Ser Gly Val Ala Gly Val Ser Ser Arg Cys Glu Lys
20 25 30

Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg Lys Leu Trp
35 40 45

Ala Asp Thr Thr Cys Gly Gln Asn Ala Thr Glu Leu Tyr Cys Phe Tyr
50 55 60

Ser Glu Asn Thr Asp Leu Thr Cys Arg Gln Pro Lys Cys Asp Lys Cys
65 70 75 80

Asn Ala Ala Tyr Pro His Leu Ala His Leu Pro Ser Ala Met Ala Asp
85 90 95

Ser Ser Phe Arg Phe Pro Arg Thr Trp Trp Gln Ser Ala Glu Asp Val
100 105 110

His Arg Glu Lys Ile Gln Leu Asp Leu Glu Ala Glu Phe Tyr Phe Thr
115 120 125

His Leu Ile Val Met Phe Lys Ser Pro Arg Pro Ala Ala Met Val Leu
130 135 140

Asp Arg Ser Gln Asp Phe Gly Lys Thr Trp Lys Pro Tyr Lys Tyr Phe
145 150 155 160

Ala Thr Asn Cys Ser Ala Thr Phe Gly Leu Glu Asp Asp Val Val Lys
165 170 175

Lys Gly Ala Ile Cys Thr Ser Lys Tyr Ser Ser Pro Phe Pro Cys Thr
180 185 190

Gly Arg Lys Val Ile Phe Lys Ala Leu Ser Pro Pro Tyr Asp Thr Glu
195 200 205

Asn Pro Tyr Ser Ala Lys Val Gln Glu Gln Leu Lys Ile Thr Asn Leu

210 215 220
Pro Arg Ala Ala Ala Glu Thr Thr Val Leu Ser Leu Ser Glu Lys Xaa
225 230 235 240

<210> 141
<211> 54
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation

<400> 141
Met Met Ile Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala
1 5 10 15
Pro Glu Asn Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg
20 25 30
His Leu Arg Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu
35 40 45
Pro Ser Tyr Phe Glu Xaa
50

<210> 142
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 142
Met Arg Ser Leu Ile Ser Ser His Pro Cys Gln His Leu Leu Leu Leu
1 5 10 15
Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile Leu Val Asp Val Lys Trp
20 25 30
Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu Met Thr Ser Asp Val Glu
35 40 45
His Leu Phe Met Cys Leu Leu Ala Ile Arg Ile Ser Ser Trp Arg Asn
50 55 60
Val Tyr Xaa
65

<210> 143
 <211> 108
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (55)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (58)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (67)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 143
 Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
 1 5 10 15
 Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
 20 25 30
 Ile Cys Ser Gln Arg Asn Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
 35 40 45
 Leu Gln Thr Thr Trp Gly Xaa Pro Asp Xaa Gln Phe Pro Gly Cys Pro
 50 55 60
 His Pro Xaa Arg Val Thr Leu Asn Ala Arg Gln Met Gly Asn Gly Lys
 65 70 75 80
 Glu Lys Lys Ala Ala Asp Leu Lys Leu Lys Phe Pro Gln Lys Arg Phe
 85 90 95
 Tyr Leu Ser Ala Phe Ser Glu Arg Ile Lys Ala Phe
 100 105

 <210> 144
 <211> 84
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (84)
 <223> Xaa equals stop translation

<400> 144

Met Ala Ser Val Gly Thr Thr Leu Val Ser Pro Leu Leu Cys Leu Leu
 1 5 10 15
 Ile Pro Thr Arg Val Ser Asp Pro Trp Leu Gln Asn Thr Pro Leu His
 20 25 30
 Pro Trp Lys Thr Ile Thr Ile Ile Asp Tyr Tyr Leu Ser Leu Gly Phe
 35 40 45
 Leu Gly Trp Thr Gly Leu Ser Trp Val Val His Phe Gly Ala Ser Ala
 50 55 60
 Val Met Gly Arg Gln Trp Leu Gly Ser Leu Gln Arg Leu Pro Cys Ile
 65 70 75 80
 Ser Gly Ser Xaa

<210> 145

<211> 166

<212> PRT

<213> Homo sapiens

<400> 145

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu
 1 5 10 15
 Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro
 20 25 30
 Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys
 35 40 45
 Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser
 50 55 60
 Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys
 65 70 75 80
 Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
 85 90 95
 Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile
 100 105 110
 Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr
 115 120 125
 Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly
 130 135 140
 Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn
 145 150 155 160
 Met Ser Ser Cys Asp Phe
 165

<210> 146
 <211> 70
 <212> PRT
 <213> Homo sapiens

<400> 146
 Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val
 1 5 10 15
 Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp
 20 25 30
 Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe
 35 40 45
 Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln
 50 55 60
 Ser Ser Pro Gly Gln His
 65 70

<210> 147
 <211> 412
 <212> PRT
 <213> Homo sapiens

<400> 147
 Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
 1 5 10 15
 Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
 20 25 30
 Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
 35 40 45
 Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
 50 55 60
 Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
 65 70 75 80
 Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
 85 90 95
 Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
 100 105 110
 Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
 115 120 125
 Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
 130 135 140
 Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
 145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
165 170 175
Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
180 185 190
Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
195 200 205
Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
210 215 220
Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
225 230 235 240
Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Leu Glu Ser Gly His Glu
245 250 255
Cys Tyr His Pro Asn Met Pro Asp Ala Phe Leu Thr Cys Glu Thr Val
260 265 270
Ile Phe Ala Trp Ala Ile Gly Gly Glu Gly Phe Ser Tyr Pro Pro His
275 280 285
Val Gly Leu Ser Leu Gly Thr Pro Leu Asp Pro His Tyr Val Leu Leu
290 295 300
Glu Val His Tyr Asp Asn Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn
305 310 315 320
Ser Gly Leu Arg Leu Phe Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala
325 330 335
Gly Val Ile Glu Ala Gly Leu Trp Val Ser Leu Phe His Thr Ile Pro
340 345 350
Pro Gly Met Pro Glu Phe Gln Ser Glu Gly His Cys Thr Leu Glu Cys
355 360 365
Leu Glu Glu Leu Trp Lys Pro Lys Ser Gln Val Glu Phe Met Cys Leu
370 375 380
Leu Phe Phe Ser Met Leu Thr Trp Leu Ala Glu His Gln Ala Ala Ser
385 390 395 400
Phe Ser Lys Arg Glu Gly Asn Glu Ile Thr Cys Leu
405 410

<210> 148

<211> 85

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (85)

<223> Xaa equals stop translation

<400> 148
 Met Asn Val Phe Leu Pro Pro Ala Leu Gly Thr Trp Gly Val Ala Arg
 1 5 10 15
 Phe Phe Pro His Leu Val Pro Glu Arg Trp Cys Leu Val Phe Cys Cys
 20 25 30
 Trp Ile Phe Phe Phe Phe Phe Phe Cys Thr Lys Val Ala Thr Arg
 35 40 45
 Ser Val Leu Gly Asp Gln Ala Gly Leu Gly Val Gly Pro His Leu
 50 55 60
 Pro Leu Pro Gly Ser His Ser Val Ser Val Pro Glu Lys Thr Ile Phe
 65 70 75 80
 Ser Leu Lys Gln Xaa
 85

<210> 149
 <211> 154
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (154)
 <223> Xaa equals stop translation

<400> 149
 Met Gly Arg Leu Pro Leu Leu Arg Arg Val Leu Lys Gly Leu Gln Leu
 1 5 10 15
 Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu Glu Val Val Ser Gln Cys
 20 25 30
 Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu Phe Val Ser Cys Ser Ala
 35 40 45
 Phe Leu Leu Ser Leu Leu Ile Leu Ile Val Tyr Cys Thr Pro Phe Tyr
 50 55 60
 Glu Arg Val Asp Thr Thr Lys Val Lys Ser Ser Asp Phe Tyr Ile Thr
 65 70 75 80
 Leu Gly Thr Gly Cys Val Phe Leu Leu Ala Ser Ile Ile Phe Val Ser
 85 90 95
 Thr His Asp Arg Thr Ser Ala Glu Ile Ala Ala Ile Val Phe Gly Phe
 100 105 110
 Ile Ala Ser Phe Met Phe Leu Leu Asp Phe Ile Thr Met Leu Tyr Glu
 115 120 125
 Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro Glu Asn Thr Thr Arg Ala
 130 135 140
 Glu Ala Leu Thr Glu Pro Leu Asn Ala Xaa

145

150

<210> 150

<211> 130

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (130)

<223> Xaa equals stop translation

<400> 150

Met Arg Gly His Leu Ala Gly Phe Pro Ala Leu Ser Gly Leu Ala Ser
1 5 10 15Val Cys Leu Trp Ala Thr Phe Ser Ala Gln Leu Pro Gly Pro Val Ala
20 25 30Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly Cys Ser Ala Ala Arg Ser
35 40 45Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala Pro Gly Ser Ala Ala Ser
50 55 60Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys Arg Val Leu Pro Val Asp
65 70 75 80Pro Ala Pro Ala Ala Leu Asn Val Arg Glu Pro Gly Trp Leu Gly Gly
85 90 95Leu Phe Asp Gly Ala Leu Leu Gln Val Leu Leu Asn Phe Leu Arg Lys
100 105 110Ser Thr Asp Val Leu Met Asp Thr Arg Glu Ala Glu Ser Leu Glu Val
115 120 125Glu Xaa
130

<210> 151

<211> 62

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (62)

<223> Xaa equals stop translation

<400> 151

Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu Ser
1 5 10 15Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn Ser
20 25 30

Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu Ala
35 40 45

Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg Xaa
50 55 60

<210> 152

<211> 225

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (225)

<223> Xaa equals stop translation

<400> 152

Met Gly Ile Phe Pro Gly Ile Ile Leu Ile Phe Leu Arg Val Lys Phe
1 5 10 15

Ala Thr Ala Ala Val Ile Val Ser Gly His Gln Lys Ser Thr Thr Val
20 25 30

Ser His Glu Met Ser Gly Leu Asn Trp Lys Pro Phe Val Tyr Gly Gly
35 40 45

Leu Ala Ser Ile Val Ala Glu Phe Gly Thr Phe Pro Val Asp Leu Thr
50 55 60

Lys Thr Arg Leu Gln Val Gln Gly Gln Ser Ile Asp Ala Arg Phe Lys
65 70 75 80

Glu Ile Lys Tyr Arg Gly Met Phe His Ala Leu Phe Arg Ile Cys Lys
85 90 95

Glu Glu Gly Val Leu Ala Leu Tyr Ser Gly Ile Ala Pro Ala Leu Leu
100 105 110

Arg Gln Ala Ser Tyr Gly Thr Ile Lys Ile Gly Ile Tyr Gln Ser Leu
115 120 125

Lys Arg Leu Phe Val Glu Arg Leu Glu Asp Glu Thr Leu Leu Ile Asn
130 135 140

Met Ile Cys Gly Val Val Ser Gly Val Ile Ser Ser Thr Ile Ala Asn
145 150 155 160

Pro Thr Asp Val Leu Lys Ile Arg Met Gln Ala Gln Gly Ser Leu Phe
165 170 175

Gln Gly Ser Met Ile Gly Ser Phe Ile Asp Ile Tyr Gln Gln Glu Gly
180 185 190

Thr Arg Gly Leu Trp Arg Val Ser Thr Leu Phe Leu Leu Leu Ser Tyr
195 200 205

Thr Leu Ser Ser Tyr Asn Leu Gln Arg Ile Phe Phe Tyr Ile Lys Thr
210 215 220

Xaa
225

<210> 153
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 153
Met Leu Met Leu Leu Thr Leu Leu Val Leu Gly Met Val Trp Val Ala
1 5 10 15
Ser Ala Ile Val Asp Lys Asn Lys Ala Asn Arg Glu Ser Leu Tyr Asp
20 25 30
Phe Trp Glu Tyr Tyr Leu Pro Tyr Leu Tyr Ser Cys Ile Ser Phe Leu
35 40 45
Gly Val Leu Leu Leu Leu Ala Ala Gly Arg Pro Gly Gly Ala Ala Val
50 55 60
Leu Leu Ser Leu Xaa
65

<210> 154
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 154
Met Tyr Gly Val Cys Leu Cys Val Ile Val Cys Val Ser Gly Val Ser
1 5 10 15
Leu Cys Leu Tyr Val Trp Gly Val Ser Val Cys Asp Cys Val Ser Val
20 25 30
Phe Met Cys Val Cys Leu Cys Val Ile Phe Cys Val Tyr Gly Lys Pro
35 40 45
Arg Thr Glu His Tyr His Ser Pro His Leu Ala Lys Gln Lys Ala Phe
50 55 60
Arg Glu Met Cys Gly Arg His Asp Val Ser Ala Ala Gly Ile Phe Gln
65 70 75 80
Ser Tyr Val Xaa

<210> 155
<211> 61
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (61)
<223> Xaa equals stop translation

<400> 155
Met His Val Leu Leu Phe Ser Phe Leu Ile Pro Phe Leu Leu Leu Ser
1 5 10 15
Pro Val Gly Val Thr Cys Asn Ser His Met Leu Glu Arg Gln Val Ser
20 25 30
Trp Leu Lys Lys Arg Ser Thr Gln Ala Ser Gln Gln Phe Asn Lys Phe
35 40 45
Leu Arg Gly Ile Ser Asn Val Gly Arg Ile Val Ile Xaa
50 55 60

<210> 156
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 156
Met Cys Leu Leu Val Glu Tyr Ser Leu Met Ile Leu Thr Ile Ile Pro
1 5 10 15
Ser Leu Leu Ser Phe Val Leu Cys Leu Lys Gly Ile Lys His Gly Asn
20 25 30
Tyr Ile Phe Gln Thr Pro Leu Pro Glu Gly Tyr Gly Trp Ile Ser Ala
35 40 45
Met Ser Gly Leu Cys Ile Lys Phe Gly Arg Arg Lys Arg Arg Lys Thr
50 55 60
Trp Leu Leu Gln Val Gly Thr Leu Ala Thr Ile Asp Thr Glu Phe Ala
65 70 75 80
Arg Ser Cys Xaa

<210> 157
<211> 162

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (162)

<223> Xaa equals stop translation

<400> 157

```

Met Ala Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn
 1           5           10           15

Val Ser Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe
          20           25           30

Ala Glu Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val
 35           40           45

Pro Val Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys
 50           55           60

Lys Thr Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu
 65           70           75           80

Ile Ala Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr
 85           90           95

Leu Gly Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met
          100           105           110

Val Ala Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Lys Met
          115           120           125

Glu Asn Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met
          130           135           140

Pro Pro Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn
          145           150           155           160

Glu Xaa

```

<210> 158

<211> 146

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (96)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (107)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
 <222> (111)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (115)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (122)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (132)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 158
 Met Glu Pro Gln Leu Gly Pro Glu Ala Ala Ala Leu Arg Pro Gly Trp
 1 5 10 15
 Leu Ala Leu Leu Leu Trp Val Ser Ala Leu Ser Cys Ser Phe Ser Leu
 20 25 30
 Pro Ala Ser Ser Leu Ser Ser Leu Val Pro Gln Val Arg Thr Ser Tyr
 35 40 45
 Asn Phe Gly Arg Thr Phe Leu Gly Leu Asp Lys Cys Asn Ala Cys Ile
 50 55 60
 Gly Thr Ser Ile Cys Lys Lys Phe Phe Lys Glu Glu Ile Arg Ser Asp
 65 70 75 80
 Asn Trp Leu Ala Ser His Leu Gly Thr Ala Ser Arg Phe Pro Leu Xaa
 85 90 95
 Ser Tyr Pro Cys Lys Leu Leu Gln Met Ile Xaa Lys Ile Trp Xaa Pro
 100 105 110
 Cys Gly Xaa Leu Leu Thr Gly Gln Gln Xaa Ser Asn Glu Ile Ser Lys
 115 120 125
 Gln Glu Ile Xaa Cys Leu Leu His Pro Pro Pro Lys Asn Leu His Ile
 130 135 140
 Asp Val
 145

<210> 159
 <211> 143
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (143)

<223> Xaa equals stop translation

<400> 159

Met Trp Trp Ala Val Met Gly Gly Val Ile Gly Ser Trp Leu Ser Pro
1 5 10 15
Leu Ser Ile Ala Glu Cys Cys His Asp Leu Trp Thr Ser Gln Ser Cys
20 25 30
Glu His Ala Gly Ala Leu Cys Gly Asp Leu Leu Cys Ala Cys Arg Lys
35 40 45
Val Gly Val Trp Cys Ala Leu Gln Gln His Trp Trp Asn Arg Cys Val
50 55 60
Cys Pro His Ala Val Ile Arg Val His Cys Thr Gly Ala Ser Tyr Thr
65 70 75 80
Leu Gln Lys Ile Cys Ser Cys Asn Pro Lys Phe Met Gly Arg His Pro
85 90 95
His Arg Trp Gln Gln Ile Arg Lys Cys Ser Gln Pro Val Leu Arg Gly
100 105 110
Ser Arg Ala Ala Phe Ile Trp Val Arg Leu Ala Ala Leu Asn Phe Ile
115 120 125
Ser Ser Phe Arg Cys Ile Ser Leu Ile Ser Tyr Ser Ala Phe Xaa
130 135 140

<210> 160

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation.

<400> 160

Met Lys Val Ser Asp Phe Asn Phe Leu Ile Phe Leu Ile Phe Ala Leu
1 5 10 15
Phe Leu Thr Leu Glu Ala Phe Leu Lys Phe Thr Lys Arg Val Leu Ala
20 25 30
Val Val Gly Asn Leu Pro Glu Pro Pro Ile Ile Lys Thr Ile Gly Phe
35 40 45
Leu Tyr Xaa
50

<210> 161

<211> 65

<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (65)
<223> Xaa equals stop translation

<400> 161
Met Val Trp Ser Ala Ala Pro Ala Pro Cys Cys Leu Leu Gly Val Leu
1 5 10 15
Gly Leu Val Gln Val Leu Gly Ala Gln Ala Val Gly Pro Trp Thr Ala
20 25 30
Ser Ala Cys Leu Gly Ala Ala Gln Ala Gln Pro Cys Arg Pro Cys Lys
35 40 45
Glu Ser Ser Leu Arg Leu Phe Ser Ala Ser Ala Pro Ser Met Thr His
50 55 60
Xaa
65

<210> 162
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 162
Met Glu Lys Tyr Cys Leu Gly Asn Asn Met Leu Ser Arg Phe Cys Leu
1 5 10 15
Phe Leu Ile Met Leu Leu His Ile Leu Leu Phe Leu Val Ile Phe Ile
20 25 30
Gln Arg His Thr Val Val Ser Leu Ser Lys His His Pro Phe Val Pro
35 40 45
Thr Asn Gly Ser Lys Ser Tyr Ser Ser Phe Xaa
50 55

<210> 163
<211> 374
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE

<222> (112)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 163

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
 1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
 20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
 35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
 50 55 60

Arg Asp Gly Gly Gln Leu Val Ser Ile Glu Ser Glu Asp Glu Gln Lys
 65 70 75 80

Leu Ile Glu Xaa Phe Ile Glu Asn Leu Leu Pro Ser Asp Gly Asp Phe
 85 90 95

Trp Ile Gly Leu Arg Arg Arg Glu Glu Lys Gln Ser Asn Ser Thr Xaa
 100 105 110

Cys Gln Asp Leu Tyr Ala Trp Thr Asp Gly Ser Ile Ser Gln Phe Arg
 115 120 125

Asn Trp Tyr Val Asp Glu Pro Ser Cys Gly Ser Glu Val Cys Val Val
 130 135 140

Met Tyr His Gln Pro Ser Ala Pro Ala Gly Ile Gly Gly Pro Tyr Met
 145 150 155 160

Phe Gln Trp Asn Asp Asp Arg Cys Asn Met Lys Asn Asn Phe Ile Cys
 165 170 175

Lys Tyr Ser Asp Glu Lys Pro Ala Val Pro Ser Arg Glu Ala Glu Gly
 180 185 190

Glu Glu Thr Glu Leu Thr Thr Pro Val Leu Pro Glu Glu Thr Gln Glu
 195 200 205

Glu Asp Ala Lys Lys Thr Phe Lys Glu Ser Arg Glu Ala Ala Leu Asn
 210 215 220

Leu Ala Tyr Ile Leu Ile Pro Ser Ile Pro Leu Leu Leu Leu Val
 225 230 235 240

Val Thr Thr Val Val Cys Trp Val Trp Ile Cys Arg Lys Arg Lys Arg
 245 250 255

Glu Gln Pro Asp Pro Ser Thr Lys Lys Gln His Thr Ile Trp Pro Ser
 260 265 270

Pro His Gln Gly Asn Ser Pro Asp Leu Glu Val Tyr Asn Val Ile Arg
 275 280 285

Lys Gln Ser Glu Ala Asp Leu Ala Glu Thr Arg Pro Asp Leu Lys Asn

290 295 300
Ile Ser Phe Arg Val Cys Ser Gly Glu Ala Thr Pro Asp Asp Met Ser
305 310 315 320
Cys Asp Tyr Asp Asn Met Ala Val Asn Pro Ser Glu Ser Gly Phe Val
325 330 335
Thr Leu Val Ser Val Glu Ser Gly Phe Val Thr Asn Asp Ile Tyr Glu
340 345 350
Phe Ser Pro Asp Gln Met Gly Arg Ser Lys Glu Ser Gly Trp Val Glu
355 360 365
Asn Glu Ile Tyr Gly Tyr
370

<210> 164
<211> 64
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (64)
<223> Xaa equals stop translation

<400> 164
Met His Pro Gln Leu Ile Pro Ser Val Ile Ala Val Val Phe Ile Leu
1 5 10 15
Leu Leu Gly Val Cys Phe Ile Ala Ser Cys Leu Val Thr His His Asn
20 25 30
Phe Ser Arg Cys Lys Arg Gly Thr Gly Val His Lys Leu Glu His His
35 40 45
Ala Lys Leu Lys Cys Ile Lys Glu Lys Ser Glu Leu Lys Ser Cys Xaa
50 55 60

<210> 165
<211> 743
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (743)
<223> Xaa equals stop translation

<400> 165
Met Ala Val Arg Glu Leu Cys Phe Pro Arg Gln Arg Gln Val Leu Phe
1 5 10 15

Leu Phe Leu Phe Trp Gly Val Ser Leu Ala Gly Ser Gly Phe Gly Arg
 20 25 30
 Tyr Ser Val Thr Glu Glu Thr Glu Lys Gly Ser Phe Val Val Asn Leu
 35 40 45
 Ala Lys Asp Leu Gly Leu Ala Glu Gly Glu Leu Ala Ala Arg Gly Thr
 50 55 60
 Arg Val Val Ser Asp Asp Asn Lys Gln Tyr Leu Leu Leu Asp Ser His
 65 70 75 80
 Thr Gly Asn Leu Leu Thr Asn Glu Lys Leu Asp Arg Glu Lys Leu Cys
 85 90 95
 Gly Pro Lys Glu Pro Cys Met Leu Tyr Phe Gln Ile Leu Met Asp Asp
 100 105 110
 Pro Phe Gln Ile Tyr Arg Ala Glu Leu Arg Val Arg Asp Ile Asn Asp
 115 120 125
 His Ala Pro Val Phe Gln Asp Lys Glu Thr Val Leu Lys Ile Ser Glu
 130 135 140
 Asn Thr Ala Glu Gly Thr Ala Phe Arg Leu Glu Arg Ala Gln Asp Pro
 145 150 155 160
 Asp Gly Gly Leu Asn Gly Ile Gln Asn Tyr Thr Ile Ser Pro Asn Ser
 165 170 175
 Phe Phe His Ile Asn Ile Ser Gly Gly Asp Glu Gly Met Ile Tyr Pro
 180 185 190
 Glu Leu Val Leu Asp Lys Ala Leu Asp Arg Glu Glu Gln Gly Glu Leu
 195 200 205
 Ser Leu Thr Leu Thr Ala Leu Asp Gly Gly Ser Pro Ser Arg Ser Gly
 210 215 220
 Thr Ser Thr Val Arg Ile Val Val Leu Asp Val Asn Asp Asn Ala Pro
 225 230 235 240
 Gln Phe Ala Gln Ala Leu Tyr Glu Thr Gln Ala Pro Glu Asn Ser Pro
 245 250 255
 Ile Gly Phe Leu Ile Val Lys Val Trp Ala Glu Asp Val Asp Ser Gly
 260 265 270
 Val Asn Ala Glu Val Ser Tyr Ser Phe Phe Asp Ala Ser Glu Asn Ile
 275 280 285
 Arg Thr Thr Phe Gln Ile Asn Pro Phe Ser Gly Glu Ile Phe Leu Arg
 290 295 300
 Glu Leu Leu Asp Tyr Glu Leu Val Asn Ser Tyr Lys Ile Asn Ile Gln
 305 310 315 320
 Ala Met Asp Gly Gly Gly Leu Ser Ala Arg Cys Arg Val Leu Val Glu
 325 330 335

Val Leu Asp Thr Asn Asp Asn Pro Pro Glu Leu Ile Val Ser Ser Phe
340 345 350
Ser Asn Ser Val Ala Glu Asn Ser Pro Glu Thr Pro Leu Ala Val Phe
355 360 365
Lys Ile Asn Asp Arg Asp Ser Gly Glu Asn Gly Lys Met Val Cys Tyr
370 375 380
Ile Gln Glu Asn Leu Pro Phe Leu Leu Lys Pro Ser Val Glu Asn Phe
385 390 395 400
Tyr Ile Leu Ile Thr Glu Gly Ala Leu Asp Arg Glu Ile Arg Ala Glu
405 410 415
Tyr Asn Ile Thr Ile Thr Val Thr Asp Leu Gly Thr Pro Arg Leu Lys
420 425 430
Thr Glu His Asn Ile Thr Val Leu Val Ser Asp Val Asn Asn Asn Ala
435 440 445
Pro Ala Phe Thr Gln Thr Ser Tyr Thr Leu Phe Val Arg Glu Asn Asn
450 455 460
Ser Pro Ala Leu His Ile Gly Ser Val Ser Ala Thr Asp Arg Asp Ser
465 470 475 480
Gly Thr Asn Ala Gln Val Thr Tyr Ser Leu Leu Pro Pro Gln Asp Pro
485 490 495
His Leu Pro Leu Ala Ser Leu Val Ser Ile Asn Ala Asp Asn Gly His
500 505 510
Leu Phe Ala Leu Arg Ser Leu Asp Tyr Glu Ala Leu Gln Ala Phe Glu
515 520 525
Phe Arg Val Gly Ala Thr Asp Arg Gly Ser Pro Ala Leu Asn Ser Glu
530 535 540
Ala Leu Gly Ala Arg Ala Gly Ala Gly Arg Gln Arg Gln Leu Ala Leu
545 550 555 560
Arg Ala Val Pro Ala Ala Glu Arg Leu Arg Ala Leu His Arg Ala Gly
565 570 575
Ala Pro Gly Gly Arg Ala Gly Leu Pro Gly Asp Gln Gly Gly Gly Gly
580 585 590
Gly Arg Arg Leu Gly Pro Glu Arg Leu Ala Val Val Pro Ala Ala Gln
595 600 605
Gly His Gly Ala Arg Ala Val Arg Cys Val Gly Ala Gln Trp Gly Gly
610 615 620
Ala His Arg Gln Ala Ala Glu Arg Ala Arg Arg Ser Gln Ala Gln Ala
625 630 635 640
Gly Gly Ala Cys Gln Gly Gln Trp Arg Ala Ser Ser Leu Gly His Arg

```
<210> 166
<211> 214
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (214)  
<223> Xaa equals stop translation
```

```

<400> 166
Met Asn Arg Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu
  1          5          10          15
Ala Met Tyr Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp
          20          25          30
Val Gln Phe Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe
          35          40          45
Thr Ser Leu Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly
          50          55          60
Ile Pro Tyr Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val
          65          70          75          80
Glu/Glu Ala Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala
          85          90          95
Ser Ser Ala Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met
          100          105          110
Asp Asp Ala Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu
          115          120          125
Ser Arg Ile His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile
          130          135          140

```

Ala Arg Leu Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser
 145 150 155 160
 Thr Lys Lys Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu
 165 170 175
 Ala Leu Arg Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln
 180 185 190
 Arg Arg Pro Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys
 195 200 205
 Pro Gly Arg Ser Val Xaa
 210

<210> 167
 <211> 213
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (213)
 <223> Xaa equals stop translation

<400> 167
 Met Pro Ser Leu Arg Phe Leu Ala Leu Ala Leu Leu Ala Ile Leu
 1 5 10 15
 Pro Ala Leu Pro Asn Ala His Ala Ala Pro Gly Ile Gly Gly Leu Ile
 20 25 30
 Gly Gly Gly Ser Gln Ala Ser Ala Lys Glu Glu Pro Gln Ser Asn Ala
 35 40 45
 Gln Pro Ser Ala Asp Glu Arg Lys Gln Arg Leu Leu Ser Gln Ala Glu
 50 55 60
 Glu Thr Arg Gln Arg Leu Thr Asp Leu Lys Ala Glu Leu Ala Gly Ala
 65 70 75 80
 Pro Lys Glu Ile Ser Glu Ala Gln Arg Thr Leu Ser Lys Leu Val Ser
 85 90 95
 Glu Asp Asn Ser Asp Leu Pro Glu Arg Leu Ser Lys Leu Ser Val Pro
 100 105 110
 Val Leu Glu Gln Arg Leu Ala Ala Arg Val Asp Glu Leu Ala Leu Trp
 115 120 125
 Gln Gln Ala Leu Ser Ala Ala Asn Ser Met Leu Ile Ser Ala Gln Thr
 130 135 140
 Arg Pro Glu Arg Ala Gln Ala Asp Ile Ser Lys Asn Gln Leu Arg Ile
 145 150 155 160
 Asp Glu Ile Asn Gly Leu Leu Lys Ser Gly Arg Glu Asn Asn Lys Pro
 165 170 175

Leu Thr Asp Glu Arg Arg Ala Leu Leu Glu Ser Thr Ser Arg Ala Ala
180 185 190

Ala Gly Pro Ser Ile Phe His Pro Gly Gly Val Pro Gly Lys Cys Thr
195 200 205

Gln Phe Ala Leu Xaa
210

<210> 168

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 168

Met Phe Thr Ser Phe Gly Leu Ala Ser Pro Arg Ile Leu Phe Cys Phe
1 5 10 15

Cys Phe Phe Asp Leu Gly Phe Ile Phe Phe Cys Val Leu Tyr Tyr Ile
20 25 30

Val Lys Gly Ile Leu Ala Glu Thr Leu Val Phe Gly Ala Arg Gly Glu
35 40 45

Gln Glu Cys Trp Ala Val Tyr Phe Arg Trp Arg Thr His Leu Gln Thr
50 55 60

Phe Gly Leu Phe Ser Phe Asn Cys Ser Val Xaa
65 70 75

<210> 169

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 169

Met Phe Leu Cys Leu Phe Phe Phe Phe Asn Ala Thr Gln Gly Asn
1 5 10 15

Ile Phe Ile Ser Phe Leu Ser Gly Leu Pro Gln Cys Ile Phe Ile Ser
20 25 30

Phe Glu Thr Lys Arg Phe Trp Lys Leu Phe Phe Cys Ser Phe Lys Xaa
35 40 45

<210> 170
<211> 88
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (88)
<223> Xaa equals stop translation

<400> 170

Met Gly Leu His Leu Arg Pro Tyr Arg Val Gly Leu Leu Pro Asp Gly
1 5 10 15
Leu Leu Phe Leu Leu Leu Leu Met Leu Leu Ala Asp Pro Ala Leu
20 25 30
Pro Ala Gly Arg His Pro Pro Val Val Leu Val Pro Gly Asp Leu Gly
35 40 45
Asn Gln Leu Glu Ala Lys Leu Asp Lys Pro Thr Val Val His Tyr Leu
50 55 60
Cys Ser Lys Lys Thr Glu Ser Tyr Phe Thr Ile Trp Leu Asn Leu Glu
65 70 75 80
Leu Leu Leu Pro Val His His Xaa
85

<210> 171
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 171

Met Ala Cys Glu Thr His Gly Val Leu Val Pro Ala His Leu Ser Gly
1 5 10 15
Leu Ile Thr Cys Leu Leu Ala Phe Trp Val Pro Ala Ser Cys Ile Gln
20 25 30
Arg Cys Ser Gly Ser Pro Leu Pro Leu Xaa
35 40

<210> 172
<211> 48
<212> PRT
<213> Homo sapiens

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals stop translation

<400> 172
 Met Gln Cys Phe Leu Phe Ser Ile Phe Leu Ile Thr Gly Leu Ala Glu
 1 5 10 15
 Glu Phe Cys Glu Gln Leu Ser Ile Ser Leu Ala Glu Glu Glu Ile Gln
 20 25 30
 Leu Ser Ser Thr Val Glu His Phe Cys Met Thr Ala Phe Ser Trp Xaa
 35 40 45

<210> 173
 <211> 233
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (233)
 <223> Xaa equals stop translation

<400> 173
 Met Ala Ala Leu Ala Ala Ala Lys Lys Val Trp Ser Ala Arg Arg
 1 5 10 15
 Leu Leu Val Leu Leu Phe Thr Pro Leu Ala Leu Leu Pro Val Val Phe
 20 25 30
 Ala Leu Pro Pro Lys Glu Gly Arg Cys Leu Phe Val Ile Leu Leu Met
 35 40 45
 Ala Val Tyr Trp Cys Thr Glu Ala Leu Pro Leu Ser Val Thr Ala Leu
 50 55 60
 Leu Pro Ile Val Leu Phe Pro Phe Met Gly Ile Leu Pro Ser Asn Lys
 65 70 75 80
 Val Cys Pro Gln Tyr Phe Leu Asp Thr Asn Phe Leu Phe Leu Ser Gly
 85 90 95
 Leu Ile Met Ala Ser Ala Ile Glu Glu Trp Asn Leu His Arg Arg Ile
 100 105 110
 Ala Leu Lys Ile Leu Met Leu Val Gly Val Gln Pro Ala Arg Leu Ile
 115 120 125
 Leu Gly Met Met Val Thr Thr Ser Phe Leu Ser Met Trp Leu Ser Asn
 130 135 140
 Thr Ala Ser Thr Ala Met Met Leu Pro Ile Ala Asn Ala Ile Leu Lys
 145 150 155 160

Ser Leu Phe Gly Gln Lys Glu Val Arg Lys Asp Pro Ser Gln Glu Ser
165 170 175
Glu Glu Asn Thr Gly Ile Glu Pro Asn Thr Phe Leu Ser Glu Glu Arg
180 185 190
Leu Lys Leu Gln Ala Pro Leu Val Ile Arg Leu Gly Gln Ile Thr Glu
195 200 205
Ser Gly Gln Trp Asn Met Ser Gly Asn Asp Val Cys Asn Phe Arg Val
210 215 220
Leu Ser Phe Leu Pro Gly Met Xaa
225 230

<210> 174
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 174
Met Gly Thr Ile Phe Gly Tyr Leu His Cys Val Lys Cys Tyr Val Leu
1 5 10 15
Tyr Phe Ile Phe Ile Leu Ile Thr Ala Val Tyr His Ser Phe Tyr Tyr
20 25 30
Pro His Tyr Arg Gly Lys Ala Leu Ile Ser Gly Thr Xaa
35 40 45

<210> 175
<211> 85
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (85)
<223> Xaa equals stop translation

<400> 175
Met Val Trp Phe Leu Phe Leu Val Phe Ile Phe Leu Lys Val Lys Gly
1 5 10 15
Asp Phe Phe Pro Pro Phe Leu Ile Cys Asn Leu Phe Cys Ile Trp Met
20 25 30

Ile Thr Gly Val Ser His Arg Leu Gln Pro Gln Ile Leu Phe Ser Arg
 35 40 45
 His Lys His Asn Gln Glu Ile Ile Leu Gln Met Val Ser Phe Ser Cys
 50 55 60
 Cys Val Phe Phe Pro Met Ile Arg Glu Val Lys Ser Xaa Leu Gly Cys
 65 70 75 80
 Ile Lys Met Ser Xaa
 85

<210> 176
 <211> 66
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (66)
 <223> Xaa equals stop translation

<400> 176
 Met Trp Val Leu Leu Ser Cys Pro Leu Pro Pro Leu Cys Leu Pro Ala
 1 5 10 15
 Ser Ala Val Pro Gly Gln Cys Leu Gly Gly Gln Trp Ser Gly His Gln
 20 25 30
 Leu Arg Leu Arg Gly Arg Gly Trp His Cys Arg Cys His Cys Arg Ala
 35 40 45
 Trp Ala Ala Asp Met Gly Arg Gly Leu His Ser Cys Gln Leu Leu Ser
 50 55 60
 Arg Xaa
 65

<210> 177
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation

<400> 177
 Met Leu Leu Leu Cys Ile Leu Leu Ile Phe Cys Val Val Gly Leu Ser
 1 5 10 15
 Val Val Gly Arg Arg Val Leu Lys Ser Thr Thr Ile Ile Val Tyr Leu
 20 25 30
 Ser Ile Thr Pro Phe Ser Ser Phe Ser Ser Ile Ser His Ile Phe Gln

35 40 45
 Leu Leu Ile Gly Ala His Xaa
 50 55

 <210> 178
 <211> 83
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (4)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (83)
 <223> Xaa equals stop translation

 <400> 178
 Met Cys Val Xaa Leu Ser Phe Cys Pro Phe Leu Ser Ser Ala Leu Pro
 1 5 10 15
 Ala Ser His Thr Gln Phe Tyr Met Pro Arg Gly Ala Lys Phe Gly Thr
 20 25 30
 Phe Thr Leu Gln Ala Ser Val Ser Pro Leu Glu Glu Lys Thr His Ser
 35 40 45
 Phe Thr His Pro Gly Ile Gly Gly Lys Leu Leu Gly His Gln Asp Pro
 50 55 60
 Gly Ala Pro Gly Pro Ser Trp Asn Ile Arg Ser Thr Trp Ser Thr Arg
 65 70 75 80
 Ser Leu Xaa

<210> 179
 <211> 330
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (247)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 179
 Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
 1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
 20 25 30
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
 35 40 45
 Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Lys His Leu Ala
 50 55 60
 Arg Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala
 65 70 75 80
 Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val
 85 90 95
 Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe
 100 105 110
 Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn
 115 120 125
 Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe
 130 135 140
 Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn
 145 150 155 160
 Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala
 165 170 175
 Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn
 180 185 190
 Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr
 195 200 205
 Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg
 210 215 220
 Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro
 225 230 235 240
 Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg
 245 250 255
 Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu
 260 265 270
 Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Gln Leu Glu Gly
 275 280 285
 Val Gly Gly Arg Tyr Leu Tyr Asn Gln Lys Glu Thr Lys Ser Leu His
 290 295 300
 Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys
 305 310 315 320
 Glu Met Thr Gly Val Leu Asp Val Thr Leu

128

325

330

<210> 180
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 180

Met Ile Ala Cys Gln Tyr Ile Ser Leu Ala Ile Met Leu Ala Phe Val
1 5 10 15

Arg Trp Ala Ala Phe Leu Leu Phe Pro Phe Leu Cys Gly Asp Asn Gly
20 25 30

Gly Asn Ile Gln Gln Lys Tyr Val Xaa
35 40

<210> 181
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 181

Met Ala Asn Ala Met Ala Tyr Leu Ser Ile Phe Leu Cys Gly Ala Ser
1 5 10 15

Ser Ser Pro Cys Asp Cys Ala Leu Leu Val Pro Val Ser Leu Phe Arg
20 25 30

Gly Arg Lys Val Ala Asn Phe Lys Asn Gln Asn Ser Asp Val Thr Ser
35 40 45

Gly Asn Ala Xaa
50

<210> 182
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 182

Met Gln Gln Ile Cys Ser Cys Leu Gly Ala Phe Ala Leu Leu Phe Phe
 1 5 10 15
 Trp Pro Gly His Phe Thr Ser Thr Phe Ser Ile Phe Tyr Asp Phe Leu
 20 25 30
 Pro Ile Phe Gly Ser Leu Phe Lys Cys His Pro Ser Lys Arg Pro Ser
 35 40 45
 Lys Leu Pro Tyr Leu Lys Xaa
 50 55

<210> 183
 <211> 62
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (62)
 <223> Xaa equals stop translation

<400> 183
 Met Arg Leu Leu Leu Gln Trp Arg Val Tyr Leu Arg Leu Thr Cys Ala
 1 5 10 15
 Thr Lys Asp Gly Met Ala Arg Glu Cys Pro Thr Thr Trp Leu Ser Pro
 20 25 30
 Pro Ala Lys Pro Asp Phe Ala Gln Arg His Ser Val Lys Pro Thr Ala
 35 40 45
 Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly Ala Ser Pro Xaa
 50 55 60

<210> 184
 <211> 148
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (148)
 <223> Xaa equals stop translation

<400> 184
 Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His
 20 25 30
 Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro
 35 40 45
 Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp
 50 55 60

Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln
 65 70 75 80
 Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr
 85 90 95
 Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu
 100 105 110
 Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser Thr
 115 120 125
 Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu Glu
 130 135 140
 Gly Phe His Xaa
 145

<210> 185
 <211> 161
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (146)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (151)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (161)
 <223> Xaa equals stop translation

<400> 185
 Met Arg Leu Leu Cys Gly Leu Trp Leu Trp Leu Ser Leu Leu Lys Val
 1 5 10 15
 Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro Pro Pro Met Gln
 20 25 30
 Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu Trp Phe Val Leu Gly Leu
 35 40 45
 Ala Gly Asn Ser Phe Arg Pro Glu His Arg Ala Leu Leu Asn Ala Phe
 50 55 60
 Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly Arg Phe Glu Val Trp Asn
 65 70 75 80
 Ala Met Thr Arg Gly Gln His Cys Asp Thr Trp Ser Tyr Val Leu Ile
 85 90 95

Pro Ala Ala Gln Pro Gly Gln Phe Thr Val Asp His Gly Val Gly Arg
100 105 110

Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp Glu Phe Ile Cys Leu Gly
115 120 125

Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile Val Phe Pro Asp Val Thr
130 135 140

Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro Trp Val Ala Ala Pro Ala
145 150 155 160

Xaa

<210> 186

<211> 122

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (122)

<223> Xaa equals stop translation

<400> 186

Met Met Leu Pro Gln Trp Leu Leu Leu Phe Leu Leu Phe Phe Phe
1 5 10 15

Leu Phe Leu Leu Thr Arg Gly Ser Leu Ser Pro Thr Lys Tyr Asn Leu
20 25 30

Leu Glu Leu Lys Glu Ser Cys Ile Arg Asn Gln Asp Cys Glu Thr Gly
35 40 45

Cys Cys Gln Arg Ala Pro Asp Asn Cys Glu Ser His Cys Ala Glu Lys
50 55 60

Gly Ser Glu Gly Ser Leu Cys Gln Thr Gln Val Phe Phe Gly Gln Tyr
65 70 75 80

Arg Ala Cys Pro Cys Leu Arg Asn Leu Thr Cys Ile Tyr Ser Lys Asn
85 90 95

Glu Lys Trp Leu Ser Ile Ala Tyr Gly Arg Cys Gln Lys Ile Gly Arg
100 105 110

Gln Lys Leu Ala Lys Lys Met Phe Phe Xaa
115 120

<210> 187

<211> 163

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (163)

<223> Xaa equals stop translation

<400> 187.

Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly Ile Ala Gln
1 5 10 15

Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly Leu Gly Ser
20 25 30

Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg Thr Pro Ile
35 40 45

Pro Cys Ser Pro Pro Ala Pro Ala Ala Ala Cys Leu Gly Ser Gly His
50 55 60

Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro Ala Asn Leu
65 70 75 80

Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe Trp Ser Ser
85 90 95

Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe Arg Asp Leu
100 105 110

Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe Gln Lys Thr
115 120 125

Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val Ala Thr Pro
130 135 140

Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala Ala Ala Asn
145 150 155 160

Trp Cys Xaa

<210> 188

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 188

Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser
1 5 10 15

Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp
20 25 30

Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp
35 40 45

Ile Gly Xaa

50

<210> 189
<211> 65
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (65)
<223> Xaa equals stop translation

<400> 189
Met Tyr Leu Tyr Leu Gly Val Phe Phe His Leu Ile Tyr Pro Gly Ala
1 5 10 15
Leu Ser Ile Thr Thr Leu Gly Lys His Ser His Pro Phe Phe Thr Ala
20 25 30
Glu Gln Asn Ser Thr Val Trp Met Glu His Thr Leu Phe His Gln Ser
35 40 45
Pro Val Ala Ser His Leu Val Cys Phe Gln Ser Phe Ala Phe Ser Glu
50 55 60
Xaa
65

<210> 190
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 190
Met Thr Leu Ser Leu Gln Leu Ala Glu Leu Val His Phe Val Cys Ala
1 5 10 15
Phe Gln Ser Gln Trp Thr Gly Val Tyr Pro Met Met Pro Pro Leu Lys
20 25 30
Pro Thr Glu Pro Leu Cys Phe Ala Cys Val Pro Cys Arg Val Xaa
35 40 45

<210> 191
<211> 144
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (144)

<223> Xaa equals stop translation

<400> 191

```

Met Ser Pro Phe His  Leu Leu Gly Leu Lys Val Phe Leu Thr Trp Ala
 1           5           10           15

Leu Thr Leu Ala Gln  Ile Cys Leu Tyr Phe Phe Glu Val Gln Pro Leu
          20           25           30

Gly Leu Leu Ala Leu Asn Phe Phe Cys Thr Ala Thr Ala Gly Leu Lys
          35           40           45

Glu Leu Cys Met His  Pro Pro Ser Leu Ala Phe Thr Pro Glu Phe His
          50           55           60

Thr Ser Leu Ser Pro  Leu Ala Ile Pro Ser Phe Cys Gly Thr Ser Val
          65           70           75           80

Ser Leu Ser Asn Ser  His Thr Ile Pro Leu Ser Leu Tyr Leu Pro Phe
          85           90           95

Pro Ser Lys Ser Arg Met Pro Asp Thr Leu His Leu Leu Val His Ser
          100          105          110

Leu Pro Leu Val His  Ser Gln Val Leu Pro Val Lys Asp Val Thr Ile
          115          120          125

Glu Trp Pro Leu Cys Gln Arg Cys Leu Gly Ser Thr Cys His Gln Xaa
          130          135          140

```

<210> 192

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 192

```

Met Phe Cys Phe Ser Ser  Ile Phe Cys Ser His Glu His Thr His Leu
 1           5           10           15

Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Phe Leu Ile Leu Pro Pro
          20           25           30

Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr Val Arg
          35           40           45

```

Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr Pro Gly
50 55 60

Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn Ser Glu
65 70 75 80

Xaa

<210> 193

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 193

Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu Leu Lys Val
1 5 10 15

His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys Ser Lys Val Pro
20 25 30

Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu Xaa
35 40 45

<210> 194

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 194

Met Pro Thr Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly
1 5 10 15

Leu Phe Pro Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val
20 25 30

Thr Leu Ala Pro Val Ser Tyr Trp Leu Xaa
35 40

<210> 195

<211> 260

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (260)

<223> Xaa equals stop translation

<400> 195

```

Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Phe
 1           5           10           15

Leu Leu Met Cys Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala
      20           25           30

Val Ala Ser Asp Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp
      35           40           45

Pro Ala His Val Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu
      50           55           60

Pro Glu Ile Arg Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys
      65           70           75           80

Gly Asp Pro Gly Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly
      85           90           95

Pro Gln Gly Glu Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu
      100          105          110

Met Gly Ser Pro Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser
      115          120          125

Val Gly Arg Lys Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu
      130          135          140

Leu Phe Glu Arg Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala
      145          150          155          160

Thr Gly Gln Phe Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu
      165          170          175

Asn Val His Ser Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His
      180          185          190

Asn Gln Lys Glu Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser
      195          200          205

Ile Met Gln Ser Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg
      210          215          220

Val Trp Val Arg Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser
      225          230          235          240

Asn Asp Phe Asp Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala
      245          250          255

Glu Asp Asp Xaa
      260

```

<210> 196

<211> 117

<212> PRT

<213> Homo sapiens

<400> 196

Met Leu Gly His Cys Cys Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu
 1 5 10 15
 Ala Leu Ala Ala Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser
 20 25 30
 Trp Lys Gln His Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu
 35 40 45
 Pro Thr Thr Thr Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly
 50 55 60
 Lys Asn Pro Ala Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly
 65 70 75 80
 Val Trp Pro Cys Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr
 85 90 95
 Pro Ser Ser Thr Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr
 100 105 110
 Trp Trp Arg Thr Pro
 115

<210> 197

<211> 698

<212> PRT

<213> Homo sapiens

<400> 197

Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
 1 5 10 15
 Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
 20 25 30
 Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
 35 40 45
 Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
 50 55 60
 Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
 65 70 75 80
 Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
 85 90 95
 Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
 100 105 110
 Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
 115 120 125
 His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys

130	135	140
Gly Ala Glu Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro 145 150 155 160		
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg 165 170 175		
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu 180 185 190		
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala 195 200 205		
Leu Arg Arg Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu 210 215 220		
Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro 225 230 235 240		
Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp 245 250 255		
Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys 260 265 270		
Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly His Gln Gly Pro Gln Arg 275 280 285		
Pro Val Lys Asp Glu Pro Gln Asp Gly Glu Asn Pro Asn Pro Pro Asn 290 295 300		
Trp Ser Arg Thr Val Val Arg Asp Val Arg Leu Ile Ser Ala Lys Thr 305 310 315 320		
Gly Tyr Gly Val Glu Glu Leu Ile Ser Ala Leu Gln Arg Ser Trp Arg 325 330 335		
Tyr Arg Gly Asp Val Tyr Leu Val Gly Ala Thr Asn Ala Gly Lys Ser 340 345 350		
Thr Leu Phe Asn Thr Leu Leu Glu Ser Asp Tyr Cys Thr Ala Lys Gly 355 360 365		
Ser Asp Ala Ile Asp Arg Ala Thr Ile Ser Pro Trp Pro Gly Thr Thr 370 375 380		
Leu Asn Leu Leu Lys Phe Pro Ile Cys Asn Pro Thr Pro Tyr Arg Met 385 390 395 400		
Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu Glu 405 410 415		
Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys His 420 425 430		
Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu Glu 435 440 445		

Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala Phe
 450 455 460
 Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys Gln
 465 470 475 480
 Val Glu Leu Thr Ala Gln Asp Val Lys Asp Ala His Trp Phe Tyr Asp
 485 490 495
 Thr Pro Gly Ile Thr Lys Glu Asn Cys Ile Leu Asn Leu Leu Thr Glu
 500 505 510
 Lys Glu Val Asn Ile Val Leu Pro Thr Gln Ser Ile Val Pro Arg Thr
 515 520 525
 Phe Val Leu Lys Pro Gly Met Val Leu Phe Leu Gly Ala Ile Gly Arg
 530 535 540
 Ile Asp Phe Leu Gln Gly Asn Gln Ser Ala Trp Phe Thr Val Val Ala
 545 550 555 560
 Ser Asn Ile Leu Pro Val His Ile Thr Ser Leu Asp Arg Ala Asp Ala
 565 570 575
 Leu Tyr Gln Lys His Ala Gly His Thr Leu Leu Gln Ile Pro Met Gly
 580 585 590
 Gly Lys Glu Arg Met Ala Gly Phe Pro Pro Leu Val Ala Glu Asp Ile
 595 600 605
 Met Leu Lys Glu Gly Leu Gly Ala Ser Glu Ala Val Ala Asp Ile Lys
 610 615 620
 Phe Ser Ser Ala Gly Trp Val Ser Val Thr Pro Asn Phe Lys Asp Arg
 625 630 635 640
 Leu His Leu Arg Gly Tyr Thr Pro Glu Gly Thr Val Leu Thr Val Arg
 645 650 655
 Pro Pro Leu Leu Pro Tyr Ile Val Asn Ile Lys Gly Gln Arg Ile Lys
 660 665 670
 Lys Ser Val Ala Tyr Lys Thr Lys Lys Pro Pro Ser Leu Met Tyr Asn
 675 680 685
 Val Arg Lys Lys Lys Gly Lys Ile Asn Val
 690 695

<210> 198

<211> 348

<212> PRT

<213> Homo sapiens

<400> 198

Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu
 1 5 10 15

Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His

140

	20		25		30
Leu	Ala	Val	Tyr	Tyr	Arg
	35			Gly	Gly
				40	Ala
					Leu
					Leu
					Thr
					45
					Pro
					Ser
					Gly
Pro	Gly	Tyr	His	Ile	Met
	50				Leu
					55
					Pro
					Phe
					Ile
					Thr
					60
					Thr
					Phe
					Arg
					Ser
					Val
Gln	Thr	Thr	Leu	Gln	Thr
	65				Asp
					70
					Glu
					Val
					Lys
					75
					Asn
					Val
					Pro
					Cys
					Gly
					80
Ser	Gly	Gly	Val	Met	Ile
					85
					Tyr
					Ile
					Asp
					90
					Arg
					Ile
					Glu
					Val
					Val
					Asn
					95
					Met
Leu	Ala	Pro	Tyr	Ala	Val
					100
					Phe
					Asp
					105
					Ile
					Val
					Arg
					Asn
					Tyr
					Thr
					110
					Ala
					Asp
Tyr	Asp	Lys	Thr	Leu	Ile
	115				Phe
					Asn
					Lys
					120
					Ile
					His
					His
					Glu
					125
					Leu
					Asn
					Gln
Phe	Cys	Ser	Ala	His	Thr
	130				Leu
					Gln
					Glu
					Val
					Tyr
					Ile
					Glu
					140
					Leu
					Phe
					Asp
Gln	Ile	Asp	Glu	Asn	Leu
	145				Lys
					Gln
					Ala
					Leu
					Gln
					Lys
					Asp
					Leu
					Asn
					Leu
					160
Met	Ala	Pro	Gly	Leu	Thr
					165
					Ile
					Gln
					Ala
					Val
					Arg
					Val
					Thr
					Lys
					Pro
					Lys
					175
Ile	Pro	Glu	Ala	Ile	Arg
					180
					Arg
					Asn
					Phe
					Glu
					Leu
					Met
					Glu
					Ala
					Glu
					Lys
					190
Thr	Lys	Leu	Leu	Ile	Ala
					Ala
					Gln
					Lys
					Gln
					Lys
					Val
					Val
					Glu
					Lys
					Glu
					195
Ala	Glu	Thr	Glu	Arg	Lys
					Lys
					Ala
					Val
					Ile
					Glu
					Ala
					Glu
					Lys
					Ile
					Ala
					210
Gln	Val	Ala	Lys	Ile	Arg
					Phe
					Gln
					Gln
					Lys
					Val
					Met
					Glu
					Lys
					Glu
					Thr
					225
Glu	Lys	Arg	Ile	Ser	Glu
					Ile
					Glu
					Asp
					Ala
					Ala
					Phe
					Leu
					Ala
					Arg
					Glu
					245
Lys	Ala	Lys	Ala	Asp	Ala
					Glu
					Tyr
					Tyr
					Ala
					Ala
					His
					Lys
					Tyr
					Ala
					Thr
					260
Ser	Asn	Lys	His	Lys	Leu
					Thr
					Pro
					Glu
					Tyr
					Leu
					Glu
					Leu
					Lys
					Lys
					Tyr
					275
Gln	Ala	Ile	Ala	Ser	Asn
					Ser
					Lys
					Ile
					Tyr
					Phe
					Gly
					Ser
					Asn
					Ile
					Pro
					290
Asn	Met	Phe	Val	Asp	Ser
					Ser
					Cys
					Ala
					Leu
					Lys
					Tyr
					Ser
					Asp
					Ile
					Arg
					305
Thr	Gly	Arg	Glu	Ser	Ser
					Leu
					Pro
					Ser
					Lys
					Glu
					Ala
					Leu
					Glu
					Pro
					Ser
					325
					330
					335

Gly Glu Asn Val Ile Gln Asn Lys Glu Ser Thr Gly
 340 345

<210> 199

<211> 401

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (307)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 199

Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met Lys Ser Pro Pro Leu
 1 5 10 15

Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val Leu Gly Phe Asn Tyr
 20 25 30

Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln Thr Arg Ile Met Glu
 35 40 45

Leu Glu Gly Arg Val Arg Arg Arg Ala Ala Glu Arg Gly Ala Val Glu
 50 55 60

Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu Lys Gln Arg Glu Gln
 65 70 75 80

Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln Leu Glu Ser Val Asn
 85 90 95

Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val Asn Asn Ile Thr Thr
 100 105 110

Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln Leu Lys Thr Leu Gln
 115 120 125

Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu Gln Phe Gln Lys Asn
 130 135 140

Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp Leu Ser Gln Cys Ile
 145 150 155 160

Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu Glu Arg Ile Glu Glu
 165 170 175

Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser Arg Asp Leu Ser Glu
 180 185 190

Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu Ser Glu Pro Gln Pro
 195 200 205

Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu Val Pro Gln Gly Lys
 210 215 220

Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr Pro Ala Pro Ser Ser
 225 230 235 240

Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu Lys Glu Glu Thr Asn
 245 250 255
 Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg Asp Arg Leu Pro Gln
 260 265 270
 Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg Pro Val Gly Gly Arg
 275 280 285
 Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr Pro Gln Val Gln Ala
 290 295 300
 Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met Glu Gly Pro Glu Arg
 305 310 315 320
 Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu Gln Glu Ala Ala
 325 330 335
 Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly Glu Asp Asp Tyr Asn
 340 345 350
 Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp Lys Gln Ala Ala Leu
 355 360 365
 Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn Val Glu Asp Gln Lys
 370 375 380
 Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu Lys Arg Asn His Thr
 385 390 395 400
 Leu

<210> 200
 <211> 324
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 200
 Met Glu Xaa Ala Lys Val Tyr Val Ala Lys Val Asp Cys Thr Ala His
 1 5 10 15
 Ser Asp Val Cys Ser Ala Gln Gly Val Arg Gly Tyr Pro Thr Leu Lys
 20 25 30
 Leu Phe Lys Pro Gly Gln Glu Ala Val Lys Tyr Gln Gly Pro Arg Asp
 35 40 45
 Phe Gln Thr Leu Glu Asn Trp Met Leu Gln Thr Leu Asn Glu Glu Pro
 50 55 60
 Val Thr Pro Glu Pro Glu Val Glu Pro Pro Ser Ala Pro Glu Leu Lys

<210> 201
<211> 90
<212> PRT
<213> Homo sapiens

<400> 201

Met Ala Leu Phe Ser Cys Leu Leu Leu Leu Lys Gln Ser Asp Gly Ala
1 5 10 15

Ser Pro Val Leu Arg Ala Leu Ala Ala Ser Cys Leu Ala Ser Pro Ala
 20 25 30
 Gly Cys Cys Gly Thr Arg Lys Ala Leu Asn Gly Asn Val Gly Glu Lys
 35 40 45
 Val Gly Phe Thr Phe Met Ser Phe Gln Gly Cys Asp Pro Ser Ser Pro
 50 55 60
 Gly Cys Leu Cys Cys Ser Leu Leu Pro Ser Asn Ser Gln Leu Val Phe
 65 70 75 80
 Ile Ser Phe Leu Val Leu Ser Gly Leu Ala
 85 90

<210> 202
 <211> 243
 <212> PRT
 <213> Homo sapiens

<400> 202
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val
 35 40 45
 Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly
 50 55 60
 Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile
 65 70 75 80
 Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu
 85 90 95
 Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser
 100 105 110
 Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys Thr Phe
 115 120 125
 Thr Lys Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser Gly Ser
 130 135 140
 Leu Arg Leu Lys Cys Arg Asn Ala Cys Cys Glu Arg Trp Tyr Phe Thr
 145 150 155 160
 Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala Ile Ile
 165 170 175
 Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn Ile His
 180 185 190

Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly Ala Gly Leu
 195 200 205
 Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp Tyr Pro Lys Gly
 210 215 220
 Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg Ile Ile Ile Glu Glu
 225 230 235 240
 Leu Pro Lys

<210> 203
 <211> 75
 <212> PRT
 <213> Homo sapiens

<400> 203
 Met Ala Gly Gln Glu Asp Pro Val Gln Arg Glu Ile His Gln Asp Trp
 1 5 10 15
 Ala Asn Arg Glu Tyr Ile Glu Ile Ile Thr Ser Ser Ile Lys Lys Ile
 20 25 30
 Ala Asp Phe Leu Asn Ser Phe Asp Met Ser Cys Arg Ser Arg Leu Ala
 35 40 45
 Thr Leu Asn Glu Lys Leu Thr Ala Leu Glu Arg Arg Ile Glu Tyr Ile
 50 55 60
 Glu Ala Arg Val Thr Lys Gly Glu Thr Leu Thr
 65 70 75

<210> 204
 <211> 248
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (185)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 204
 Met Thr Ser Gln Pro Val Pro Asn Glu Thr Ile Ile Val Leu Pro Ser
 1 5 10 15
 Asn Val Ile Asn Phe Ser Gln Ala Glu Lys Pro Glu Pro Thr Asn Gln
 20 25 30
 Gly Gln Asp Ser Leu Lys Lys His Leu His Ala Glu Ile Lys Val Ile
 35 40 45
 Gly Thr Ile Gln Ile Leu Cys Gly Met Met Val Leu Ser Leu Gly Ile
 50 55 60
 Ile Leu Ala Ser Ala Ser Phe Ser Pro Asn Phe Thr Gln Val Thr Ser


```

65          70          75          80
Thr Leu Leu Asn Ser Ala Tyr Pro Phe Ile Gly Pro Phe Phe Phe Ile
      85          90          95
Ile Ser Gly Ser Leu Ser Ile Ala Thr Glu Lys Arg Leu Thr Lys Leu
      100         105         110
Leu Val His Ser Ser Leu Val Gly Ser Ile Leu Ser Ala Leu Ser Ala
      115         120         125
Leu Val Gly Phe Ile Ile Leu Ser Val Lys Gln Ala Thr Leu Asn Pro
      130         135         140
Ala Ser Leu Gln Cys Glu Leu Asp Lys Asn Asn Ile Pro Thr Arg Ser
      145         150         155         160
Tyr Val Ser Tyr Phe Tyr His Asp Ser Leu Tyr Thr Thr Asp Cys Tyr
      165         170         175
Thr Ala Lys Ala Ser Leu Ala Gly Xaa Leu Ser Leu Met Leu Ile Cys
      180         185         190
Thr Leu Leu Glu Phe Cys Leu Ala Val Leu Thr Ala Val Leu Arg Trp
      195         200         205
Lys Gln Ala Tyr Ser Asp Phe Pro Gly Ser Val Leu Phe Leu Pro His
      210         215         220
Ser Tyr Ile Gly Asn Ser Gly Met Ser Ser Lys Met Thr His Asp Cys
      225         230         235         240
Gly Tyr Glu Glu Leu Leu Thr Ser
      245

```

<210> 205

<211> 168

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (83)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 205

```

Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val Leu Cys Ala Gly
  1          5          10         15

```

```

Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro Ser Asp Asp Gly
  20         25         30

```

```

Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro Glu Ala His Val
  35         40         45

```

```

Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys Val Leu His Gln
  50         55         60

```

Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala Gly Ala Ala Leu
 65 70 75 80
 Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys Arg Glu Phe His
 85 90 95
 Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro Gly Glu Cys Gly
 100 105 110
 Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser Ala Pro Val Arg
 115 120 125
 Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg Ala Arg Gly Glu
 130 135 140
 Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser Leu Met Phe Thr
 145 150 155 160
 Ser Arg Asn Gly Leu Val Gly Cys
 165
 <210> 206
 <211> 218
 <212> PRT
 <213> Homo sapiens
 <400> 206
 Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
 1 5 10 15
 Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
 20 25 30
 Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
 35 40 45
 Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly His Met Gln Cys
 50 55 60
 Lys Val Tyr Asp Ser Val Leu Ala Leu Ser Thr Glu Val Gln Ala Ala
 65 70 75 80
 Arg Ala Leu Thr Val Ser Ala Val Leu Leu Ala Phe Val Ala Leu Phe
 85 90 95
 Val Thr Leu Ala Gly Ala Gln Cys Thr Thr Cys Val Ala Pro Gly Pro
 100 105 110
 Ala Lys Ala Arg Val Ala Leu Thr Gly Gly Val Leu Tyr Leu Phe Cys
 115 120 125
 Gly Leu Leu Ala Leu Val Pro Leu Cys Trp Phe Ala Asn Ile Val Val
 130 135 140
 Arg Glu Phe Tyr Asp Pro Ser Val Pro Val Ser Gln Lys Tyr Glu Leu
 145 150 155 160
 Gly Ala Ala Leu Tyr Ile Gly Trp Ala Ala Thr Ala Leu Leu Met Val

165 170 175
Gly Gly Cys Leu Leu Cys Cys Gly Ala Trp Val Cys Thr Gly Arg Pro
180 185 190
Asp Leu Ser Phe Pro Val Lys Tyr Ser Ala Pro Arg Arg Pro Thr Ala
195 200 205
Thr Gly Asp Tyr Asp Lys Lys Asn Tyr Val
210 215

<210> 207
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (73).
<223> Xaa equals stop translation

<400> 207
Met Thr Ser Tyr Ile Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly
1 5 10 15
Cys Ile Glu Lys Asp Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg
20 25 30
Leu His Leu Leu Phe Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu
35 40 45
Arg Gly Glu Leu Ser Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu
50 55 60
Gln Leu Gly Gly Cys Thr Cys Phe Xaa
65 70

<210> 208
<211> 348
<212> PRT
<213> Homo sapiens

<400> 208
Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Ile Leu
1 5 10 15
Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn
20 25 30
Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
35 40 45
Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
50 55 60
Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
65 70 75 80

Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr
85 90 95
Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys
100 105 110
Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile
115 120 125
Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr
130 135 140
Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro
145 150 155 160
Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro
165 170 175
Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala
180 185 190
Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp
195 200 205
Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys
210 215 220
Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His
225 230 235 240
Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro
245 250 255
Val Pro Gly Ala Lys Lys Ser Ala Lys Leu Tyr Ile Pro Tyr Ile Ile
260 255 270
Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Phe Ile Trp Leu Leu Lys
275 280 285
Val Asn Gly Cys Arg Lys Tyr Lys Leu Asn Lys Thr Glu Ser Thr Pro
290 295 300
Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Ser Tyr Thr Glu Lys
305 310 315 320
Asn Asn Pro Leu Tyr Asp Thr Thr Asn Lys Val Lys Ala Ser Glu Ala
325 330 335
Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu
340 345

<210> 209

<211> 73

<212> PRT

<213> Homo sapiens

<220>

<221> SITE
 <222> (73)
 <223> Xaa equals stop translation

 <400> 209
 Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe
 1 5 10 15
 Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile
 20 25 30
 Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met
 35 40 45
 Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile
 50 55 60
 Phe Ser Tyr Leu Leu Cys Thr Pro Xaa
 65 70

 <210> 210
 <211> 608
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (265)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (597)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 210
 Met Val Gly Thr Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile
 1 5 10 15
 Leu His Asp Leu Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser
 20 25 30
 Asn Arg Ile Lys Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp
 35 40 45
 Ser Ile Arg Asp Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly
 50 55 60
 Gly Thr Asp Ile Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn
 65 70 75 80
 Lys Tyr Val Ala His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile
 85 90 95
 Val Phe Leu Thr Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu
 100 105 110
 Lys Ile Leu Asn Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile

115	120	125
Phe Thr Ile Gly Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys 130 135 140		
Leu Ser Leu Glu Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu 145 150 155 160		
Asp Ala Gly Ser Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro 165 170 175		
Leu Leu Ser Asp Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln 180 185 190		
Ala Thr Lys Thr Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile 195 200 205		
Ile Ala Gly Lys Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu 210 215 220		
Val Thr Ala Ser Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val 225 230 235 240		
Pro Val Arg Pro Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg 245 250 255		
Pro Gly Gly Asp Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp 260 265 270		
Ser Tyr Leu Thr Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp 275 280 285		
Asp Glu Pro Glu Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala 290 295 300		
Val Ser Tyr Arg Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly 305 310 315 320		
Pro Val Pro Arg Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala 325 330 335		
Ala Met Gly Pro Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr 340 345 350		
Gln Pro Gly Pro Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile 355 360 365		
Ser Lys Thr Ser Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro 370 375 380		
Leu Ser Arg Leu Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp 385 390 395 400		
Ile Leu Arg Leu Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn 405 410 415		
Gly Glu Leu Ile Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln 420 425 430		

Arg Thr Tyr Leu Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg
 435 440 445
 Ser Tyr Leu Glu Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp
 450 455 460
 Arg Leu Val Leu Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly
 465 470 475 480
 Leu Glu Val Ser Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln
 485 490 495
 Gly Ser Ile Ala Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala
 500 505 510
 Pro Phe Gln Arg His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly
 515 520 525
 Leu Ser Ser Asn Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp
 530 535 540
 Ala Arg Leu Thr Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His
 545 550 555 560
 Pro Leu Leu Leu Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val
 565 570 575
 Lys Gly His Gln Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn
 580 585 590
 Gly Glu Glu Gln Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn
 595 600 605

<210> 211
 <211> 252
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (252)
 <223> Xaa equals stop translation.

<400> 211
 Met Ala Pro Ala Ser Arg Leu Leu Ala Leu Trp Ala Leu Ala Ala Val
 1 5 10 15
 Ala Leu Pro Gly Ser Gly Ala Glu Gly Asp Gly Gly Trp Arg Pro Gly
 20 25 30
 Gly Pro Gly Ala Val Ala Glu Glu Glu Arg Cys Thr Val Glu Arg Arg
 35 40 45
 Ala Asp Leu Thr Tyr Ala Glu Phe Val Gln Gln Tyr Ala Phe Val Arg
 50 55 60

Pro Val Ile Leu Gln Gly Leu Thr Asp Asn Ser Arg Phe Arg Ala Leu
 65 70 75 80
 Cys Ser Arg Asp Arg Leu Leu Ala Ser Phe Gly Asp Arg Val Val Arg
 85 90 95
 Leu Ser Thr Ala Asn Thr Tyr Ser Tyr His Lys Val Asp Leu Pro Phe
 100 105 110
 Gln Glu Tyr Val Glu Gln Leu Leu His Pro Gln Asp Pro Thr Ser Leu
 115 120 125
 Gly Asn Asp Thr Leu Tyr Phe Phe Gly Asp Asn Asn Phe Thr Glu Trp
 130 135 140
 Ala Ser Leu Phe Arg His Tyr Ser Pro Pro Pro Phe Gly Leu Leu Gly
 145 150 155 160
 Thr Ala Pro Ala Tyr Ser Phe Gly Ile Ala Gly Ala Gly Ser Gly Val
 165 170 175
 Pro Phe His Trp His Gly Pro Gly Tyr Ser Glu Val Ile Tyr Gly Arg
 180 185 190
 Lys Arg Trp Phe Leu Tyr Pro Pro Glu Lys Thr Pro Glu Phe His Pro
 195 200 205
 Asn Lys Thr Thr Leu Ala Trp Leu Arg Asp Thr Tyr Pro Ala Cys Thr
 210 215 220
 Val Cys Thr Ala Leu Glu Cys Thr Ile Arg Ala Gly Glu Val Leu Thr
 225 230 235 240
 Ser Arg Pro Leu Val Ala Cys Tyr Ala Gln Pro Xaa
 245 250

<210> 212
 <211> 226
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (226)
 <223> Xaa equals stop translation

<400> 212
 Met Lys Glu Ile Pro Ala Leu Leu His Leu Pro Val Leu Ile Ile Met
 1 5 10 15
 Ala Leu Ala Ile Leu Ser Phe Cys Tyr Gly Ala Gly Lys Ser Val His
 20 25 30
 Val Leu Arg His Ile Gly Gly Pro Glu Arg Glu Pro Pro Gln Ala Leu
 35 40 45
 Arg Pro Arg Asp Arg Arg Arg Gln Glu Glu Ile Asp Tyr Arg Pro Asp

[illegible]

```
<210> 213
<211> 51
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (51)  
<223> Xaa equals stop translation
```

```

<400> 213
Met Met Gly Leu Leu Glu Thr Gly Asn Val Leu Phe Trp Val Trp Val
 1              5              10              15
Val Val Thr Cys Val Tyr Ser Leu Tyr Ala Asn Ser Leu Asn Cys Thr
 20              25              30
Asp Met Asp Cys Ala Pro Phe Tyr Met Cys Val Met Leu Gln Gln Lys
 35              40              45
Cys Gln Xaa
 50

```

<210> 214
<211> 172
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (172)
<223> Xaa equals stop translation

<400> 214
Met Trp Leu Trp Ala Val Ser Pro Val Arg Pro Arg Thr Cys Leu Pro
1 5 10 15
Pro Cys Pro Arg Leu Trp Leu Trp Ile Ser Met Thr Leu Val Pro Ser
20 25 30
Ser Ser Ala Trp Lys Ser His Gly Ala Pro Ser Thr Arg Met Thr Ser
35 40 45
Pro Gln Leu Leu Leu Leu Ser Thr Arg Pro Pro Gln Ser Pro Ser Ala
50 55 60
Ser Pro Pro Ile Ala Arg Ala His Arg Thr His Pro His Phe Gly Asn
65 70 75 80
Arg Leu Ser Ile Thr Cys Cys Asp Gly Arg Arg Ser Trp Arg Met Gly
85 90 95
Gln His Gly Pro Cys His Leu Asn Leu Gln Thr Thr His Pro Ala His
100 105 110
Ser Ser Gln Ala Leu Pro Ala Thr His Gln Pro Leu Gly Pro Trp Cys
115 120 125
Ser Ser Pro Ser Pro Phe Pro Ser Lys Leu Pro Ser Ala Gly Leu Arg
130 135 140
Pro Pro Ala Leu Gly Pro Trp Met Arg Arg Gly Pro Trp Pro Gln Ser
145 150 155 160
Trp Gln Met Gly Met His Pro Thr Val Gly Leu Xaa
165 170

<210> 215
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 215
Met Trp Leu Leu Ile Ile Phe Cys Lys Ser Ala Ser Ala Ser Val Leu
1 5 10 15

Cys Trp Ile Lys Lys Phe His Pro Val Phe Gln Glu Ser Leu Leu Tyr
 20 25 30
 Leu Val Gln Glu Gly Ser Leu Cys Tyr Val Gln Gln Lys Val Pro Xaa
 35 40 45

<210> 216
 <211> 139
 <212> PRT
 <213> Homo sapiens

<400> 216
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
 1 5 10 15
 Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
 20 25 30
 Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val
 35 40 45
 Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met
 50 55 60
 Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp
 65 70 75 80
 Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe
 85 90 95
 Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys
 100 105 110
 Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr
 115 120 125
 Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp
 130 135

<210> 217
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals stop translation

<400> 217
 Met Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu
 1 5 10 15

Val Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg
20 25 30

Val Gln Ser Gly Gln Asp Gln Lys Xaa
35 40

<210> 218
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 218
Met Pro Ser His Ile Arg Ala His Leu Phe Leu Leu Phe Phe Leu
1 5 10 15

Phe Ile Tyr Gln Gly Ile Ser Ser Ile Ser Gln Ala Ser Gly Leu Thr
20 25 30

Leu Lys Thr Gln Asn Glu Lys Asp Ile Gln Val Ser Ile Leu Lys Glu
35 40 45

Phe Val Val Xaa
50

<210> 219
<211> 49
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (49)
<223> Xaa equals stop translation

<400> 219
Met Cys Ile Tyr Gln Ser Glu Gln Met Leu Ala Leu Leu Val Leu
1 5 10 15

Val Phe Cys Ile Ser Leu Leu Val Leu Val Cys Trp Gly Ser His Asn
20 25 30

Lys Val Pro Gln Lys Phe Ile Phe Ser Gln Phe Trp Gly Leu Glu Asp
35 40 45

Xaa

<210> 220
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 220
Met Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu
1 5 10 15
Pro Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser
20 25 30
Ser Ser Ser Glu Ser Lys Ser Ser Leu Xaa
35 40

<210> 221
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 221
Met Gly Met Leu Leu Ala Phe Trp Leu Pro Gly Ala Ser Trp Gln Glu
1 5 10 15
Ala Gly Pro Arg Ala Ser Thr Gln Arg Met Arg Thr Gln Thr Gln Met
20 25 30
Ser Thr Arg Lys Pro Lys Pro Ala Xaa
35 40

<210> 222
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 222
Met Glu Pro Ala Met Val Leu Lys Phe Leu Ser Ser Leu Pro Glu Asn
1 5 10 15
Leu Phe Leu Pro Ser Leu Leu Phe Phe Ala Trp Leu Cys Trp Asn Met
20 25 30
Val Cys Gly Ser Pro Val Ser Cys Pro Tyr Xaa
35 40

<210> 223
<211> 204
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (204)
<223> Xaa equals stop translation

<400> 223
Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
1 5 10 15
Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
20 25 30
Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
35 40 45
Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
50 55 60
Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
65 70 75 80
Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
85 90 95
Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
100 105 110
Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
115 120 125
Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
130 135 140
Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
145 150 155 160
Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
165 170 175
Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro
180 185 190
Gly Cys Thr Ala Ala Pro Cys His Ala Ala His Xaa
195 200

<210> 224
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)

<223> Xaa equals stop translation

<400> 224

Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
20 25 30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg Xaa
35 40

<210> 225

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (156)

<223> Xaa equals stop translation

<400> 225

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro
85 90 95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro
100 105 110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His
115 120 125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro
130 135 140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg Xaa
145 150 155

<210> 226

<211> 74

<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (74)
<223> Xaa equals stop translation

<400> 226
Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
1 5 10 15
Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
20 25 30
Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
35 40 45
Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser
50 55 60
Pro Pro Leu Xaa Ser Asp Pro Lys Arg Xaa
65 70

<210> 227
<211> 167
<212> FRT
<213> Homo sapiens

<220>
<221> SITE
<222> (167)
<223> Xaa equals stop translation

<400> 227

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu
 1 5 10 15
 Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro
 20 25 30
 Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys
 35 40 45
 Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser
 50 55 60
 Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys
 65 70 75 80
 Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
 85 90 95
 Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile
 100 105 110
 Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr
 115 120 125
 Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly
 130 135 140
 Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn
 145 150 155 160
 Met Ser Ser Cys Asp Phe Xaa
 165

<210> 228
 <211> 71
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (71)
 <223> Xaa equals stop translation

<400> 228
 Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val
 1 5 10 15
 Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp
 20 25 30
 Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe
 35 40 45
 Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln
 50 55 60
 Ser Ser Pro Gly Gln His Xaa
 65 70

<210> 229
 <211> 273
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (273)
 <223> Xaa equals stop translation

<400> 229

Met Cys Cys Trp Pro Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
 1 5 10 15
 Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
 20 25 30
 Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
 35 40 45
 Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
 50 55 60
 Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
 65 70 75 80
 Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
 85 90 95
 Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
 100 105 110
 Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
 115 120 125
 Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
 130 135 140
 Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
 145 150 155 160
 Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
 165 170 175
 Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
 180 185 190
 Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
 195 200 205
 Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
 210 215 220
 Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
 225 230 235 240
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg

245 250 255
 Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu
 260 265 270

Xaa

<210> 230
 <211> 82
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (82)
 <223> Xaa equals stop translation

<400> 230
 Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
 1 5 10 15
 Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
 20 25 30
 Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
 35 40 45
 Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
 50 55 60
 Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg
 65 70 75 80
 Asn Xaa

<210> 231
 <211> 71
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 231
 Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
 1 5 10 15
 Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
 20 25 30
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
 35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
50 55 60

Asp Leu Ala Cys Met Leu Ser
65 70

<210> 232
<211> 225
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 232
His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser
1 5 10 15

Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser
20 25 30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala
35 40 45

Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu
50 55 60

Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile
65 70 75 80

Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly
85 90 95

Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr
100 105 110

Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala
115 120 125

Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His
130 135 140

Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr
145 150 155 160

Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala
165 170 175

Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys
180 185 190

Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr
195 200 205

Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr
210 215 220

Pro
225

<210> 233
<211> 314
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (211)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 233
Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
1 5 10 15
Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
20 25 30
Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
35 40 45
Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
50 55 60
Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
65 70 75 80
Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
85 90 95
Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
100 105 110
Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
115 120 125
His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
130 135 140
Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
145 150 155 160
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
165 170 175
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
180 185 190
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
195 200 205

Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
 210 215 220
 Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
 225 230 235 240
 Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
 245 250 255
 Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
 260 265 270
 Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala
 275 280 285
 Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr
 290 295 300
 Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly
 305 310

<210> 234
 <211> 93
 <212> PRT
 <213> Homo sapiens

<400> 234
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
 35 40 45
 Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
 50 55 60
 Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
 65 70 75 80
 Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
 85 90

<210> 235
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (73)
 <223> Xaa equals stop translation
 <400> 235

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
 1 5 10 15
 Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
 20 25 30
 Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
 35 40 45
 Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala
 50 55 60
 Lys Cys Thr Thr Arg Cys Trp Leu Xaa
 65 70

<210> 236
 <211> 349
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (283)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (293)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (325)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (326)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (349)
 <223> Xaa equals stop translation

<400> 236
 Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Ile Leu
 1 5 10 15
 Thr Ile Phe Leu Val Ala Glu Ala Gly Ala Ala Gln Pro Asn Asn
 20 25 30
 Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
 35 40 45
 Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
 50 55 60

Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
 65 70 75 80
 Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr
 85 90 95
 Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys
 100 105 110
 Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile
 115 120 125
 Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr
 130 135 140
 Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro
 145 150 155 160
 Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro
 165 170 175
 Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala
 180 185 190
 Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp
 195 200 205
 Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys
 210 215 220
 Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His
 225 230 235 240
 Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro
 245 250 255
 Val Pro Gly Ala Lys Lys Ser Ser Lys Leu Tyr Ile Pro Tyr Ile Ile
 260 265 270
 Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Xaa Ile Trp Leu Leu Lys
 275 280 285
 Val Asn Gly Cys Xaa Lys Tyr Lys Leu Asn Lys Pro Glu Ser Thr Pro
 290 295 300
 Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Phe Tyr Thr Glu Lys
 305 310 315 320
 Asn Asn Pro Leu Xaa Xaa Thr Thr Asn Lys Val Lys Ala Ser Glu Ala
 325 330 335
 Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu Xaa
 340 345

<210> 237

<211> 17

<212> PRT

<213> Homo sapiens

<400> 237

Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr Leu
1 5 10 15

Asn

<210> 238

<211> 14

<212> PRT

<213> Homo sapiens

<400> 238

Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro Leu
1 5 10

<210> 239

<211> 9

<212> PRT

<213> Homo sapiens

<400> 239

Ile Gly Ile Ser Met Pro Ile Val Thr
1 5

<210> 240

<211> 13

<212> PRT

<213> Homo sapiens

<400> 240

Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu
1 5 10

<210> 241

<211> 11

<212> PRT

<213> Homo sapiens

<400> 241

Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln
1 5 10

<210> 242

<211> 13

<212> PRT

<213> Homo sapiens

<400> 242

Val Ala Leu Ser Cys Phe Gly Gly Leu Asn Ala Ser Ile
1 5 10

<210> 243
<211> 15
<212> PRT
<213> Homo sapiens

<400> 243
Ser Arg Leu Phe Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp
1 5 10 15

<210> 244
<211> 11
<212> PRT
<213> Homo sapiens

<400> 244
Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser
1 5 10

<210> 245
<211> 11
<212> PRT
<213> Homo sapiens

<400> 245
Val Gly Gln Leu Tyr Leu Arg Trp Lys Glu Pro
1 5 10

<210> 246
<211> 16
<212> PRT
<213> Homo sapiens

<400> 246
Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe Pro Ile Val Phe Cys
1 5 10 15

<210> 247
<211> 9
<212> PRT
<213> Homo sapiens

<400> 247
Asp Thr Ile Asn Ser Leu Ile Gly Ile
1 5

<210> 248
<211> 44
<212> PRT
<213> Homo sapiens

<400> 248

Ala Thr Ala Leu Pro Pro Lys Ile Val Gly Ser Ala Thr Arg Tyr Leu
 1 5 10 15
 Gln Val Leu Cys Met Ser Val Ala Ala Glu Met Asp Leu Glu Asp Gly
 20 25 30
 Gly Glu Met Pro Lys Gln Arg Asp Pro Lys Ser Asn
 35 40

<210> 249
 <211> 352
 <212> PRT
 <213> Homo sapiens

<400> 249
 Leu Leu Ala Ala Ala Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala
 1 5 10 15
 Tyr Val Lys Trp Gly Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys
 20 25 30
 Val Leu Ala Leu Ile Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly
 35 40 45
 Gln Gly Ala Ser Thr His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe
 50 55 60
 Ala Val Gly Asp Ile Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr
 65 70 75 80
 Ser Gly Trp Asp Thr Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro
 85 90 95
 Glu Arg Asn Leu Pro Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr
 100 105 110
 Ile Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met
 115 120 125
 Arg Asp Ile Leu Ala Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln
 130 135 140
 Ile Phe Gly Ile Phe Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser
 145 150 155 160
 Cys Phe Gly Gly Leu Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe
 165 170 175
 Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile
 180 185 190
 His Val Glu Arg Phe Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile
 195 200 205
 Met Ala Leu Ile Tyr Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn
 210 215 220
 Tyr Tyr Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly

225 230 235 240
 Gln Leu Tyr Leu Arg Trp Lys Glu Pro Asp Arg Pro Arg Pro Leu Lys
 245 250 255
 Leu Ser Val Phe Phe Pro Ile Val Phe Cys Leu Cys Thr Ile Phe Leu
 260 265 270
 Val Ala Val Pro Leu Tyr Ser Asp Thr Ile Asn Ser Leu Ile Gly Ile
 275 280 285
 Ala Ile Ala Leu Ser Gly Leu Pro Phe Tyr Phe Leu Ile Ile Arg Val
 290 295 300
 Pro Glu His Lys Arg Pro Leu Tyr Leu Arg Arg Ile Val Gly Ser Ala
 305 310 315 320
 Thr Arg Tyr Leu Gln Val Leu Cys Met Ser Val Ala Ala Glu Met Asp
 325 330 335
 Leu Glu Asp Gly Gly Glu Met Pro Lys Gln Arg Asp Pro Lys Ser Asn
 340 345 350

<210> 250
 <211> 119
 <212> PRT
 <213> Homo sapiens

<400> 250
 Ala Ala Arg Gly Ser Gly Val Arg Asp Pro Leu Glu Glu Ala Val Cys
 1 5 10 15
 Pro Phe Ser Asp Leu Gln Leu His Ala Gly Arg Thr Thr Ala Leu Phe
 20 25 30
 Lys Ala Val Arg Gln Gly His Leu Ser Leu Gln Arg Leu Leu Ser
 35 40 45
 Phe Val Cys Leu Cys Pro Ala Pro Arg Gly Gly Ala Tyr Arg Gly Arg
 50 55 60
 Gln Ala Ser Leu Ser Cys Gly Gly Leu His Pro Val Arg Ala Ser Arg
 65 70 75 80
 Leu Leu Cys Leu Pro Lys Gln Ala Trp Ala Met Ala Gly Ala Pro Pro
 85 90 95
 Pro Val Ser Leu Pro Pro Cys Ser Leu Ile Ser Asp Cys Cys Ala Ser
 100 105 110
 Asn Gln Arg Asp Ser Val Gly
 115

<210> 251

<211> 356
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (280)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 251
 Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu
 1 5 10 15
 Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala
 20 25 30
 Leu Lys Leu Arg Xaa Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val
 35 40 45
 Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly
 50 55 60
 Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile
 65 70 75 80
 Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile
 85 90 95
 Val Tyr Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile Asp Gly
 100 105 110
 Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu Leu Val
 115 120 125
 Glu Ile Gly Glu Ser Leu Asn Ile Gly Val Val Gln Thr Ala Tyr Ala
 130 135 140
 Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu Val Met Lys Val Pro Val
 145 150 155 160
 Tyr Cys Thr Lys Thr Gly Val Lys His Leu His His Lys Ala Gln Glu
 165 170 175
 Phe Asp Ile Gly Val Tyr Phe Glu Ala Asn Gly His Gly Thr Ala Leu
 180 185 190
 Phe Ser Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu
 195 200 205
 Glu Asp Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile Ile Asp
 210 215 220
 Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu Val Ile
 225 230 235 240

Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr Val Gln Gln Trp Asp Ala
 245 250 255
 Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu Lys Val Gln Val Ala Asp
 260 265 270
 Arg Arg Val Ile Ser Thr Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro
 275 280 285
 Pro Gly Leu Gln Glu Ala Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu
 290 295 300
 Ser Arg Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val
 305 310 315 320
 Tyr Ala Glu Ala Asp Ser Gln Glu Ser Ala Asp His Leu Ala His Glu
 325 330 335
 Val Ser Leu Ala Val Phe Gln Leu Ala Gly Gly Ile Gly Glu Arg Pro
 340 345 350
 Gln Pro Gly Phe
 355

<210> 252
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 252
 Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu
 1 5 10 15
 Met Asn Thr Asp His Leu Arg Leu Thr Val
 20 25

<210> 253
 <211> 28
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 253
 Pro Asn Gly Ile Gly Ala Leu Lys Leu Arg Xaa Met Glu His Tyr Phe
 1 5 10 15
 Ser Gln Gly Leu Ser Val Gln Leu Phe Asn Asp Gly
 20 25

<210> 254
 <211> 28

<212> PRT

<213> Homo sapiens

<400> 354

Ser Lys Gly Lys Leu Asn His Leu Cys Gly Ala Asp Phe Val Lys Ser
1 5 10 15

His Gln Lys Pro Pro Gln Gly Met Glu Ile Lys Ser
20 25

<210> 255

<211> 28

<212> PRT

<213> Homo sapiens

<400> 255

Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile Val Tyr
1 5 10 15

Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile
20 25

<210> 256

<211> 28

<212> PRT

<213> Homo sapiens

<400> 256

Asp Gly Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu
1 5 10 15

Leu Val Glu Ile Gly Glu Ser Leu Asn Ile Gly Val
20 25

<210> 257

<211> 28

<212> PRT

<213> Homo sapiens

<400> 257

Val Gln Thr Ala Tyr Ala Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu
1 5 10 15

Val Met Lys Val Pro Val Tyr Cys Thr Lys Thr Gly
20 25

<210> 258

<211> 28

<212> PRT

<213> Homo sapiens

<400> 258

Val Lys His Leu His His Lys Ala Gln Glu Phe Asp Ile Gly Val Tyr
1 5 10 15

Phe Glu Ala Asn Gly His Gly Thr Ala Leu Phe Ser
20 25

<210> 259
<211> 28
<212> PRT
<213> Homo sapiens

<400> 259
Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu Glu Asp
1 5 10 15

Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile
20 25

<210> 260
<211> 28
<212> PRT
<213> Homo sapiens

<400> 260
Ile Asp Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu
1 5 10 15

Val Ile Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr
20 25

<210> 261
<211> 28
<212> PRT
<213> Homo sapiens

<400> 261
Val Gln Gln Trp Asp Ala Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu
1 5 10 15

Lys Val Gln Val Ala Asp Arg Arg Val Ile Ser Thr
20 25

<210> 262
<211> 28
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 262
Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro Pro Gly Leu Gln Glu Ala
1 5 10 15

Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu Ser Arg
20 25

<210> 263
<211> 24
<212> PRT
<213> Homo sapiens

<400> 263
Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val Tyr Ala
1 5 10 15
Glu Ala Asp Ser Gln Glu Ser Ala
20

<210> 264
<211> 26
<212> PRT
<213> Homo sapiens

<400> 264
Asp His Leu Ala His Glu Val Ser Leu Ala Val Phe Gln Leu Ala Gly
1 5 10 15
Gly Ile Gly Glu Arg Pro Gln Pro Gly Phe
20 25

<210> 265
<211> 443
<212> PRT
<213> Homo sapiens

<400> 265
Gly Thr Arg Ala Ala Pro Gly Leu Gly Ala Trp Gly Arg Arg Ser Pro
1 5 10 15
Pro Ser Phe Ser Pro Pro Arg Pro Arg Pro Gly Val Met Ala Gly
20 25 30
Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu Leu Leu Gly
35 40 45
Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile Ala Leu Pro
50 55 60
Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr Pro Thr Leu
65 70 75 80
Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His Ile Thr Met
85 90 95
Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe Ser Cys Gln
100 105 110
Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn Ile Asp Cys
115 120 125
Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln Pro Ser Thr

130 135 140
Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp Val Lys Ala
145 150 155 160
His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro Arg Leu Arg
165 170 175
Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr His Ser Ile
180 185 190
Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr Phe Cys Ser
195 200 205
Asn Gly Thr Val Ser Arg Ile Lys Met Gln Glu Gly Val Lys Met Ala
210 215 220
Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly Phe Ser Ile
225 230 235 240
Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu Ser Val Phe
245 250 255
Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr Pro Glu Gly
260 265 270
Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val Pro Ala His
275 280 285
Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser Asn Cys Glu
290 295 300
Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser Thr Thr Asn
305 310 315 320
Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn Met Ala Gly
325 330 335
Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala Gln Ser Pro
340 345 350
Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His Pro Gln Asn
355 360 365
Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu Arg Ala Met
370 375 380
Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg Lys Phe Val
385 390 395 400
Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser Ser Asn Leu
405 410 415
Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu Cys Asp Asp
420 425 430
Leu Thr Arg Leu Trp Met Asn Val Glu Lys Pro
435 440

<210> 266
<211> 159
<212> PRT
<213> Homo sapiens

<400> 266
Phe Glu Ile Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys
1 5 10 15
Leu Gly Thr Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser
20 25 30
Lys Arg His Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val
35 40 45
Phe Thr Phe Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile
50 55 60
Gln Lys Asn Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val
65 70 75 80
Gln Leu Gln Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe
85 90 95
Ile Trp Asp Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe
100 105 110
Ser Ile Pro Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp
115 120 125
Gly Val Thr His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg
130 135 140
Ile Gly Thr Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met
145 150 155

<210> 267
<211> 9
<212> PRT
<213> Homo sapiens

<400> 267
Phe Val Arg Asp Pro Phe Val Arg Leu
1 5

<210> 268
<211> 13
<212> PRT
<213> Homo sapiens

<400> 268
Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser
1 5 10

<210> 269

<211> 15
 <212> PRT
 <213> Homo sapiens

<400> 269
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe
 1 5 10 15

<210> 270
 <211> 380
 <212> PRT
 <213> Homo sapiens

<400> 270
 Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro Leu Pro
 1 5 10 15
 Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser Asp Val
 20 25 30
 Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln Ser Asp
 35 40 45
 Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser Met Glu
 50 55 60
 Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg Arg Ser
 65 70 75 80
 Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu Arg Gly
 85 90 95
 Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg Ala Phe
 100 105 110
 Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp Asp Arg
 115 120 125
 His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr Asn Trp
 130 135 140
 Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg Gly Ala
 145 150 155 160
 Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His Asn Ala
 165 170 175
 Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly Lys Leu
 180 185 190
 Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys Phe Leu
 195 200 205
 Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg Ser Lys
 210 215 220
 Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val Pro Met
 225 230 235 240

Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala Arg Glu
 245 250 255
 Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile Gln Tyr
 260 265 270
 Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu His Trp
 275 280 285
 Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr Asp Phe
 290 295 300
 Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu Leu Gln
 305 310 315 320
 Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr Arg Asn
 325 330 335
 Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile Pro Leu
 340 345 350
 Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe Val Leu
 355 360 365
 Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp
 370 375 380

<210> 271
 <211> 274
 <212> PRT
 <213> Homo sapiens

<400> 271
 Lys Leu Val Arg Leu Gln Val Pro Val Arg Asn Ser Arg Val Asp Pro
 1 5 10 15
 Arg Val Arg Ser Lys Ile Gly Ser Arg Arg Trp Met Leu Gln Leu Ile
 20 25 30
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
 35 40 45
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
 50 55 60
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
 65 70 75 80
 Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
 85 90 95
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
 100 105 110
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
 115 120 125

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 130 135 140

Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
 145 150 155 160

Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 165 170 175

Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 180 185 190

Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 195 200 205

Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu
 210 215 220

Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala
 225 230 235 240

Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu
 245 250 255

Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr
 260 265 270

Asp Gly

<210> 272
 <211> 203
 <212> PRT
 <213> Homo sapiens

<400> 272
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
 1 5 10 15

Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
 20 25 30

Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
 35 40 45

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
 50 55 60

Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
 65 70 75 80

Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
 85 90 95

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 100 105 110

Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr

115 120 125
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 130 135 140
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 145 150 155 160
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 165 170 175
 Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro
 180 185 190
 Gly Cys Thr Ala Ala Pro Cys His Ala Ala His
 195 200

<210> 273
 <211> 407
 <212> PRT
 <213> Homo sapiens

<400> 273
 Ser Asn Glu Ile Leu Leu Ser Phe Pro Gln Asn Tyr Tyr Ile Gln Trp
 1 5 10 15
 Leu Asn Gly Ser Leu Ile His Gly Leu Trp Asn Leu Ala Ser Leu Phe
 20 25 30
 Ser Asn Leu Cys Leu Phe Val Leu Met Pro Phe Ala Phe Phe Phe Leu
 35 40 45
 Glu Ser Glu Gly Phe Ala Gly Leu Lys Lys Gly Ile Arg Ala Arg Ile
 50 55 60
 Leu Glu Thr Leu Val Met Leu Leu Leu Ala Leu Leu Ile Leu Gly
 65 70 75 80
 Ile Val Trp Val Ala Ser Ala Leu Ile Asp Asn Asp Ala Ala Ser Met
 85 90 95
 Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr Ser
 100 105 110
 Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro Val
 115 120 125
 Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys Pro
 130 135 140
 Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu Glu
 145 150 155 160
 Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val Glu
 165 170 175
 Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr Leu
 180 185 190

Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg Asn
 195 200 205
 Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser Ile
 210 215 220
 Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp Glu
 225 230 235 240
 Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala Ser
 245 250 255
 Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu Ile
 260 265 270
 Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg Phe
 275 280 285
 Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys Ile
 290 295 300
 Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro Val
 305 310 315 320
 Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp Phe
 325 330 335
 Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr Asn
 340 345 350
 Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe Thr
 355 360 365
 Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys Leu
 370 375 380
 His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser Val
 385 390 395 400
 Asn Gly His Gln Lys Ala Leu
 405

<210> 274
 <211> 165
 <212> PRT
 <213> Homo sapiens

<400> 274
 Arg Ser Tyr Met Cln Ser Val Trp Thr Glu Clu Ser Gln Cys Thr Leu
 1 5 10 15
 Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys Gly
 20 25 30
 Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr Val
 35 40 45

Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu Glu
 50 55 60
 Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly Lys
 65 70 75 80
 Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn Phe
 85 90 95
 Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn Gln
 100 105 110
 Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe His
 115 120 125
 Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile Val
 130 135 140
 Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg Ile
 145 150 155 160
 Gln Arg Ile Asn Arg
 165

<210> 275
 <211> 155
 <212> PRT
 <213> Homo sapiens

<400> 275
 Ala Phe Ala His Leu Gln Leu Gly Pro Met Trp Lys Leu Trp Arg Ala
 1 5 10 15
 Glu Glu Gly Ala Ala Ala Leu Gly Gly Ala Leu Phe Leu Leu Phe
 20 25 30
 Ala Leu Gly Val Arg Gln Leu Leu Lys Gln Arg Arg Pro Met Gly Phe
 35 40 45
 Pro Pro Gly Pro Pro Gly Leu Pro Phe Ile Gly Asn Ile Tyr Ser Leu
 50 55 60
 Ala Ala Ser Ser Glu Leu Pro His Val Tyr Met Arg Lys Gln Ser Gln
 65 70 75 80
 Val Tyr Gly Glu Val Gln Pro Arg Arg Ala Pro Gly Arg Glu Gly Arg
 85 90 95
 Gln Ala Gly Pro Gly Trp Pro Gly Pro Ser Trp Leu Asp Leu Trp Pro
 100 105 110
 Pro Leu Gly Arg Leu Val Gly Thr Ser Pro Cys Ala Gly Cys Pro Leu
 115 120 125
 Arg Asp Thr Arg Phe Pro Gly Leu Glu Gly Arg Ser Pro Arg Arg Arg
 130 135 140
 Ala Pro Leu Gln Gly Glu Pro Arg Pro Cys Arg

145

150

155

<210> 276
<211> 42
<212> PRT
<213> Homo sapiens

<400> 276
Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
1 5 10 15
Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
20 25 30
Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg
35 40

<210> 277
<211> 155
<212> PRT
<213> Homo sapiens

<400> 277
Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15
Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30
Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45
Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Leu Ala His
50 55 60
Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80
Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro
85 90 95
His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro
100 105 110
Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His
115 120 125
Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro
130 135 140
Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg
145 150 155

<210> 278
<211> 207
<212> PRT

<213> Homo sapiens

<400> 278

Gly Thr Ser Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu Glu Lys
 1 5 10 15
 Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly Met Ala
 20 25 30
 Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser Asp Lys
 35 40 45
 Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu Ile Thr
 50 55 60
 Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys
 65 70 75 80
 Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser
 85 90 95
 Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala
 100 105 110
 His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser
 115 120 125
 Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr
 130 135 140
 Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala
 145 150 155 160
 Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe
 165 170 175
 Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile
 180 185 190
 Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr
 195 200 205

<210> 279

<211> 85

<212> PRT

<213> Homo sapiens

<400> 279

Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys
 1 5 10 15
 Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu
 20 25 30
 Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val
 35 40 45
 Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly

```

50          55          60
Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly
65          70          75          80
Ala Ala Arg Ala Leu
85

<210> 280
<211> 7
<212> PRT
<213> Homo sapiens

<400> 280
Ala Leu Met Arg Leu Gln Asp
1          5

<210> 281
<211> 7
<212> PRT
<213> Homo sapiens

<400> 281
Val Glu Ala Gly Gly Ala Thr
1          5

<210> 282
<211> 489
<212> PRT
<213> Homo sapiens

<400> 282
Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys
1          5          10          15
Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu
20          25          30
Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val
35          40          45
Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly
50          55          60
Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly
65          70          75          80
Ala Ala Arg Ala Leu Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val
85          90          95
Lys Gly Leu Ala Arg Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile
100          105          110
Thr Asp Leu Tyr Ser Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp
115          120          125

```

Cys Phe Gln Val Gly Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His
 130 135 140
 Ala Ile Pro Trp Leu Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr
 145 150 155 160
 Gly Glu Trp Lys Thr Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp
 165 170 175
 His Leu Ala Phe Ala Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu
 180 185 190
 Ser Leu Ser Arg Glu Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met
 195 200 205
 Ala Arg Asn Val Leu Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn
 210 215 220
 His Val Val Ala Glu Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu
 225 230 235 240
 Gln Thr Arg Asp Thr Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln
 245 250 255
 Pro Thr Leu Tyr Gln Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn
 260 265 270
 Ser Asn Ala Tyr Leu Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His
 275 280 285
 Leu Gln Pro Tyr Ile Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu
 290 295 300
 Ala Gln Lys Ile Arg Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val
 305 310 315 320
 Val Ala Ser Gly Glu Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys
 325 330 335
 Ser Ala Trp Leu Lys Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn
 340 345 350
 His Arg Ile Ala Ala Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala
 355 360 365
 Glu Tyr Leu Gln Val Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro
 370 375 380
 His Phe Asp His Ala Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys
 385 390 395 400
 Ser Gly Asn Arg Val Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu
 405 410 415
 Ala Gly Gly Ala Thr Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val
 420 425 430
 Val Arg Asn Ala Ala Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu
 435 440 445

Gly Asp Ser Asp Thr Leu His Ala Gly Cys Pro Val Leu Val Gly Asp
 450 455 460
 Lys Trp Val Ala Asn Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg
 465 470 475 480
 Arg Pro Cys Ser Ser Pro Glu Asp
 485

<210> 283
 <211> 136
 <212> PRT
 <213> Homo sapiens

<400> 283
 Ile Gln Pro Ser His Ala Ala Leu Leu His Cys Arg Ser Thr Phe Arg
 1 5 10 15
 Lys Thr Glu Cys Leu Asp Pro Trp Trp Val Arg Arg Gln Leu Gly
 20 25 30
 Met Ala Gly Ile Gly Gly Leu Gln Lys Met Lys Ala Pro His Thr Gly
 35 40 45
 Val Leu His Leu Gly Ser Val Trp Val Phe Leu Gly Pro Phe Leu Leu
 50 55 60
 Gly Val Gly Tyr Thr Leu Thr Phe Asn Pro Leu Ser Gly Cys Met Ser
 65 70 75 80
 Thr Val Arg Trp Leu Asn Ser Asn Ile Thr Ala Asn Arg Thr Leu Ser
 85 90 95
 Arg Ser Val Cys His Val Thr Pro Leu His Arg Ser Leu Ser Pro His
 100 105 110
 Asp Gly Glu Tyr Leu Arg Gln Met Leu Leu Asn Ser Ser Ser Arg Ala
 115 120 125
 Gly Glu Ala Gly Ser Trp Gly Tyr
 130 135

<210> 284
 <211> 86
 <212> PRT
 <213> Homo sapiens

<400> 284
 Cys Ser Ser Pro Pro Gly Arg Leu Pro Trp Cys Trp Thr Ala Pro Arg
 1 5 10 15
 Thr Leu Gly Lys His Gly Ser Leu Ile Ser Thr Leu Arg Leu Thr Ala
 20 25 30
 Pro Leu His Leu Ala Trp Lys Met Met Leu Ser Arg Lys Ala Leu Phe
 35 40 45

Val Leu Leu Asn Thr Pro Val Leu Phe His Ala Leu Glu Gly Arg Leu
50 55 60
Phe Ser Lys Leu Cys His His His Thr Ile Gln Arg Thr Leu Thr Val
65 70 75 80
Pro Lys Phe Arg Ser Ser
85

<210> 285
<211> 75
<212> PRT
<213> Homo sapiens

<400> 285
Arg Ser Pro Thr Ser Arg Val Gln Leu Leu Lys Arg Gln Ser Cys Pro
1 5 10 15
Cys Gln Arg Asn Asp Leu Asn Glu Glu Pro Gln His Phe Thr His Tyr
20 25 30
Ala Ile Tyr Asp Phe Ile Val Lys Gly Ser Cys Phe Cys Asn Gly His
35 40 45
Ala Asp Gln Cys Ile Pro Val His Gly Phe Arg Pro Val Lys Ala Pro
50 55 60
Gly Thr Phe His Met Val His Gly Lys Cys Met
65 70 75

<210> 286
<211> 296
<212> PRT
<213> Homo sapiens

<400> 286
His Asn Thr Ala Gly Ser His Cys Gln His Cys Ala Pro Leu Tyr Asn
1 5 10 15
Asp Arg Pro Trp Glu Ala Ala Asp Gly Lys Thr Gly Ala Pro Asn Glu
20 25 30
Cys Arg Thr Cys Lys Cys Asn Gly His Ala Asp Thr Cys His Phe Asp
35 40 45
Val Asn Val Trp Glu Ala Ser Gly Asn Arg Ser Gly Gly Val Cys Asp
50 55 60
Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys Lys Pro
65 70 75 80
Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp Ala Cys
85 90 95
Lys Pro Cys Ser Cys His Pro Val Gly Ser Ala Val Leu Pro Ala Asn
100 105 110

Ser Val Thr Phe Cys Asp Pro Ser Asn Gly Asp Cys Pro Cys Lys Pro
 115 120 125
 Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met Val Gly Tyr Trp Gly
 130 135 140
 Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys Ala Gly Ser Cys Asp
 145 150 155 160
 Pro Ile Thr Gly Asp Cys Ile Ser Ser His Thr Asp Ile Asp Trp Tyr
 165 170 175
 His Glu Val Pro Asp Phe Arg Pro Val His Asn Lys Ser Glu Pro Ala
 180 185 190
 Trp Glu Trp Glu Asp Ala Gln Gly Phe Ser Ala Leu Leu His Ser Gly
 195 200 205
 Lys Cys Glu Cys Lys Glu Gln Thr Leu Gly Asn Ala Lys Ala Phe Cys
 210 215 220
 Gly Met Lys Tyr Ser Tyr Val Leu Lys Ile Lys Ile Leu Ser Ala His
 225 230 235 240
 Asp Lys Gly Thr His Val Glu Val Asn Val Lys Ile Lys Lys Val Leu
 245 250 255
 Lys Ser Thr Lys Leu Lys Ile Phe Arg Gly Lys Ala Asn Ile Ile Ser
 260 265 270
 Arg Ile Met Asp Gly Gln Arg Met His Leu Ser Asn Pro Gln Ser Trp
 275 280 285
 Phe Gly Ile Pro Cys Ser Arg Thr
 290 295

<210> 287
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 287
 Cys Asp Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys
 1 5 10 15
 Lys Pro Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp
 20 25 30
 Ala Cys Lys Pro Cys
 35

<210> 288
 <211> 36
 <212> PRT
 <213> Homo sapiens

<400> 288

Cys Pro Cys Lys Pro Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met
1 5 10 15Val Gly Tyr Trp Gly Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys
20 25 30Ala Gly Ser Cys
35

<210> 289

<211> 66

<212> PRT

<213> Homo sapiens

<400> 289

Asn Ile Ser Ser Gln Tyr Cys Ile Leu Lys Ser Leu Glu Met Met Ile
1 5 10 15Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala Pro Glu Asn
20 25 30Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg His Leu Arg
35 40 45Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu Pro Ser Tyr
50 55 60Phe Glu
65

<210> 290

<211> 88

<212> PRT

<213> Homo sapiens

<400> 290

Pro Ile Glu Gly Thr Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg
1 5 10 15Pro Thr Arg Pro Gln Arg Met Arg Ser Leu Ile Ser Ser His Pro Cys
20 25 30Gln His Leu Leu Leu Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile
35 40 45Leu Val Asp Val Lys Trp Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu
50 55 60Met Thr Ser Asp Val Glu His Leu Phe Met Cys Leu Leu Ala Ile Arg
65 70 75 80Ile Ser Ser Trp Arg Asn Val Tyr
85

<210> 291

<211> 60
<212> PRT
<213> Homo sapiens

<400> 291
Asn Trp Val Pro Thr Cys Leu Cys Pro Ser Ala Pro Cys Ser Phe His
1 5 10 15
Leu Leu Ser Arg Phe Lys Cys Leu Phe Ser Pro Gln Arg Leu Thr Asp
20 25 30
Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly Trp Ile Gln Val Ser
35 40 45
Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile Val
50 55 60

<210> 292
<211> 33
<212> PRT
<213> Homo sapiens

<400> 292
Gln Arg Leu Thr Asp Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly
1 5 10 15
Trp Ile Gln Val Ser Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile
20 25 30
Val

<210> 293
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 293

```

Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
 1             5             10             15

Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
          20             25             30

Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
          35             40             45

Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser
          50             55             60

Pro Pro Leu Xaa Ser Asp Pro Lys Arg
65             70

```

<210> 294

<211> 95

<212> PRT

<213> Homo sapiens

<400> 294

```

Thr Ser Ser Pro Val Phe Ser Phe Cys Ser Met Ala Val Arg Glu Pro
 1             5             10             15

Asp His Leu Gln Arg Val Ser Leu Pro Arg Tyr Asn Val Ser Ala Ser
          20             25             30

Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp His Met
          35             40             45

Cys Ala Met Trp Glu Leu Gly Gln Val Leu Phe His Pro Val Ala Pro
          50             55             60

Arg Glu Gly Ala Ala Pro Ser Pro Val Ser Thr Leu Thr Trp Pro Ser
          65             70             75             80

Ser Cys Ser His Ser Glu Ser Thr Met Glu Leu Glu Leu Gln Phe
          85             90             95

```

<210> 295

<211> 16

<212> PRT

<213> Homo sapiens

<400> 295

```

Met Ala Val Arg Glu Pro Asp His Leu Gln Arg Val Ser Leu Pro Arg
 1             5             10             15

```

<210> 296
<211> 7
<212> PRT
<213> Homo sapiens

<400> 296
Leu Pro Cys His Arg Ile Val
1 5

<210> 297
<211> 15
<212> PRT
<213> Homo sapiens

<400> 297
Ser Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp
1 5 10 15

<210> 298
<211> 454
<212> PRT
<213> Homo sapiens

<400> 298
Cys Phe Lys Arg Lys Pro Lys Arg Glu His Cys Ser Cys Pro Ile Thr
1 5 10 15
Tyr Gln Ser Leu Gly Asp Ile Leu Asn Ala Ser Phe Phe Ser Lys Arg
20 25 30
Lys Gly Met Gln Glu Val Lys Leu Asn Ser Tyr Val Val Ser Gly Thr
35 40 45
Ile Gly Leu Lys Glu Lys Ile Ser Leu Ser Glu Pro Val Phe Leu Thr
50 55 60
Phe Arg His Asn Gln Pro Gly Asp Lys Arg Thr Lys His Ile Cys Val
65 70 75 80
Tyr Trp Glu Gly Ser Glu Gly Gly Arg Trp Ser Thr Glu Gly Cys Ser
85 90 95
His Val His Ser Asn Gly Ser Tyr Thr Lys Cys Lys Cys Phe His Leu
100 105 110
Ser Ser Phe Ala Val Leu Val Ala Leu Ala Pro Lys Glu Asp Pro Val
115 120 125
Leu Thr Val Ile Thr Gln Val Gly Leu Thr Ile Ser Leu Leu Cys Leu
130 135 140
Phe Leu Ala Ile Leu Thr Phe Leu Leu Cys Arg Pro Ile Gln Asn Thr
145 150 155 160
Ser Thr Ser Leu His Leu Glu Leu Ser Leu Cys Leu Phe Leu Ala His
165 170 175

Leu Leu Phe Leu Thr Gly Ile Asn Arg Thr Glu Pro Glu Val Leu Cys
 180 185 190
 Ser Ile Ile Ala Gly Leu Leu His Phe Leu Tyr Leu Ala Cys Phe Thr
 195 200 205
 Trp Met Leu Leu Glu Gly Leu His Leu Phe Leu Thr Val Arg Asn Leu
 210 215 220
 Lys Val Ala Asn Tyr Thr Ser Thr Gly Arg Phe Lys Lys Arg Phe Met
 225 230 235 240
 Tyr Pro Val Gly Tyr Gly Ile Pro Ala Val Ile Ile Ala Val Ser Ala
 245 250 255
 Ile Val Gly Pro Gln Asn Tyr Gly Thr Phe Thr His Cys Trp Leu Lys
 260 265 270
 Leu Asp Lys Gly Phe Ile Trp Ser Phe Met Gly Pro Val Ala Val Ile
 275 280 285
 Ile Leu Ile Asn Leu Val Phe Tyr Phe Gln Val Leu Trp Ile Leu Arg
 290 295 300
 Ser Lys Leu Ser Ser Leu Asn Lys Glu Val Ser Thr Ile Gln Asp Thr
 305 310 315 320
 Arg Val Met Thr Phe Lys Ala Ile Ser Gln Leu Phe Ile Leu Gly Cys
 325 330 335
 Ser Trp Gly Leu Gly Phe Phe Met Val Glu Glu Val Gly Lys Thr Ile
 340 345 350
 Gly Ser Ile Ile Ala Tyr Ser Phe Thr Ile Ile Asn Thr Leu Gln Gly
 355 360 365
 Val Leu Leu Phe Val Val His Cys Leu Leu Asn Arg Gln Val Arg Met
 370 375 380
 Glu Tyr Lys Lys Trp Phe Ser Gly Met Arg Lys Gly Val Glu Thr Glu
 385 390 395 400
 Ser Thr Glu Met Ser Arg Ser Thr Thr Gln Thr Lys Thr Glu Glu Val
 405 410 415
 Gly Lys Ser Ser Glu Ile Phe His Lys Gly Gly Thr Ala Ser Ser Ser
 420 425 430
 Ala Glu Ser Thr Lys Gln Pro Gln Pro Gln Val His Leu Val Ser Ala
 435 440 445
 Ala Trp Leu Lys Met Asn
 450

<210> 299
 <211> 101
 <212> PRT

<213> Homo sapiens

<400> 299

Phe Phe Trp Lys Glu Asn Leu Arg Arg Asn Gly Ser Arg Glu Asp Phe
 1 5 10 15
 Ala Arg Arg Ala Thr Gln Leu Ile Gln Ser Val Glu Leu Ser Ile Trp
 20 25 30
 Asn Ala Ser Phe Ala Ser Pro Gly Lys Gly Gln Ile Ser Glu Phe Asp
 35 40 45
 Ile Val Tyr Glu Thr Lys Arg Cys Asn Glu Thr Arg Glu Asn Ala Phe
 50 55 60
 Leu Glu Ala Gly Asn Asn Thr Met Asp Ile Asn Cys Ala Asp Ala Leu
 65 70 75 80
 Lys Gly Asn Leu Arg Glu Ser Thr Ala Val Ala Leu Ser Leu Ile Asn
 85 90 95
 Leu Leu Gly Ile Phe
 100

<210> 300

<211> 27

<212> PRT

<213> Homo sapiens

<400> 300

Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys Cys Lys Tyr Lys Ala
 1 5 10 15
 Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
 20 25

<210> 301

<211> 12

<212> PRT

<213> Homo sapiens

<400> 301

Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys Ser Cys
 1 5 10

<210> 302

<211> 331

<212> PRT

<213> Homo sapiens

<400> 302

Ala Leu Cys Pro His Pro His Leu Ile Leu Asn Val Thr Val Ser Pro
 1 5 10 15
 Ala Pro Ser Cys Arg His Val Lys Lys Val Val Ala Ser Pro Ser Pro
 20 25 30

Ser Thr Thr Met Ile Ala Met Asp Ala Pro His Ser Lys Ala Ala Leu
 35 40 45
 Asp Ser Ile Asn Glu Leu Pro Glu Asn Ile Leu Leu Glu Leu Phe Thr
 50 55 60
 His Val Pro Ala Arg Gln Leu Leu Leu Asn Cys Arg Leu Val Cys Ser
 65 70 75 80
 Leu Trp Arg Asp Leu Ile Asp Leu Met Thr Leu Trp Lys Arg Lys Cys
 85 90 95
 Leu Arg Glu Gly Phe Ile Thr Lys Asp Trp Asp Gln Pro Val Ala Asp
 100 105 110
 Trp Lys Ile Phe Tyr Phe Leu Arg Ser Leu His Arg Asn Leu Leu Arg
 115 120 125
 Asn Pro Cys Ala Glu Glu Asp Met Phe Ala Trp Gln Ile Asp Phe Asn
 130 135 140
 Gly Gly Asp Arg Trp Lys Val Glu Ser Leu Pro Gly Ala His Gly Thr
 145 150 155 160
 Asp Phe Pro Asp Pro Lys Val Lys Lys Tyr Phe Val Thr Ser Tyr Glu
 165 170 175
 Met Cys Leu Lys Ser Gln Leu Val Asp Leu Val Ala Glu Gly Tyr Trp
 180 185 190
 Glu Glu Leu Leu Asp Thr Phe Arg Pro Asp Ile Val Val Lys Asp Trp
 195 200 205
 Phe Ala Ala Arg Ala Asp Cys Gly Cys Thr Tyr Gln Leu Lys Val Gln
 210 215 220
 Leu Ala Ser Ala Asp Tyr Phe Val Leu Ala Ser Phe Glu Pro Pro Pro
 225 230 235 240
 Val Thr Ile Gln Gln Trp Asn Asn Ala Thr Trp Thr Glu Val Ser Tyr
 245 250 255
 Thr Phe Ser Asp Tyr Pro Arg Gly Val Arg Tyr Ile Leu Phe Gln His
 260 265 270
 Gly Gly Arg Asp Thr Gln Tyr Trp Ala Gly Trp Tyr Gly Pro Arg Val
 275 280 285
 Thr Asn Ser Ser Ile Val Val Ser Pro Lys Met Thr Arg Asn Gln Ala
 290 295 300
 Ser Ser Glu Ala Gln Pro Gly Gln Lys His Gly Gln Glu Glu Ala Ala
 305 310 315 320
 Gln Ser Pro Tyr Arg Ala Val Val Gln Ile Phe
 325 330

<210> 303
 <211> 328
 <212> PRT
 <213> Homo sapiens

<400> 303

```

Arg Gln Arg Ser Trp Asn Pro Gly Thr Asn Cys Tyr His Pro Asn Met
  1          5          10          15

Pro Asp Ala Phe Leu Thr Cys Glu Thr Val Ile Phe Ala Trp Ala Ile
      20          25          30

Gly Gly Glu Gly Phe Ser Tyr Pro Pro His Val Gly Leu Ser Leu Gly
  35          40          45

Thr Pro Leu Asp Pro His Tyr Val Leu Leu Glu Val His Tyr Asp Asn
  50          55          60

Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn Ser Gly Leu Arg Leu Phe
  65          70          75          80

Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala Gly Val Ile Glu Ala Gly
      85          90          95

Leu Trp Val Ser Leu Phe His Thr Ile Pro Pro Gly Met Pro Glu Phe
      100          105          110

Gln Ser Glu Gly His Cys Thr Leu Glu Cys Leu Glu Glu Ala Leu Glu
      115          120          125

Ala Glu Lys Pro Ser Gly Ile His Val Phe Ala Val Leu Leu His Ala
      130          135          140

His Leu Ala Gly Arg Gly Ile Arg Leu Arg His Phe Arg Lys Gly Lys
      145          150          155          160

Glu Met Lys Leu Leu Ala Tyr Asp Asp Asp Phe Asp Phe Asn Phe Gln
      165          170          175

Glu Phe Gln Tyr Leu Lys Glu Glu Gln Thr Ile Leu Pro Gly Asp Asn
      180          185          190

Leu Ile Thr Glu Cys Arg Tyr Asn Thr Lys Asp Arg Ala Glu Met Thr
      195          200          205

Trp Gly Gly Leu Ser Thr Arg Ser Glu Met Cys Leu Ser Tyr Leu Leu
      210          215          220

Tyr Tyr Pro Arg Ile Asn Leu Thr Arg Cys Ala Ser Ile Pro Asp Ile
      225          230          235          240

Met Glu Gln Leu Gln Phe Ile Gly Val Lys Glu Ile Tyr Arg Pro Val
      245          250          255

Thr Thr Trp Pro Phe Ile Ile Lys Ser Pro Lys Gln Tyr Lys Asn Leu
      260          265          270

Ser Phe Met Asp Ala Met Asn Lys Phe Lys Trp Thr Lys Lys Glu Gly
      275          280          285
  
```


Leu Ser Phe Asn Lys Leu Val Leu Ser Leu Pro Val Asn Val Arg Cys
290 295 300

Ser Lys Thr Asp Asn Ala Glu Trp Ser Ile Pro Arg Asn Asp Ser Ile
305 310 315 320

Thr Ser Arg Tyr Arg Lys Thr Leu
325

<210> 304

<211> 272

<212> PRT

<213> Homo sapiens

<400> 304

Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
1 5 10 15

Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
20 25 30

Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
35 40 45

Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
50 55 60

Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
65 70 75 80

Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
85 90 95

Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
100 105 110

Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
115 120 125

Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
130 135 140

Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
165 170 175

Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
180 185 190

Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
195 200 205

Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
210 215 220

Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
 225 230 235 240
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg
 245 250 255
 Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu
 260 265 270

<210> 305
 <211> 207
 <212> PRT
 <213> Homo sapiens

<400> 305
 Thr Gly Thr Phe Trp Ser Pro Arg Ser Gln Arg Arg Gly Cys Cys Gly
 1 5 10 15
 Arg Arg Ala Pro Arg Pro Glu Ala Met Glu Asn Gly Ala Val Tyr Ser
 20 25 30
 Pro Thr Thr Glu Glu Asp Pro Gly Pro Ala Arg Gly Pro Arg Ser Gly
 35 40 45
 Leu Ala Ala Tyr Phe Phe Met Gly Arg Leu Pro Leu Leu Arg Arg Val
 50 55 60
 Leu Lys Gly Leu Gln Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu
 65 70 75 80
 Glu Val Val Ser Gln Cys Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu
 85 90 95
 Phe Val Ser Cys Ser Ala Phe Leu Leu Ser Leu Leu Ile Leu Ile Val
 100 105 110
 Tyr Cys Thr Pro Phe Tyr Glu Arg Val Asp Thr Thr Lys Val Lys Ser
 115 120 125
 Ser Asp Phe Tyr Ile Thr Leu Gly Thr Gly Cys Val Phe Leu Leu Ala
 130 135 140
 Ser Ile Ile Phe Val Ser Thr His Asp Arg Thr Ser Ala Glu Ile Ala
 145 150 155 160
 Ala Ile Val Phe Gly Phe Ile Ala Ser Phe Met Phe Leu Leu Asp Phe
 165 170 175
 Ile Thr Met Leu Tyr Glu Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro
 180 185 190
 Glu Asn Thr Thr Arg Ala Glu Ala Leu Thr Glu Pro Leu Asn Ala
 195 200 205

<210> 306
 <211> 135
 <212> PRT
 <213> Homo sapiens

<400> 306
 Ala Ser Ala Pro Arg Val Met Arg Gly His Leu Ala Gly Phe Pro Ala
 1 5 10 15
 Leu Ser Gly Leu Ala Ser Val Cys Leu Trp Ala Thr Phe Ser Ala Gln
 20 25 30
 Leu Pro Gly Pro Val Ala Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly
 35 40 45
 Cys Ser Ala Ala Arg Ser Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala
 50 55 60
 Pro Gly Ser Ala Ala Ser Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys
 65 70 75 80
 Arg Val Leu Pro Val Asp Pro Ala Pro Ala Ala Leu Asn Val Arg Glu
 85 90 95
 Pro Gly Trp Leu Gly Gly Leu Phe Asp Gly Ala Leu Leu Gln Val Leu
 100 105 110
 Leu Asn Phe Leu Arg Lys Ser Thr Asp Val Leu Met Asp Thr Arg Glu
 115 120 125
 Ala Glu Ser Leu Glu Val Glu
 130 135

<210> 307
 <211> 188
 <212> PRT
 <213> Homo sapiens

<400> 307
 Asn Lys Leu His Ser Phe Pro Val Phe Leu Ser Gln Leu Leu Asp
 1 5 10 15
 Arg Gln Leu Leu His Ala Pro Gln Thr Leu Pro Thr Pro His Cys Gly
 20 25 30
 Gly Ser Ser Arg Pro Gly Pro Ser His Pro Pro Trp Leu Leu Ile Gln
 35 40 45
 Leu Pro Cys Val His Val Ala Leu Trp Gln Met Leu Arg Asp Phe Ser
 50 55 60
 Asp Ser Arg Ile Thr Pro Ser Thr Leu Thr Thr Gln Pro Ala Ala Gln
 65 70 75 80
 Thr Ala Ala Pro Ala Lys Asp Gln Glu Ser Asp Ile Val Gly Gly Glu
 85 90 95
 Gly Ile Leu Cys Asp Ile Ala Phe Leu Gln Glu Asp His Pro Leu Gly

100 105 110
 Val Gly Gly Ala Ser Ala Pro Ser Ser Arg Arg Glu Leu Ser Arg Arg
 115 120 125
 Gly Val His Thr Gln Thr Leu Pro Glu Asp Gly Thr Leu His Gly Thr
 130 135 140
 Pro Ser Ser Ser Phe Asp Cys Gly Ile Lys Tyr Ile Ile Ser Trp Pro
 145 150 155 160
 Leu Ala Pro Gly Cys Asp Leu Pro Ser Leu Glu Leu Ser Leu Val Cys
 165 170 175
 Lys Gly Val Ser Ser Cys Met Gly Phe Ala Ala Gly
 180 185

<210> 308
 <211> 78
 <212> PRT
 <213> Homo sapiens

<400> 308
 Pro Gly Arg Pro Thr Arg Pro Thr Lys Asn Lys Val Cys Val Cys Leu
 1 5 10 15
 Gly Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu
 20 25 30
 Ser Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn
 35 40 45
 Ser Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu
 50 55 60
 Ala Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg
 65 70 75

<210> 309
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 309
 Pro Val Asp Leu Thr Lys Thr Arg Leu Gln
 1 5 10

<210> 310
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 310
 Pro Thr Asp Val Leu Lys Ile Arg Met Gln
 1 5 10

<210> 311
<211> 313
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 311
Met Thr Phe Gly Ser Thr Ile Ser Pro Thr Ser Thr His Ala Ser Pro
1 5 10 15
Ser Leu Gly Phe Cys Cys Ser Trp Leu Leu Glu Asp Leu Glu Glu Gln
20 25 30
Leu Tyr Cys Ser Ala Phe Glu Glu Ala Ala Leu Thr Arg Arg Ile Cys
35 40 45
Asn Pro Thr Ser Cys Trp Leu Pro Leu Asp Met Glu Leu Leu His Arg
50 55 60
Gln Val Leu Ala Leu Gln Thr Gln Arg Val Leu Leu Gly Met Trp Leu
65 70 75 80
Arg Arg Ala Trp Asp Thr Trp Val Ser Pro Arg Arg Val Ala Pro Gly
85 90 95
Ser Arg Cys Leu Leu Thr Ala Ser His Pro Cys Thr Glu Lys Arg Arg
100 105 110
Lys Ala Ser Ala Xaa Gln Arg Asn Leu Gly Tyr Pro Leu Ala Met Leu
115 120 125
Cys Leu Leu Val Leu Thr Gly Leu Ser Val Leu Ile Val Ala Ile His
130 135 140
Ile Leu Glu Leu Leu Ile Asp Glu Ala Ala Met Pro Arg Gly Met Gln
145 150 155 160
Gly Thr Ser Leu Gly Gln Val Ser Phe Ser Lys Leu Gly Ser Phe Gly
165 170 175
Ala Val Ile Gln Val Val Leu Ile Phe Tyr Leu Met Val Ser Ser Val
180 185 190
Val Gly Phe Tyr Ser Ser Pro Leu Phe Arg Ser Leu Arg Pro Arg Trp
195 200 205
His Asp Thr Ala Met Thr Gln Ile Ile Gly Asn Cys Val Cys Leu Leu
210 215 220
Val Leu Ser Ser Ala Leu Pro Val Phe Ser Arg Thr Leu Gly Leu Thr
225 230 235 240
Arg Phe Asp Leu Leu Gly Asp Phe Gly Arg Phe Asn Trp Leu Gly Asn
245 250 255

Phe Tyr Ile Val Phe Leu Tyr Asn Ala Ala Phe Ala Gly Leu Thr Thr
260 265 270

Leu Cys Leu Val Lys Thr Phe Thr Ala Ala Val Arg Ala Glu Leu Ile
275 280 285

Arg Ala Phe Gly Leu Asp Arg Leu Pro Leu Pro Val Ser Gly Phe Pro
290 295 300

Gln Ala Ser Arg Lys Thr Gln His Gln
305 310

<210> 312

<211> 92

<212> PRT

<213> Homo sapiens

<400> 312

Leu Cys Val Cys Leu Val Tyr Leu Cys Met Tyr Gly Val Cys Leu Cys
1 5 10 15

Val Ile Val Cys Val Ser Gly Val Ser Leu Cys Leu Tyr Val Trp Gly
20 25 30

Val Ser Val Cys Asp Cys Val Ser Val Phe Met Cys Val Cys Leu Cys
35 40 45

Val Ile Phe Cys Val Tyr Gly Lys Pro Arg Thr Glu His Tyr His Ser
50 55 60

Pro His Leu Ala Lys Gln Lys Ala Phe Arg Glu Met Cys Gly Arg His
65 70 75 80

Asp Val Ser Ala Ala Gly Ile Phe Gln Ser Tyr Val
85 90

<210> 313

<211> 207

<212> PRT

<213> Homo sapiens

<400> 313

Gly His Met Pro Tyr Gly Trp Leu Thr Glu Ile Arg Ala Val Tyr Pro
1 5 10 15

Ala Phe Asp Lys Asn Asn Pro Ser Asn Lys Leu Val Ser Thr Ser Asn
20 25 30

Thr Val Thr Ala Ala His Ile Lys Lys Phe Thr Phe Val Cys Met Ala
35 40 45

Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn Val Ser
50 55 60

Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe Ala Glu
65 70 75 80

Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val Pro Val
85 90 95
Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys Lys Thr
100 105 110
Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu Ile Ala
115 120 125
Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr Leu Gly
130 135 140
Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met Val Ala
145 150 155 160
Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Lys Met Glu Asn
165 170 175
Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met Pro Pro
180 185 190
Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn Glu
195 200 205

<210> 314
<211> 114
<212> PRT
<213> Homo sapiens

<400> 314
Gln Val Val Phe Val Ala Ile Leu Leu His Ser His Leu Glu Cys Arg
1 5 10 15
Glu Pro Leu Leu Ile Pro Ile Leu Ser Leu Tyr Met Gly Ala Leu Val
20 25 30
Arg Cys Thr Thr Leu Cys Leu Gly Tyr Tyr Lys Asn Ile His Asp Ile
35 40 45
Ile Pro Asp Arg Ser Gly Pro Glu Leu Gly Gly Asp Ala Thr Ile Arg
50 55 60
Lys Met Leu Ser Phe Trp Trp Pro Leu Ala Leu Ile Leu Ala Thr Gln
65 70 75 80
Arg Ile Ser Arg Pro Ile Val Asn Leu Phe Val Ser Arg Asp Leu Gly
85 90 95
Gly Ser Ser Ala Ala Thr Glu Ala Val Ala Ile Leu Thr Ala Thr Tyr
100 105 110
Pro Val

<210> 315
<211> 115

<212> PRT

<213> Homo sapiens

<400> 315

Arg Cys Cys Cys Arg Gly Cys Ser Cys Arg Ala Arg Leu Cys Pro Pro
1 5 10 15
Ala Arg Ser Thr Ala Val Ala Pro Glu Cys Arg Gly Ala His Pro Ser
20 25 30
Arg Ala Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Ala Val
35 40 45
Leu Leu Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln
50 55 60
Pro Val Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr
65 70 75 80
Phe His Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala
85 90 95
Cys Arg Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met
100 105 110
Asn Arg Asn
115

<210> 316

<211> 81

<212> PRT

<213> Homo sapiens

<400> 316

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
1 5 10 15
Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
20 25 30
Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
35 40 45
Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
50 55 60
Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg
65 70 75 80
Asn

<210> 317

<211> 290

<212> PRT

<213> Homo sapiens

<400> 317

Ile Arg His Glu Gln Gln Gly Glu Glu Asp Asp Glu His Ala Arg Pro
 1 5 10 15
 Leu Ala Glu Ser Leu Leu Leu Ala Ile Ala Asp Leu Leu Phe Cys Pro
 20 25 30
 Asp Phe Thr Val Gln Ser His Arg Arg Ser Thr Val Asp Ser Ala Glu
 35 40 45
 Asp Val His Ser Leu Asp Ser Cys Glu Tyr Ile Trp Glu Ala Gly Val
 50 55 60
 Gly Phe Ala His Ser Pro Gln Pro Asn Tyr Ile His Asp Met Asn Arg
 65 70 75 80
 Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu Ala Met Tyr
 85 90 95
 Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp Val Gln Phe
 100 105 110
 Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe Thr Ser Leu
 115 120 125
 Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly Ile Pro Tyr
 130 135 140
 Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val Glu Glu Ala
 145 150 155 160
 Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala Ser Ser Ala
 165 170 175
 Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met Asp Asp Ala
 180 185 190
 Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu Ser Arg Ile
 195 200 205
 His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile Ala Arg Leu
 210 215 220
 Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser Thr Lys Lys
 225 230 235 240
 Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu Ala Leu Arg
 245 250 255
 Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln Arg Arg Pro
 260 265 270
 Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys Pro Gly Arg
 275 280 285
 Ser Val
 290

<210> 318
 <211> 318
 <212> PRT
 <213> Homo sapiens

<400> 318

```

Arg Leu Val Tyr Asn Lys Thr Ser Arg Ala Thr Gln Phe Pro Asp Gly
 1           5           10           15
Val Asp Val Arg Val Pro Gly Phe Gly Lys Thr Phe Ser Leu Glu Phe
 20           25           30
Leu Asp Pro Ser Lys Ser Ser Val Gly Ser Tyr Phe His Thr Met Val
 35           40           45
Glu Ser Leu Val Gly Trp Gly Tyr Thr Arg Gly Glu Asp Val Arg Gly
 50           55           60
Ala Pro Tyr Asp Trp Arg Arg Ala Pro Asn Glu Asn Gly Pro Tyr Phe
 65           70           75           80
Leu Ala Leu Arg Glu Met Ile Glu Glu Met Tyr Gln Leu Tyr Gly Gly
 85           90           95
Pro Val Val Leu Val Ala His Ser Met Gly Asn Met Tyr Thr Leu Tyr
100          105          110
Phe Leu Gln Arg Gln Pro Gln Ala Trp Lys Asp Lys Tyr Ile Arg Ala
115          120          125
Phe Val Ser Leu Gly Ala Pro Trp Gly Gly Val Ala Lys Thr Leu Arg
130          135          140
Val Leu Ala Ser Gly Asp Asn Asn Arg Ile Pro Val Ile Gly Pro Leu
145          150          155          160
Lys Ile Arg Glu Gln Gln Arg Ser Ala Val Ser Thr Ser Trp Leu Leu
165          170          175
Pro Tyr Asn Tyr Thr Trp Ser Pro Glu Lys Val Phe Val Gln Thr Pro
180          185          190
Thr Ile Asn Tyr Thr Leu Arg Asp Tyr Arg Lys Phe Phe Gln Asp Ile
195          200          205
Gly Phe Glu Asp Gly Trp Leu Met Arg Gln Asp Thr Glu Gly Leu Val
210          215          220
Glu Ala Thr Met Pro Pro Gly Val Gln Leu His Cys Leu Tyr Gly Thr
225          230          235          240
Gly Val Pro Thr Pro Asp Ser Phe Tyr Tyr Glu Ser Phe Pro Asp Arg
245          250          255
Asp Pro Lys Ile Cys Phe Gly Asp Gly Asp Gly Thr Val Asn Leu Lys
260          265          270
Ser Ala Leu Gln Cys Gln Ala Trp Gln Ser Arg Gln Glu His Gln Val
275          280          285

```

Leu Leu Gln Glu Leu Pro Gly Ser Glu His Ile Glu Met Leu Ala Asn
 290 295 300

Ala Thr Thr Leu Ala Tyr Leu Lys Arg Val Leu Leu Gly Pro
 305 310 315

<210> 319

<211> 362

<212> PRT

<213> Homo sapiens

<400> 319

Met Asn Lys Glu Asp Lys Val Trp Asn Asp Cys Lys Gly Val Asn Lys
 1 5 10 15

Leu Thr Asn Leu Glu Glu Gln Tyr Ile Ile Leu Ile Phe Gln Asn Gly
 20 25 30

Leu Asp Pro Pro Ala Asn Met Val Phe Glu Ser Ile Ile Asn Glu Ile
 35 40 45

Gly Ile Lys Asn Asn Ile Ser Asn Phe Phe Ala Lys Ile Pro Phe Glu
 50 55 60

Glu Ala Asn Gly Arg Leu Val Ala Cys Thr Arg Thr Tyr Glu Glu Ser
 65 70 75 80

Ile Lys Gly Ser Cys Gly Gln Lys Glu Asn Lys Ile Lys Thr Val Ser
 85 90 95

Phe Glu Ser Lys Ile Gln Leu Arg Ser Lys Gln Glu Phe Gln Phe Phe
 100 105 110

Asp Glu Glu Glu Glu Thr Gly Glu Asn His Thr Ile Phe Ile Gly Pro
 115 120 125

Val Glu Lys Leu Ile Val Tyr Pro Pro Pro Pro Ala Lys Gly Gly Ile
 130 135 140

Ser Val Thr Asn Glu Asp Leu His Cys Leu Asn Glu Gly Glu Phe Leu
 145 150 155 160

Asn Asp Val Ile Ile Asp Phe Tyr Leu Lys Tyr Leu Val Leu Glu Lys
 165 170 175

Leu Lys Lys Glu Asp Ala Asp Arg Ile His Ile Phe Ser Ser Phe Phe
 180 185 190

Tyr Lys Arg Leu Asn Gln Arg Glu Arg Arg Asn His Glu Thr Thr Asn
 195 200 205

Leu Ser Ile Gln Gln Lys Arg His Gly Arg Val Lys Thr Trp Thr Arg
 210 215 220

His Val Asp Ile Phe Glu Lys Asp Phe Ile Phe Val Pro Leu Asn Glu
 225 230 235 240

213

Ala Ala His Trp Phe Leu Ala Val Val Cys Phe Pro Gly Leu Glu Lys
245 250 255

Pro Lys Tyr Glu Pro Asn Pro His Tyr His Glu Asn Ala Val Ile Gln
260 265 270

Lys Cys Ser Thr Val Glu Asp Ser Cys Ile Ser Ser Ser Ala Ser Glu
275 280 285

Met Glu Ser Cys Ser Gln Asn Ser Ser Ala Lys Pro Val Ile Lys Lys
290 295 300

Met Leu Asn Lys Lys His Cys Ile Ala Val Ile Asp Ser Asn Pro Gly
305 310 315 320

Gln Glu Glu Ser Asp Pro Arg Tyr Lys Arg Asn Ile Cys Ser Val Lys
325 330 335

Tyr Ser Val Lys Lys Ile Asn His Thr Ala Ser Glu Asn Glu Glu Phe
340 345 350

Asn Lys Gly Glu Ser Thr Ser Gln Lys Ser
355 360

<210> 320

<211> 330

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (247)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 320

Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
20 25 30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
50 55 60

Asp Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala
65 70 75 80

Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val
85 90 95

Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe
 100 105 110
 Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn
 115 120 125
 Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe
 130 135 140
 Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn
 145 150 155 160
 Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala
 165 170 175
 Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn
 180 185 190
 Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr
 195 200 205
 Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg
 210 215 220
 Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro
 225 230 235 240
 Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg
 245 250 255
 Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu
 260 265 270
 Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly
 275 280 285
 Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His
 290 295 300
 Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys
 305 310 315 320
 Glu Met Thr Gly Val Leu Asp Val Thr Leu
 325 330

<210> 321

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 321

Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
 1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
20 25 30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
50 55 60

Asp Leu Ala Cys Met Leu Ser
65 70

<210> 322

<211> 266

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (97)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (174)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (195)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (199)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (206)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 322

Met Glu Val Thr Thr Glu Asp Thr Ser Arg Thr Asp Val Ser Glu Pro
1 5 10 15

Ala Thr Ser Gly Gly Ala Ala Asp Gly Val Thr Ser Ile Ala Pro Thr
20 25 30

Ala Val Ala Ser Ser Thr Thr Ala Ala Ser Ile Thr Thr Ala Ala Ser
35 40 45

Ser Met Thr Val Ala Ser Ser Ala Pro Thr Thr Ala Ala Ser Ser Thr
50 55 60

Thr Val Ala Ser Ile Ala Pro Thr Thr Thr Ala Ser Ser Met Thr Ala
65 70 75 80

Ala Ser Ser Thr Pro Met Thr Leu Ala Leu Pro Ala Pro Thr Ser Thr
85 90 95
Xaa Thr Gly Arg Thr Pro Ser Thr Thr Ala Thr Gly His Pro Ser Leu
100 105 110
Ser Thr Ala Leu Ala Gln Val Pro Lys Ser Ser Ala Leu Pro Arg Thr
115 120 125
Ala Thr Leu Ala Thr Leu Ala Thr Arg Ala Gln Thr Val Ala Thr Thr
130 135 140
Ala Asn Thr Ser Ser Pro Met Ser Thr Arg Pro Ser Pro Ser Lys His
145 150 155 160
Met Pro Ser Asp Thr Ala Ala Ser Pro Val Pro Pro Met Xaa Pro Gln
165 170 175
Ala Gln Gly Pro Ile Ser Gln Val Ser Val Asp Gln Pro Val Val Asn
180 185 190
Thr Thr Xaa Lys Ser Thr Xaa Met Pro Ser Asn Thr Thr Xaa Glu Pro
195 200 205
Leu Thr Gln Ala Val Val Asp Lys Thr Leu Leu Leu Val Val Leu Leu
210 215 220
Leu Gly Val Thr Leu Phe Ile Thr Val Leu Val Leu Phe Ala Leu Gln
225 230 235 240
Ala Tyr Glu Ser Tyr Lys Lys Lys Asp Tyr Thr Gln Val Asp Tyr Leu
245 250 255
Ile Asn Gly Met Tyr Ala Asp Ser Glu Met
260 265

<210> 323
<211> 99
<212> PRT
<213> Homo sapiens

<400> 323
Ala Arg Cys Pro Glu Leu Pro Gly Leu Arg Cys Arg Pro Arg Pro Arg
1 5 10 15
Ala Gly Pro Gln Ala Pro Ser Tyr Cys Pro Arg Ala Thr Arg Pro Pro
20 25 30
Gly Ala Cys Cys Ala Arg Met Arg Leu Leu Leu Glu Trp Arg Val Tyr
35 40 45
Leu Arg Leu Thr Cys Ala Thr Lys Asp Gly Met Ala Arg Glu Cys Pro
50 55 60
Thr Thr Trp Leu Ser Pro Pro Ala Lys Pro Asp Phe Ala Gln Arg His
65 70 75 80

Ser Val Lys Pro Thr Ala Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly
85 90 95

Ala Ser Pro

<210> 324

<211> 96

<212> PRT

<213> Homo sapiens

<400> 324

Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser
1 5 10 15

Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys
20 25 30

Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly
35 40 45

Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe
50 55 60

Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile
65 70 75 80

Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys
85 90 95

<210> 325

<211> 166

<212> PRT

<213> Homo sapiens

<400> 325

Leu Leu Trp Ala Arg Gly Leu Gly Arg Ala Lys Ser Ala Val Pro Thr
1 5 10 15

Val Ser Thr Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala
20 25 30

Leu Leu Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp
35 40 45

His Phe His Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg
50 55 60

Tyr Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln
65 70 75 80

Ser Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp
85 90 95

Lys Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu
 100 105 110
 Gly Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His
 115 120 125
 Phe Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr
 130 135 140
 Ile Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr
 145 150 155 160
 Cys Leu Glu Gly Phe His
 165

<210> 326
 <211> 214
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (200)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (205)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 326
 Leu Glu Gln Lys Leu Glu Leu His Arg Gly Gly Gly Arg Ser Arg Thr
 1 5 10 15
 Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Glu Glu Arg Gly
 20 25 30
 Glu Gly Glu Gln Arg Thr Gly Arg Glu Phe Ser Gly Asn Gly Gly Arg
 35 40 45
 Ala Val Glu Ala Ala Arg Met Arg Leu Leu Cys Gly Leu Trp Leu Trp
 50 55 60
 Leu Ser Leu Leu Lys Val Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro
 65 70 75 80
 Leu Pro Pro Pro Met Gln Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu
 85 90 95
 Trp Phe Val Leu Gly Leu Ala Gly Asn Ser Phe Arg Pro Glu His Arg
 100 105 110
 Ala Leu Leu Asn Ala Phe Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly
 115 120 125
 Arg Phe Glu Val Trp Asn Ala Met Thr Arg Gly Gln His Cys Asp Thr
 130 135 140

Trp Ser Tyr Val Leu Ile Pro Ala Ala Gln Pro Gly Gln Phe Thr Val
145 150 155 160

Asp His Gly Val Gly Arg Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp
165 170 175

Gln Phe Ile Cys Leu Gly Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile
180 185 190

Val Phe Pro Asp Val Thr Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro
195 200 205

Trp Val Ala Ala Pro Ala
210

<210> 327

<211> 181

<212> PRT

<213> Homo sapiens

<400> 327

Met Cys Val Cys Glu Arg Lys Arg Gly Arg Glu Lys Glu Gly Gly Val
1 5 10 15

Thr Pro Thr Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly
20 25 30

Ile Ala Gln Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly
35 40 45

Leu Gly Ser Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg
50 55 60

Thr Pro Ile Pro Cys Ser Pro Pro Ala Pro Ala Ala Cys Leu Gly
65 70 75 80

Ser Gly His Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro
85 90 95

Ala Asn Leu Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe
100 105 110

Trp Ser Ser Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe
115 120 125

Arg Asp Leu Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe
130 135 140

Gln Lys Thr Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val
145 150 155 160

Ala Thr Pro Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala
165 170 175

Ala Ala Asn Trp Cys
180

<210> 328
 <211> 195
 <212> PRT
 <213> Homo sapiens

<400> 328
 Tyr Leu Trp Gly Arg Pro Arg Leu Arg Met Arg Ala Gly Thr Ser Pro
 1 5 10 15
 Ser Ala Pro Trp Gly Glu Lys Arg Glu Lys Leu Gly His Lys Leu Pro
 20 25 30
 Val Ala Leu Gln Gly Tyr His Pro Trp Ile Leu Leu Glu Cys Thr Val
 35 40 45
 Phe Trp Ala Arg Val Val Leu Ala Cys Phe Ser Leu Tyr Leu Ile Arg
 50 55 60
 Gly Pro Asn Cys Ile Asn Arg Gln Pro Glu Pro Thr Tyr Gln Lys Ala
 65 70 75 80
 Cys Asn Leu Asp Cys Ser Ser Asp Phe Gly Gln Glu Arg Ala Pro Ala
 85 90 95
 Trp Glu Leu Leu Gly Pro Glu Ser Glu Gln Arg Leu Arg Glu Tyr Thr
 100 105 110
 Ala Gln Gly Leu Gln Ser Leu Ala Ser Ser His Arg Trp Arg Gln Phe
 115 120 125
 Lys Thr Glu Gly Lys Met Arg Gly Gly Ala Ser Pro Leu Pro Trp Leu
 130 135 140
 Ile Cys Phe Trp Leu Cys Ser Tyr Lys Gly Ser Asp Asn Ser Leu Lys
 145 150 155 160
 Pro Val Val Pro Gly Pro Thr Leu Cys Pro Gln Ser Leu Val Ser Pro
 165 170 175
 Ser Val His Pro Ser Thr Arg Ser Ala Ser Leu Gly Arg His Arg Ala
 180 185 190
 Glu Ala Ala
 195

<210> 329
 <211> 50
 <212> PRT
 <213> Homo sapiens

<400> 329
 Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser
 1 5 10 15
 Leu Leu Gln Gly Phe Arg Leu Leu Leu Cys Val Cys Pro Gly Trp
 20 25 30
 Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp

35

40

45

Ile Gly
50

<210> 330
<211> 90
<212> PRT
<213> Homo sapiens

<400> 330
Ala Lys Gly Glu Glu Arg Lys Glu Ala Phe Ser Leu Lys Met Val Gln
1 5 10 15
Leu Ser Ser Glu Pro Ile Ser Phe Gly Leu Met Tyr Leu Tyr Leu Gly
20 25 30
Val Phe Phe His Leu Ile Tyr Pro Gly Ala Leu Ser Ile Thr Thr Leu
35 40 45
Gly Lys His Ser His Pro Phe Phe Thr Ala Glu Gln Asn Ser Thr Val
50 55 60
Trp Met Glu His Thr Leu Phe His Gln Ser Pro Val Ala Ser His Leu
65 70 75 80
Val Cys Phe Gln Ser Phe Ala Phe Ser Glu
85 90

<210> 331
<211> 56
<212> PRT
<213> Homo sapiens

<400> 331
Gly Pro Ala His Pro Ala Ser Pro Pro Leu Met Thr Leu Ser Leu Gln
1 5 10 15
Leu Ala Glu Leu Val His Phe Val Cys Ala Phe Gln Ser Gln Trp Thr
20 25 30
Gly Val Tyr Pro Met Met Pro Pro Leu Lys Pro Thr Glu Pro Leu Cys
35 40 45
Phe Ala Cys Val Pro Cys Arg Val
50 55

<210> 332
<211> 19
<212> PRT
<213> Homo sapiens

<400> 332
Met Leu Leu Glu Val Tyr Gly Asp Ser Ile Ser Val Thr Val Ala Ile
1 5 10 15

Pro Leu

<210> 333
<211> 19
<212> PRT
<213> Homo sapiens

<400> 333
Met His Ser Pro Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser
1 5 10 15

Glu Thr Glu

<210> 334
<211> 10
<212> PRT
<213> Homo sapiens

<400> 334
Met Leu Lys Ser Leu Gly Leu Ser Thr Asn
1 5 10

<210> 335
<211> 200
<212> PRT
<213> Homo sapiens

<400> 335
Ala Gln Arg Leu Ala Glu Glu Cys Phe Tyr Met Leu Leu Glu Val Tyr
1 5 10 15

Gly Asp Ser Ile Ser Val Thr Val Ala Ile Pro Leu Met His Ser Pro
20 25 30

Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser Glu Thr Glu Met
35 40 45

Leu Lys Ser Leu Gly Leu Ser Thr Asn Met Ser Pro Phe His Leu Leu
50 55 60

Gly Leu Lys Val Phe Leu Thr Trp Ala Leu Thr Leu Ala Gln Ile Cys
65 70 75 80

Leu Tyr Phe Phe Glu Val Gln Pro Leu Gly Leu Leu Ala Leu Asn Phe
85 90 95

Phe Cys Thr Ala Thr Ala Gly Leu Lys Glu Leu Cys Met His Pro Pro
100 105 110

Ser Leu Ala Phe Thr Pro Glu Phe His Thr Ser Leu Ser Pro Leu Ala
115 120 125

Ile Pro Ser Phe Cys Gly Thr Ser Val Ser Leu Ser Asn Ser His Thr
130 135 140

Ile Pro Leu Ser Leu Tyr Leu Pro Phe Pro Ser Lys Ser Arg Met Pro
145 150 155 160

Asp Thr Leu His Leu Leu Val His Ser Leu Pro Leu Val His Ser Gln
165 170 175

Val Leu Pro Val Lys Asp Val Thr Ile Glu Trp Pro Leu Cys Gln Arg
180 185 190

Cys Leu Gly Ser Thr Cys His Gln
195 200

<210> 336

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 336

Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Val Gln Val Ser Leu
1 5 10 15

Phe Gln Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr
20 25 30

His Leu Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Ile Leu
35 40 45

Pro Pro Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr
50 55 60

Val Arg Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr
65 70 75 80

Pro Gly Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn
85 90 95

Ser Glu Xaa

<210> 337

<211> 96

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 337

Xaa Asn Xaa Lys Ser Pro Leu Thr Ile Gly Asn Lys Ser Trp Ser Ser
 1 5 10 15

Thr Ala Val Ala Ala Ala Leu Glu Leu Val Asp Pro Pro Gly Cys Arg
 20 25 30

Asn Ser Ala Arg Asp Ser Pro Glu Leu Val His Leu Gly Lys Gly Arg
 35 40 45

Pro Arg Lys Leu Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu
 50 55 60

Leu Leu Lys Val His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys
 65 70 75 80

Ser Lys Val Pro Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu
 85 90 95

<210> 338

<211> 54

<212> PRT

<213> Homo sapiens

<400> 338

Gly Pro Glu Glu Asn Leu Ser Pro Ser Thr Pro Ser Gln Met Pro Thr
 1 5 10 15

Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly Leu Phe Pro
 20 25 30

Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val Thr Leu Ala
 35 40 45

Pro Val Ser Tyr Trp Leu
 50

<210> 339

<211> 287

<212> PRT

<213> Homo sapiens

<400> 339

Pro Arg Val Arg Lys Glu Pro Glu Ala Met Gln Trp Leu Arg Val Arg
 1 5 10 15

Glu Ser Pro Gly Glu Ala Thr Gly His Arg Val Thr Met Gly Thr Ala
20 25 30
Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe Leu Leu Met Cys
35 40 45
Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala Val Ala Ser Asp
50 55 60
Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val
65 70 75 80
Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg
85 90 95
Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly
100 105 110
Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu
115 120 125
Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro
130 135 140
Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg Lys
145 150 155 160
Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe Glu Arg
165 170 175
Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr Gly Gln Phe
180 185 190
Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu Asn Val His Ser
195 200 205
Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His Asn Gln Lys Glu
210 215 220
Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser Ile Met Gln Ser
225 230 235 240
Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg Val Trp Val Arg
245 250 255
Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser Asn Asp Phe Asp
260 265 270
Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala Glu Asp Asp
275 280 285

<210> 340

<211> 339

<212> PRT

<213> Homo sapiens

<400> 340

Met Leu Tyr Pro Gly Ser Val Tyr Leu Leu Gln Lys Ala Leu Met Pro

1	5	10	15
Val Leu Leu Gln Gly Gln Ala Arg Leu Val Glu Glu Cys Asn Gly Arg	20	25	30
Arg Ala Lys Leu Leu Ala Cys Asp Gly Asn Glu Ile Asp Thr Met Phe	35	40	45
Val Asp Arg Arg Gly Thr Ala Glu Pro Gln Gly Gln Lys Leu Val Ile	50	55	60
Cys Cys Glu Gly Asn Ala Gly Phe Tyr Glu Val Gly Cys Val Ser Thr	65	70	75
Pro Leu Glu Ala Gly Tyr Ser Val Leu Gly Trp Asn His Pro Gly Phe	85	90	95
Ala Gly Ser Thr Gly Val Pro Phe Pro Gln Asn Glu Ala Asn Ala Met	100	105	110
Asp Val Val Val Gln Phe Ala Ile His Arg Leu Gly Phe Gln Pro Gln	115	120	125
Asp Ile Ile Ile Tyr Ala Trp Ser Ile Gly Gly Phe Thr Ala Thr Trp	130	135	140
Ala Ala Met Ser Tyr Pro Asp Val Ser Ala Met Ile Leu Asp Ala Ser	145	150	155
Phe Asp Asp Leu Val Pro Leu Ala Leu Lys Val Met Pro Asp Ser Trp	165	170	175
Arg Gly Leu Val Thr Arg Thr Val Arg Gln His Leu Asn Leu Asn Asn	180	185	190
Ala Glu Gln Leu Cys Arg Tyr Gln Gly Pro Val Leu Leu Ile Arg Arg	195	200	205
Thr Lys Asp Glu Ile Ile Thr Thr Thr Val Pro Glu Asp Ile Met Ser	210	215	220
Asn Arg Gly Asn Asp Leu Leu Leu Lys Leu Leu Gln His Arg Tyr Pro	225	230	235
Arg Val Met Ala Glu Glu Gly Leu Arg Val Val Arg Gln Trp Leu Glu	245	250	255
Ala Ser Ser Gln Leu Glu Glu Ala Ser Ile Tyr Ser Arg Trp Glu Val	260	265	270
Glu Glu Asp Trp Cys Leu Ser Val Leu Arg Ser Tyr Gln Ala Glu His	275	280	285
Gly Pro Asp Phe Pro Trp Ser Val Gly Glu Asp Met Ser Ala Asp Gly	290	295	300
Arg Arg Gln Leu Ala Leu Phe Leu Ala Arg Lys His Leu His Asn Phe	305	310	315
			320

Glu Ala Thr His Cys Thr Pro Leu Pro Ala Gln Asn Phe Gln Met Pro
 325 330 335

Trp His Leu

<210> 341
 <211> 127
 <212> PRT
 <213> Homo sapiens

<400> 341
 Val Cys Pro Lys Trp Cys Arg Phe Leu Thr Met Leu Gly His Cys Cys
 1 5 10 15

Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu Ala Leu Ala Ala Gly Pro
 20 25 30

Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His Ile Gly
 35 40 45

Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr Leu Thr
 50 55 60

Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala Ala Gly
 65 70 75 80

Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys Phe Ala
 85 90 95

Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr Gly Leu
 100 105 110

Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr Pro
 115 120 125

<210> 342
 <211> 554
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (16)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (109)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 342
 Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Ile Tyr Arg Glu Xaa
 1 5 10 15

Asp Ser Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val
 20 25 30

Thr Ala Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala
 35 40 45
 Leu Glu Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp
 50 55 60
 Ser Ile Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg
 65 70 75 80
 Lys Gly Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala
 85 90 95
 Gly Thr Leu Leu Leu Leu Ala Gly Val Ala Cys Xaa Arg Gly Ile
 100 105 110
 Gly Arg Trp Thr Asn Pro Gln Tyr Arg Gln Phe Ile Thr Ile Leu Glu
 115 120 125
 Ala Thr His Arg Asn Gln Ser Ser Glu Asn Lys Arg Gln Leu Ala Asn
 130 135 140
 Tyr Asn Phe Asp Phe Arg Ser Trp Pro Val Asp Phe His Trp Glu Glu
 145 150 155 160
 Pro Ser Ser Arg Lys Glu Ser Arg Gly Gly Pro Ser Arg Arg Gly Val
 165 170 175
 Ala Leu Leu Arg Pro Glu Pro Leu His Arg Gly Thr Ala Asp Thr Leu
 180 185 190
 Leu Asn Arg Val Lys Lys Leu Pro Cys Gln Ile Thr Ser Tyr Leu Val
 195 200 205
 Ala His Thr Leu Gly Arg Arg Met Leu Tyr Pro Gly Ser Val Tyr Leu
 210 215 220
 Leu Gln Lys Ala Leu Met Pro Val Leu Leu Gln Gly Gln Ala Arg Leu
 225 230 235 240
 Val Glu Glu Cys Asn Gly Arg Arg Ala Lys Leu Leu Ala Cys Asp Gly
 245 250 255
 Asn Glu Ile Asp Thr Met Phe Val Asp Arg Arg Gly Thr Ala Glu Pro
 260 265 270
 Gln Gly Gln Lys Leu Val Ile Cys Cys Glu Gly Asn Ala Gly Phe Tyr
 275 280 285
 Glu Val Gly Cys Val Ser Thr Pro Leu Glu Ala Gly Tyr Ser Val Leu
 290 295 300
 Gly Trp Asn His Pro Gly Phe Ala Gly Ser Thr Gly Val Pro Phe Pro
 305 310 315 320
 Gln Asn Glu Ala Asn Ala Met Asp Val Val Val Gln Phe Ala Ile His
 325 330 335
 Arg Leu Gly Phe Gln Pro Gln Asp Ile Ile Ile Tyr Ala Trp Ser Ile

340 345 350
 Gly Gly Phe Thr Ala Thr Trp Ala Ala Met Ser Tyr Pro Asp Val Ser
 355 360 365
 Ala Met Ile Leu Asp Ala Ser Phe Asp Asp Leu Val Pro Leu Ala Leu
 370 375 380
 Lys Val Met Pro Asp Ser Trp Arg Gly Leu Val Thr Arg Thr Val Arg
 385 390 395 400
 Gln His Leu Asn Leu Asn Asn Ala Glu Gln Leu Cys Arg Tyr Gln Gly
 405 410 415
 Pro Val Leu Leu Ile Arg Arg Thr Lys Asp Glu Ile Ile Thr Thr Thr
 420 425 430
 Val Pro Glu Asp Ile Met Ser Asn Arg Gly Asn Asp Leu Leu Leu Lys
 435 440 445
 Leu Leu Gln His Arg Tyr Pro Arg Val Met Ala Glu Glu Gly Leu Arg
 450 455 460
 Val Val Arg Gln Trp Leu Glu Ala Ser Ser Gln Leu Glu Glu Ala Ser
 465 470 475 480
 Ile Tyr Ser Arg Trp Glu Val Glu Glu Asp Trp Cys Leu Ser Val Leu
 485 490 495
 Arg Ser Tyr Gln Ala Glu His Gly Pro Asp Phe Pro Trp Ser Val Gly
 500 505 510
 Glu Asp Met Ser Ala Asp Gly Arg Arg Gln Leu Ala Leu Phe Leu Ala
 515 520 525
 Arg Lys His Leu His Asn Phe Glu Ala Thr His Cys Thr Pro Leu Pro
 530 535 540
 Ala Gln Asn Phe Gln Met Pro Trp His Leu
 545 550

<210> 343

<211> 225

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 343

His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser
 1 5 10 15
 Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser
 20 25 30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala
 35 40 45
 Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu
 50 55 60
 Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile
 65 70 75 80
 Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly
 85 90 95
 Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr
 100 105 110
 Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala
 115 120 125
 Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His
 130 135 140
 Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr
 145 150 155 160
 Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala
 165 170 175
 Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys
 180 185 190
 Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr
 195 200 205
 Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr
 210 215 220
 Pro
 225

<210> 344
 <211> 299
 <212> PRT
 <213> Homo sapiens

<400> 344
 Met Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu
 1 5 10 15
 Glu Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys
 20 25 30
 His Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu
 35 40 45
 Glu Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala
 50 55 60
 Phe Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys

65		70		75		80
Gln Val Glu Leu Thr	Ala Gln Asp Val	Lys Asp Ala His	Trp Phe Tyr			
	85		90			95
Asp Thr Pro Gly Ile	Thr Lys Glu Asn	Cys Ile Leu Asn	Leu Leu Thr			
	100		105			110
Glu Lys Glu Val Asn	Ile Val Leu Pro	Thr Gln Ser Ile	Val Pro Arg			
	115		120			125
Thr Phe Val Leu Lys	Pro Gly Met Val	Leu Phe Leu Gly	Ala Ile Gly			
	130		135			140
Arg Ile Asp Phe Leu	Gln Gly Asn Gln	Ser Ala Trp Phe	Thr Val Val			
	145		150			155
Ala Ser Asn Ile Leu	Pro Val His Ile	Thr Ser Leu Asp	Arg Ala Asp			
	165		170			175
Ala Leu Tyr Gln	Lys His Ala Gly	His Thr Leu Leu	Gln Ile Pro Met			
	180		185			190
Gly Gly Lys Glu	Arg Met Ala Gly	Phe Pro Pro Leu	Val Ala Glu Asp			
	195		200			205
Ile Met Leu Lys	Glu Gly Leu Gly	Ala Ser Glu Ala	Val Ala Asp Ile			
	210		215			220
Lys Phe Ser Ser	Ala Gly Trp Val	Ser Val Thr Pro	Asn Phe Lys Asp			
	225		230			235
Arg Leu His Leu	Arg Gly Tyr Thr	Pro Glu Gly Thr	Val Leu Thr Val			
	245		250			255
Arg Pro Pro Leu	Leu Pro Tyr Ile	Val Asn Ile Lys	Gly Gln Arg Ile			
	260		265			270
Lys Lys Ser Val	Ala Tyr Lys Thr	Lys Lys Pro Pro	Ser Leu Met Tyr			
	275		280			285
Asn Val Arg Lys	Lys Lys Lys Gly	Lys Ile Asn Val				
	290		295			

<210> 345

<211> 314

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (147)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (211)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 345

Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
1 5 10 15
Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
20 25 30
Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
35 40 45
Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
50 55 60
Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
65 70 75 80
Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
85 90 95
Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
100 105 110
Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
115 120 125
His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
130 135 140
Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
145 150 155 160
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
165 170 175
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
180 185 190
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
195 200 205
Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
210 215 220
Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
225 230 235 240
Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
245 250 255
Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
260 265 270
Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala
275 280 285
Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr
290 295 300

Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly
305 310

<210> 346
<211> 380
<212> PRT
<213> Homo sapiens

<400> 346

Pro Ser Phe Arg Arg Glu Arg Val Glu Thr Gly Gly Gly Gly Pro Val
1 5 10 15
Thr His Gly Thr Glu Gly Pro Phe Leu Pro Leu Pro Gly Gly Thr Arg
20 25 30
Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu
35 40 45
Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His
50 55 60
Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly
55 70 75 80
Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val
85 90 95
Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr
100 105 110
Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met
115 120 125
Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp
130 135 140
Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln
145 150 155 160
Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp
165 170 175
Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu
180 185 190
Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys
195 200 205
Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys
210 215 220
Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu
225 230 235 240
Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala
245 250 255
Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr

[illegible]

```
<210> 347
<211> 422
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (328)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 347
Trp Ser Thr Gly Asn Ala Ser Trp Glu Lys Lys Asp Asn Phe Ile Leu
  1          5          10          15
Ser Ala Asp Phe Glu Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met
          20          25          30
Lys Ser Pro Pro Leu Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val
          35          40          45
Leu Gly Phe Asn Tyr Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln
  50          55          60
Thr Arg Ile Met Glu Leu Glu Gly Arg Val Arg Arg Arg Ala Ala Glu
  65          70          75          80
Arg Gly Ala Val Glu Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu
          85          90          95
Lys Gln Arg Glu Gln Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln
          100          105          110
Leu Glu Ser Val Asn Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val
          115          120          125

```

Asn Asn Ile Thr Thr Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln
 130 135 140
 Leu Lys Thr Leu Gln Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu
 145 150 155 160
 Gln Phe Gln Lys Asn Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp
 165 170 175
 Leu Ser Gln Cys Ile Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu
 180 185 190
 Glu Arg Ile Glu Glu Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser
 195 200 205
 Arg Asp Leu Ser Glu Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu
 210 215 220
 Ser Glu Pro Gln Pro Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu
 225 230 235 240
 Val Pro Gln Gly Lys Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr
 245 250 255
 Pro Ala Pro Ser Ser Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu
 260 265 270
 Lys Glu Glu Thr Asn Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg
 275 280 285
 Asp Arg Leu Pro Gln Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg
 290 295 300
 Pro Val Gly Gly Arg Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr
 305 310 315 320
 Pro Gln Val Gln Ala Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met
 325 330 335
 Glu Gly Pro Glu Arg Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu
 340 345 350
 Glu Gln Glu Ala Ala Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly
 355 360 365
 Glu Asp Asp Tyr Asn Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp
 370 375 380
 Lys Gln Ala Ala Leu Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn
 385 390 395 400
 Val Glu Asp Gln Lys Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu
 405 410 415
 Lys Arg Asn His Thr Leu
 420

<210> 348

<211> 14
<212> PRT
<213> Homo sapiens

<400> 348
Ser Leu His Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu
1 5 10

<210> 349
<211> 19
<212> PRT
<213> Homo sapiens

<400> 349
Phe Ile Lys Phe Phe Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala
1 5 10 15

Pro Thr Trp

<210> 350
<211> 19
<212> PRT
<213> Homo sapiens

<400> 350
Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala
1 5 10 15

Pro Thr Trp

<210> 351
<211> 363
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 351
Arg Arg Gly Arg Gly Val Pro Gly Pro Arg Gly Arg Arg Arg Leu Trp
1 5 10 15

Ser Ala Ala Cys Gly His Cys Gln Arg Leu Gln Pro Thr Trp Asn Asp
20 25 30

Leu Gly Asp Lys Tyr Asn Ser Met Glu Xaa Ala Lys Val Tyr Val Ala
35 40 45

Lys Val Asp Cys Thr Ala His Ser Asp Val Cys Ser Ala Gln Gly Val
50 55 60

Arg Gly Tyr Pro Thr Leu Lys Leu Phe Lys Pro Gly Gln Glu Ala Val

65 70 75 80
 Lys Tyr Gln Gly Pro Arg Asp Phe Gln Thr Leu Glu Asn Trp Met Leu
 85 90 95
 Gln Thr Leu Asn Glu Glu Pro Val Thr Pro Glu Pro Glu Val Glu Pro
 100 105 110
 Pro Ser Ala Pro Gln Leu Lys Gln Gly Leu Tyr Glu Leu Ser Ala Ser
 115 120 125
 Asn Phe Glu Leu His Val Ala Gln Gly Asp His Phe Ile Lys Phe Phe
 130 135 140
 Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala Pro Thr Trp Glu Gln
 145 150 155 160
 Leu Ala Leu Gly Leu Glu His Ser Glu Thr Val Lys Ile Gly Lys Val
 165 170 175
 Asp Cys Thr Gln His Tyr Glu Leu Cys Ser Gly Asn Gln Val Arg Gly
 180 185 190
 Tyr Pro Thr Leu Leu Trp Phe Arg Asp Gly Lys Lys Val Asp Gln Tyr
 195 200 205
 Lys Gly Lys Arg Asp Leu Glu Ser Leu Arg Glu Tyr Val Glu Ser Gln
 210 215 220
 Leu Gln Arg Thr Glu Thr Gly Ala Thr Glu Thr Val Thr Pro Ser Glu
 225 230 235 240
 Ala Pro Val Leu Ala Ala Glu Pro Glu Ala Asp Lys Gly Thr Val Leu
 245 250 255
 Ala Leu Thr Glu Asn Asn Phe Asp Asp Thr Ile Ala Glu Gly Ile Thr
 260 265 270
 Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala
 275 280 285
 Pro Thr Trp Glu Glu Leu Ser Lys Lys Glu Phe Pro Gly Leu Ala Gly
 290 295 300
 Val Lys Ile Ala Glu Val Asp Cys Thr Ala Glu Arg Asn Ile Cys Ser
 305 310 315 320
 Lys Tyr Ser Val Arg Gly Tyr Pro Thr Leu Leu Leu Phe Arg Gly Gly
 325 330 335
 Lys Lys Val Ser Glu His Ser Gly Gly Arg Asp Leu Asp Ser Leu His
 340 345 350
 Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu
 355 360

<210> 352

<211> 93

<212> PRT

<213> Homo sapiens

<400> 352

Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15

Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30

Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
 35 40 45

Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
 50 55 60

Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
 65 70 75 80

Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
 85 90

<210> 353

<211> 273

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (210)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 353

Glu Thr Arg Val Lys Thr Ser Leu Glu Leu Arg Thr Gln Leu Glu
 1 5 10 15

Pro Thr Gly Thr Val Gly Asn Thr Ile Met Thr Ser Gln Pro Val Pro
 20 25 30

Asn Glu Thr Ile Ile Val Leu Pro Ser Asn Val Ile Asn Phe Ser Gln
 35 40 45

Ala Glu Lys Pro Glu Pro Thr Asn Gln Gly Gln Asp Ser Leu Lys Lys
 50 55 60

His Leu His Ala Glu Ile Lys Val Ile Gly Thr Ile Gln Ile Leu Cys
 65 70 75 80

Gly Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe
 85 90 95

Ser Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr
 100 105 110

Pro Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile
 115 120 125

Ala Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val

130 135 140
 Gly Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu
 145 150 155 160
 Ser Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu
 165 170 175
 Asp Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His
 180 185 190
 Asp Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala
 195 200 205
 Gly Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu
 210 215 220
 Ala Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe
 225 230 235 240
 Pro Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly
 245 250 255
 Met Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr
 260 265 270
 Ser

<210> 354
 <211> 192
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (129)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 354
 Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe Ser
 1 5 10 15
 Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr Pro
 20 25 30
 Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala
 35 40 45
 Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly
 50 55 60
 Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu Ser
 65 70 75 80
 Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu Asp
 85 90 95

Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His Asp
 100 105 110
 Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala Gly
 115 120 125
 Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu Ala
 130 135 140
 Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe Pro
 145 150 155 160
 Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly Met
 165 170 175
 Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr Ser
 180 185 190

<210> 355

<211> 204

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (119)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 355

Gly Ala Ser Cys Glu Gly Gly Gly Ala Ala Ala Arg Ala Ala Leu Gly
 1 5 10 15
 Val His Arg Ser Gln Lys Ala Leu Leu Val Phe Arg Arg Thr Leu Ser
 20 25 30
 Asn Leu Leu Tyr Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val
 35 40 45
 Leu Cys Ala Gly Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro
 50 55 60
 Ser Asp Asp Gly Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro
 65 70 75 80
 Glu Ala His Val Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys
 85 90 95
 Val Leu His Gln Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala
 100 105 110
 Gly Ala Ala Leu Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys
 115 120 125
 Arg Glu Phe His Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro
 130 135 140

Gly Glu Cys Gly Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser
145 150 155 160

Ala Pro Val Arg Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg
165 170 175

Ala Arg Gly Glu Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser
180 185 190

Leu Met Phe Thr Ser Arg Asn Gly Leu Val Gly Cys
195 200

<210> 356

<211> 72

<212> PRT

<213> Homo sapiens

<400> 356

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
1 5 10 15

Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
20 25 30

Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Trp Lys
35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala
50 55 60

Lys Cys Thr Thr Arg Cys Trp Leu
65 70

<210> 357

<211> 115

<212> PRT

<213> Homo sapiens

<400> 357

Leu Lys Arg Ala Pro Pro Gly Pro Ala Leu Ala Lys Gly Leu Leu Gln
1 5 10 15

Pro Ser Ser Thr Phe Gln Ala Leu Glu Thr Asn Ile Gly Asp Gln Val
20 25 30

Arg Arg His Ser Thr Ala Val Val Ile Arg Glu Met Thr Ser Tyr Ile
35 40 45

Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly Cys Ile Glu Lys Asp
50 55 60

Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg Leu His Leu Leu Phe
65 70 75 80

Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu Arg Gly Glu Leu Ser
85 90 95

Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu Gln Leu Gly Gly Cys
 100 105 110

Thr Cys Phe
 115

<210> 358
 <211> 88
 <212> PRT
 <213> Homo sapiens

<400> 358
 Val Ile Lys Leu Ile Cys Pro Ala Ala Phe Pro Val Tyr Phe Gln Asp
 1 5 10 15

Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe
 20 25 30

Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile
 35 40 45

Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met
 50 55 60

Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile
 65 70 75 80

Phe Ser Tyr Leu Leu Cys Thr Pro
 85

<210> 359
 <211> 716
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (373)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (705)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 359
 Tyr Xaa Ile Pro Gly Ser Thr His Ala Ser Gly Arg Gln Arg Gly Ser
 1 5 10 15

Gly Arg Gly Glu Asp Asp Ser Gly Pro Pro Pro Ser Thr Val Ile Asn
 20 25 30

Gln Asn Glu Thr Phe Ala Asn Ile Ile Phe Lys Pro Thr Val Val Gln
 35 40 45
 Gln Ala Arg Ile Ala Gln Asn Gly Ile Leu Gly Asp Phe Ile Ile Arg
 50 55 60
 Tyr Asp Val Asn Arg Glu Gln Ser Ile Gly Asp Ile Gln Val Leu Asn
 65 70 75 80
 Gly Tyr Phe Val His Tyr Phe Ala Pro Lys Asp Leu Pro Pro Leu Pro
 85 90 95
 Lys Asn Val Val Phe Val Leu Asp Ser Ser Ala Ser Met Val Gly Thr
 100 105 110
 Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile Leu His Asp Leu
 115 120 125
 Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser Asn Arg Ile Lys
 130 135 140
 Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp Ser Ile Arg Asp
 145 150 155 160
 Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly Gly Thr Asp Ile
 165 170 175
 Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn Lys Tyr Val Ala
 180 185 190
 His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile Val Phe Leu Thr
 195 200 205
 Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu Lys Ile Leu Asn
 210 215 220
 Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile Phe Thr Ile Gly
 225 230 235 240
 Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys Leu Ser Leu Glu
 245 250 255
 Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu Asp Ala Gly Ser
 260 265 270
 Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro Leu Leu Ser Asp
 275 280 285
 Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln Ala Thr Lys Thr
 290 295 300
 Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile Ile Ala Gly Lys
 305 310 315 320
 Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu Val Thr Ala Ser
 325 330 335
 Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val Pro Val Arg Pro

340 345 350
 Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg Pro Gly Gly Asp
 355 360 365
 Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp Ser Tyr Leu Thr
 370 375 380
 Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp Asp Glu Pro Glu
 385 390 395 400
 Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala Val Ser Tyr Arg
 405 410 415
 Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly Pro Val Pro Arg
 420 425 430
 Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala Ala Met Gly Pro
 435 440 445
 Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr Gln Pro Gly Pro
 450 455 460
 Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile Ser Lys Thr Ser
 465 470 475 480
 Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro Leu Ser Arg Leu
 485 490 495
 Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp Ile Leu Arg Leu
 500 505 510
 Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn Gly Glu Leu Ile
 515 520 525
 Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln Arg Thr Tyr Leu
 530 535 540
 Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg Ser Tyr Leu Glu
 545 550 555 560
 Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp Arg Leu Val Leu
 565 570 575
 Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly Leu Glu Val Ser
 580 585 590
 Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln Gly Ser Ile Ala
 595 600 605
 Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala Pro Phe Gln Arg
 610 615 620
 His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly Leu Ser Ser Asn
 625 630 635 640
 Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp Ala Arg Leu Thr
 645 650 655

Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His Pro Leu Leu Leu
660 665 670

Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val Lys Gly His Gln
675 680 685

Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn Gly Glu Glu Gln
690 695 700

Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn
705 710 715

<210> 360

<211> 387

<212> PRT.

<213> Homo sapiens

<400> 360

Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn
1 5 10 15

His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala
20 25 30

Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile
35 40 45

Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln
50 55 60

Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg
65 70 75 80

Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu
85 90 95

Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly
100 105 110

Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro
115 120 125

Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val
130 135 140

Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu
145 150 155 160

Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val
165 170 175

Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser
180 185 190

Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val
195 200 205

Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala

210 215 220
Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro
225 230 235 240
Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro
245 250 255
Thr Ser Thr Asp Pro Ala Pro Ser Ala His Leu Asp Ser Val His Lys
260 265 270
Ser Thr Asp Ser Gly Pro Ser Glu Leu Pro Gly Pro Thr His Thr Thr
275 280 285
Thr Gly Ser Thr Tyr Ser Ala Ile Thr Thr Thr His Ser Ala Pro Ser
290 295 300
Pro Leu Thr His Thr Thr Thr Gly Ser Thr His Lys Pro Ile Ile Ser
305 310 315 320
Thr Leu Thr Thr Thr Gly Pro Thr Leu Asn Ile Ile Gly Pro Val Gln
325 330 335
Thr Thr Thr Ser Pro Thr His Thr Met Pro Ser Pro Ser Ser His Ser
340 345 350
Asn Ser Pro Gln Tyr Val Asp Phe Cys Ser Ser Val Cys Asp Asn Ile
355 360 365
Phe Val His Tyr Val Ile Gly Ile Phe Phe His Thr Leu Tyr Ser Ser
370 375 380
Lys Thr Leu
385

<210> 361
<211> 260
<212> PRT
<213> Homo sapiens

<400> 361
Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn
1 5 10 15
His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala
20 25 30
Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile
35 40 45
Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln
50 55 60
Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg
65 70 75 80
Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu
85 90 95

Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly
 100 105 110
 Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro
 115 120 125
 Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val
 130 135 140
 Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu
 145 150 155 160
 Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val
 165 170 175
 Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser
 180 185 190
 Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val
 195 200 205
 Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala
 210 215 220
 Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro
 225 230 235 240
 Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro
 245 250 255
 Thr Ser Thr Asp
 260

<210> 362
 <211> 155
 <212> PRT
 <213> Homo sapiens

<400> 362
 Tyr Gly Cys Glu Lys Thr Thr Glu Gly Gly Arg Arg Arg Arg Arg Arg
 1 5 10 15
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
 20 25 30
 Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
 35 40 45
 Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val
 50 55 60
 Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met
 65 70 75 80
 Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp
 85 90 95

Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe
100 105 110
Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys
115 120 125
Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr
130 135 140
Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp
145 150 155

<210> 363
<211> 70
<212> PRT
<213> Homo sapiens

<400> 363
Ala Arg Ala Pro Ala Pro Ser Leu Pro Pro Leu Pro Ser Pro Ala Pro
1 5 10 15
Ala Leu Ala Pro Ala His Ser Leu Leu Gly Leu Leu Leu Gly Arg Met
20 25 30
Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Leu Val
35 40 45
Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg Val
50 55 60
Gln Ser Gly Gln Asp Gln
65 70

<210> 364
<211> 56
<212> PRT
<213> Homo sapiens

<400> 364
Gly Thr Ser Lys Asp Cys Val Leu Tyr Ala Phe Leu Asp Pro Gly Met
1 5 10 15
Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu Pro
20 25 30
Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser Ser
35 40 45
Ser Ser Glu Ser Lys Ser Ser Leu
50 55

PCT/US99/17130

Applicant's or agent's file reference number	P2031PCT	International application	Unassigned
--	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

REC'D 18 AUG 1999	
A. The indications made below relate to the microorganism referred to in the description on page <u>280</u> , line <u>N/A</u>	WIPO PCT
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203069
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer Yvette G. Smith PCT International Division	For International Bureau use only <input checked="" type="checkbox"/> This sheet was received by the International Bureau on: 18 AUGUST 1999 Authorized officer P. G. J. J.

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

PCT/US99/17130

Applicant's or agent's file reference number	PZ031PCT	International application:	Unassigned
--	----------	----------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>243</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit June 11, 1998	Accession Number 209965
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <i>[Signature]</i> PCT/US99/17130 Division	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned
--	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>249</u> line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit June 26, 1998	Accession Number 203027
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	
<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Yvonne E. Starnis PCT International Division</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International applicant or	Unassigned
--	----------	----------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>253</u> line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203071
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Yvonne E. Simms PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International applicant or
--	----------	----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>259</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1988	Accession Number 203070
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the International application Authorized officer Yvonne E. Elms PCT International Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet US CL : Please See Extra Sheet According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1, 23.5; 435/69.1, 320.1, 252.3, 325, 6, 7.1; 530/350, 300, 387.1; 514/2 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, DIALOG - Biotech Files				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	JACOBS, K. A. et al. A Genetic Selection For Isolating cDNAs Encoding Secreted Proteins. Gene. 1997, Vol. 198, pages 289-296, see entire document.	1-23		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"><tr><td>* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *U* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family</td></tr></table>			* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *U* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *U* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family			
Date of the actual completion of the international search 05 OCTOBER 1999		Date of mailing of the international search report 21 OCT 1999		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer ELIZABETH C. KEMMERER Telephone No. (703) 308-6196		

Form PCT/ISA 210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.